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Abstract 
Cancer continues to be an ongoing global health concern placing a considerable burden on the 
health system. Similarly, antibiotic resistant microbial infections are increasing with 
projections for both illnesses becoming the leading cause of death worldwide. The 
outstanding success of platinum-based chemotherapeutics such as cisplatin and the promising 
results of ruthenium anticancer drugs such as NAMI-A and KP1019, supports further 
investigation into transition metals as anticancer drugs. However, problems that are associated 
with platinum-based drugs include toxicity, resistance, selectivity, or limitations concerning 
the degree of activity. This has prompted investigation into optimisation strategies based on 
different transition metals and ligands. While the metal complexes previously investigated for 
biological activity have demonstrated anticancer activity, synthetic advances have also 
contributed to the development of antibacterial activity. Ruthenium(II) based complexes are 
of particular interest, as they are versatile, stable and commonly bio-active, suggesting that 
further research in this field would be advantageous. Ligands play a significant role in 
coordination chemistry, both independently and when coordinated to transition metals. The 
study of multidentate ligands, has contributed profoundly to the understanding of coordinated 
structures, the development of compounds displaying biological activity, and their influence 
on compound stereochemistry. 
The research presented in this thesis focuses on synthetic techniques to expand the 
utility of N4-tetradentate ligands (N4-TLs); it includes the synthesis of N4-TLs, the 
coordination of N4-TLs and bidentate ligands to ruthenium(II), and the assessment of their 
biological activity against cancer and bacterial cells. A series of N4-TLs (1 – 33) with the 
general name N,Nʹ-bis(2-pyridylmethyl)-1,2-diaminoethane (picen, N4-TL-1) and its 
analogues with varying length of achiral and chiral diamine chains and their methylated 
nitrogens have been synthesised. The N4-TLs were successfully synthesised and characterised. 
All structures were confirmed using NMR, ESI-MS, HPLC, UV-Vis and where appropriate 
CD spectroscopy. 
The anticancer properties of the N4-TLs were determined. N4-TLs-7, 13, 19, 25, 26, 28, 
and 30 – 33 were revealed to be comparable to cisplatin, oxaliplatin, and carboplatin in human 
cell lines. N4-TL, 25 (picenBz2), was 4, 2, and 16-fold more potent than cisplatin (3.69 µM), 
oxaliplatin (1.68 µM), and carboplatin (14.43 µM) in human cell lines. Cell specific activity 
revealed N4-TL, 25 was potent against ovarian (A2780) cells with a GI50 of 0.06 µM. The 
order of activity of the top five N4-TLs, 25 > 32 > 33 > 26 > 13 increases for these ligands as 
they become more lipophilic and therefore have a higher log P value.  
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Antimicrobial studies for N4-TLs-1, 13, 25, 26, and 27 revealed activity against Gram-
negative over Gram-positive bacteria. Notably, the activity of the N4-TLs were less effective 
as antimicrobial agents compared to streptomycin across most bacteria. Cell specific activity 
was demonstrated with N4-TL 1 which was ~8 fold more potent than Ampicillin (MIC = > 64 
µg/mL) and streptomycin (MIC = > 64 µg/mL) for A. baumannii. Overall, the order of 
activity increases for these ligands, N4-TLs-1 > 13 > 26 = 27 > 25 as they become more polar 
and therefore have lower log P values. N4-TLs-13 and 25, were selected to coordinate with 
ruthenium(II) as they both demonstrated different activity against cancer and bacterial cells 
and exhibit different stereo-chemistries. These N4-TLs are synthetically versatile and 
structurally flexible, making them ideal scaffolds for the coordination of metals. 
Ruthenium(II/III) complexes have demonstrated potential as anticancer agents with several 
exhibiting ideal anticancer and antimetastatic properties. 
A series of complexes of the type rac-[Ru(N4-TL)(DMSO)Cl]
+ (Ru-1 and 2) and rac-
[Ru(N4-TL)(PL)]
2+ (Ru-3 – 14) (where N4-TL = 1,6-di(2'-pyridyl)-2,5-dimethyl-2,5-
diazahexane (picenMe2, N4-TL-13) or 1,6-di(2'-pyridyl)-2,5-dibenzyl-2,5-diazahexane 
(picenMe2, N4-TL-25) and PL= 1,10-phenanthroline (phen), dipyrido[3,2-d:2',3'-f]quinoxaline 
(dpq), 7,8-dimethyl-dipyrido[3,2-a:2',3'-c] phenazine (dppzMe2), 2-phenyl-1H-imidazo[4,5-
f][1,10]phenanthroline (phenpyrBz), 2-(p-tolyl)-1H-imidazo[4,5-f][1,10]phenanthroline 
(phenpyrBzMe), 2-(4-nitrophenyl)-1H-imidazo[4,5-f][1,10]phenanthroline (phenpyrBzNO2), 
were synthesised. All structures were confirmed using NMR, ESI-MS, HPLC, UV-Vis and 
where applicable X-ray crystallography.  
The in vitro cytotoxicity assays revealed that Ru-5 and 7, and Ru-11 and 13, were 
overall more potent than cisplatin, oxaliplatin, and carboplatin on average. The polyaromatic 
ligands altered the baseline cytotoxicity, in the case of Ru-5/11 and Ru-7/13, the polyaromatic 
ligands dppzMe2 and phenpyrBzMe, enhanced the activity and decreased the GI50 values. The 
methyl substituents on the polyaromatic ligands influenced the activity more than the N4-TL 
substituents, methyl and benzyl. The antimicrobial properties of the ruthenium(II) complexes 
slightly favoured Gram-positive over Gram-negative bacteria. The activity was relatively poor 
in comparison to ampicillin and streptomycin. Complexes Ru-5 and 11, were as active as 
ampicillin and streptomycin with a MIC of 5 µM against E.aerogenes, S.aureus, and 
M.luteus.  
In conclusion, throughout this thesis several N4-TLs together with their respective 
ruthenium(II) complexes were successfully synthesised and characterised in detail. The N4-
TLs and ruthenium(II) complexes also revealed varying levels of anticancer and antimicrobial 
properties. 










Cancer drug development has been established for a long time and there is enormous interest 
to improve methods of treatment and eradicate cancerous cells. Like cancer, bacterial 
infections are also amongst one of the leading causes of death worldwide. There has been 
considerable examination of the biological activity of transition metal complexes. However, 
the problems that are associated with metal complexes include toxicity, resistance, selectivity 
issues, or limitations to the degree of activity. In order to address the major issue of drug 
resistance, it has prompted investigation into optimisation strategies based on different 
transition metals and ligands. 
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1.1Cancer 
1.1.1 What is cancer? 
Cancer is a disease of the cells, whereby a mutation of the cells’ genetic makeup causes 
uncontrolled division of abnormal cells in the body. As the cells grow and reproduce, they 
gradually invade surrounding healthy tissue to form tumours.1, 2 Tumours often start at a 
primary site, such as tissue, and exist as either benign (non-cancerous) or malignant 
(cancerous) tumours. Once malignant cancer becomes invasive, it may enter the bloodstream 
and travel to a secondary area, a process known as metastasis.1, 2 Cancerous tumours can be 
categorised by the areas from which they develop; this includes carcinoma (skin or tissue), 
sarcoma (bone, fat, muscle, blood vessels or other connective tissue), leukaemia (blood-
forming tissue), lymphoma/myeloma (immune system), and the central nervous system (brain 
and spinal cord).2 The ubiquity of cancer creates a socio-economic burden, as traditional 
treatment methodologies are unable to keep up with the rate of new cancer cases in a growing 
population. Consequently, this has resulted in the need for innovative research into anticancer 
drug design and development strategies. 
1.1.2 The burden of cancer 
The socio-economic burdens of cancer have increased proportionately with population 
growth. There are many factors influencing this increase, including an ageing population, 
genetics, exposure to chemical, physical, and biological carcinogens, in addition to lifestyle 
choices such as smoking, inactivity, and a westernised diet.1-3 Interestingly, population 
growth is reflected in an increase in estimated new cancer cases worldwide, from 14.1 million 
in 2012 to 18.1 million in 2018 (Figure 1.1, A).4-6 These rates are comparable in a smaller 
population such as Australia, where the number of new cancer cases in 2010 (~120, 000) rose 
to 200, 000 in 2018 (Figure 1.1, B).1, 6 The top 4 cancer types expressed worldwide and in 
Australia are lung, breast, colorectal, and prostate, as shown in Figure 1.1, C and D.5, 6 As 
new cancer cases continue to rise, the rate of death after diagnosis remains concerning; it is 
estimated that cancer death rates worldwide increased from 8.2 million in 2012 to 9.6 million 
in 2018 (Figure 1.1, A).5, 6 This increasing trend is also evident in Australia, where the 
number of deaths due to cancer increased from 42, 800 in 2010 to 49, 500 in 2018 (Figure 1.1, 
B).1, 6 Hence, rising cancer incidence and death rates necessitate more efficient and rapid 
detection methods, in addition to the development detection and development of new and 
more effective drugs.  
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Figure 1.1 Incidence and mortality rates worldwide 2012 – 2018 (A) and Australia 2010 - 2018 (B) for both 
sexes. Top 4 cancer incidence and mortality rates worldwide (C) and Australia (D) for both sexes.1, 5 
 
1.1.3 Understanding cancer 
Specialised genes within an organism are responsible for the regulation of cell growth, 
division, death, and DNA (Deoxyribonucleic acid) repair. Functional proto-oncogenes, 
tumour suppressor (anti-oncogene) and DNA repair genes, respectively, are translated into 
proteins that maintain normal cell proliferation and repair DNA damage/error.7 In response to 
genetic predispositions or lifestyle choices, these genomes may become mutated, produce 
oncogenes, and disrupt regulated processes. The increased production of oncogenes over-
express functional proteins that initiate accelerated cell division, decreased cell 
differentiation, and inhibit normal cell death.7, 8 Mutations to tumour suppressor and DNA 
repair genes deactivate the suppression of cell proliferation and inhibit the repair of DNA 
damage/error, and consequently propagate additional mutation. Therefore, uncontrolled cell 
regulation contributes to the formation of various cancerous cells.7 Tumour progression to a 
secondary site can develop from additional genetic transformations, contributing to the 
process known as metastasis.9 Tumour progression towards metastasis consists of a multistep 
process encompassing; (1) local invasion of the surrounding extracellular matrix and 
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blood vessels or lymph vessels; (3) transportation through the vasculature or lymphatic 
system; (4) arrest at a distant location; (5) extravasate via the walls of blood or lymphatic 
vessels, and migration to distant tissue; (6) survival in foreign environment without being 
attacked by the immune system to allow proliferation as micro-metastases; and (7) stimulation 
of blood vessel growth by micro-metastases in a process known as angiogenesis (Figure 
1.2).9-12 Treatment is available to eradicate both primary and secondary cancerous cells and 
significant efforts have been undertaken to extend/improve upon these therapeutic options. 
 
 
Figure 1.2 The normal cell growth and division controlled by genes that may lose their function from mutation, 
therefore the regulation of normal cell growth is lost. As a result, mutated cells may become cancerous. Tumour 
progression may occur by metastasis.13 
 
1.1.4 Cancer treatments and drug development 
Cancer drug development has been established for a long time and there is enormous interest 
to improve the methods of treatment for the purpose of eradicating cancerous cells. Currently, 
available cancer treatments include surgery, radiation, immunotherapy, targeted therapy, 
hormones, stem-cell therapy, and chemotherapy.14-16 Chemotherapy treatments, however, are 
particularly prone to side effects and drug resistance. For example, the platinum-based 
complex, cis-dichlorodiammine platinum(II) (cisplatin), is one of the most widely used 
anticancer drugs in the clinic.17-19 However, cisplatin exhibits severe toxicity, side effects, and 
cellular resistance.19, 20 This has prompted the investigation of other transition metal 
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complexes to improve selectivity, targeting, resistance, side effects, and toxicity. Other 
platinum complexes available worldwide for cancer treatments include cis-diamine(1,1-
cyclobutanedicarboxylato)platinum(II) (Carboplatin), and 1R,2R-cyclohexanediamine-N,Nʹ-
ethanedioato-O,Oʹ)platinum(II) (Oxaliplatin), whereas ruthenium complexes such as trans-
[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019), and (ImH)[trans-RuCl4(DMSO-S)(Im)] 
(NAMI-A) are being investigated for use; their administration method, mechanism of action, 
and biological target are shown in Table 1.1.19, 21-29  
Synthetic advances have enabled a variety of compounds to be developed as treatment 
options for bacterial infections. The evolution of drug discovery dates to the 19th century and 
has been significantly influenced by an increased understanding of chemistry, pharmacology, 
microbiology, and biochemistry. There are hundreds of biologically active molecules that 
have been identified, developed, clinically evaluated, and approved for use as drugs to date.30 
This development has resulted in many modern-day drug classes including antimicrobials, 
anti-inflammatories, anticancer, anti-acid, analgesics, and anti-psychotics.30 A major 
contribution to drug development was the discovery of penicillin in 1929 by Alexander 
Fleming.31-33 Penicillin is an antibacterial molecule produced from the fungus Penicillium 
notatum (P. notatum).33 The mechanism of action of this antibiotic involves the prevention of 
peptidoglycan cross-linking during the final stages of bacterial cell wall formation. The 
weakened cell wall causes the bacterium to lyse and burst from osmotic pressure. However, 
acquired resistance has arisen through exposure and misuse, leading to even the longest 
serving compounds becoming ineffective. This has necessitated the development of new 
drugs to effectively treat bacterial infections.31, 32 Advances in synthesis and purification 
techniques have contributed to improved methods in drug development. However, cancer cell 
lines, and bacterial/fungal strains have demonstrated signs of resistance to anticancer and 
antimicrobial drug classes, respectively. Therefore, it is important to develop novel bioactive 
molecules with a distinctly different mechanism of action to overcome drug resistance and 
improve activity. Transitional metals provide interesting synthetic spaces to explore 
anticancer and antimicrobial compounds. 
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Table 1.1 Current metal complexes used for anticancer treatment. 
 




Intravenously as short-term 
infusion in normal saline 
Inhibiting DNA replication 
DNA, testicular, ovarian, cervical, breast, 
bladder, head and neck, lung cancer, meso-
thelioma, brain tumour, and neuroblastoma. 
Cis-diammine(1,1-
cyclobutanedicarboxylato)platinum
(II) (Carboplatin)19, 21, 22, 34 
[Pt(NH3)2(C6H6O4)] Intravenous injection Inhibiting DNA replication 




(Oxaliplatin)19, 21, 22, 34 
[Pt(NH2)2(C8H10O4)] 
Intravenous injection and in 
combination with 
fluorouracil and folic acid. 





Intravenous injection as 
sodium salt 
Activation by reduction, serum 
proteins, and DNA interaction. 
Colorectal cancer 
(ImH)[trans-RuCl4(DMSO-S)(Im)] 




Binds to proteins (integrins, 
transferrin, and albumin), 
Lung metastasis of solid tumours. 
Ruthenium(II) NHCs28, 35, 36 [Ru2(ƞ6-p-cymene)2Cl4]NHC Under investigation 
Mimics iron, interacts with 
plasmid DNA. 
DNA, solid tumours, renal cancer, and breast 
cancer 
Caffeine-derived rhodium(I) NHC34 [Rh(I)Cl(COD)(NHC)] Under investigation 
Inhibition of thioredoxin reductase 
(TrxR), produces ROS formation, 
and DNA damage. 
TrxR, breast, liver, colon, prostate, pancreatic 
cancer, and solid tumours. 
Iron(II) cyclopentadienyl 
complexes34 
[Fe(ƞ5-C5H5)(dppe)L][X] Under investigation 
Interacts with DNA, induces 
apoptosis. 
DNA, promyelocytic leukemia, and non-solid 
tumours. 
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1.2 Significance of bacterial infections 
1.2.1 What are bacteria? 
Bacteria are single-celled organisms that constitute larger domain of microbes.37 They can 
thrive in diverse environments in areas such as land, water, and the human body,38 these cells 
can be classified as either prokaryotic or eukaryotic organisms.39, 40 Prokaryotic cells lack 
formal organelles and membrane-bound structures such as a nucleus and mitochondria. 
Eukaryotic cells, however, contain a nucleus and organelles that are enclosed by a plasma 
membrane.39, 40 Bacteria can also be distinguished by the presence of a cell wall (Gram-
positive or negative) (Figure 1.3), their shape (spherical, rod, and spiral), and their genetic 
makeup.41, 42 Identifying the composition of a bacterial cell wall via gram stain techniques 
reveals Gram-positive bacteria have a thick peptidoglycan layer, cytoplasmic membrane, 
periplasmic space, and a lack of an outer membrane. Examples of these include; Bacillus 
cereus (B. cereus), Enterococcus faecalis (E. faecalis), Micrococcus luteus (M. luteus), 
Staphylococcus epidermidis (S. epidermidis), and Staphylococcus aureus (S. aureus).42 The 
Gram-negative bacterial membrane is composed of a thin peptidoglycan layer, cytoplasmic 
membrane, periplasmic space, and outer lipopolysaccharide layer, and these bacterial types 
include; Enterobacter aerogenes (E. aerogenes), Klebsiella pneumoniae (K. pneumoniae), 
Proteus vulgaris (P. vulgaris), Pseudomonas aeruginosa (P. aeruginosa), Serratia 
marcescens (S. marcescens), and Escherichia coli (E. coli).42 In humans, bacteria can be 
beneficial and assist in processes such as digestion, but they can also inhabit the host without 
causing harm or benefits, an association termed commensalism.43 However, under 
immunocompromised or imbalanced conditions, commensal bacteria are able to overcome 
protective host responses and exert pathogenic effects.37 Disease-causing micro-organisms 
and commensal bacteria can be known as pathogenic bacteria when they are able to generate 




Figure 1.3 Gram-positive and negative bacteria differentiated by their cell structure. 
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1.2.2 The burden of bacterial infections 
Bacterial infections are amongst one of the leading causes of death worldwide.44, 45 Infections 
are commonly found in the digestive, urinary, and respiratory tracts, in addition to wounds 
and burns. The spread of disease is caused by insufficient decontamination of clothing, hands, 
gloves, and surgical equipment prior to surgeries. Furthermore, poor food handling, poor 
sanitation, lack of sexual education, and general health education are also factors in the spread 
of disease.46 Pathogenic initiation is specific to individual species and generally involves the 
release of endotoxins, exotoxins, or the formation of biofilms (Figure 1.4).47, 48 Endotoxins 
comprise a toxic lipopolysaccharide component from the outer membrane of Gram-negative 
bacteria.49 They are ubiquitous in nature displaying potent toxicity causing pyrogenicity 
(fever-inducing) capacity, and they can be stable under extreme conditions. When endotoxins 
are present in bacteria, they can exert profound biological effects that can be lethal to the 
host.49 Exotoxins, in contrast to endotoxins, are toxic proteins secreted into the external 
medium by pathogenic bacteria.50 When exotoxins are secreted or released during lysis of the 
cell, it may destroy the host cell or disrupt normal metabolism of the host. The 
formation/release of endo- and exotoxins is a pathogen defence mechanism initiated via an 
immune response or targeting agent. This process can cause a lethal response in the host, 
resulting in acute illness or septic shock.50 Bacteria can also assemble complex extracellular 
polymeric substances called biofilms.51, 52 Biofilms are adherent microbial cells that become 
embedded within a surface such as medical devices or tissue, forming a slimy extracellular 
matrix. Biofilms play an important role in infectious diseases. Pathogens such as Legionella 
pneumophila (L. pneumonphila), S. aureus, E. coli, Listeria monocytogenes (L. 
monocytogenes), Salmonella typhimurium (S. typhimurium), Vibrio cholera (V. cholera), and 
Helicobacter pylori (H. pylori) have been associated with biofilm formation.51 Although the 
interactions between biofilm and pathogens are not completely understood, pathogenic 
survival and growth can be enhanced by metabolic interactions with indigenous organisms 
within biofilms. Biofilms have also been associated with infectious diseases like cystic 
fibrosis, endocarditis, periodontitis and chronic prostatitis.51, 52 The characteristics of biofilms 
that are important to infectious diseases are their reduced susceptibility to antimicrobial 
agents, their resistance to host immune responses, the production of endotoxins in Gram-
negative bacteria, and the detachment of cells that results in bloodstream and urinary tract 
infections. 51 
The toxins released by bacteria are only one of the many challenges associated with 
bacterial infection. Sophisticated strains of bacteria with complex adaptive and metabolic 
mechanisms can become resistant to antibiotic drugs under extreme conditions.53, 54 These 
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examples are known as superbugs (Figure 1.4).54 The inappropriate use of antibiotics has 
given rise to superbugs that have adapted to resist multiple antibiotics, including last line 
drugs. A commonly known superbug is methicillin-resistant Staphylococcus aureus (MRSA), 
a bacterium resistant to methicillin.55 Another known superbug is Neisseria gonorrhoea (N. 
gonorrhoea) that is resistant to penicillin, tetracycline, and ciprofloxacin. Developing 
effective antibiotics to eradicate pathogens without releasing bacterial toxins, and preventing 
the formation of biofilms and superbugs, is therefore essential.53, 54, 56  
 
 
Figure 1.4 Pathogenic initiation generally involves the release of endotoxins, exotoxins, or the formation of 
biofilms or superbugs.13 
 
Antimicrobial resistance is a global concern as superbugs have the ability to adapt 
when exposed to antimicrobial drugs such as antibiotics, antifungals, antivirals, antimalarials, 
and antiparasitic.56, 57 As antimicrobial drugs become ineffective and infections persist, the 
risk of transmission is increased. Antimicrobial resistance develops naturally over time 
through diverse environments and genetic changes, but other attributes are hastening this 
process. The main contributor to accelerating the emergence and spread of antimicrobial 
resistance is both the misuse and overuse of antimicrobial drugs.56, 58 The ineffective use of 
antimicrobial drugs becomes problematic when treating common infections and results in 
chronic illness, disability and mortality. Medical procedures, such as organ transplantation, 
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caesarean sections, chemotherapy, diabetes management, and heart surgeries, thus become 
higher risks because of the increased probability of infection. Drug resistance then becomes a 
burden to society, requiring increased health care system expenses for extended patient care, 
and in some cases, more intensive care.57, 59 Therefore, a better understanding of microbial 
mechanisms, management in minimising the spread of infection, and controlling how 
antimicrobial drugs are distributed and used, is essential for the development of more 
effective antimicrobial drugs. 
1.2.3 Understanding bacterial infections in humans 
Bacterial pathogens are organisms that cause disease. They utilise their cellular machinery to 
invade a host and procreate. Microbes are versatile in both harsh and hospitable environments. 
A human host provides an ideal environment, containing abundant nutrients and an optimal 
temperature for microbial survival and reproduction. The human body has a complex 
ecosystem that manifests its own microbes, known as normal flora.60 Normal flora are usually 
found and limited to certain areas of the body such as the skin, mouth, large intestine, and 
vagina.60 They are relatively stable and aid the host by competing for microenvironments 
more effectively than pathogens. Normal flora also have a unique role whereby they provide 
nutrients to the host, or present as commensal microbes by inhabiting the host without causing 
harm or benefits. Although normal flora can be harmless, they too may behave pathogenically 
when the host is immunocompromised or injured.60 Disease-causing pathogens are highly 
developed, with specialised mechanisms for crossing both cellular and biochemical barriers, 
as well as inducing specific responses from the host in order to survive and multiply. 
Opportunistic pathogens will also take advantage of an immunocompromised host or 
breached barriers to alter normal flora and cause disease.37 Pathogens have been able to 
efficiently evolve their mechanisms to be able to exploit the biology of their host in any 
diverse environment. The treatments used to either kill or inhibit the growth of microbes are 
antibiotics. The mechanism for pathogenic survival and areas for drug targeting are, (1), 
colonise the host; (2), find a nutritional supply; (3), circumvent the hosts’ immune response; 
(4), replicate using the hosts’ resources, and; (5), exit and spread to a new host.37 Antibiotics 
are used to treat bacterial infections by targeting areas or processes of the microbial cell such 
as the cell wall, cell membrane, DNA gyrase, RNA (Ribonucleic acid) gyrase, protein 
synthesis, 30S or 50S inhibition, and folic acid biosynthesis (Figure 1.5).61, 62 




Figure 1.5 Antibiotics used to treat bacterial infections by targeting areas or processes of the microbial cell. 
 
1.2.4 Antibiotic drugs and development 
Antibiotics are a type of antimicrobial agent that are used for the treatment and/or prevention 
of bacterial infections; their actions either killing or inhibiting the growth of bacteria. 
Antibiotics have revolutionised medicine since the early days of natural products, and are still 
commonly utilised to this day (Figure 1.6).58, 63 Natural products, such as rosemary, lemon 
verbena, and bael tree extracts, are terpenoids that affect a wide range of bacteria and fungi. 
Polyphenols with antimicrobial activity are extracted from plants such as cascara sagrada, 
wintergreen, and thyme.63, 64 Their mechanism of action involves penetrating the cell wall and 
accumulating within the cell, with the hydrophobicity of these products typically helping to 
increase their antimicrobial activity.63, 64 The major drawback of using natural antimicrobial 
agents is intrinsic natural resistance. However, the resistance developed from antimicrobial 
agents has contributed to understanding and developing new synthetic agents and other 
variants. Almost all approved antibiotics to date are organic in nature; the common antibiotics 
and their targets are listed in Table 1.2.65 The following are targets that antibiotics may act 
upon, including: (1), inhibiting peptidoglycan formation by disrupting peptide cross-links, or 
through blocking both trans-glycosidase and transpeptidase which are essential for cross-link 
formation; (2), altering the translation process by binding to 30S or 50S ribosomal subunits, 
therefore preventing transcription RNA (tRNA) from binding; (3), altering the cytoplasmic 
membrane so that a cationic peptide can interact and disrupt the cell membrane, therefore 
increasing permeability; (4), inhibiting nucleic acid replication by blocking topoisomerases 
that are responsible for supercoiling; and (5), inhibiting transcription by blocking RNA 
polymerase from transcribing DNA to messenger RNA (mRNA).61, 62, 66 Despite the variety of 
modes of action, resistance continues to be a challenge for existing antibiotics. 
  




Figure 1.6 Timeline of antibiotic development.58  
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Bacteria (broad) Sulphonamides 
 
1.3 Transition metals with biologically active properties 
There has been considerable examination of the biological activity of transition metal 
complexes in order to address resistance to anticancer and antimicrobial agents, with some 
having been reported to exhibit a broad spectrum of biological activity. The Australian 
chemist Francis Patrick Dwyer advocated the use of transition metals and the investigation of 
their biological activity.67 Others have followed, providing a rich source of coordinated 
transition metals with therapeutic potential, based on the following metals; platinum(II),68-73 
copper(II),74, 75 iron(II),76, 77 cobalt(I)/(II),78-80 and ruthenium(II)/(III).81-83 Problems that are 
associated with metal complexes include; toxicity, resistance, selectivity issues, or limitations 
concerning the degree of activity. This has prompted investigation into optimisation strategies 
based on different transition metals and ligands. While the metal complexes previously 
investigated for biological activity have demonstrated anticancer activity, synthetic advances 
have also contributed to the development of antibacterial activity. Ruthenium(II) based 
complexes are of particular interest, as they are versatile, stabile and commonly bio-active, 
suggesting that further research in this field would be advantageous. 
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1.3.1 Platinum anticancer complexes 
Many platinum(II)-based complexes have been designed, synthesized, and examined for 
anticancer activity.19 The fortuitous discovery of cisplatin [1] by Rosenberg in 1965 prompted 
its investigation as a treatment for cancer (Figure 1.7).84 Cisplatin entered phase I clinical 
trials in 1971, and by 1978 was approved for clinical use by the Food and Drug 
Administration (FDA).17-19 Cisplatin is currently the most widely utilized anticancer drug and 
is effective for treating testicular, ovarian, head, neck, and small-cell lung cancer.19 Despite 
these successes, cisplatin has several notable disadvantages, including cell resistance, in 
addition to several side effects, such as kidney damage (nephrotoxicity), nervous system 
damage (neurotoxicity), hearing loss (ototoxicity), and vomiting (emetogenesis).19, 20 
 
 
Figure 1.7 The structures of platinum anticancer agents used in therapy today. [1] cisplatin, [2] carboplatin, [3] 
oxaliplatin. 
 
Analogues of cisplatin have been developed in an effort to overcome the 
disadvantages associated with its use,85 these include carboplatin [2] and oxaliplatin [3].19, 21, 
22 Carboplatin, a second generation anticancer drug, is effectively employed to treat ovarian 
cancer. While it exhibits fewer negative side effects than cisplatin and does not induce 
nephrotoxicity,19, 86, 87 carboplatin is cross-resistant with cisplatin.86, 88, 89 Oxaliplatin, a third 
generation anticancer drug, is used for treating colorectal and ovarian cancer; it shows no 
evidence of cross-resistance and demonstrates low levels of nephronic and haematological 
toxicity, however, it does induce significant neurotoxicity.19, 86 Other available second and 
third generation platinum chemotherapeutic drugs include: diammine[(hydroxy-κO)acetato(2-
)-κO]platinum(II) nedaplatin [4] (2nd generation), [1R,2R-2-(aminomethyl)cyclobutyl] 
methanamine-2-hydroxypropanoic acid platinum(II) lobaplatin [5] (3nd generation), and [SP-
4-2-[4R-(2a,4a,5b)]]-[2-(1-methylethyl)-1,3-dioxolane-4,5-dimethanamine-N,Nʹ][propanediol 
ato(2-)-O,Oʹ]-platinum(II) heptaplatin [6] (3nd generation) (Figure 1.8).90 Cisplatin efficacy 
has been narrowed to a small range of tumours because of primary intrinsic resistance, and the 
development of secondary resistance after initial treatment.91 Cisplatin resistance, both in 
vitro and in vivo, has been attributed to the loss of DNA mismatch repair and the reduction of 
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transport mechanisms due to of increased levels of glutathione (GSH) and metallothionein 
detoxification.91-95 
 
Figure 1.8 The structures of platinum anticancer agents used in therapy today. [4] nedaplatin, [5] heptaplatin, [6] 
lobaplatin. 
 
The mode of action involved in cisplatin-induced cytotoxicity is mediated by covalent 
adduct formation with DNA.96 Cisplatin, initially a neutral square-planar complex, reacts with 
DNA and activates several biological transduction pathways involving recognition proteins 
such as ATR, p53, p73, and MAPK, that culminate in the activation of apoptosis [7] (Figure 
1.9).96 In order for cisplatin to covalently interact with DNA, a series of aquation reactions 
occur by the replacement of cis-chloro ligands with water molecules to produce a charged 
molecule.95, 97 The cytotoxicity effects involve covalent binding with nucleophilic N7 purine 
bases of DNA, forming either DNA-protein or DNA-DNA inter- or intra-strand crosslinks [8 
and 9] (Figure 1.9).98 Evidence from both in vitro and in vivo studies suggests cisplatin 
favours the intra-strand adducts, primarily on adjacent guanosine residues.99, 100 Disruptions to 
the structure of DNA interfere with several cellular processes such as transcription and 
replication, therefore, after cell cycle arrest the platinum complex may be removed via 
nucleotide excision and may induce apoptosis.101 Complexes with different DNA binding 
modes such as intercalation, minor and major groove binding have the potential to succeed 
cisplatin as future chemotherapeutic agents. 
 
  




Figure 1.9 [7] shows the biological transduction pathway involved in mediating the cisplatin-induced 
cytotoxicity. Cell death or survival will vary depending on the intensity of cell signal generated and the crosstalk 
between cellular pathways.96 Cisplatin interaction with double stranded DNA forming intra-strand crosslink 
adducts [8] (1AIO) and inter-strand crosslink adducts [9] (1A2E) crosslinks. DNA images provided from 
PDB.101 
 
A potent example of a class of non-covalent binders are platinum(II) complexes of the 
type ([Pt(PL)(AL)]
2+, where PL = polyaromatic ligand, and AL = ancillary ligand).
102-109 These 
complexes are stable, relatively inert to substitution, and demonstrate a broad spectrum of 
cytotoxicity. Evidence suggests that complex activity can be modulated through different 
combinations of polyaromatics and, more profoundly, the ancillary ligand. Activity can also 
be influenced by changing the functional groups and substitution positions on a PL, such as 
1,10-phenanthroline (phen, [10], Figure 1.10), 5-methyl-1,10-phenanthroline [11] (5Mephen), 
or 5,6-dimethyl-1,10-phenanthroline [12] (56Me2phen), regardless of the AL.
106-108 The most 
active complex of this type is [(5,6-dimethyl-1,10-phenanthroline)(1S,2S-
diaminocyclohexane)platinum]2+ [10] (56MESS), which exhibits a ~100-fold increase in 
anticancer activity compared to cisplatin in murine leukaemia (L1210) cell lines. 56MESS 
also demonstrates excellent activity in other cisplatin-resistant cell lines,106 and it circumvents 
DNA repair through the regulation of several genes as demonstrated by experiments with 
Saccharomyces cerevisiae (S. cerevisiae, yeast).110 
A similar platinum(II) complex that is relatively inert to substitution and appears to 
exert its activity through physical interactions is [Pt(BDIQQ)]Cl [13] (Figure 1.10).68, 69 The 
N4-tetradentates comprising of β-diketiminate (BDI) and quinoline (BDI
QQH), produce a 
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square planar platinum(II) compound with cytotoxic activity and photo-luminescence upon 
DNA binding.70 The photophysical evidence suggests that this DNA interaction may induce 
[Pt(BDIQQ)]Cl cytotoxicity. These studies were conducted using calf-thymus DNA (CT-
DNA) in aqueous buffer via UV-Vis and emission spectroscopy.111 The planar cationic 
structure of the platinum complex would allow it to act as an intercalator. The large 
hyperchromic effects reported for [Pt(BDIQQ)]+ indicate that the complex preferentially 
aggregates in aqueous solution. However, in the presence of DNA, [Pt(BDIQQ)]+ disperses 
into single molecules that may intercalate between base pairs and cause DNA to unwind.112 
While the precise mode of DNA interaction remains unclear, [Pt(BDIQQ)]Cl has been reported 
to induce mitochondrial-mediated apoptosis due to its lipophilic and cationic properties, 
causing direct mitochondrial damage.112 [Pt(BDIQQ)]+ exhibits cytotoxicity effects, expressed 
as IC50 values, in human lung carcinoma (A549, 1.2 μM) and human cervical (HeLa, 2.8 μM) 
cell lines that are comparable to, or better than, cisplatin (A549:5.2 μM, HeLa:2.3 μM).70 
 
Figure 1.10 Platinum(II) complexes [Pt(PL)(AL)]2+, (where L1 is phen, L2 is 5Mephen and L3 is 56Me2phen), 
demonstrate a broad spectrum of cytotoxicity as a result of functional group and substitution position 
modulation. The chemical structure of platinum(II) complex coordinated to tetradentate ligand β-diketiminate 
(BDI) with quinolone (BDIQQH). 
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1.3.2 Copper anticancer and antibacterial complexes 
Considerable attention has been focused on copper complexes of phen, because these 
complexes have demonstrated higher biological activity than uncoordinated or non-substituted 
ligands. Phen and its derivatives are planar and are relatively rigid in structure, and when 
coordinated they demonstrate high binding affinity to DNA.113-115 Copper complexes are toxic 
towards cancer cell lines, bacteria, and fungi. Their mode of action may involve the 
interference of crucial cellular functions which include DNA replication/transcription, protein 
expression, oxidative stress, and respiration. Copper(II) complexes [Cu(PL)(AL)]
2+ (where PL 
is phen or derivative, AL is 1S,2S-diaminocyclohexane (SS-dach) or 1R,2R-
diaminocyclohexane (RR-dach)) have been investigated for antibacterial activity and exhibit 
excellent growth inhibition against S. aureus at concentrations as low as 2.5 μM in minimal 
inhibitory concentration (MIC) assays.114 Complexes [Cu(3478Me2phen)(SS-dach)](ClO4)2, 
[Cu(3478Me2phen)(RR-dach)](ClO4)2, [Cu(DIP)(SS-dach)](ClO4)2, and [Cu(DIP)(RR-
dach)](ClO4)2 (where 3478Me2phen = 3,4,7,8-tetramethyl-1,10-phenanthroline, DIP = 4,7-
diphenyl-1,10-phenanthroline) [14 and 15] (Figure 1.11), all exhibit high antimicrobial 
potential into MIC values between 1.25 – 2.5 μM against S. aureus compared to poor MIC 
values > 20 μM against E. coli, P. aeriginosa and S. cerevisiae.116 
 
Figure 1.11 Copper(II) antibacterial complexes [Cu(PL)(AL)]2+ (where L1 is 3478Me2phen, L2 is DIP and AL is 
1S,2S-diaminocyclohexane (SS-dach) or 1R,2R-diaminocyclohexane (RR-dach)) exhibit excellent growth 
inhibition against S. aureus. 
 
Complexes such as [Cu(N-(9H-purin-6-yl)benzenesulfonamine)(phen)2] act as 
efficient nucleases in the presence of a reducing agent (ascorbate), in addition to 
demonstrating high cytotoxicity.117 Complexes that contain an amino acid and phen, or its 
derivatives, have shown promising anticancer activity. For example, [Cu(phen)(L-
Thr)(H2O)](ClO4), (where L-Thr is L-threonine) [16] (Figure 1.12), has exhibited greater in 
vitro cytotoxicity towards human leukemia, with an IC50 of 10
-6 M (HL-60, 100%), and 
human gastric cells (SCG-7901, 91%), comparative to cisplatin (HL-60, 48.9% and SCG-790, 
50.5%).117 Copper(II) amino acid complexes have demonstrated useful anticancer properties, 
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as copper is a bio-essential element in trace amounts and amino acids are important entities in 
biological systems. The mono-positive copper(II) complexes are reported to be more 
lipophilic than corresponding di-cationic complexes, and exhibit improved cellular uptake and 
cytotoxicity. Copper(II) L-tyrosine (L-Tyr) complexes, [17] [Cu(L-Tyr)(phen)](ClO4), [18] 
[Cu(L-Tyr)(56Me2phen)](ClO4) and [19] [Cu(L-Tyr)(dpq)](ClO4) (where dpq = dipyrido[3,2-
d:2ʹ,3ʹ-f]quinoxaline) exhibit significant in vitro cytotoxicity towards human non-small lung 
cancer cell lines (NCL-H460, IC50 = 0.9 – 4.9 μM).
118 Other novel copper complexes are 
believed to induce cell death via apoptosis in cisplatin sensitive and resistant cell lines.117, 119-
121 
 
Figure 1.12 Copper(II) complexes [Cu(PL)(Amino-acid)(H2O)](ClO4), (where PL is phen, 56Me2phen and DPQ, 
amino-acid is threonine and thyrosine) [16 – 19], exhibit in vitro cytotoxicity towards human cell lines. 
 
Casiopeinas (Cas) are a mix of chelated copper(II) compounds that have reported anti-
proliferative activity against the human stromal neuroblastoma cell line (CHP-212).117, 122 The 
compounds studied included [Cu(47-Me2phen)(glycinato)(H2O)]NO3 [20] (Figure 1.13), 
[Cu(47Me2phen)(acetylacetonato)(H2O)]NO3 [21], and [Cu(4,4ʹ-Me2bipy)(glycinato)(H2O)] 
NO3 [22], (where 4,7-Me2phen = 4,7-dimethyl-1,10-phenanthroline and 4,4ʹ-Me2bipy = 4,4
ʹ-
dimethyl-2,2ʹ-bipyridine). The IC50 values range from 18 to 47 μM, with an increase of 
growth inhibition potency 5 to 12 times better than cisplatin (IC50 = 226.7 μM). 
Neuroblastoma (CHP-212) cell death is reported to occur via apoptosis.122 Manual docking 
experiments between DNA and [Cu(2,2ʹ-bipyridine)(acetylacetonato)(H2O)]NO3 suggests that 
the interaction with B-DNA is likely based on intercalation. 
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Figure 1.13 The casiopeinas family of copper(II) complexes [20] CasII-gly, [21] CasIII-Ea, and [22] CasIII-Ia. 
 
1.3.3 Iron anticancer and antibacterial complexes 
Iron complexes have demonstrated promising biological activity including antitumor activity 
and their use as organometallic cages for drug delivery. Nucleosides are of significant 
importance, as they make up the structural modules of nucleic acids, co-factors, and 
messenger substances in living systems. Organometallic iron complexes of nucleoside 
analogues appended to either a ferrocenyl or an ƞ4-butadiene-Fe(CO)3 group exhibit 
pronounced apoptotic activity against tumour cells.123, 124 Analogues that are appended to 
Fe(CO)3 were evaluated in vivo and in vitro against Burkitt-like lymphoma (BJAB) tumour 
cells and primary lymphoblasts from children with acute lymphoblastic leukemia (ALL).125 
The ferrocenyl nucleoside derivatives exhibited apoptosis inducing properties against BJAB 
tumour, and leukemia cells resistant to cytostatic drugs, such as complex [23] (Figure 1.14) 
(LD90 = 20 μM).
126 Complexes [24] and [25] have both shown significant apoptosis-inducing 
properties against BJAB and ALL in the low micromolar range (LD90 = 10 – 20 μM).
124 
Physical characteristics observed during cytotoxicity studies show changes to cell shape, 
nuclear envelope, cytoplasm condensation, and blebbing of the cancer cells, indicating 
apoptosis.124 
 
Figure 1.14 Iron(III) complexes have demonstrated promising anticancer activity. [23] nucleoside-Fe(CO)3, [24] 
and [25] ferrocenyl nucleosides. 
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DNA is also a target of interest for developing effective antibiotics. Iron triple 
helicates have been investigated for their antibacterial activity and to determine whether they 
potentially target DNA specifically. The antimicrobial activity of iron triple helicate [Fe2L]
3+ 
[26] (Figure 1.15) against B. subtilis and E. coli has demonstrated that B. subtilis is more 
susceptible to [26] than E. coli, with MIC values of 32 and 64 mg/L, respectively.127 The 
surviving fraction of B. subtilis treated with [26], determined the period of time required for 
treatment action. Complex [26], with an MIC value of 25 μM, was shown to completely 
eradicate B. subtilis within 2 mins. The lower concentrations of 5 and 15 μM were also 
investigated and revealed that killing efficiency increased with time, and that [26] therefore 
acted in a bactericidal manner.127 DNA interaction studies with isolated B. subtilis DNA has 
shown [26] binds in the major groove, causing DNA coiling that can be detected using 
spectroscopy methods. 
 
Figure 1.15 Iron triple helicate [26] demonstrates antibacterial activity and potential DNA targeting agent. 
 
The iron-bleomycin complex (FeBLM) exhibits anticancer activity by causing 
oxidative DNA damage.128, 129 Iron(II) complexes coordinated with pentadentate ligands have 
been reported to be stable in physiological conditions and exhibit cytotoxicity against a series 
of carcinoma cells.130 Complexes [27 – 29] (Figure 1.16) also exhibit cytotoxic activity (IC50 
= 0.13 – 68.5 μM) and are more potent than FeBLM against the human liver (HepG2) cancer 
cell line (IC50 = 5.4 μM) over a 5-day period.
131 The mechanism leading to HeLa cell death 
after treatment with complex [27] was thought to be via apoptosis. However, complex [27] 
has also been shown to induce the S-phase cycle arrest against HeLa cells through flow 
cytometry studies, which may indicate interruptions to the DNA replication mechanism. Both 
FeBLM and complex [27] form reactive oxygen species (ROS) such as O2 and H2O2 species, 
causing oxidative DNA damage and stress.131 Oxidative stress has been indicated by in vitro 
studies that measured the formation of florescent rhodamine-123+. DNA binding and cleavage 
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studies with supercoiled plasmid DNA (pCR 2.1) and iron complexes have shown the dose 
dependent formation of nicked DNA with complexes [27] and [28]. Complex [29], however, 
showed no DNA cleavage activity.130, 131  
 
 
Figure 1.16 Iron(II) complexes coordinated with pentapyridyl ligands [27 – 29] exhibit cytotoxicity against 
carcinoma cells. 
 
1.3.4 Cobalt anticancer and antibacterial complexes 
Various cobalt complexes have also been reported to exhibit promising anticancer activity.132-
134 Cobalt alkyne complexes exhibit high cytotoxicity in cancer cell lines, with the most active 
groups being the hexacarbonylcobalt complexes of the progarglyic ester of acetylsalicylic 
acid.133 The active derivative [(2-propy-1-yl)acetylsalicylate] hexacarbonylcobalt has shown 
high activity towards human breast cancer cells and is more active than cisplatin.135 Cobalt 
complexes of Schiff base ligands, such as N,Nʹ-ethylenebis(salicylimine) [30] (Figure 1.17), 
have also been reported to exhibit anticancer activity. These Co(III) complexes have shown 
high anti-proliferative activity against hormone sensitive, human mammary gland (MCF-7, 
IC50 > 10 μM), as well as hormone insensitive, human mammary gland (MDA-MB 231, IC50 
= 10 μM), cancer cells and human prostate (LNCaP/FGC, IC50 = 10 μM) cancer cells.
133 The 
cytotoxicity is dependent on either the type, but not position of the substituents on the 
aromatic rings, on addition to the 1,2-diaminoethane linker and its configuration. Cobalt(III) 
complexes containing a methoxy substituent and D or L bridge configuration are reported to 
be as active as cisplatin, but hydroxyl substituents or compounds with meso linking bridge 
configuration show no activity.133 Cobalt(II) complexes coordinated with a nitrogen mustard 
have demonstrated selectivity for hypoxic regions of cancer cells, such as hamster ovarian 
(AA8) and mouse mammary cells (EMT6).132 Cobalt complexes of marimastat that also 
contain the matrix metalloproteinase (MMP) inhibitor [31] (Figure 1.17) provide an inert 
scaffold that transports the inhibitor to be released upon bio-reduction. Cobalt(III) drugs have 
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shown more growth inhibition with mammary carcinomas in vivo than marimastat, and are 
therefore being investigated for the treatment of metastatic tumours.134  
 
Figure 1.17 These are the structures of cobalt complexes [30] [Co(salen)]+ and [31] [Co(marimastat)(tris-
(methylpyridyl)-amine)]+. 
 
Cobalt(II) complexes with the quinolone antimicrobial agent oxolinic acid (Hoxo) 
have also been investigated. Hoxo, a first generation quinolone antimicrobial agent, is used to 
treat urinary tract infection; as it acts as a DNA-gyrase (topoisomerase II) inhibitor (important 
for DNA replication/transcription).136 Cobalt also plays an important role in the active centre 
of vitamin B12, which is indirectly involved in the regulation of DNA synthesis.136 Cobalt(II) 
hoxo complexes [Co(oxo)2(bipy)].3MeOH [32], [Co(oxo)2(bipyam)] [33], [Co(oxo)2(phen)] 
[34], [Co(oxo)2(py)2] [35], and [Co(oxo)2(4bzpy)2] [36] (Figure 1.18) demonstrate inhibitory 
action against B. subtilis, E. coli and Xanthomonas campestris (X. campestris), with a MIC 
range of 1 – 2 μg mL-1, while S. aureus was resistant to cobalt(II) complexes with a MIC of > 
64 μg mL-1. Cobalt(II) complexes have therefore shown promising results for their potential 
as antibacterial agents. 
 
 
Figure 1.18 Cobalt(II) hoxo complexes [32] [Co(oxo)2(bipy)].3MeOH, [33] [Co(oxo)2(bipyam)], [34] 
[Co(oxo)2(phen)], [35] [Co(oxo)2(py)2], and [36] [Co(oxo)2(4bzpy)2] exhibit inhibitory action against a range of 
bacteria. 
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1.3.5 Ruthenium anticancer and antibacterial complexes 
The synthetic versatility, photophysical, and kinetic properties, and established cytotoxicites 
of ruthenium(II/III) complexes have seen them scrutinized extensively for their potential 
application as anticancer agents.137-139 The activities of RuII-polypyridal complexes were 
extensively investigated by Dwyer and co-workers in the 1950s for their potential 
antibacterial and cytotoxic properties.140-143 However, more recently, some ruthenium 
complexes have shown promise for the treatment of cancer, including, (ImH)[trans-
RuCl4(DMSO-S)(Im)] (where Im = imidazole, DMSO = dimethylsulfoxide) NAMI-A [37], 
trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) [38], and ruthenium(II) arene 
complexes [39] (Figure 1.19).23, 24, 26-28 Synthesized in the 1980’s, NAMI-A prevents 
metastasis, and unlike cisplatin, inhibits tumours in the advanced stages.67, 144 In addition, 
NAMI-A has been reported to be as effective as cisplatin in vivo when studying solid 
metastasizing tumours, including mouse MCa mammary carcinoma, adenocarcinoma cell 
lines, and Lewis lung carcinoma cell lines.144-146 Furthermore, NAMI-A exhibits reduced 
patient toxicity, is tolerated over a range of doses, and has successfully completed phase I 
clinical trials.23, 24, 147 However, in phase II clinical trials, combination therapy using NAMI-A 
and gemcitabine was conducted on patients with non-small cell lung carcinoma (NSCLC), but 
showed insufficient reduction of tumours and hence was deemed unsuitable for 
chemotherapy. In order to pass through phase II trials and progress, at least one patient needed 
to show partial remission. Unfortunately, no partial remission was observed with NAMI-A 
treatment.148 The mechanism by which NAMI-A exerts its biological effect is unknown; 
however, in vitro studies suggest that hydrolysis may occur via the loss of two chlorides.23  
 
Figure 1.19 Ruthenium(III) complexes that show some anticancer or antimetastatic activity. [37] NAMI-A, [38] 
KP1019 and [39] generic arene complex. 
 
KP1019 [38] successfully completed phase I clinical trials.25-27 Complex [38] is 
octahedral, containing N-donor imidazole ligands in the axial plane and four chlorides in the 
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equatorial plane. However, its poor solubility in water is due to the labile chlorides, 
constituting a problem.26, 149, 150 To overcome its poor solubility, KP1019 is instead 
synthesised as a sodium salt derivative, known as KP1339.149 Both KP1019 and KP1339 are 
well tolerated by patients, with limited side effects against colorectal tumour cells SW480 and 
HT29.151 KP1019 has successfully entered into the final stages of assessment as a 
chemotherapeutic for platinum-resistant colorectal tumours. The mechanism of action is still 
being investigated for its activities both in vivo and in vitro. [38], similarly to [37], undergoes 
aquation and hydrolysis via chloride substitution, as well as having stronger hydrophobicity 
from its N-indazole ligands. Its increased stability also promotes improved accumulation of 
[38] in cells over [37].143, 152-155 Both KP1019 and KP1339 induce cell apoptosis via intrinsic 
mitochondrial pathways and both also initiate the formation of ROS.156 KP1019 also interacts 
with DNA and serum proteins such as transferrin and albumin.157 
Ruthenium(II) arene half-sandwich or pseudo piano-stool complexes (Figure 1.20) 
have a unique structure compared to other octahedral Ru(II) complexes and they have also 
entered into clinical trials.29 Complexes with the general formula [RuII(ƞ6-arene)(X)(Y)(Z)] 
are water soluble and the metal ligand bonds are relatively inert under physiological 
conditions. The ligands that occupy the 3 pendant coordination sites control the stability and 
ligand-exchange kinetics of the complex, which depend on the number and lability of the 
ligands.29, 158-160 Studies with human ovarian cancer (A2780) have shown that the anticancer 
activity of the complex, [(η6-arene)Ru(en)(Cl)]+ [40], increases with arene size.158, 161 The 
class of complex effects its activity by targeting guanine bases of DNA and forming 
adducts.162, 163 Ruthenium(II)-arene analogues, such as [Ru(η6-cymene)(RAPTA)(Cl2)], 
showed high selectivity towards a TS/A adenocarcinoma cell line and also showed activity 
against secondary lung tumours in mice, however this complex hydrolyses quickly.164 Given 
that ruthenium complexes have broad spectrum activity against cancer cells and bacteria, it 
appears that this biological activity can be “tuned” through judicial choice of coordinating 
ligands. Organometallic anticancer ruthenium(II) arene complexes bearing a 4-
anilinoquinazoline pharmacophore induces cellular apoptosis, while maintaining the 
inhibitory activity of 4-anilinoquinazolines against epidermal growth factor receptor 
(EGFR).165 
Ruthenium(II) complexes [(η6-arene)-Ru(en)Cl][PF6] (en = ethylenediamine) [40], 
(Figure 1.20) and [(η6-arene)-Ru(pta)Cl2] (pta = 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]-
decane)) [41]28, 35, 36 both demonstrated in vitro and in vivo anticancer activity. Their cytotoxic 
activity indicated that the ruthenium(II) metal centre, and ligand, both appear to have 
cooperative roles in tuning the biological activity of the complexes.166-168 A range of 
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ruthenium(II) complexes have been synthesised through modifications of [(η6-arene)-
Ru(en)Cl][PF6] by attaching 4-anilinoquinazoline to the ‘en’ chelating ligand, which represent 
analogues of an EGFR inhibitor that have been used for the clinical treatment of locally 
advanced or metastatic non-small cell lung cancer (NSCLC).166, 169, 170 The activity of newly 
synthesised ruthenium(II) complexes (arene)RuII with 4-anilinoquinazoline have become an 
excellent EGFR inhibitor and have high binding affinity towards the CT-DNA minor 
groove.137 In vitro biological activity has been investigated to evaluate the anti-proliferation 
activities of ruthenium(II) complexes towards a human cervical cancer cell line (HeLa) in the 
presence or absence of growth factor (EGF). Results demonstrate that ruthenium(II) 
complexes can selectively inhibit the EGF-stimulated growth of HeLa cervical cancer, with 
the most active ruthenium(II) complex reported being [(η6-arene)Ru-(N,N-L13)Cl]PF6 (IC50 = 
1.36 μM, L13 = 4-(3ʹ-chloro-4ʹ-fluoroaniline)-6-(2-(2-aminoethyl)aminoethoxy)-7-
methoxyquinazoline) [42] (Figure 1.20). The addition of the L13 ligand makes [42] 29-fold 
more active than the analogous complex [(η6-arene)Ru(N,N-ethylenediamine)Cl]PF6.
137 
 
Figure 1.20 Ruthenium(II) arene complexes induce cellular apoptosis. [40] [(η6-arene)-Ru(en)Cl][PF6] (en = 
ethylenediamine), [41] [(η6-arene)-Ru(pta)Cl2] (pta = 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]-decane)), and [42] 
[(η6-arene)Ru-(N,N-L13)Cl]PF6 (L13 = 4-(3ʹ- chloro-4ʹ-fluoroaniline)-6-(2-(2-aminoethyl)aminoethoxy)-7-
methoxyquinazoline). 
 
Despite the development of a wide variety of ruthenium complexes, few have been 
reported to inhibit cellular enzymes or have direct anticancer and anti-metastatic activity. The 
limited anticancer activity of mononuclear and dinuclear ruthenium(II) complexes, however, 
does not inhibit their potential antimicrobial activity against both Gram-positive and negative 
bacteria.171 The complex, [Ru(2,9-Me2phen)2(dppz)]
2+ (2,9-Me2phen = 2,9-dimethyl-1,10-
phenanthroline; dppz = dipyrido-[3,2-a:2ʹ,3ʹ-c]phenazine) [43] (Figure 1.21),172, 173 was 
reported to be effective against methicillin-resistant S. aureus (MRSA). The dinuclear 
complex, [(µ-bis[4-(4ʹ-methyl-2,2ʹ-bipyridyl)]-1,n-alkane)]4+ [44] demonstrated cytotoxicity 
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against the bacterial cell strains S. aureus (0.6 µM) and E. coli (2.5 µM).174 Ruthenium 
complexes of this type may thus have the potential to be used as broad-spectrum antibiotics 
capable of working effectively against drug resistant strains.171  
Analogous complexes, like [Ru(phen)2(dppz)]
2+ [47] have been reported to bind to 
DNA strongly via the intercalative dppz ligand [46] (Figure 1.23).175-177 Examining DNA-
metal complex interactions has helped to develop an understanding of their binding 
behaviour. NMR binding experiments with the DNA sequence d(GTCGAC)2 and Δ-
[Ru(Me2phen)2(dppz)]
2+ showed that the complexes intercalated in the minor groove of DNA 
[45] (Figure 1.22).173, 178 With the use of molecular binding models and X-ray crystallography 
studies, the binding interaction of Δ-[Ru(Me2phen)2(dppz)]
2+ with DNA173 was recently 




Figure 1.21 Mononuclear ruthenium(II) complex [43] [Ru(2,9-Me2Phen)2dppz]2+ and dinuclear ruthenium(II) 
complex [44] [(Ru(phen)2)(µ-bis[4-(4ʹ-methyl-2,2ʹ-bipyridyl)]-1,n-alkane)]4+ tested for antimicrobial activity 
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Figure 1.23 X-ray crystal structure of the complex rac-[Ru(phen)2(dppz)]2+ intercalated with the DNA sequence 
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Ruthenium(II) N4-tetradentate (N4-TL) complexes have been developed as structural 
probes for DNA.83 Metals which coordinate N4-TLs, such as 1,6-di(2ʹ-pyridyl)2,5-diazahexane 
(picen), were first described by Goodwin and Lions in 1960.180 The structural versatility of 
N4-TLs have led to different geometric configurations formed when coordinated to octahedral 
metals, like ruthenium(II). These products include the trans (planar), dissymmetric (C2) cis-α, 
and the asymmetric (C1) cis-β forms. Derivatised N4-TLs, used to enhance stereoselective 
behaviour, were demonstrated with alkyl substitution on secondary amines, with this chemical 
moiety classified as a prime stereo-chemical determinant.80-82 Additionally, the choice of 
chiral precursors have been shown to influence the stereochemistry upon coordination to 
metals.181, 182 The degree of stereochemical control has not been demonstrated with 
ruthenium(II) complexes due to kinetic inertness forming intact isomeric products. 
Ruthenium(II) complexes of the general form racemic cis-α-[Ru(N4-tetradentate)(N2-
bidentate]Cl2, (where N4-tetradentate are 1,6-di(2ʹ-pyridyl)-2,5-dimethyl-2,5-diazahexane 
(picenMe2) or 1,6-di(2ʹ-pyridyl)-2,5-dibenzyl-2,5-diazahexane (picenBz2), and N2-bidentate 
ligands 2,2ʹ-bipyridine (bipy), 1,10-phenanthroline (phen), and dipyrido[3,2-f:2ʹ,3ʹ-
h]quinoxaline (dpq)), demonstrated DNA binding properties with calf-thymus DNA (CT-
DNA).82, 83, 183 The order of intercalating abilities of the bidentate ligands was dpq > phen > 
bipy. The surface area of these bidentate ligands and their binding affinity showed correlation 
with self-association studies. Interestingly, the coordinated N4-TLs demonstrated the less 
bulky N4-TL, picenMe2, increased the propensity to self-associate and bind strongly to DNA. 
This opens up a promising opportunity to investigate the biological properties of 
ruthenium(II) N4-tetradentate complexes. 
 
α  β 
 
Figure 1.24 Ruthenium(II) complexes of the general form racemic cis-α-[Ru(N4-tetradentate)(N2-bidentate]Cl2 
(where N4-tetradentate are picenMe2, picenBz2, and N2-bidentate ligands bipy, phen, and dpq demonstrated DNA 
binding properties with calf-thymus DNA (CT-DNA).  
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1.4 Project rationale and aims 
Cancer remains a growing problem in Australia and worldwide. Despite ongoing research, 
current treatments become less effective as a result of resistance and new clinical treatment 
options are therefore imperative. Metal based complexes present a novel avenue for 
innovative potential chemotherapeutics. Furthermore, these complexes can be explored as 
antimicrobial agents. Ruthenium(II) based complexes are of particular interest as they are 
versatile, stable and commonly bio-active. Advanced examples of ruthenium(II/III) 
complexes such as NAMI-A, KP1019, Ru(II)arene, and Ru(II/III) multidentate complexes 
suggests that further research in this field would be clearly advantageous. Ruthenium(II/III) 
multidentate ligands have great potential for the tuning of biological activity. Ligands play a 
significant role in coordination chemistry, both independently and when coordinated to 
transition metals. The study of multidentate ligands, such as the N4-tetradentate ligand (N4-
TLs), has contributed profoundly to the understanding of coordinated structures, the 
development of compounds displaying biological activity, and their influence on compound 
stereochemistry. This research focuses on synthetic techniques to expand the utility of N4-TLs; 
it includes the synthesis of N4-TLs, the coordination of N4-TLs and bidentate ligands to 
ruthenium(II), and assessment of their biological activity against cancer cells and bacteria. 
This research will produce new N4-TLs for coordination to metal centres. Details of the 
synthesis and characterisation of the N4-TLs and their ruthenium(II) complexes will be 
provided together with their cytotoxicity and antimicrobial activities against a panel of cancer 
and bacterial cells. 
In summary: 
Chapter 2: Synthesis and characterisation of N4-tetradentate ligands 
 Synthesis of N4-tetradentate ligands (N4-TLs) with varying length of diamine chain (2 
– 7)n carbons. Methylation techniques will be used to functionalise the secondary 
nitrogen. 
 Comprehensively characterise and verify the purity of all N4-TLs produced using 
techniques such as nuclear magnetic resonance spectroscopy (NMR), ultraviolet-
visible spectroscopy (UV-Vis), high performance liquid chromatography (HPLC), 
high resolution electrospray ionisation mass spectrometry (ESI-MS), and where 
appropriate, circular dichroism (CD). 
Chapter 3: Investigating the biological activity of synthesised N4-TLs against both cancer 
and bacterial cells 
 Assess the antimicrobial activity of N4-TLs against Gram-positive and negative 
bacteria, using replicate minimal inhibitory concentration assays (MIC)  
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 Assess the anticancer activity of N4-TLs as GI50 values against 10 – 12 cancer cell 
lines. 
Chapter 4: Synthesis and characterisation of coordinated ruthenium(II) complexes 
 Coordinate selected N4-TLs to ruthenium(II) to produce complexes of the form 
[Ru(N4-TL)(X)(Y)](PF6) (where X = dimethyl-sulfoxide (DMSO) and Y = chlorine). 
The intermediate Ru(II) N4-TL complexes will be then coordinated to phenanthroline 
based bidentate ligands to form [Ru(N4-TL)(bidentate)](PF6)2. 
 Comprehensively characterise and verify purity of Ru(II)-N4-TLs using techniques 
such as NMR, UV-Vis, HPLC, ESI-MS, and where appropriate CD. 
Chapter 5: Investigating the biological activity of ruthenium(II) complexes against both 
cancer and bacterial cells 
 Assess the antimicrobial activity of [Ru(N4-TL)(bidentate)](PF6)2 against Gram-
positive and negative bacteria using replicate minimal inhibitory concentration assays 
(MIC).  




Figure 1.25 Thesis plan, synthesising N4-tetradentate ligands and together with a bidentate ligand coordinate 
them to ruthenium(II), where the biological activity will be investigate against cancer and bacteria cells. 
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2. CHAPTER TWO: Synthesis and 
characterisation of N4-Tetradentate 
ligands (N4-TLs) with increasing 
polyamine chain and alkyl substitution 




N4-tetradentate ligands with achiral polyamine chain and chiral diamine were synthesised and 
methylated in a 4-step process, (1) Schiff-base formation, (2) hydrogenation, (3) methylation, 
and (4) benzylation (optional) forming achiral Schiff-base N4-TLs-1a – 12a, hydrogenated N4-
TLs-1 – 12, methylated N4-TLs-13 – 24, benzylated N4-TLs-25, and chiral Schiff-base N4-TLs-
26a – 29a, hydrogenated N4-TLs-26 – 29, and methylated N4-TLs-30 – 33. The synthesised 
N4-TLs were produced in moderate yields ranging 59 – 96%. Characterisation techniques 
including, 1D and 2D-NMR (1H, 13C, Dept, HMQC, and COSY), UV-Vis, and, where 
appropriate, MS and CD, successfully confirmed the identity and purity of the synthesised N4-
TLs.  
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2.1 Introduction 
Multidentate ligands are synthetically versatile and structurally flexible, making them ideal 
scaffolds for the coordination of metals or application in biological and medicinal chemistry. 
Multidentate ligands such as ethylenediaminetetraacetic acid (EDTA) and ethylenediamine-
N,Nʹ-disuccinic acid (EDDS) have been developed to exploit their influence on the stereo-
chemistries of metal complexes. Nitrogen based linear N4-tetradentate ligands (N4-TLs) such 
as N,Nʹ-bis(pyridylmethyl-1,2-diaminoethane) (picen), produce a diverse range of structural 
isomers that are dependent upon the coordinating transition metals (Figure 2.1).180 The stereo-
chemistries adopted by linear N4-TLs, such as picen, are due to torsional strains and steric 
constraints. When a N4-TL coordinates to an octahedral metal, it may adopt different stereo-
isomeric forms. These products include the trans (planar), dissymmetric (C2) cis-α, and the 
asymmetric (C1) cis-β forms. The stereo-selective behaviour of N4-TLs may be enhanced by 
the alkyl substitution of the inner secondary amine nitrogen atoms;81, 184 this chemical moiety 
is classified as a prime stereo-chemical determinant.80 The choice of N-substituents such as 
methyl and benzyl groups may also provide some control over coordination and result in 
stereo-selectivity (Figure 2.2).81, 185 Additionally, stereospecific coordination has been 
demonstrated with picen and vicinal substituents such as methyl, benzyl, and cyclohexane on 
the carbon backbone of the ligand. 
 
 
Figure 2.1 The variety of N-substituents and polyamines used to synthesise tetradentate ligands. 
 
Metals that coordinate N4-TLs, like picen, were first described by Goodwin and Lions 
in 1960.180 There has been an increased interest in synthesising and characterising 
multidentate ligands because of their usefulness as chelating agents. Transition metals, 
Fe(III),76, 77 Cu(II),74, 75 Co(III),78, 79 and Ru(II/III)81, 82 for example, form relatively stable 
complexes with N4-TLs. The type of complex formed, either cis-α or cis-β, is governed by the 
stereo-chemical requirements of the secondary amine nitrogen atom of N4-TL (Figure 2.2). 
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For example, the chirality of cobalt(III) complexes of N,Nʹ-bis(2ʹ-picolyl)-2,5-dimethyl-2,5-
diaminocyclohexane (picchxnMe2), was predetermined by the choice of diamine precursor, as 
R,R-diaminocyclohexane has been shown to adopt a largely cis-α-configuration.181, 182 The use 
of N4-TLs comprising of β-diketiminate (BDI) and quinolone (BDI
QQH) established a stable 
square planar (trans) photoluminescent platinum(II) complex, [Pt(BDIQQ)]Cl.68-70 This degree 
of stereo-chemical control has not been explored with ruthenium as its larger atomic size 
introduces greater strain on the coordinating N4-TL, and results in both α and β-isomers being 
produced in various ratios.82 
 
Figure 2.2 The possible stereo-chemistries formed upon coordination of N4-TLs with metals. 
 
In this chapter, synthetic strategies developed to deliver stereo-chemical specificity for 
the coordination of N4-TLs with ruthenium(II) complexes and improve their biological activity 
are discussed. The synthetic strategy chosen for these N4-TLs involved increasing the multi-
carbon diamine chain length and alkyl substitution on the secondary nitrogen. 
Characterisation techniques were used to provide  product verification and purity.  
  




Deuterated solvents chloroform (CDCl3), deuterium oxide (D2O) and dimethyl-sulfoxide 
(DMSO-d6), were purchased from Cambridge Isotope Laboratories. The ethyl-acetate, 
acetone, diethyl ether, chloroform, ethanol, methanol, and dichloromethane used as solvents 
were all analytical grade or higher and were obtained from Chem-Supply. 2-Pyridine-
carboxaldehyde, 6-methyl-2-pyridinecarboxaldehyde, sodium borohydride, was purchased 
from Sigma-Aldrich. The diamine bridges 1,2-diaminoethane, 1,3-diaminopropane, 1,4-
diaminobutane, 1,5-diaminopentane, 1,6-diaminohexane, 1,7-diaminoheptane, 1R,2R-
diaminocyclohexane and 1S,2S-diaminocyclohexane were all purchased from Chem-Supply. 
Formaldehyde and formic acid were obtained from VWR. Ruthenium(III) chloride (n) hydrate 
was purchased from Precious Metals Online. Potassium hexafluorophosphate was purchased 
from Sigma-Aldrich. Hydrochloric acid (32%), sodium hydroxide, and sodium sulphate were 
obtained from Merck. Purification of starting reagents, solvents, and synthesised products 
were not required. 
2.2.2 Instrumentation 
2.2.2.1 Nuclear Magnetic Resonance Spectroscopy (NMR) 
NMR spectra were obtained on a 400 MHz Bruker Avance Nuclear magnetic resonance 
spectrometer. Deuterated solvents DMSO-d6, chloroform CDCl3, and D2O, (500 μL) were 
used to characterise the tetradentate ligands (N4-TLs) and metal complexes. The probe 
temperature was maintained at 35 ˚C for DMSO-d6 and 25 ˚C for CDCl3 and D2O solubilised 
samples. One-dimensional 1H spectra were obtained using a spectral width of 20 ppm and 256 
accumulations. 13C spectra were obtained using a spectral width of 220 ppm and 1024 
accumulations. 1H-13C HMQC spectra were obtained with a spectral width of 185 ppm and 
128 data points for 13C (F1-dimension), and a 
1H (F2-dimension) spectral width of 10 ppm and 
1024 data points. 1H-1H COSY spectral data were acquired using a spectral width of 8 ppm, 
256 data points in the F1-dimension, and 2048 data points in the F2-dimension for analysing 
1H-1H correlation. The abbreviations applied to spin multiplicity are: s (singlet), d (doublet), t 
(triplet), and m (multiplet). 
2.2.2.2 Ultra-violet/Visible Absorption Spectroscopy (UV-Vis) 
UV-Vis absorption spectra were recorded on a Cary 1E spectrophotometer at 25 ˚C in the 
range of 200 – 800 nm using a 1 cm quartz cell. A scan rate of 600 nm/min, data interval of  
1 nm and average scan time of 0.1 s was used. Samples were corrected for solvent baseline 
with either chloroform or DMSO and made up to a volume of 1.5 mL to form concentrations 
ranging from ~ 5 to 12 mM. The prepared sample stock solutions were titrated into 3 mL of 
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initial reference solvent to produce spectra with increasing concentrations. Complex 
concentration was plotted verses absorbance to determine the extinction coefficient (ε) of each 
complex. 
2.2.2.3 Mass Spectrometry (MS) 
Mass spectra were obtained on a Waters Xeno TQ MS detector. These experiments were 
performed by the Western Sydney University Mass Spectrometry facility. Samples were 
prepared in trace amounts in a solution of either ethanol or methanol. Each sample was 
injected with a cone voltage of 30 V, and desolvation temperature of 500 °C. The results were 
obtained with an m/z ratio ranging from 100 – 2000. 
2.2.2.4 High Performance Liquid Chromatography Analysis (HPLC) 
High performance liquid chromatography (HPLC) was performed using an Agilent 
Technologies 1260 Infinity HPLC, using a Phenomenex column (C18 150 × 4.6 mm column, 
5 μm pore size). The mobile phase consisted of solvent A, 0.06 % TFA in water, and solvent 
B, 0.06 % TFA in CH3CN:H2O (90:10). In each experiment absorbance traces were acquired 
at a flow rate of 1 mL/min, injection volume of 10 μL, gradient 0 – 10 and 0 – 40 (%B) over 
15 min, with a detection wavelength of 254 nm. 
2.2.2.5 Circular Dichroism (CD) 
CD spectra were recorded in water at room temperature from 200 – 300 nm using a Jasco J-
810 CD spectropolarimeter with nitrogen gas flow at 6 L min-1. The instrument was calibrated 
prior to use with ammonium d-10-camphor sulfonate 0.01% w/v (λmax = 291.5 nm). 20 
accumulations were obtained per sample using a 1 cm cylindrical quartz cuvette. A scan speed 
of 100 nm min-1 was used with a response of 1 s, spectral bandwidth of 1 nm. A water 
baseline was subtracted from each sample. 
2.2.2.6 Lipophilicity (Log P) 
The Log P values were obtained using Chem-draw (Professional, Version 17.1.0.105.(19)) 
using predicted atom-based calculations of partition coefficient to determine lipophilicity.186, 
187 
2.3 Synthesis of N4-tetradentate ligands (N4-TLs) 
2.3.1 General method for the synthesis of N4-TLs such as N,Nʹ-bis(2-pyridylmethyl)-1,2-
diaminoethane (picen, N4-TL-1) 
A solution of 2-pyridinecarboxaldehyde (2.145 g, 20 mmol) dissolved in ethyl acetate (20 
mL) was added to a solution of 1,2-diaminoethane (0.60 g, 10 mmol) in ethyl acetate (60 
mL); this mixture was left stirring for 30 min. The ethyl acetate was evaporated to produce the 
diimine N4-TL. The diimine N4-TL was reduced by the addition of methanol (80 mL) and 
NaBH4 (1:5, 2.15 g) and the mixture was left stirring overnight at 25 ˚C. Methanol was 
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removed under reduced pressure and the remaining residue dissolved in water (50 mL). The 
mixture was extracted several times with chloroform (5 × 30 mL); the organic phases were 
combined and dried with Na2SO4. The product was filtered, and chloroform was evaporated 
under vacuum to obtain a yellow oil of N4-TL-1. Yield: 2.28 g (94%). Picen (N4-TL-1) 
1H-
NMR (400 MHz, D2O) δ: 8.56 (d, 2H, J1 = 4.56 Hz, H11), 7.94 (t, 2H, J1 = 7.74 Hz, H13), 
7.50 (d, 2H, J1 = 7.88 Hz, H14), 7.45 (m, 2H, H12), 3.93 (s, 4H, H16a/b), 2.81 (s, 4H, H1a/b). 
13C-NMR (400 MHz, D2O) δ: 158.03 (C15), 148.55 (C11), 138.30 (C13), 123.28 (C12), 
123.05 (C14), 53.34 (C16), 47.15 (C1). ESI-MS (MeOH, m/z): calculated (m/z): 242.33, 
found (m/z): 243.41. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, CHCl3): 262 (7.7 ± 0.3 × 10
3). RP-
HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 0-40 % B over 15 min, tR 6.68 min at 254 nm. 
 
Scheme 2.1 Methodology to synthesis Schiff-base and hydrogenated N4-TLs. 
 
2.4 The synthesis of N4-TLs of increasing carbon chain length (N4-TLs 2 – 6) 
The method used to synthesise N4-TLs using diamines of increasing carbon chain length (3 – 
7) followed the procedure detailed in Section 2.3.1 with one modification. Depending on the 
chain length required, 1,3-diaminopropane (0.74 g, 10 mmol), 1,4-diaminobutane (0.88 g, 10 
mmol), 1,5-diaminopentane (1.02 g, 10 mmol), 1.6-diaminohexane (1.16 g, 10 mmol), or 1,7-
diaminoheptane (1.30 g, 10 mmol), was used instead of 1,2-diaminoethane. Yellow or light 
brown oily products were obtained.  
2.4.1 N,Nʹ-bis(2-pyridylmethyl)-1,3-diaminopropane (picpn, N4-TL-2) 
Yield: 2.23 g (87%). Picpn (N4-TL-2) 
1H-NMR (400 MHz, 
D2O) δ: 8.56 (d, 2H, J1 = 4.56 Hz, H11), 7.94 (t, 2H, J1 = 7.74 
Hz, H13), 7.50 (d, 2H, J1 = 7.88 Hz, H14), 7.45 (m, 2H, H12), 
3.93 (s, 4H, H16a/b), 2.70 (t, 4H, J1 = 7.24 Hz, H1a/b, 2a/b), 
1.80 (m, 2H, H17a/b). 13C-NMR (400 MHz, D2O) δ: 158.06 (C15), 148.52 (C11), 138.27 
(C13), 123.28 (C12), 123.01 (C14), 53.32 (C16), 46.08 (C1/2), 28.40 (C17). ESI-MS (MeOH, 
m/z): Calculated (m/z): 256.35, found (m/z): 257.40. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, 
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CHCl3): 262 (6.5 ± 0.9 × 10
3). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 0-40 % B 
over 15 min, tR 6.79 min at 254 nm. 
2.4.2 N,Nʹ-bis(2-pyridylmethyl)-1,4-diaminobutane (picbn, N4-TL-3) 
Yield: 2.57 g (95%). Picbn (N4-TL-3) 
1H-NMR (400 MHz, 
D2O) δ: 8.56 (d, 2H, J1 = 4.56 Hz, H11), 7.94 (t, 2H, J1 = 
7.74 Hz, H13), 7.50 (d, 2H, J1 = 7.88 Hz, H14), 7.45 (m, 2H, 
H12), 3.93 (s, 4H, H16a/b), 2.64 (m, 4H, H1a/b, 2a/b), 1.59 
(m, 4H, H17a/b, 18a/b). 13C-NMR (400 MHz, D2O) δ: 
158.18 (C15), 148.50 (C11), 138.25 (C13), 123.28 (C12), 
122.98 (C14), 53.32 (C16), 47.74 (C1/2), 26.32 (C17/18). ESI-MS (MeOH, m/z): Calculated 
(m/z): 270.38, found (m/z): 271.40. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, CHCl3): 262 (7.0 ± 
0.6 × 103). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 0-40 % B over 15 min, tR 7.09 
min at 254 nm. 
2.4.3 N,Nʹ-bis(2-pyridylmethyl)-1,5-diaminopentane (picptn, N4-TL-4) 
Yield: 2.46 g (87%). Picptn (N4-TL-4) 
1H-NMR (400 
MHz, D2O) δ: 8.56 (d, 2H, J1 = 4.76 Hz, H11), 7.94 (t, 
2H, J1 = 7.68 Hz, H13), 7.52 (d, 2H, J1 = 7.72 Hz, H14), 
7.45 (m, 2H, H12), 3.91 (s, 4H, H16a/b), 2.63 (m, 4H, 
H1a/b, 2a/b), 1.56 (m, 4H, H17a/b, 18a/b), 1.38 (m, 2H, H19a/b). 13C-NMR (400 MHz, D2O) 
δ: 158.34 (C15), 148.48 (C11), 138.23 (C13), 123.27 (C12), 122.95 (C14), 53.36 (C16), 47.88 
(C1/2), 28.35 (C17/18), 24.20 (C19). ESI-MS (MeOH, m/z): Calculated (m/z): 284.41, found 
(m/z): 285.46. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, CHCl3): 262 (6.4 ± 0.6 × 10
3). RP-HPLC 
Phenomenex C18 5 μm 150 × 4.6 mm, 0-40 % B over 15 min, tR 7.63 min at 254 nm. 
2.4.4 N,Nʹ-bis(2-pyridylmethyl)-1,6-diaminohexane (pichex, N4-TL-5) 
Yield: 2.69 g (90%). Pichex (N4-TL-5) 
1H-NMR (400 
MHz, D2O) δ: 8.56 (d, 2H, J1 = 4.56 Hz, H11), 7.94 
(t, 2H, J1 = 7.74 Hz, H13), 7.52 (d, 2H, J1 = 7.88 Hz, 
H14), 7.45 (m, 2H, H12), 3.92 (s, 4H, H16a/b), 2.62 
(t, 4H, J1 = 7.24 Hz, H1a/b, 2a/b), 1.55 (m, 4H, 
H17a/b, 18a/b), 1.35 (m, 4H, H19a/b, 20a/b). 13C-
NMR (400 MHz, D2O) δ: 158.33 (C15), 148.49 (C11), 138.23 (C13), 123.29 (C12), 123.96 
(C14), 53.34 (C16), 47.86 (C1/2), 28.36 (C17/18), 26.18 (C19/20). ESI-MS (MeOH, m/z): 
Calculated (m/z): 298.43, found (m/z): 299.46. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, CHCl3): 
262 (6.5 ± 0.1 × 103). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 0-40 % B over 15 
min, tR 8.35 min at 254 nm. 
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2.4.5 N,Nʹ-bis(2-pyridylmethyl)-1,7-diaminoheptane (pichpn, N4-TL-6) 
Yield: 2.72 g (87%). Pichpn (N4-TL-6) 
1H-NMR 
(400 MHz, D2O) δ: 8.56 (d, 2H, J1 = 4.32 Hz, H11), 
7.94 (t, 2H, J1 = 7.72 Hz, H13), 7.52 (d, 2H, J1 = 
7.88 Hz, H14), 7.45 (m, 2H, H12), 3.93 (s, 4H, 
H16a/b), 2.63 (t, 4H, J1 = 7.24 Hz, H1a/b, 2a/b), 1.55 (m, 4H, H17a/b, 18a/b), 1.33 (m, 6H, 
H19a/b, 20a/b, 27a/b). 13C-NMR (400 MHz, D2O) δ: 158.33 (C15), 148.51 (C11), 138.23 
(C13), 123.29 (C12), 123.96 (C14), 53.34 (C16), 47.89 (C1/2), 28.39 (C17/18), 26.29 
(C19/20/27). ESI-MS (MeOH, m/z): Calculated (m/z): 312.46, found (m/z): 313.45. UV-Vis 
λmax nm (ε mol
-1 dm-3 cm-1, CHCl3): 262 (7.8 ± 0.9 × 10
3). RP-HPLC Phenomenex C18 5 μm 
150 × 4.6 mm, 0-40 % B over 15 min, tR 9.23 min at 254 nm. 
2.5 The synthesis of N4-TLs with methyl substitution and increasing carbon chain length 
(N4-TLs 7 – 12) 
2.5.1 Synthesis of N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,2-diaminoethane (Me2picen, N4-
TL-7) 
The method used to synthesise Me2picen followed the 
procedure detailed in Section 2.3.1 with one modification, 6-
methyl-2-pyridinecarboxaldehyde (2.145 g, 17 mmol) was used 
instead of 2-pyridinecarboxaldehyde. A light brown oily N4-TL-
7 was obtained. Yield: 2.56 g (95%). Me2picen (N4-TL-7) 
1H-
NMR (400 MHz, D2O) δ: 7.81 (t, 2H, J1 = 7.72 Hz, H13), 7.30 
(d, 4H, J1 = 7.76 Hz, H14/12), 3.87 (s, 4H, H16a/b), 2.80 (s, 4H, H1a/b), 2.58 (s, 6H, CH3-
py). 13C-NMR (400 MHz, D2O) δ: 158.06 (C15), 157.51 (C11), 138.42 (C13), 122.65 (C12), 
120.10 (C14), 53.29 (C16), 47.08 (C1), 22.84 (CH3-py). ESI-MS (MeOH, m/z): Calculated 
(m/z): 270.38, found (m/z): 271.40. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, CHCl3): 266 (8.3 ± 
0.2 × 103). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 0-40 % B over 15 min, tR 8.08 
min at 254 nm. 
2.5.2 N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,3-diaminopropane (Me2picpn, N4-TL-8) 
Yield: 2.65 g (93%). Me2picpn (N4-TL-8) 
1H-NMR (400 
MHz, D2O) δ: 7.80 (t, 2H, J1 = 7.72 Hz, H13), 7.29 (d, 4H, 
J1 = 7.76 Hz, H14/12), 3.86 (s, 4H, H16a/b), 2.69 (t, 4H, J1 
= 7.28 Hz H1a/b, 2a/b), 2.57 (s, 6H, CH3-py), 1.79 (m, 2H, 
H17a/b). 13C-NMR (400 MHz, D2O) δ: 158.06 (C15), 157.51 (C11), 138.41 (C13), 122.61 
(C12), 120.10 (C14), 53.29 (C16), 46.01 (C1/2), 28.32 (C17), 22.54 (CH3-py). ESI-MS 
(MeOH, m/z): Calculated (m/z): 284.41, found (m/z): 285.46. UV-Vis λmax nm (ε mol
-1 dm-3 
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cm-1, CHCl3): 266 (8.5 ± 0.2 × 10
3). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 0-40 % 
B over 15 min, tR 8.16 min at 254 nm. 
2.5.3 N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,4-diaminobutane (Me2picbn, N4-TL-9) 
Yield: 2.60 g (87%). Me2picbn (N4-TL-9) 
1H-NMR (400 
MHz, D2O) δ: 7.80 (t, 2H, J1 = 7.72 Hz, H13), 7.28 (d, 
4H, J1 = 7.76 Hz, H14/12), 3.86 (s, 4H, H16a/b), 2.60 (m, 
4H, H1a/b), 2.57 (s, 6H, CH3-py), 1.59 (m, 4H, H17a/b). 
13C-NMR (400 MHz, D2O) δ: 158.02 (C15), 157.61 
(C11), 138.38 (C13), 122.59 (C12), 120.10 (C14), 53.28 
(C16), 47.60 (C1/2), 26.26 (C17/18), 22.84 (CH3-py). 
ESI-MS (MeOH, m/z): Calculated (m/z): 298.43, found (m/z): 299.45. UV-Vis λmax nm (ε mol
-
1 dm-3 cm-1, CHCl3): 266 (7.9 ± 0.3 × 10
3). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 
0-40 % B over 15 min, tR 8.19 min at 254 nm. 
2.5.4 N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,5-diaminopentane (Me2picptn, N4-TL-10) 
Yield: 2.70 g (86%). Me2picptn (N4-TL-10) 
1H-NMR 
(400 MHz, D2O) δ: 7.80 (t, 2H, J1 = 7.76 Hz, H13), 7.29 
(t, 4H, J1 = 7.76 Hz, H14/12), 3.85 (s, 4H, H16a/b), 2.61 
(m, 4H, H1a/b, 2a/b), 2.57 (s, 6H, CH3-py), 1.54 (m, 
4H, H17a/b, 18a/b), 1.37 (m, 2H, H19a/b, 20a/b). 13C-NMR (400 MHz, D2O) δ: 158.01 
(C15), 157.84 (C11), 138.37 (C13), 122.54 (C12), 120.10 (C14), 53.35 (C16), 47.80 (C1/2), 
28.33 (C17/18), 24.16 (C19), 22.85 (CH3-py). ESI-MS (MeOH, m/z): Calculated (m/z): 
312.46, found (m/z): 313.45. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, CHCl3): 266 (9.7 ± 0.1 × 
103). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 0-40 % B over 15 min, tR 8.56 min at 
254 nm. 
2.5.5 N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,6-diaminohexane (Me2pichex, N4-TL-11) 
Yield: 2.82 g (86%). Me2pichxn (N4-TL-11) 
1H-NMR 
(400 MHz, D2O) δ: 7.79 (t, 2H, J1 = 7.72 Hz, H13), 
7.28 (t, 4H, J1 = 8.56 Hz, H14/12), 3.85 (s, 4H, 
H16a/b), 2.66 (m, 4H, Hz H1a/b, 2a/b), 2.57 (s, 6H, 
CH3-py), 1.53 (m, 4H, H17a/b, 18a/b), 1.31 (m, 4H, 
H19a/b, 20a/b). 13C-NMR (400 MHz, D2O) δ: 158.02 
(C15), 157.75 (C11), 138.34 (C13), 122.55 (C12), 
120.13 (C14), 53.29 (C16), 47.71 (C1/2), 28.32 (C17/18), 26.10 (C19/20), 22.86 (CH3-py). 
ESI-MS (MeOH, m/z): Calculated (m/z): 326.49, found (m/z): 327.45. UV-Vis λmax nm (ε mol
-
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1 dm-3 cm-1, CHCl3): 266 (9.1 ± 0.9 × 10
3). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 
0-40 % B over 15 min, tR 9.14 min at 254 nm. 
2.5.6 N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,7-diaminoheptane (Me2pichpn, N4-TL-12) 
Yield: 2.95 g (86%). Me2pichpn (N4-TL-12) 
1H-
NMR (400 MHz, D2O) δ: 7.80 (t, 2H, J1 = 7.64 Hz, 
H13), 7.31 (m, 4H, H14/12), 3.85 (s, 4H, H16a/b), 
2.60 (m, 4H, H1a/b, 2a/b), 2.57 (s, 6H, CH3-py), 
1.54 (m, 4H, H17a/b, 18a/b), 1.39 (m, 6H, H19a/b, 
20a/b, 27a/b). 13C-NMR (400 MHz, D2O) δ: 158.02 (C15), 157.40 (C11), 138.36 (C13), 
122.54 (C12), 120.14 (C14), 53.33 (C16), 47.72 (C1/2), 28.36 (C17/18), 26.10 (C19/20/27), 
22.86 (CH3-py). ESI-MS (MeOH, m/z): Calculated (m/z): 340.51, found (m/z): 341.51. UV-
Vis λmax nm (ε mol
-1 dm-3 cm-1, CHCl3): 266 (8.1 ± 0.2 × 10
3). RP-HPLC Phenomenex C18 5 
μm 150 × 4.6 mm, 0-40 % B over 15 min, tR 9.91 min at 254 nm. 
2.6 N-Methylation of N4-tetradentate ligands (N4-TLs 13 - 18) 
2.6.1 Synthesis of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,2-diaminoethane 
(picenMe2, N4-TL-13) 
Methylation of picen (N4-TL-1) and Me2picen (N4-TL-7) was 
achieved using the published method of Goldsmith et al.76 A 
mixture of picen, N4-TL-1 (0.277 g, 1.02 mmol), 
formaldehyde (0.190 g, 6.33 mmol) and formic acid (0.730 
g, 16.0 mmol) was stirred and refluxed at 85 ˚C for 3 days. 
The mixture was left to cool to room temperature, and then the pH was increased to pH 12 
with 1 M KOH. The methylated product was extracted with chloroform (3 × 20 mL) and dried 
over Na2SO4. The extract was filtered, and the chloroform was evaporated under reduced 
pressure to yield product as a viscous brown oil. Yield: 0.26 g (96%). picenMe2 (N4-TL-13) 
1H-NMR (400 MHz, CDCl3) δ: 8.58 (d, 2H, J1 = 4.20 Hz, H11), 7.71 (t, 2H, J1 = 8.00 Hz, 
H13), 7.56 (d, 2H, J1 = 7.76 Hz, H14), 7.24 (m, 2H, H12), 4.00 (s, 4H, H16a/b), 3.04 (s, 4H, 
H1a/b), 2.50 (s, 6H, N-CH3). 
13C-NMR (400 MHz, CDCl3) δ: 149.34 (C11), 136.96 (C13), 
124.23 (C14), 122.86 (C12), 62.35 (C16), 53.58 (C1), 42.12 (N-CH3). ESI-MS (MeOH, m/z): 
Calculated (m/z): 270.38, found (m/z): 271.40. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, CHCl3): 
262 (6.4 ± 0.1 × 103). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 0-40 % B over 15 
min, tR 7.22 min at 254 nm. 
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2.6.2 N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,3-diaminopropane (picpnMe2, N4-TL-
14) 
Yield: 0.27 g (93%). picpnMe2 (N4-TL-14) 
1H-NMR (400 
MHz, CDCl3) δ: 7.53 (t, 2H, J1 = 7.68 Hz, H13), 7.25 (d, 
2H, J1 = 7.64 Hz, H14), 7.03 (d, 2H, J1 = 7.52 Hz, H12), 
3.71 (s, 4H, H16a/b), 2.80 (m, 4H, H1a/b, 2a/b), 2.53 (s, 
6H, CH3-py), 2.33 (s, 6H, N-CH3), 1.88 (m, 2H, H17a/b). 
13C-NMR (400 MHz, CDCl3) δ: 
157.75 (C11/15), 136.72 (C13), 121.71 (C12), 120.26 (C14), 63.48 (C16), 55.53 (C1), 42.46 
(N-CH3), 24.45 (CH3-py/C17). ESI-MS (MeOH, m/z): Calculated (m/z): 284.41, found (m/z): 
284.46. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, CHCl3): 266 (6.3 ± 0.3 × 10
3). RP-HPLC 
Phenomenex C18 5 μm 150 × 4.6 mm, 0-40 % B over 15 min, tR 7.43 min at 254 nm. 
2.6.3 N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,4-diaminobutane (picbnMe2, N4-TL-15) 
Yield: 0.25 g (83%). picbnMe2 N4-TL-15) 
1H-NMR (400 
MHz, CDCl3) δ: 7.56 (t, 2H, J1 = 7.64 Hz, H13), 7.29 (d, 
2H, J1 = 8.64 Hz, H14), 7.04 (d, 2H, J1 = 7.60 Hz, H12), 
3.70 (s, 4H, H16a/b), 2.54 (s, 6H, CH3-py), 2.52 (m, 4H, 
H1a/b, 2a/b), 2.32 (s, 6H, N-CH3), 1.62 (m, 4H, H17a/b, 
18a/b). 13C-NMR (400 MHz, CDCl3) δ: 157.75 (C11/15), 
136.75 (C13), 121.71 (C12), 120.32 (C14), 63.45 (C16), 57.27 (C1/2), 42.17 (N-CH3), 24.47 
(C17/18), 24.47 (py-CH3). ESI-MS (MeOH, m/z): Calculated (m/z): 298.43, found (m/z): 
299.46. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, CHCl3): 266 (3.7 ± 0.08 × 10
3). RP-HPLC 
Phenomenex C18 5 μm 150 × 4.6 mm, 0-40 % B over 15 min, tR 7.71 min at 254 nm. 
2.6.4 N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,5-diaminopentane (picptnMe2, N4-TL-
16) 
Yield: 0.26 g (85%). picptnMe2 (N4-TL-16) 
1H-NMR 
(400 MHz, CDCl3) δ: 7.56 (t, 2H, J1 = 7.68 Hz, H13), 
7.31 (d, 2H, J1 = 7.72 Hz, H14), 7.05 (d, 2H, J1 = 7.60 
Hz, H12), 3.71 (s, 4H, H16a/b), 2.55 (s, 6H, CH3-py), 
2.51 (m, 4H, H1a/b, 2a/b), 2.33 (s, 6H, N-CH3), 1.60 (m, 4H, H17a/b, 18a/b), 1.35 (m, 2H, 
H19a/b). 13C-NMR (400 MHz, CDCl3) δ: 157.78 (C11/15), 136.76 (C13), 121.77 (C12), 
120.38 (C14), 63.39 (C16), 57.40 (C1/2), 42.15 (N-CH3), 26.68 (C17/18), 25.02 (C19), 24.48 
(py-CH3). ESI-MS (MeOH, m/z): Calculated (m/z): 312.46, found (m/z): 313.45. UV-Vis λmax 
nm (ε mol-1 dm-3 cm-1, CHCl3): 266 (6.4 ± 0.04 × 10
3). RP-HPLC Phenomenex C18 5 μm 150 
× 4.6 mm, 0-40 % B over 15 min, tR 8.24 min at 254 nm. 
71 | P a g e  
 
2.6.5 N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,6-diaminohexane (pichexMe2, N4-TL-
17) 
Yield: 0.25 g (76%). pichexMe2 (N4-TL-17) 
1H-NMR 
(400 MHz, CDCl3) δ: 7.55 (t, 2H, J1 = 7.64 Hz, H13), 
7.27 (d, 2H, J1 = 8.40 Hz, H14), 7.03 (d, 2H, J1 = 7.56 
Hz, H12), 3.66 (s, 4H, H16a/b), 2.55 (s, 6H, CH3-py), 
2.45 (m, 4H, H1a/b, 2a/b), 2.29 (s, 6H, N-CH3), 1.55 
(m, 4H, H17a/b, 18a/b), 1.33 (m, 4H, H19a/b, 20a/b). 
13C-NMR (400 MHz, CDCl3) δ: 157.64 (C11/15), 136.65 (C13), 121.51 (C12), 120.07 (C14), 
63.79 (C16), 57.71 (C1/2), 42.40 (N-CH3), 27.29 (C17/18), 27.12 (C19/20), 24.48 (py-CH3). 
ESI-MS (MeOH, m/z): Calculated (m/z): 326.49, found (m/z): 327.45. UV-Vis λmax nm (ε mol
-
1 dm-3 cm-1, CHCl3): 266 (5.7 ± 0.2 × 10
3). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 
0-40 % B over 15 min, tR 8.94 min at 254 nm.  
2.6.7 N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,7-diaminoheptane (pichpnMe2, N4-TL-
18) 
Yield: 0.26 g (76%). pichpnMe2 (N4-TL-18) 
1H-
NMR (400 MHz, CDCl3) δ: 7.57 (t, 2H, J1 = 7.68 
Hz, H13), 7.31 (d, 2H, J1 = 7.68 Hz, H14), 7.05 (d, 
2H, J1 = 7.60 Hz, H12), 3.71 (s, 4H, H16a/b), 2.55 
(s, 6H, CH3-py), 2.50 (m, 4H, H1a/b, 2a/b), 2.33 (s, 6H, N-CH3), 1.57 (m, 4H, H17a/b, 
18a/b), 1.31 (m, 6H, H19a/b, 20a/b, 27a/b). 13C-NMR (400 MHz, CDCl3) δ: 157.75 (C11/15), 
136.74 (C13), 121.71 (C12), 120.32 (C14), 63.45 (C16), 57.58 (C1/2), 42.21 (N-CH3), 29.33 
(C19/20/27), 27.27 (C17/18), 24.48 (py-CH3). ESI-MS (MeOH, m/z): Calculated (m/z): 
340.51, found (m/z): 341.51. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, CHCl3): 266 (6.4 ± 0.2 × 
103). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 0-40 % B over 15 min, tR 9.82 min at 
254 nm. 
2.7 N-methylation of N4-TLs with methyl substitution and increasing carbon chain length 
(N4-TLs 19 – 24) 
2.7.1 Synthesis of N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,2-diaminoethane 
(Me2picenMe2, N4-TL-19) 
The method used to synthesise Me2picenMe2 followed the 
same procedure as detailed in Section 2.6.1, but instead used 
N,Nʹ-bis(6-methyl-2-pyridinylmethyl)-1,2-diaminoethane 
(Me2picen, N4-TL-7) (0.276 g, 1.02 mmol). Yield: 0.24 g 
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(80%). Me2picenMe2 (N4-TL-19) 
1H-NMR (400 MHz, CDCl3) δ: 7.56 (t, 2H, J1 = 7.64 Hz, 
H13), 7.30 (d, 2H, J1 = 7.64 Hz, H14), 7.05 (d, 2H, J1 = 7.60 Hz, H12), 3.83 (s, 4H, H16a/b), 
2.86 (m, 4H, H1a/b), 2.53 (s, 6H, CH3-py), 2.41 (s, 6H, N-CH3). 
13C-NMR (400 MHz, 
CDCl3) δ: 157.89 (C11/15), 136.90 (C13), 122.00 (C12), 120.61 (C14), 63.38 (C16), 54.23 
(C1), 42.46 (N-CH3), 24.40 (CH3-py). ESI-MS (MeOH, m/z): Calculated (m/z): 298.43, found 
(m/z): 299.46. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, CHCl3): 267 (7.3 ± 0.3 × 10
3). RP-HPLC 
Phenomenex C18 5 μm 150 × 4.6 mm, 0-40 % B over 15 min, tR 8.80 min at 254 nm. 
2.7.2 N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,3-diaminopropane (Me2picpn 
Me2, N4-TL-20) 
Yield: 0.24 g (75%). Me2picpnMe2 (N4-TL-20) 
1H-NMR 
(400 MHz, CDCl3) δ: 7.53 (t, 2H, J1 = 7.68 Hz, H13), 7.25 
(d, 2H, J1 = 7.64 Hz, H14), 7.03 (d, 2H, J1 = 7.52 Hz, H12), 
3.71 (s, 4H, H16a/b), 2.80 (m, 4H, H1a/b, 2a/b), 2.53 (s, 6H, 
CH3-py), 2.33 (s, 6H, N-CH3), 1.88 (m, 2H, H17a/b). 
13C-
NMR (400 MHz, CDCl3) δ: 157.75 (C11/15), 136.72 (C13), 121.71 (C12), 120.26 (C14), 
63.48 (C16), 55.53 (C1), 42.46 (N-CH3), 24.45 (CH3-py/C17). ESI-MS (MeOH, m/z): 
Calculated (m/z): 312.46, found (m/z): 313.45. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, CHCl3): 
266 (7.4 ± 0.1 × 103). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 0-40 % B over 15 
min, tR 9.24 min at 254 nm. 
2.7.3 N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,4-diaminobutane (Me2picbn 
Me2, N4-TL-21) 
Yield: 0.25 g (76%). Me2picbnMe2 (N4-TL-21) 
1H-NMR 
(400 MHz, CDCl3) δ: 7.56 (t, 2H, J1 = 7.64 Hz, H13), 7.29 
(d, 2H, J1 = 8.64 Hz, H14), 7.04 (d, 2H, J1 = 7.60 Hz, H12), 
3.70 (s, 4H, H16a/b), 2.54 (s, 6H, CH3-py), 2.52 (m, 4H, 
H1a/b, 2a/b), 2.32 (s, 6H, N-CH3), 1.62 (m, 4H, H17a/b, 
18a/b). 13C-NMR (400 MHz, CDCl3) δ: 157.75 (C11/15), 
136.75 (C13), 121.71 (C12), 120.32 (C14), 63.45 (C16), 
57.27 (C1/2), 42.17 (N-CH3), 24.47 (C17/18), 24.47 (py-CH3). ESI-MS (MeOH, m/z): 
Calculated (m/z): 326.59, found (m/z): 327.45. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, CHCl3): 
266 (7.7 ± 0.2 × 103). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 0-40 % B over 15 
min, tR 9.34 min at 254 nm. 
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2.7.4 N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,5-diaminopentane (Me2picptn 
Me2, N4-TL-22) 
Yield: 0.25 g (75%). Me2picptnMe2 (N4-TL-22) 
1H-NMR 
(400 MHz, CDCl3) δ: 7.56 (t, 2H, J1 = 7.68 Hz, H13), 
7.31 (d, 2H, J1 = 7.72 Hz, H14), 7.05 (d, 2H, J1 = 7.60 
Hz, H12), 3.71 (s, 4H, H16a/b), 2.55 (s, 6H, CH3-py), 
2.51 (m, 4H, H1a/b, 2a/b), 2.33 (s, 6H, N-CH3), 1.60 (m, 4H, H17a/b, 18a/b), 1.35 (m, 2H, 
H19a/b). 13C-NMR (400 MHz, CDCl3) δ: 157.78 (C11/15), 136.76 (C13), 121.77 (C12), 
120.38 (C14), 63.39 (C16), 57.40 (C1/2), 42.15 (N-CH3), 26.68 (C17/18), 25.02 (C19), 24.48 
(py-CH3). ESI-MS (MeOH, m/z): Calculated (m/z): 340.51, found (m/z): 341.51. UV-Vis λmax 
nm (ε mol-1 dm-3 cm-1, CHCl3): 266 (7.8 ± 0.2 × 10
3). RP-HPLC Phenomenex C18 5 μm 150 
× 4.6 mm, 0-40 % B over 15 min, tR 9.71 min at 254 nm. 
2.7.5 N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,6-diaminohexane (Me2pichex 
Me2, N4-TL-23) 
Yield: 0.26 g (74%). Me2pichxnMe2 (N4-TL-23) 
1H-
NMR (400 MHz, CDCl3) δ: 7.55 (t, 2H, J1 = 7.64 Hz, 
H13), 7.27 (d, 2H, J1 = 8.40 Hz, H14), 7.03 (d, 2H, J1 = 
7.56 Hz, H12), 3.66 (s, 4H, H16a/b), 2.55 (s, 6H, CH3-
py), 2.45 (m, 4H, H1a/b, 2a/b), 2.29 (s, 6H, N-CH3), 
1.55 (m, 4H, H17a/b, 18a/b), 1.33 (m, 4H, H19a/b, 
20a/b). 13C-NMR (400 MHz, CDCl3) δ: 157.64 (C11/15), 136.65 (C13), 121.51 (C12), 120.07 
(C14), 63.79 (C16), 57.71 (C1/2), 42.40 (N-CH3), 27.29 (C17/18), 27.12 (C19/20), 24.48 (py-
CH3). ESI-MS (MeOH, m/z): Calculated (m/z): 354.54, found (m/z): 355.51. UV-Vis λmax nm 
(ε mol-1 dm-3 cm-1, CHCl3): 266 (7.3 ± 0.2 × 10
3). RP-HPLC Phenomenex C18 5 μm 150 × 
4.6 mm, 0-40 % B over 15 min, tR 10.34 min at 254 nm. 
2.7.6 N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,7-diaminoheptane (Me2 
pichpnMe2, N4-TL-24) 
Yield: 0.27 g (72%). Me2pichpnMe2 (N4-TL-24) 
1H-
NMR (400 MHz, CDCl3) δ: 7.57 (t, 2H, J1 = 7.68 
Hz, H13), 7.31 (d, 2H, J1 = 7.68 Hz, H14), 7.05 (d, 
2H, J1 = 7.60 Hz, H12), 3.71 (s, 4H, H16a/b), 2.55 
(s, 6H, CH3-py), 2.50 (m, 4H, H1a/b, 2a/b), 2.33 (s, 
6H, N-CH3), 1.57 (m, 4H, H17a/b, 18a/b), 1.31 (m, 6H, H19a/b, 20a/b, 27a/b). 
13C-NMR (400 
MHz, CDCl3) δ: 157.75 (C11/15), 136.74 (C13), 121.71 (C12), 120.32 (C14), 63.45 (C16), 
57.58 (C1/2), 42.21 (N-CH3), 29.33 (C19/20/27), 27.27 (C17/18), 24.48 (py-CH3). ESI-MS 
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(MeOH, m/z): Calculated (m/z): 368.57, found (m/z): 369.51. UV-Vis λmax nm (ε mol
-1 dm-3 
cm-1, CHCl3): 266 (8.0 ± 0.3 × 10
3). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 0-40 % 
B over 15 min, tR 11.13 min at 254 nm. 
2.8 N-benzylation of (N4-TL-1) 
2.8.1 Synthesis of N,Nʹ-bis(2-pyridylmethyl)-N,N'-dibenzyl-1,2-diaminohexane 
(picenBz2, N4-TL-25) 
A solution of benzyl chloride (2.9 g, 23 mmol) in DCM (10 
mL) was added slowly to a stirred solution of N4-TL-1 (2.17 g, 
8.9 mmol) in DCM (10 mL) the sodium hydroxide (0.3 M, 33 
mL) was added. The reaction vessel was flushed with nitrogen, 
sealed securely, and was magnetically stirred. After 24 hr the DCM layer was collected and 
the remaining aqueous reaction mixture was extracted further with DCM (2 × 20 mL). The 
combined DCM extracts were washed with water (10 mL) and extracted with 1M HCl (3 × 20 
mL). The combined acid extracts were washed with DCM (20 mL) to remove any unreacted 
benzyl chloride, the pH was adjusted to 10 and the mixture extracted with DCM (3 × 20 mL). 
The DCM extracts were dried over sodium sulphate, filtered, and evaporated to dryness to 
yield a pale yellow solid. Yield: 2.14 g (56%). PicenBz2 (N4-TL-25) 
1H-NMR (400 MHz, 
D2O) δ: 8.45 (d, 2H, J1 = 4.76 Hz, H11), 7.71 (t, 2H, J1 = 7.55 Hz, H13), 7.40 (d, 2H, J1 = 
7.76 Hz, H14), 7.30 – 7.23 (m, 10H, Ar-H), 7.22 (m, 2H, H12), 3.62 (s, 4H, H16a/b), 3.53 (s, 
4H, H110a/b), 2.59 (s, 4H, H1a/b). 13C-NMR (400 MHz, D2O) δ: 159.97 (C15), 149.12 
(C11), 139.53 (Ar-C), 136.86 (C13), 128.99 (Ar-C), 128.58 (Ar-C), 127.28 (Ar-C), 122.84 
(C14), 122.45 (C12), 60.18 (C16), 58.54 (C110), 51.40 (C1). ESI-MS (MeOH, m/z): 
calculated (m/z): 423.48, found (m/z): 423.48. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, CHCl3): 
237 (4.5 ± 0.2 × 103), 259 (6.5 ± 0.2 × 103), 263 (6.6 ± 0.2 × 103). RP-HPLC Phenomenex 
C18 5 μm 150 × 4.6 mm, 0-100 % B over 15 min, tR 8.74 min at 254 nm.  
2.9 Synthesis of RR/SS-diaminocyclohexane chiral N4-tetradentate ligands (N4-TLs) 
2.9.1 Synthesis of N,Nʹ-bis(pyridylmethyl)-1R,2R-diaminocyclohexane (R,R-pichxn, N4-
TL-26 
The method used to synthesise R,R-pichxn followed the 
procedure detailed in Section 2.3.1 with a minor modification, 
1R,2R-diaminocyclohexane (0.16 g, 1.40 mmol) was used 
instead of 1,2-diaminoethane. The starting reagents 1R,2R-
diaminocyclohexane and 2-pyridinecarboxaldehyde (0.25 g, 
2.38 mmol) were both reacted in methanol (40 mL), and NaBH4 (0.5 g, 13.22 mmol) was 
used for the hydrogenation of the ligand. A yellow oily product was obtained. Yield: 0.34 g 
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(81%). R,R-pichxn (N4-TL-26) 
1H-NMR (400 MHz, DMSO) δ: 8.47 (d, 2H, J1 = 4.20 Hz, 
H11), 7.73 (t, 2H, J1 = 7.64 Hz, H13), 7.45 (d, 2H, J1 = 7.80 Hz, H14), 7.22 (m, 2H, H12), 
3.90 (s, 1H, H16a), 3.86 (s, 1H, H16b), 3.73 (s, 1H, H26a), 3.69 (s, 1H, H26b), 2.22 (m, 2H, 
H1a, 2a), 2.01 (m, 2H, H17a, 18a), 1.63 (m, 2H, H19a, 20a), 1.15 (m, 2H, H17b, 18b), 1.01 
(m, 2H, H19b, 20b). 13C-NMR (400 MHz, DMSO) δ: 161.44 (C15), 149.08 (C11), 136.80 
(C13), 122.36 (C14), 122.19 (C12), 61.06 (C1/2), 52.24 (C16/26), 31.26 (C17/18/19/20), 
24.99 (C17/18/19/20). ESI-MS (MeOH, m/z): calculated (m/z): 296.20, found (m/z): 297.47. 
UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, CHCl3): 262 (6.0 ± 0.3 × 10
3). RP-HPLC Phenomenex 
C18 5 μm 150 × 4.6 mm, 0-40 % B over 15 min, tR 8.60 min at 254 nm. CD spectrum λmax nm 
(mdeg.mol/L, H2O): 276 (-1.6), 258 (0.8), 210 (-3.1). 
2.9.2 Synthesis of N,Nʹ-bis(pyridylmethyl)-1S,2S-diaminocyclohexane (S,S-pichxn, N4-
TL-27) 
The method used to synthesise S,S-pichxn followed the 
procedure detailed in Section 2.3.1 with one modification, 
1S,2S-diaminocyclohexane (0.16 g, 1.40 mmol) was used 
instead of 1R,2R-diaminocyclohexane. Yield: 0.36 g (86%). S,S-
pichxn (N4-TL-27) 
1H-NMR (400 MHz, DMSO) δ: 8.47 (d, 2H, 
J1 = 4.20 Hz, H11), 7.73 (t, 2H, J1 = 7.64 Hz, H13), 7.45 (d, 2H, J1 = 7.80 Hz, H14), 7.22 (m, 
2H, H12), 3.90 (s, 1H, H16a), 3.86 (s, 1H, H16b), 3.73 (s, 1H, H26a), 3.69 (s, 1H, H26b), 
2.22 (m, 2H, H1a, 2a), 2.01 (m, 2H, H17a, 18a), 1.63 (m, 2H, H19a, 20a), 1.15 (m, 2H, H17b, 
18b), 1.01 (m, 2H, H19b, 20b). 13C-NMR (400 MHz, DMSO) δ: 161.44 (C15), 149.08 (C11), 
136.80 (C13), 122.36 (C14), 122.19 (C12), 61.06 (C1/2), 52.24 (C16/26), 31.26 
(C17/18/19/20), 24.99 (C17/18/19/20). ESI-MS (MeOH, m/z): calculated (m/z): 296.20, found 
(m/z): 297.47. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, CHCl3): 262 (6.1 ± 0.1 × 10
3). RP-HPLC 
Phenomenex C18 5 μm 150 × 4.6 mm, 0-40 % B over 15 min, tR 8.58 min at 254 nm. CD 
spectrum λmax nm (mdeg.mol/L, H2O): 276 (1.4), 258 (-0.4), 210 (2.9). 
2.9.3 Synthesis of N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1R,2R-diaminocyclohexane (R,R-
Me2pichxn, N4-TL-28)  
The method used to synthesise R,R-dachMe2picen followed the 
procedure detailed in Section 2.3.1 with one modification, 6-
methyl-2-pyridinecarboxaldehyde (0.13 g, 1.07 mmol) was 
used instead of 2-pyridinecarboxaldehyde. A yellow oily 
product was obtained. Yield: 0.33 g (73%). R,R-Me2pichxn 
(N4-TL-28) 
1H-NMR (400 MHz, DMSO) δ: 7.60 (t, 2H, J1 = 
7.62 Hz, H13), 7.25 (d, 2H, J1 = 7.64 Hz, H14), 7.07 (d, 2H, J1 = 7.60 Hz, H12), 3.87 (s, 1H, 
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H16a), 3.83 (s, 1H, H16b), 3.67 (s, 1H, H26a), 3.63 (s, 1H, H26b), 2.42(s, 6H, py-CH3), 2.21 
(m, 2H, H1a, 2a), 2.02 (m, 2H, H17a, 18a), 1.64 (m, 2H, H19a, 20a), 1.16 (m, 2H, H17b, 
18b), 1.01 (m, 2H, H19b, 20b). 13C-NMR (400 MHz, DMSO) δ: 160.23 (C15), 157.26 (C11), 
137.01 (C13), 121.37 (C12), 119.23 (C14), 61.19 (C1/2), 52.23 (C16/26), 31.35 
(C17/18/19/20), 25.04 (C17/18/19/20), 24.45 (py-CH3). ESI-MS (MeOH, m/z): calculated 
(m/z): 324.23, found (m/z): 325.52. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, CHCl3): 267 (9.1 ± 
0.2 × 103). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 0-40 % B over 15 min, tR 9.73 
min at 254 nm. CD spectrum λmax nm (mdeg.mol/L, H2O): 282 (0.5), 266 (4.4), 241 (-0.3), 
229 (0.7), 214 (-1.0). 
2.9.4 N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1R,2R-diaminocyclohexane (S,S-Me2pichxn, 
N4-TL-29) 
The method used to synthesise S,S-Me2pichxn followed the 
procedure detailed in Section 2.3.1. A yellow oily product was 
obtained. Yield: 0.33 g (73%). S,S-Me2pichxn (N4-TL-29) 
1H-
NMR (400 MHz, DMSO) δ: 7.60 (t, 2H, J1 = 7.69 Hz, H13), 
7.25 (d, 2H, J1 = 7.64 Hz, H14), 7.08 (d, 2H, J1 = 7.56 Hz ,H12), 
3.87 (s, 1H, H16a), 3.83 (s, 1H, H16b), 3.67 (s, 1H, H26a), 3.64 
(s, 1H, H26b), 2.42(s, 6H, py-CH3), 2.21 (m, 2H, H1a, 2a), 2.02 (m, 2H, H17a, 18a), 1.64 (m, 
2H, H19a, 20a), 1.16 (m, 2H, H17b, 18b), 1.01 (m, 2H, H19b, 20b). 13C-NMR (400 MHz, 
DMSO) δ: 160.73 (C15), 157.26 (C11), 137.01 (C13), 121.37 (C12), 119.23 (C14), 61.19 
(C1/2), 52.23 (C16/26), 31.35 (C17/18/19/20), 25.04 (C17/18/19/20), 24.45 (py-CH3). ESI-
MS (MeOH, m/z): calculated (m/z): 324.23, found (m/z): 325.52. UV-Vis λmax nm (ε mol
-1 
dm-3 cm-1, CHCl3): 267 (7.0 ± 0.7 × 10
3). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 0-
40 % B over 15 min, tR 9.69 min at 254 nm. CD spectrum λmax nm (mdeg.mol/L, H2O): 282 
(0.8), 266 (-1.7), 241 (2.3), 229 (1.9), 214 (4.5) 
2.10 N-methylation of RR/SS-diaminocyclohexane chiral N4-tetradentate ligands (N4-
TLs) 
2.10.1 Synthesis of N,Nʹ-bis(pyridylmethyl)-N,N'-dimethyl-1R,2R-diaminocyclohexane 
(R,R-pichxnMe2, N4-TL-30)  
The method used to methylate the N4-TLs followed the 
procedure detailed in Section 2.6.1, R,R-pichxn (N4-TL-26) 
(100 mg, 0.34 mmol), formaldehyde (62.9 mg, 2.09 mmol), and 
formic acid (244 mg, 5.30 mmol) were used. Yield: 99.1 mg 
(70%). R,R-pichxnMe2 (N4-TL-30). 
1H-NMR (400 MHz, 
DMSO) δ: 8.45 (d, 2H, J1 = 4.48 Hz, H11), 7.69 (t, 2H, J1 = 7.59 Hz, H13), 7.51 (d, 2H. J1 = 
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7.80 Hz, H14), 7.20 (m, 2H, H12), 3.84 (s, 1H, H16a), 3.81 (s, 1H, H16b), 3.75 (s, 1H, H26a), 
3.71 (s, 1H, H26b), 2.67 (m, 2H, H1a, 2a), 2.20 (m, 6H, N-CH3), 1.89 (m, 2H, H17a, 18a), 
1.69 (m, 2H, H19a, 20a), 1.25 (m, 2H, H17b, 18b), 1.13 (m, 2H, H19b, 20b). 13C-NMR (400 
MHz, DMSO) δ: 161.38 (C15), 148.88 (C11), 136.65 (C13), 122.76 (C14), 122.19 (C12), 
64.10 (C1/2), 60.43 (C16/26), 36.84 (N-CH3), 26.01 (C17/18/19/20), 25.75 (C17/18/19/20). 
ESI-MS (MeOH, m/z): calculated (m/z): 324.23, found (m/z): 325.52. UV-Vis λmax nm (ε mol
-
1 dm-3 cm-1, CHCl3): 261 (6.1 ± 0.6 × 10
3). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 
0-40 % B over 15 min, tR 9.57 min at 254 nm. CD spectrum λmax nm (mdeg.mol/L, H2O): 276 
(-1.6), 258 (0.8), 210 (-3.1). 
2.10.2 Synthesis of N,Nʹ-bis(pyridylmethyl)-N,N'-dimethyl-1S,2S-diaminocyclohexane 
(S,S-pichxnMe2, N4-TL-31) 
The method used to synthesise S,S-picenMe2 followed the 
procedure detailed in Section 2.6.1 and 2.10.1, S,S-pichxn (N4-
TL-27) (100 mg, 0.34 mmol) was used. Yield: 83.1 g (59%). 
S,S-pichxnMe2 (N4-TL-31). 
1H-NMR (400 MHz, DMSO) δ: 
8.44 (d, 2H, J1 = 4.20 Hz, H11), 7.69 (t, 2H, J1 = 7.64 Hz, 
H13), 7.51 (d, 2H. J1 = 7.80 Hz, H14), 7.20 (m, 2H, H12), 3.84 (s, 1H, H16a), 3.80 (s, 1H, 
H16b), 3.74 (s, 1H, H26a), 3.71 (s, 1H, H26b), 2.67 (m, 2H, H1a, 2a), 2.20 (m, 6H, N-CH3), 
1.89 (m, 2H, H17a, 18a), 1.69 (m, 2H, H19a, 20a), 1.25 (m, 2H, H17b, 18b), 1.13 (m, 2H, 
H19b, 20b). 13C-NMR (400 MHz, DMSO) δ: 161.38 (C15), 148.88 (C11), 136.66 (C13), 
122.76 (C14), 122.19 (C12), 64.10 (C1/2), 60.43 (C16/26), 36.84 (N-CH3), 26.01 
(C17/18/19/20), 25.75 (C17/18/19/20). ESI-MS (MeOH, m/z): calculated (m/z): 324.23, found 
(m/z): 325.52. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, CHCl3): 261 (5.1 ± 0.3 × 10
3). RP-HPLC 
Phenomenex C18 5 μm 150 × 4.6 mm, 0-40 % B over 15 min, tR 9.56 min at 254 nm. CD 
spectrum λmax nm (mdeg.mol/L, H2O): 276 (1.4), 258 (-0.4), 210 (2.9). 
2.10.3 Synthesis of N,Nʹ-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1R,2R-diamino 
cyclohexane (R,R-Me2pichxnMe2, N4-TL-32)  
The method used to synthesise R,R-Me2picenMe2 followed the 
procedure detailed in Section 2.6.1 and 2.10.1, R,R-Me2pichxn 
(N4-TL-28) (100 mg, 0.34 mmol) was used. Yield: 98.1 mg (83%). 
R,R-Me2pichxnMe2 (N4-TL-32). 
1H-NMR (400 MHz, DMSO) δ: 
7.58 (t, 2H, J1 = 7.59 Hz, H13), 7.32 (d, 2H, J1 = 7.72 Hz, H14), 
7.06 (d, 2H, J1 = 7.56 Hz, H12), 3.80 (s, 1H, H16a), 3.76 (s, 1H, 
H16b), 3.70 (s, 1H, H26a), 3.67 (s, 1H, H26b), 2.65 (m, 2H, H1a, 2a), 2.42 (s, 6H, py-CH3), 
2.20 (s, 6H, N-CH3), 1.89 (m, 2H, H17a, 18b), 1.69 (m, 2H, H19a, 20a), 1.24 (m, 2H, H17b, 
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18b), 1.13 (m, 2H, H19a, 20b). 13C-NMR (400 MHz, DMSO) δ: 160.74 (C15), 157.02 (C11), 
136.91 (C13), 121.29 (C12), 119.54 (C14), 64.20 (C1/2), 60.44 (C16/26), 36.84 (N-CH3), 
26.02 (C17/18/19/20), 25.77 (C17/18/19/20), 24.43 (py-CH3). ESI-MS (MeOH, m/z): 
calculated (m/z): 352.26, found (m/z): 353.51. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, CHCl3): 
266 (8.0 ± 0.4 × 103). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 0-40 % B over 15 
min, tR 11.11 min at 254 nm. CD spectrum λmax nm (mdeg.mol/L, H2O): 282 (0.5), 266 (4.4), 
241 (-0.3), 229 (0.7), 214 (-1.0). 
2.10.4 Synthesis of N,Nʹ-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1R,2R-diamino 
cyclohexane (S,S-Me2pichxnMe2, N4-TL-32)  
The method used to synthesise S,S-Me2picenMe2 followed the 
procedure detailed in Section 2.6.1 and 2.10.1, S,S-Me2pichxn 
(N4-TL-29) (100 mg, 0.34 mmol) was used. Yield: 93.9 mg 
(79%). S,S-Me2pichxnMe2 (N4-TL-33). 
1H-NMR (400 MHz, 
DMSO) δ: 7.58 (t, 2H, J1 = 7.64 Hz, H13), 7.32 (d, 2H, J1 = 
7.68 Hz, H14), 7.06 (d, 2H, J1 = 7.52 Hz, H12), 3.80 (s, 1H, 
H16a), 3.76 (s, 1H, H16b), 3.70 (s, 1H, H26a), 3.67 (s, 1H, H26b), 2.65 (m, 2H, H1a, 2a), 
2.42 (s, 6H, py-CH3), 2.20 (s, 6H, N-CH3), 1.88 (m, 2H, H17a, 18a), 1.69 (m, 2H, H19a, 20a), 
1.24 (m, 2H, H17b, 18b), 1.14 (m, 2H, H19b, 20b). 13C-NMR (400 MHz, DMSO) δ: 160.74 
(C15), 157.02 (C11), 136.90 (C13), 121.29 (C12), 119.54 (C14), 64.20 (C1/2), 60.44 
(C16/26), 36.85 (N-CH3), 26.02 (C17/18/19/20), 25.77 (C C17/18/19/20), 24.43 (py-CH3). 
ESI-MS (MeOH, m/z): calculated (m/z): 352.26, found (m/z): 353.51. UV-Vis λmax nm (ε mol
-
1 dm-3 cm-1, CHCl3): 266 (8.3 ± 0.4 × 10
3). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 
0-40 % B over 15 min, tR 11.11 min at 254 nm. CD spectrum λmax nm (mdeg.mol/L, H2O): 
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2.11 Results and Discussion 
2.11.1 Synthesis of hydrogenated and methylated achiral of N4-TLs 
The N4-tetradentate ligands (N4-TLs) were synthesised utilising a modified literature 
method.82 The synthesis involved a condensation reaction (formation of water during the 
reaction) and nucleophilic addition. The electrophilic carbon from a carboxyl group, for 
example, 2-pyridine-carboxaldehyde, acted as a target for nucleophilic attack by amines such 
as 1,2-diaminoethane to form a Schiff base (imine) product and water (Figure 2.3). The choice 
of solvent is crucial to ensure the water can be azeotropically removed. Benzene, which was 
previously used, forms an azeotrope with water that boils at a fixed ratio, containing 29.5% 
water, at a lower temperature (taz = 69.3 ºC) than pure benzene (80 ºC) or water (100 ºC). 
However, benzene is classified as a carcinogen under the National Industrial Chemicals 
Notification and Assessment Scheme, and an alternative solvent was sought to improve the 
safety of the reaction. Ethyl acetate was chosen as the solvent based on the azeotropic 
temperature (taz/°C) and the mole fraction (x1) listed in the azeotropic data for binary 
mixtures.188 As ethyl acetate has very similar taz/°C and x1 values (taz = 70.4 °C, x1 = 0.312), it 
replaced benzene for the synthesis of the N4-TLs. All diimine N4-TLs (1a – 12a and 26a – 
29a) were formed effectively under the modified solvent conditions. The imine chemical shift 
of Schiff base N4-TLs was clearly identified by 
1H-NMR in the downfield region at ~8.16 – 
8.45 ppm.  
 
Figure 2.3 Condensation reaction between an aldehyde and amine, forming a Schiff-base (imine) product. 
 
The rigid structure of Schiff base N4-TLs makes metal coordination difficult, unless a 
planar product is the desired outcome. Therefore, increasing the flexibility of N4-TLs for 
coordination, the Schiff base (N=CH) diimines were reduced to diamines (N-CH2). There are 
various techniques available to hydrogenate a diimine, these include using a hydrogenator or 
hydrogen-filled balloon with a Pd/C catalyst. Both methods posed safety risks. An alternative 
method using a reducing agent such as sodium borohydride (NaBH4) was a safer and more 
versatile option. This reaction is known as a reductive amination (Figure 2.4). This method 
was carried out in situ without the need to isolate the intermediate, Schiff base. Other 
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reducing agents such as sodium cyanoborohydride and sodium triacetoborohydride could 
have also been used for controlled alkylation of imines. However, NaBH4 was ideal to reduce 
the diimine via syn-addition where the hydrogen enters at the least hindered position. The 
reaction also provided a clear indication of reaction progress as it produced a gas (bubbling) 
as the product was reduced, and the completion of the reaction was evident once the fizzing 
had ceased. This method modification was effective for reducing diimines to diamines N4-TLs 
(1 – 12 and 26 – 29) and was used for all the remaining N4-TLs which afforded their isolation 
as oils. The product was extracted from excess NaBH4 and then isolated as an oil in high 
yields of 85 – 98% (Table 2.1). 1H-NMR was effectively employed to confirm the successful 
reduction of all the N4-TL diimines. 
 
Figure 2.4 Reductive amination using a reducing agent such as sodium borohydride to hydrogenate the Schiff-
base product to an amine. 
 
1H-NMR spectra of Schiff base N4-TLs showed traces of starting material including, 
the carboxyl group from 2-pyridine-carboxaldehyde present at ~ 10 ppm, aromatics ~ 7.0 – 
9.0 ppm, and polyamines ~ 2.0 – 3.0 ppm. After hydrogenation, any remaining starting 
material was removed by solvent extraction to produce a clean 1H-NMR spectrum. 1H-NMR 
spectroscopy confirmed that hydrogenation was successful, the diimine proton shifted upfield 
as it became a diamine proton due to shielding effects. For example, 1H-NMR spectrum of 
picen (N4-TL-1 and 1a) the diimine proton H16/26a appeared at 8.43 ppm whereas after 
reduction the chemical shift of the diamine proton H16/26ab was observed at 3.85 ppm. There 
were no traces of a diimine proton visible in the 1H-NMR spectra of each of the N4-TLs after 
hydrogenation. The polyamine and chiral diamino-cyclohexane N4-TLs were all characterised 
to determine their product development and purity. 
2.11.2 Methylation of hydrogenated N4-TLs 
The methylation of secondary amines of N4-TLs was achieved using the method of Goldsmith 
et al.76 This is accomplished using an Eschweiler-Clarke substitution reaction whereby a 
primary or secondary amine is methylated using excess formic acid and formaldehyde. The 
reaction begins with the formation of an imine with formaldehyde and formic acid acting as a 
source of hydride to reduce the imine to a secondary amine (reductive amination) (Figure 
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2.5). Reductive amination provided control of N4-TLs methylation, and only tertiary 
methylamines were formed, not quaternary amines or ammonium salt by-products. The 
method was successfully applied to the N4-TLs achiral (1 – 12) and chiral (26 – 29), producing 
methylated N4-TLs achiral (13 – 24) and chiral (30 – 33) in yields of ~75 – 90%. The yields 
recovered varied depending on the extraction process. Multiple solvent extractions were 
required as a viscous mid-layer between the aqueous and organic layer prevented the product 
from partitioning efficiently into the organic phase. Methylated N4-TLs were obtained as 
brown oils. The synthesis was efficient and produced only minor traces of starting material, as 
detected using H1-NMR (carboxyl group at ~ 10 ppm). Characterisation was used to confirm 
the structure and purity (Table 2.1). The methylation was successfully validated by H1-NMR 
spectra where a singlet peak appeared for (N-CH3) at ~ 2.0 – 2.5 ppm (6H), slightly downfield 
due to the partially electronegative nitrogen group. 
 
Figure 2.5 The secondary amine methylation using the Eschweiler-Clarke substitution reaction, were 
formaldehyde and formic acid are used in excess. 
 
2.11.3 Benzylation of hydrogenated N4-TLs (1) 
The benzylation of secondary amines of hydrogenated N4-TL-1 followed literature methods.
82, 
83 The reaction was accomplished via nucleophilic Sn2 reaction, whereby the secondary 
amines (picen, 1) acts as a nucleophile and the benzyl chloride as the electrophile. The 
method was applied to synthesise N4-TL, picenBz2 25, producing a moderate yield of 56%. 
Multiple solvent extractions were required for the removal of excess benzyl-chloride, 
therefore losing some product in each extraction. Benzylated N4-TL was obtained as a pale 
yellow solid. The synthesis was efficient and produced only minor traces of starting material, 
as detected using H1-NMR. Characterisation was used to confirm the structure and purity 
(Table 2.1). The benzylation was successfully validated by H1-NMR spectra where the benzyl 
aromatic peaks appear for (Ar-H) at ~ 7.0 – 7.3 ppm. 
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   ESI-MS (m/z)  UV-Vis Extinction Coefficient 
Name  Yield Calc. Found UV/ λmax (ε/mol-1.dm3cm-1) 
N4-TL No. N4-TLs % [M+H]+ [M+H]+ (nm) × 103 
Picen (1) C14H18N4 94 243.33 243.41 262 (7.7 ± 0.3) 
Picpn (2) C15H20N4 87 257.35 257.40 262 (6.5 ± 0.9) 
Picbn (3) C16H22N4 95 271.38 271.40 262 (7.0 ± 0.6) 
Picptn (4) C17H24N4 87 285.41 285.46 262 (6.4 ± 0.6) 
Pichex (5) C18H26N4 90 299.43 299.46 262 (6.5 ± 0.1) 
Pichpn (6) C19H28N4 87 313.46 313.45 262 (7.8 ± 0.9) 
Me2picen (7) C16H22N4 95 271.38 271.40 266 (8.3 ± 0.2) 
Me2picpn (8) C17H24N4 93 285.41 285.46 266 (8.5 ± 0.2) 
Me2picbn (9) C18H26N4 87 299.43 299.45 266 (7.9 ± 0.3) 
Me2picptn (10) C19H28N4 86 313.46 313.45 266 (9.7 ± 0.1) 
Me2pichex (11) C20H30N4 86 327.49 327.45 266 (9.1 ± 0.9) 
Me2pichpn (12) C21H32N4 86 341.51 341.51 266 (8.1 ± 0.2) 
PicenMe2 (13) C16H22N4 96 271.38 271.40 262 (6.4 ± 0.1) 
PicpnMe2 (14) C17H24N4 93 285.41 284.46 262 (6.3 ± 0.3) 
PicbnMe2 (15) C18H26N4 83 299.43 299.46 259 (3.7 ± 0.08) 
PicptnMe2 (16) C19H28N4 85 313.46 313.45 262 (6.4 ± 0.04) 
PichexMe2 (17) C20H30N4 76 327.49 327.45 262 (5.7 ± 0.2) 
pichpnMe2 (18) C21H32N4 76 341.51 341.51 262 (6.4 ± 0.2) 
Me2picenMe2 (19) C18H26N4 80 299.43 299.46 267 (7.3 ± 0.3) 
Me2picpnMe2 (20) C19H28N4 75 313.46 313.45 266 (7.4 ± 0.1) 
Me2picbnMe2 (21) C20H30N4 76 327.59 327.45 266 (7.7 ± 0.2) 
Me2picptnMe2 (22) C21H32N4 75 341.51 341.51 266 (7.8 ± 0.2) 
Me2pichexMe2 (23) C22H34N4 74 355.54 355.51 266 (7.3 ± 0.2) 
Me2pichpnMe2 (24) C23H36N4 72 369.57 369.51 266 (8.1 ± 0.2) 
PicenBz2 (25) C25H30N4 56 424.48 423.59 263 (6.6 ± 0.2) 
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   ESI-MS (m/z) UV-Vis Extinction Coefficient 
Name  Yield Calc. Found UV/ λmax (ε/mol-1.dm3cm-1) 
N4-TL-No. N4-TLs % [M-H]+ [M-H]+ (nm) × 103 
RR-pichxn (26) C18H24N4 81 296.20 297.47 262 (6.0 ± 0.3) 
SS-pichxn (27) C18H24N4 86 296.20 297.47 262 (6.1 ± 0.1) 
RR-Me2pichxn (28) C20H28N4 73 324.23 325.52 267 (9.1 ± 0.2) 
SS-Me2pichxn (29) C20H28N4 73 324.23 325.52 267 (7.0 ± 0.7) 
RR-pichxnMe2 (30) C20H28N4 70 324.23 325.52 261 (6.1 ± 0.6) 
SS-pichxnMe2 (31) C20H28N4 59 324.23 325.52 261 (5.1 ± 0.3) 
RR-Me2pichxnMe2 (32) C22H32N4 83 352.26 353.51 266 (8.0 ± 0.4) 
SS-Me2pichxnMe2 (33) C22H32N4 79 352.26 353.51 266 (8.3 ± 0.4) 
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2.11.4 Characterisation of synthesised achiral N4-TLs 
The synthesis and methylation of N4-TLs was a 3-step process; (1) Schiff-base formation, (2) 
hydrogenation, and (3) methylation. For each step, a combination of NMR techniques such as 
1D and 2D-NMR (1H, 13C, Dept, HMQC, and COSY), UV-Vis, and, where appropriate, MS 
and CD, were used to confirm identity and purity of synthesised polyamine N4-TLs. 
2.11.4.1 Characterisation of Schiff base and hydrogenated polyamine N4-TLs 
NMR spectra were obtained on the 400 MHz Bruker Avance NMR using deuterated solvents 
CDCl3 and D2O with temperatures maintained at 25 and 35 ℃, respectively. N4-TLs have a 
two-fold symmetry, where the symmetrical proton and carbon peaks resonate at the same 
chemical shift. The NMR of picen (1) both Schiff-base (N4-TL-1a), and hydrogenated (N4-TL-
1), form was consistent with those reported in the literature.82 The elucidation of the NMR 
spectra is shown in Figure 2.6 and used to demonstrate the method of assignment for the 
remaining polyamine N4-TLs NMR spectra. The proton spectra of N4-TL-1a exhibited 
pyridine aromatic (H11 – 14) and diimine (H16, N=CH) protons resonating in the aromatic 
region downfield at ~7.0 – 9.0 ppm. The H11 resonance is furthest downfield at ~8.65 ppm, 
because of the proximity to the electronegative nitrogen. The Schiff-base proton, H16 is 
observed at ~8.45 ppm due to the increased electronegativity of the sp2-hybridised (N=C); 
H14 at ~8.0 ppm is closest to the Schiff-base, H13 at ~7.75 ppm is para to the electronegative 
nitrogen, and slightly upfield, H12 at ~7.40 ppm is furthest from the Schiff-base and pyridine 
nitrogen. The aliphatic chemical shift of H1a/b of the 1,2-diaminoethane appears furthest 
upfield at ~4.0 ppm (Figure 2.6). H14 and H1a/b, are near diimine H16, and, therefore, the 
electronegativity of the diimine also influences their downfield shift. Once the diimine is 
reduced to diamine, the H16 peak shifts upfield towards the aliphatic region at ~4.0 ppm. A 
slight upfield shift is noticed for H14 by ~ 0.6 ppm and H1a/b at ~ 1.4 ppm after reduction 
(Figure 2.6). The same chemical shift trend is evident with the remaining achiral polyamine 
N4-TLs with the addition of aliphatic protons from the polyamine chain (Supplementary A, 
Sections 1.1 and 1.2). For the achiral polyamine N4-TLs with a methyl group in the 6-position 
(N4-TL-7 and 7a), H11 exhibits a similar spectrum to N4-TL-1 and 1a however, H11 is absent 
and a singlet appears in the aliphatic region at 2.5 ppm for the py-CH3 resonance 
(Supplementary A, Sections 1.1 and 1.2). 
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Figure 2.6 1H-NMR of N4-TLs-1a and 1 was obtained on the 400 MHz Bruker Avance NMR using deuterated 
solvent CDCl3 with temperature maintained at 25 ℃. The downfield peak H16 (N4-TL-1a) is shifted upfield 
H16a/b (N4-TL-1) after hydrogenation. 
 
COSY and HMQC-NMR were used to confirm the assignments in the 1H-NMR 
spectra and assist in determining the 13C and dept-NMR spectra. COSY studies presented 
clear correlations between neighbouring protons 1H – 1H as shown in Supplementary A, 
Sections 1.29 and 1.30. The N4-TL-1 and 1a, pyridine aromatic peaks H11 – 14 show proton 
correlations and a close neighbouring relationship with diamine N4-TL-1 H16. The 1,2-
diaminoethane aliphatic peak, H1, shows correlations with diamine N4-TL-1a H16. The 
remaining polyamine N4-TLs show additional polyamine chain correlation as shown in 
Supplementary A, Sections 1.29 and 1.30. Carbon and proton correlations were studied using 
HMQC (13C – 1H) for N4-TL-1 and 1a. The aromatic protons H11 – 14 correlated with C11 – 
14 at ~ 100 – 150 ppm, diimine H16 correlated with C16 at ~ 160 ppm but after reduction the 
diamine H16 – C16 was observed at ~55 ppm. The aliphatic peak H1 correlated with C1 at ~ 
50 ppm (Figure 2.7). Both 13C and dept spectra are consistent, the additional singlet carbon 
C15 was visible on 13C and absent on dept-NMR spectra, and the diimine/diamine C16 shift is 
evident. The positive-dept CH/CH3 peaks correctly confirm the peaks C11 – 14 and C16 
(diamine). Whereas, the negative-dept CH2 peaks confirm the H1 (polyamine) and H16 
(diimine) peaks. The chemical shift of the assigned protons for each of the N4-TL-1 – 6 are 
reported in Table 2.3 and Supplementary A, Sections 1.8, 1.9, 1.15, 1.16, 1.22, and 1.23. 
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Table 2.3 Summary of NMR data of achiral diamine N4-TLs 1 – 6 showing chemical shifts (ppm), integration, multiplicity and coupling constant shown for 6 hydrogenated complexes 
synthesised. Experiments were performed in D2O. 
N4-TL (No.) 
Label picen (1) picpn (2) picbn (3) picptn (4) pichxn (5) pichpn (6) 
1H-NMR       
H1a,b/ H2a,b 2.81 (4H, s) 2.70 (4H, t  
J1 = 7.24 Hz) 
2.64 (4H, m) 2.63 (4H, m) 2.62 (4H, t  
J1 = 7.24 Hz) 
2.63 (4H, t 
J1 = 7.24 Hz) 
H16a,b/ H26a,b 3.93 (4H, s) 3.93 (4H, s) 3.93 (4H, s) 3.91 (4H, s) 3.92 (4H, s) 3.93 (4H, s) 
H17a,b/or H18a,b - 1.80 (2H, m) 1.59 (4H, m) 1.56 (4H, m) 1.55 (4H, m) 1.55 (4H, m) 
H19a,b/or H20a,b/or 
H27a,b 
- - - 1.38 (2H, m) 1.35 (4H, m) 1.33 (6H, m) 
H14/ H24 7.50 (2H, d,  
J1 = 7.88 Hz) 
7.50 (2H, d,  
J1 = 7.88 Hz) 
7.50 (2H, d,  
J1 = 7.88 Hz) 
7.52 (2H, d,  
J1 = 7.72 Hz) 
7.52 (2H, d,  
J1 = 7.88 Hz) 
7.52 (2H, d,  
J1 = 7.88 Hz) 
H13/ H23 7.94 (2H, t,  
J1 = 7.74 Hz) 
7.94 (2H, t,  
J1 = 7.74 Hz) 
7.94 (2H, t,  
J1 = 7.74 Hz) 
7.94 (2H, t,  
J1 = 7.68 Hz) 
7.94 (2H, t,  
J1 = 7.74 Hz) 
7.94 (2H, t,  
J1 = 7.72 Hz) 
H12/ H22 7.45 (2H, m) 7.45 (2H, m) 7.45 (2H, m) 7.45 (2H, m) 7.45 (2H, m) 7.45 (2H, m) 
H11/ H21 8.56 (2H, d,  
J1 = 4.56 Hz) 
8.56 (2H, d,  
J1 = 4.56 Hz) 
8.56 (2H, d,  
J1 = 4.56 Hz) 
8.56 (2H, d,  
J1 = 4.76 Hz) 
8.56 (2H, d,  
J1 = 4.56 Hz) 
8.56 (2H, d,  
J1 = 4.32 Hz) 
13C-NMR       
C1/ C2 47.15 46.08 47.74 47.88 47.86 47.89 
C16/ C26 53.34 53.32 53.32 53.36 53.34 53.34 
C17/or C18 - 28.40 26.32 28.35 28.36 28.39 
C19/or C20/or C27 - - - 24.20 26.18 26.29 
C15/ C25 158.03 158.06 158.18 158.34 158.33 158.33 
C14/ C24 123.05 123.01 122.98 122.95 123.96 123.96 
C13/ C23 138.30 138.27 138.25 138.23 138.23 138.23 
C12/ C22 123.28 123.28 123.28 123.27 123.29 123.29 
C11/ C21 148.55 148.52 148.50 148.48 148.49 148.51 
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Figure 2.7 13C and HMQC-NMR of N4-TLs-1a and 1 was obtained on the 400 MHz Bruker Avance NMR using 
deuterated solvent CDCl3 with temperature maintained at 25 ℃. The downfield peak H16 (N4-TL-1a) is shifted 
upfield H16a/b (N4-TL-1) after hydrogenation. 
 
2.11.4.2 NMR characterisation of methylated pyridine polyamine N4-TLs (7 – 12) 
N4-TL-7a and 7 with methyl groups at 6-position of the pyridine show close COSY 
correlations with their pyridine protons and HMQC carbon correlation with py-CH3 at ~ 25 
ppm (Table 2.4). NMR studies revealed similar chemical shift trends as those described for 
N4-TL-1a and 1. Overall, NMR studies afforded the successful characterisation of the 
polyamine achiral N4-TLs-7 – 12 and this data was consistent with similar published 
structures. 
2.11.4.3 NMR characterisation of N-methylated polyamine N4-TLs (13 – 18) 
The characterisation of N-methylated N4-TL, picenMe2 (N4-TL-13) was used to illustrate the 
process for characterising the methylated polyamine N4-TLs 13 – 18 (Table 2.5). The proton 
spectrum of N4-TL-13 showed pyridine aromatic peaks resonating in the aromatic (downfield) 
region at ~ 7.0 – 9.0 ppm. A direct comparison of chemical shift of the protons N4-TL-1 and 
N4-TL-13 was not possible as different deuterated solvents were required to solubilise the 
ligands in order to obtain spectra. In the aliphatic region, the peak attributed to H16 is shifted 
slightly downfield at ~ 4 ppm as it is adjacent to the electronegative nitrogen. The H1 of the 
polyamine chain is observed ~ 3.0 ppm, with a singlet peak for methyl groups on the 
secondary nitrogen, integrating for 6H and resonating at ~ 2.3 ppm (Figure 2.8). The assigned 
peaks and chemical shift changes of N4-TL-13 are consistent with N4-TL-1, but with the 
appearance of the additional N-methyl peak, and this trend is observed with the remaining N-
methylated polyamine N4-TLs (Supplementary A, Section 1.3.). 
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Table 2.4 Summary of NMR data of achiral diamine N4-TLs 7 – 12 showing chemical shifts (ppm), integration, multiplicity and coupling constant shown for 6 hydrogenated complexes 
synthesised. Experiments were performed in D2O. 
 
N4-TL (No.) 
Label Me2picen (7) Me2picpn (8) Me2picbn (9) Me2picptn (10) Me2pichex (11) Me2pichpn (12) 
1H-NMR       
H1a,b/ H2a,b 2.80 (4H, s) 2.69 (4H, t 
J1 = 7.28 Hz) 
2.60 (4H, m) 2.61 (4H, m) 2.66 (4H, m)  2.60 (4H, m) 
H16a,b/ H26a,b 3.87 (4H, s) 3.86 (4H, s) 3.86 (4H, s) 3.85 (4H, s) 3.85 (4H, s) 3.85 (4H, s) 
H17a,b/or H18a,b - 1.79 (2H, m) 1.59 (4H, m) 1.54 (4H, m) 1.53 (4H, m) 1.54 (4H, m) 
H19a,b/or H20a,b/or 
H27a,b 
- - - 1.37 (2H, m) 1.31 (4H, m) 1.39 (6H, m) 
H14/ H24 7.30 (2H, d,  
J1 = 7.76 Hz) 
7.29 (2H, d,  
J1 = 7.76 Hz) 
7.28 (2H, d,  
J1 = 7.76 Hz) 
7.29 (2H, d,  
J1 = 7.76 Hz) 
7.28 (2H, d,  
J1 = 8.56 Hz) 
7.31 (2H, m) 
H13/ H23 7.81 (2H, t,  
J1 = 7.72 Hz) 
7.80 (2H, t,  
J1 = 7.72 Hz) 
7.80 (2H, t,  
J1 = 7.72 Hz) 
7.80 (2H, t,  
J1 = 7.76 Hz) 
7.79 (2H, t,  
J1 = 7.72 Hz) 
7.80 (2H, t,  
J1 = 7.64 Hz) 
H12/ H22 7.30 (2H, d,  
J1 = 7.76 Hz) 
7.29 (2H, d,  
J1 = 7.76 Hz) 
7.28 (2H, d,  
J1 = 7.76 Hz) 
7.29 (2H, d,  
J1 = 7.76 Hz) 
7.28 (2H, d,  
J1 = 8.56 Hz) 
7.31 (2H, m) 
CH3-Py 2.58 (6H, s) 2.57 (6H, s) 2.57 (6H, s) 2.57 (6H, s) 2.57 (6H, s) 2.57 (6H, s) 
13C-NMR       
C1/ C2 47.08 46.01 47.60 47.80 47.71 47.72 
C16/ C26 53.29 53.29 53.28 53.35 53.29 53.33 
C17/or C18 - 28.32 26.26 28.33 28.32 28.36 
C19/or C20/or C27 - - - 24.16 26.10 26.10 
C15/ C25 158.06 158.06 158.02 158.01 158.02 158.02 
C14/ C24 120.10 120.10 120.10 120.10 120.13 120.14 
C13/ C23 138.42 138.41 138.38 138.37 138.34 138.36 
C12/ C22 122.65 122.61 122.59 122.54 122.55 122.54 
C11/ C21 157.51 157.51 157.61 157.84 157.75 157.40 
CH3-py 22.84 22.54 22.84 22.85 22.86 22.86 
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Table 2.5 Summary of NMR data of achiral N4-TLs 13 – 18 showing chemical shifts (ppm), integration, multiplicity and coupling constant shown for 6 methylated complexes synthesised. 
Experiments were performed in CDCl3. 
 
N4-TL (No.) 
Label picenMe2 (13) picpnMe2 (14) picbnMe2 (15) picptnMe2 (16) pichexMe2 (17) pichpnMe2 (18) 
1H-NMR       
H1a,b/ H2a,b 3.04 (4H, s) 2.64 (4H, m)  2.57 (4H, m) 2.55 (4H, m) 2.56 (4H, m)  2.55 (4H, m) 
N-CH3 2.50 (6H, s) 2.36 (6H, s) 2.35 (6H, s) 2.35 (6H, s) 2.37 (6H, s) 2.36 (6H, s) 
H16a,b/ H26a,b 4.00 (4H, s) 3.79 (4H, s) 3.78 (4H, s) 3.77 (4H, s) 3.70 (4H, s) 3.78 (4H, s) 
H17a,b/or H18a,b - 1.90 (2H, m) 1.65 (4H, m) 1.63 (4H, m) 1.61 (4H, m) 1.59 (4H, m) 
H19a,b/or H20a,b/or 
H27a,b 
- - - 1.39 (2H, m) 1.34 (4H, m) 1.31 (6H, m) 
H14/ H24 7.56 (2H, d,  
J1 = 7.76 Hz) 
7.44 (2H, d) 
J1 = 7.80 Hz) 
7.51 (2H, d,  
J1 = 7.80 Hz) 
7.51 (2H, d,  
J1 = 7.80 Hz) 
7.54 (2H, d,  
J1 = 7.76 Hz) 
7.53 (2H, d,  
J1 = 7.76 Hz) 
H13/ H23 7.71 (2H, t,  
J1 = 8.00 Hz) 
7.66 (2H, t,  
J1 = 7.64 Hz) 
7.68 (2H, t,  
J1 = 8.00 Hz) 
7.69 (2H, t,  
J1 = 7.64 Hz) 
7.70 (2H, t,  
J1 = 7.64 Hz) 
7.69 (2H, t,  
J1 = 7.64 Hz) 
H12/ H22 7.24 (2H, m) 7.19 (2H, m) 7.19 (2H, m) 7.20 (2H, m) 7.21 (2H, m) 7.20 (2H, m) 
H11/ H21 8.58 (2H, d,  
J1 = 4.20 Hz) 
8.54 (2H, d,  
J1 = 4.86 Hz) 
8.55 (2H, d,  
J1 = 4.00 Hz) 
8.55 (2H, d,  
J1 = 4.86 Hz) 
8.55 (2H, d,  
J1 = 4.90 Hz) 
8.56 (2H, d,  
J1 = 4.86 Hz) 
13C-NMR       
C1/ C2 53.58 55.70 57.11 57.27 57.27 57.42 
N-CH3 42.12 42.15 42.01 42.02 41.96 41.01 
C16/ C26 62.35 63.17 63.19 63.18 63.03 63.12 
C17/or C18 - 24.12 24.52 24.52 27.03 26.62 
C19/or C20/or C27 - - - 24.94 26.53 27.18 
C15/ C25 - 158.06 158.18 158.34 158.33 158.33 
C14/ C24 124.23 123.58 123.70 123.72 123.83 123.76 
C13/ C23 136.96 136.58 136.62 136.61 136.65 136.61 
C12/ C22 122.86 122.32 122.37 122.38 122.45 122.39 
C11/ C21 149.34 149.18 149.18 149.21 149.22 149.20 
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Figure 2.8 1H-NMR of N4-TLs-1 and 13 was obtained on the 400 MHz Bruker Avance NMR using deuterated 
solvent CDCl3 with temperature maintained at 25 ℃. Methyl-group (N4-TLs-13) observed at ~2.3 ppm. 
 
COSY and HMQC-NMR spectra were used to confirm the assigned 1H-NMR spectra 
and assist in determining the 13C and dept-NMR spectra Supplementary A, Sections 1.10, 
1.17, 1.24, and 1.31. COSY experiments showed clear correlations between neighbouring 
protons 1H – 1H. The COSY study of N4-TL-13 show proton correlations between pyridine 
aromatic peaks, H11 – 14, and a close neighbouring association with H16. The singlet 
aliphatic peaks H1 and N-CH3 show no evident correlations with neighbouring protons. 
HMQC (13C – 1H) of N4-TL-13 showed correlations between the aromatic protons H11 – 14 
and C11 – 14 at ~ 100 – 150 ppm, while the aliphatic protons H1 and H16 correlated with C1 
and C16 at ~ 50 – 60 ppm, respectively. In the HMQC spectrum the protons of the N-CH3 
correlated with the methyl carbon at ~ 40 ppm (Figure 2.9). The carbon and dept spectra for 
N4-TL-13 are comparable to N4-TL-1, with the addition of the N-methyl resonance. The 
positive-dept CH/CH3 peaks confirms pyridine peaks of C11 – 14, and the N-CH3. The 
negative-dept CH2 peaks, corroborate the aliphatic carbons C16 (diamine) and C1 
(polyamine) assignments. A summary of the 1H and 13C chemical shifts is presented in Table 
2.5. 
For N4-TL-19 – 24 a methyl group is also in the 6-position (H11) on the pyridine (py-
CH3) the peak appears in the aliphatic region at ~ 2.5 ppm with the N-methylated group N-
CH3 found at ~ 2.3 ppm (Supplementary A, Section 1.3). The pyridine methylated N4-TL-19 
the py-CH3 showed slight correlations with pyridine protons H12 – 14 in COSY spectra, and 
in HMQC enables the assignment of the carbon of py-CH3 at ~ 25 ppm. carbon and dept 
spectra provide supporting evidence, with C11 and 15 resonance observed in 13C-NMR and 
absent on dept-NMR spectra. The spectra produced for N4-TL-19 – 24 are consistent with N4-
TL-1 and N4-TL-13 (Supplementary A, Sections 1.2 and 1.3). A summary of the 
1H and 13C 
chemical shifts is presented in Table 2.6.  
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Table 2.6 Summary of NMR data of achiral N4-TLs 19 – 24 showing chemical shifts (ppm), integration, multiplicity and coupling constant shown for 6 methylated complexes synthesised. 
Experiments were performed in CDCl3. 
N4-TL (No.) 
Label Me2picenMe2 (19) Me2picpnMe2 (20) Me2picbnMe2 (21) Me2picptnMe2 (22) Me2pichxnMe2 (23) Me2pichpnMe2 (24) 
1H-NMR       
H1a,b/ H2a,b 2.86 (4H, s) 2.80 (4H, m)  2.52 (4H, m) 2.51 (4H, m) 2.45 (4H, m)  2.50 (4H, m) 
N-CH3 2.41 (6H, s) 2.33 (6H, s) 2.32 (6H, s) 2.33 (6H, s) 2.29 (6H, s) 2.33 (6H, s) 
H16a,b/ H26a,b 3.83 (4H, s) 3.71 (4H, s) 3.70 (4H, s) 3.71 (4H, s) 3.66 (4H, s) 3.71 (4H, s) 
H17a,b/or H18a,b - 1.88 (2H, m) 1.62 (4H, m) 1.60 (4H, m) 1.55 (4H, m) 1.57 (4H, m) 
H19a,b/or H20a,b/or 
H27a,b 
- - - 1.35 (2H, m) 1.33 (4H, m) 1.31 (6H, m) 
H14/ H24 7.30 (2H, d,  
J1 = 7.64 Hz) 
7.25 (2H, d,  
J1 = 7.64 Hz) 
7.29 (2H, d,  
J1 = 8.64 Hz) 
7.31 (2H, d,  
J1 = 7.72 Hz) 
7.27 (2H, d,  
J1 = 8.40 Hz) 
7.31 (2H, d,  
J1 = 7.68 Hz) 
H13/ H23 7.56 (2H, t,  
J1 = 7.64 Hz) 
7.53 (2H, t,  
J1 = 7.68 Hz) 
7.56 (2H, t,  
J1 = 7.64 Hz) 
7.56 (2H, t,  
J1 = 7.68 Hz) 
7.55 (2H, t,  
J1 = 7.64 Hz) 
7.57 (2H, t,  
J1 = 7.68 Hz) 
H12/ H22 7.05 (2H, d,  
J1 = 7.60 Hz) 
7.03 (2H, d,  
J1 = 7.52 Hz) 
7.04 (2H, d,  
J1 = 7.60 Hz) 
7.05 (2H, d,  
J1 = 7.60 Hz) 
7.03 (2H, d,  
J1 = 7.56 Hz) 
7.05 (2H, d,  
J1 = 7.60 Hz) 
CH3-Py 2.53 (6H, s) 2.54 (6H, s) 2.55 (6H, s) 2.57 (6H, s) 2.55 (6H, s) 2.55 (6H, s) 
13C-NMR       
C1/ C2 54.23 55.53 57.27 57.40 57.71 57.58 
N-CH3 42.46 42.46 42.17 42.15 42.40 42.21 
C16/ C26 63.38 63.48 63.45 63.39 63.79 63.45 
C17/or C18 - 24.45 24.47 26.68 27.29 27.27 
C19/or C20/or C27 - - - 25.02 27.12 29.33 
C15/ C25 157.89 157.75 157.75 157.78 157.64 157.75 
C14/ C24 120.61 120.26 120.32 120.38 120.07 120.32 
C13/ C23 136.90 136.72 136.75 136.76 136.65 136.74 
C12/ C22 122.00 121.71 121.71 121.71 121.51 121.71 
C11/ C21 157.89 157.75 157.75 157.78 157.64 157.75 
CH3-py 24.40 24.45 24.47 24.48 24.48 24.48 
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Figure 2.9 13C and HMQC-NMR of N4-TLs-1 and 13 was obtained on the 400 MHz Bruker Avance NMR using 
deuterated solvent CDCl3 with temperature maintained at 25 ℃. Addition peak N-CH3 is visible on the spectra. 
 
2.11.4.4 NMR characterisation of N-benzylated polyamine N4-TL 25 
The benzylated ligand (picenBz2, N4-TL-25) was re-synthesised from published methods in 
moderate yields of 56%. NMR spectra of N4-TL-25 which has a two-fold symmetry, were 
consistent with the reported structure in the literature and comparable to N4-TL-1.
82, 83 The 
proton spectra of N4-TL-25 showed pyridine aromatic (H11 – 14) and dibenzyl groups (Ar-H) 
resonating in the aromatic region at ~7.0 – 9.0 ppm. Proton peak H11 is furthest downfield at 
~8.45 ppm, because it is adjacent to the electronegative nitrogen. H13 resonates at ~7.71 ppm 
as it is para to the electronegative nitrogen, H14 at ~7.76 ppm is closest to the benzyl group, 
and slightly upfield H12 resonates at ~7.30 – 7.22 ppm. The aliphatic peaks of the 1,2-
diaminoethane, H16a/b and H110a/b, are slightly downfield at ~3.62 and 3.53 ppm, 
respectively, and are adjacent to the amine nitrogen. The furthest upfield resonance is H1a/b 
at ~3.53 ppm. 1H spectra of N4-TL-25 has obvious similarities to N4-TL-1 with the additional 
peaks for Ar-H and H110a/b as demonstrated on Figure 2.10 and Supplementary A, Section 
1.4.  
COSY and HMQC-NMR spectra were used to confirm the 1H-NMR assignments, 
COSY experiments exhibited clear correlations between neighbouring protons 1H – 1H as 
shown in Supplementary A, Section 1.32. The N4-TL-25, pyridine aromatic peaks, H11 – 14, 
show proton correlations between each other and a close neighbouring relationship with 
amine H16. The benzyl protons have correlations with its adjacent protons and no other 
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correlations are evident. Protons in the aliphatic region H1, 16, and 110 are observed as 
singlets, with no proton correlations evident on the COSY spectra. HMQC (13C – 1H) for N4-
TL-25 (Figure 2.10 and Supplementary A, Section 1.25) show correlations between the 
aromatic protons H11 – 14 and Ar-H with C11 – 14 and 110 at ~100 – 150 ppm. The aliphatic 
peak H1, 16 and 110 correlated with C1, 16 and 110 at ~50 – 70 ppm (Figure 2.10). Both 13C 
and dept spectra are consistent, with the peak assignments, singlet carbon C15 and Ar-C were 
visible in 13C and absent in dept-NMR spectra. The positive-dept CH/CH3 peaks correctly 
confirm the peaks C11 – 14 and Ar-C (Supplementary A, Sections 1.11 and 1.18). Whereas, 
the negative-dept CH2 peaks confirm the assignment of H1, 16, and 110. Overall, NMR 
studies successfully confirmed structural identity of N4-TL-25 and this data is consistent with 
published information.  
 
 
Figure 2.10 1H, 13C and HMQC-NMR spectra of N4-TLs-1 and 25 were obtained on the 400 MHz Bruker 
Avance NMR using deuterated solvent D2O and DMSO-d6 with temperature maintained at 25 and 35 ℃, 
respectively.  
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2.11.4.5 NMR characterisation of Schiff-base and hydrogenated chiral 1R*/2R*-
diaminocyclohexane N4-TL (26 – 33) 
A group of chiral C2-symmetric ligands, chiral 1R
*/2R* diaminocyclohexane N4-TLs were 
synthesised using 1R,2R or 1S,2S-diaminocyclohexane (RR/SS-pichxn-N4-TLs). The NMR 
spectra were consistent with those reported in the literature and are comparable to N4-TL-1 
and 1a, see Section 2.11.4.1.80, 189 The characterisation of both Schiff-base N4-TL-26a and 
hydrogenated N4-TL-26 was used to assist in analysing the remaining chiral N4-TLs. The 
proton spectra of diimine N4-TL-26a showed aromatic H11 – 14 and diimine H16 peaks 
resonating in the aromatic region (downfield) at ~7.0 – 9.0 ppm. H11 – 14 and H16 resonate 
in the same region as N4-TL-1 and 1a, at ~7.0 – 9.0 ppm. In the aliphatic region the protons 
from 1,2-diamino-cyclohexane H1 and H18 – 19 are observed between ~1.0 – 4.0 ppm. The 
aliphatic peak H1 was shifted slightly downfield at ~ 4 ppm, as it was adjacent to the 
electronegative nitrogen of the Schiff base. H18, H19, and H1 are upfield at ~1 – 2 ppm as 
they are sequentially further away from the Schiff base (Figure 2.11).  
 
Figure 2.11 1H-NMR of N4-TLs-26a and 26 was obtained on the 400 MHz Bruker Avance NMR using 
deuterated solvent DMSO-d6 with temperature maintained at 35 ℃. The downfield peak H16 (N4-TL-26a) is 
shifted upfield H16a/b (N4-TL-26) after hydrogenation. 
 
Once the diimine is reduced to diamine, the H16 peak shifts upfield to ~ 4 ppm. There 
is a slight upfield shift of H14 and H1 by ~ 0.6 and ~ 1.4 ppm, respectively as after reduction 
as the electronegativity was decreased. The assigned peaks and chemical shift changes for N4-
TL-26 was consistent with those seen for N4-TL-1, and this trend was observed with all the 
remaining chiral N4-TLs (26 – 33) (Supplementary A, Sections 1.5 and 1.6). The chiral N4-TL-
27, with a methyl substitution in the 6-position (H11) of the pyridine exhibited a similar 1H 
spectra to N4-TL-25 and N4-TL-1 with a slight difference where proton H11 is absent and a py-
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CH3 peak appears in the aliphatic region at 2.5 ppm (Supplementary A, Sections 1.5 and 1.6). 
A summary of the 1H and 13C chemical shifts is presented in Table 2.7. COSY and HMQC 
confirm the 1H-NMR assignments showing clear correlations between neighbouring protons 
1H – 1H and 1H – 13C as shown in Supplementary A, Sections 1.26, 1.27, 1.33, and 1.34. 
COSY spectra of N4-TL-26 and 26a indicated that pyridine aromatic peaks H11 – 14 show 
proton correlations with each other. Diimine/diamine peak H16 had no proton correlations as 
there were no neighbouring protons, and the aliphatic 1,2-diaminocyclohexane protons, H1 
correlates with H18, and H18 correlates with H19. HMQC (13C – 1H) for N4-TL-26 and 26a 
show that the pyridine aromatic protons H11 – 14 correlates with C11 – 14 at ~ 100 – 150 
ppm. For the diamine N4-TL-26, H16 correlated with C16 at ~ 160 ppm. After reduction, N4-
TL-26a, the diamine, H16 was found to correlate with C16 at ~ 55 ppm. The aliphatic protons 
of 1,2-diaminocycohexane H1/18/19 correlated with C1/18/19 at ~ 20 – 80 ppm (Figure 2.12). 
The HMQC spectra confirmed the accurate assignment of carbon resonances (Figure 2.12) in 
the 13C and dept-NMR spectra (Supplementary A, Sections 1.12, 1.13, 1.19, and 1.20). The 
additional singlet carbon C15 was evident in 13C-NMR and absent on dept-NMR. Positive-
dept CH/CH3 peaks correctly confirmed peaks C11 – 14, H16 (diimine) assignment, and 
negative-dept CH2 peaks confirm C1/18/19, and after reduction C16 (diamine). N4-TLs with a 
methyl group in the 6-position (H11) showed a singlet py-CH3 resonance without any 
neighbouring proton or carbon correlation, a singlet carbon peak C11 was present in the 13C-
NMR and absent on dept-NMR. This N4-TL-26 elucidation was used to assign peaks for the 
remaining chiral diamine-cyclohexane N4-TLs 27 – 33. 
 
Figure 2.12 13C and HMQC-NMR of N4-TLs-26a and 26 was obtained on the 400 MHz Bruker Avance NMR 
using deuterated solvent DMSO-d6 with temperature maintained at 35 ℃. The downfield peak H16 (N4-TL-26a) 
is shifted upfield H16a/b (N4-TL-26) after hydrogenation. 
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Table 2.7 Summary of NMR data of chiral N4-TLs 26 – 29 showing chemical shifts (ppm), integration, 
multiplicity and coupling constant shown for 4 hydrogenated complexes synthesised. Experiments were 
performed in DMSO-D6. 
N4-TL (No.) 
Label RR-pichxn (26) SS-pichxn (27) RR-Me2pichxn (28) SS-Me2pichxn (29) 
1H-NMR     
H1a/H2a 2.22 (2H, m) 2.22 (2H, m)  2.21 (2H, m) 2.21 (2H, m) 
H16a 3.90 (1H, s) 3.90 (1H, s) 3.87 (1H, s) 3.87 (1H, s) 
H16b 3.86 (1H, s) 3.86 (1H, s) 3.83 (1H, s) 3.83 (1H, s) 
H26a 3.73 (1H, s) 3.73 (1H, s) 3.67 (1H, s) 3.67 (1H, s) 
H26b 3.69 (1H, s) 3.69 (1H, s) 3.63 (1H, s) 3.64 (1H, s) 
H17a/H18a 2.01 (2H, m) 2.01 (2H, m) 2.02 (2H, m) 2.02 (2H, m) 
H19a/H20a 1.63 (2H, m) 1.63 (2H, m) 1.64 (2H, m) 1.64 (2H, m) 
H17b/H18b 1.15 (2H, m) 1.15 (2H, m) 1.16 (2H, m) 1.16 (2H, m) 
H19b/H20b 1.01 (2H, m) 1.01 (2H, m) 1.01 (2H, m) 1.01 (2H, m) 
H14/H24 7.45 (2H, d,  
J1 = 7.80 Hz) 
7.45 (2H, d,  
J1 = 7.80 Hz) 
7.25 (2H, d,  
J1 = 7.64 Hz) 
7.25 (2H, d,  
J1 = 7.64 Hz) 
H13/H23 7.73 (2H, t,  
J1 = 7.64 Hz) 
7.73 (2H, t,  
J1 = 7.64 Hz) 
7.60 (2H, t,  
J1 = 7.62 Hz) 
7.60 (2H, t,  
J1 = 7.69 Hz) 
H12/H22 7.22 (2H, m) 7.22 (2H, m) 7.07 (2H, d,  
J1 = 7.60 Hz) 
7.08 (2H, d,  
J1 = 7.56 Hz) 
H11/H21 8.47 (2H, d,  
J1 = 4.20 Hz) 
8.47 (2H, d,  
J1 = 4.20 Hz) 
- - 
CH3-Py - - 2.42 (6H, s) 2.42 (6H, s) 
13C-NMR     
C1/C2 61.06 61.06 61.19 61.19 
C16/C26 52.24 52.24 52.23 52.23 
C17/ 18/ 19/ 20 24.99 24.99 25.04 25.04 
C17/ 18/ 19/ 20 31.26 31.26 31.35 31.35 
C15/C25 161.44 161.44 160.23 160.73 
C14/C24 122.36 122.36 119.23 119.23 
C13/C23 136.80 136.80 137.01 137.01 
C12/C22 122.19 122.19 121.37 121.37 
C11/C21 149.08 149.08 157.26 157.26 
CH3-Py - - 24.45 24.45 
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2.11.4.6 NMR characterisation of N-methylated chiral 1R*/2R*-diaminocyclohexane N4-
TL (30 – 33) 
The N-methylated chiral N4-TLs (30 – 33) were characterised using NMR spectra. The spectra 
were consistent with those reported in the literature and are comparable to RR-pichxn N4-TL-
26 in Section 2.11.4.5.76, 83 The proton spectra of N4-TL-30 showed pyridine peaks H11 - 14 
resonating in the aromatic (downfield) region at ~ 7.0 – 9.0 ppm, the same region as N4-TL-
26. In the aliphatic region the peak H16 is slightly downfield at ~ 3.5 – 4.0 ppm. The 
remaining aliphatic peaks H1 and H18 – 29 were found upfield at ~ 1.0 – 3.0 ppm (Figure 
2.13). Successful methylation was made apparent by a singlet N-CH3 peak that resonated at ~ 
2.2 ppm and integrated to 6H in the proton spectra. A slight upfield shift is evident with 
protons neighbouring the diamine as the electronegativity of the nitrogen was reduced by the 
methyl substituent. Peaks assigned for N4-TL-30 was consistent with N4-TL-26 
(Supplementary A, Section 1.7) 
For N4-TLs with a methyl substitution in the 6-position of the pyridine, for example 
N4-TL-32, the aromatic peak (H11) is replaced by a py-CH3 resonance in the aliphatic region 
at ~ 2.5 ppm with the methylation N-CH3 peak occurring at ~ 2.3 ppm (Supplementary A, 
Section 1.7). The peak py-CH3 is further downfield than N-CH3 as the pyridine methyl group 
was adjacent to an electronegative nitrogen and is directly connected to a conjugated system 
of pyridine. A summary of the 1H and 13C chemical shifts is presented in Table 2.8. 
 
Figure 2.13 1H-NMR of N4-TLs-26 and 30 was obtained on the 400 MHz Bruker Avance NMR using deuterated 
solvent DMSO-d6 with temperature maintained at 35 ℃. Methyl-group (N4-TLs-30) observed at ~2.3 ppm. 
 
2D-NMR spectra were used to confirm the assignments in the proton spectra. The 
COSY spectra of N4-TL-30 showed that pyridine aromatic peaks H11 – 14 are correlated with 
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each other (Supplementary A, Section 1.35). The aliphatic peaks H16 and N-CH3 show no 
evident proton correlations. The remaining 1,2-diaminocyclohexane aliphatic peaks, H18 – 
19, show proton correlations with each other. The HMQC (13C – 1H) of N4-TL-30 showed the 
pyridine aromatic peaks, H11 – 14, correlated with C11 – 14 peaks at ~ 100 – 150 ppm. In the 
aliphatic region H1 and H16 correlated with C1 and C16 at ~ 60 – 50 ppm. The methyl 
protons N-CH3 correlated with the methyl carbon at ~ 40 ppm, while the 1,2-
diaminocyclohexane protons H18 – 19 correlated with C18 – 19 at ~ 30 ppm (Figure 2.14 and 
Supplementary A, Section 1.28). Carbon and dept spectra were consistent and comparable to 
(N4-TL-26) differing only with addition of the N-methyl substituent (Supplementary A, 
Section 1.14 and 1.21). Positive-dept CH/CH3 peaks correctly confirm peaks C11 – 14, C1, 
and N-CH3, whereas, the negative-dept CH2 peaks confirm the aliphatic carbons C16 – 19. 
N4-TLs (32 and 33) with a methyl group in the 6-position exhibited the loss of H11 and the 
appearance of a py-CH3 proton peak without any COSY or HMQC correlations. The 2D and 
carbon NMR studies were produced for the remaining chiral methylated N4-TLs, using both 
(N4-TL-26) and (N4-TL-30) as exemplars for the assignment of peaks. The NMR spectra were 
consistent with previously published structures. 
 
Figure 2.14 13C and HMQC-NMR of N4-TLs-26 and 30 was obtained on the 400 MHz Bruker Avance NMR 
using deuterated solvent DMSO-d6 with temperature maintained at 35 ℃. Addition peak N-CH3 is visible on the 
spectra. 
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Table 2.8 Summary of NMR data of N4-TLs 30 – 33 showing chemical shifts (ppm), integration, multiplicity and 




Label RR-pichxnMe2 (30) SS-pichxnMe2 (31) RR-Me2pichxnMe2 (31) SS-Me2pichxnMe2 (33) 
1H-NMR     
H1a/ H2a 2.67 (2H, m) 2.67 (2H, m)  2.65 (2H, m) 2.65 (2H, m) 
N-CH3 2.20 (6H, s) 2.20 (6H, s) 2.20 (6H, s) 2.20 (6H, s) 
H16a 3.84 (1H, s) 3.84 (1H, s) 3.80 (1H, s) 3.80 (1H, s) 
H16b 3.81 (1H, s) 3.80 (1H, s) 3.76 (1H, s) 3.76 (1H, s) 
H26a 3.75 (1H, s) 3.74 (1H, s) 3.70 (1H, s) 3.70 (1H, s) 
H26b 3.71 (1H, s) 3.71 (1H, s) 3.67 (1H, s) 3.67 (1H, s) 
H17a/H18a 1.89 (2H, m) 1.89 (2H, m) 1.89 (2H, m) 1.88 (2H, m) 
H19a/H20a 1.69 (2H, m) 1.69 (2H, m) 1.69 (2H, m) 1.69 (2H, m) 
H17b/H18b 1.25 (2H, m) 1.25 (2H, m) 1.24 (2H, m) 1.24 (2H, m) 
H19b/H20b 1.13 (2H, m) 1.13 (2H, m) 1.13 (2H, m) 1.14 (2H, m) 
H14/ H24 7.51 (2H, d,  
J1 = 7.80 Hz) 
7.51 (2H, d,  
J1 = 7.80 Hz) 
7.32 (2H, d,  
J1 = 7.72 Hz) 
7.32 (2H, d,  
J1 = 7.68 Hz) 
H13/ H23 7.69 (2H, t,  
J1 = 7.59 Hz) 
7.69 (2H, t,  
J1 = 7.64 Hz) 
7.58 (2H, t,  
J1 = 7.59 Hz) 
7.58 (2H, t,  
J1 = 7.64 Hz) 
H12/ H22 7.20 (2H, m) 7.20 (2H, m) 7.06 (2H, d,  
J1 = 7.56 Hz) 
7.06 (2H, d,  
J1 = 7.52 Hz) 
H11/ H21 8.45 (2H, d,  
J1 = 4.48 Hz) 
8.44 (2H, d , 
J1 = 4.20 Hz) 
- - 
CH3-Py - - 2.42 (6H, s) 2.42 (6H, s) 
13C-NMR     
C1/ C2 64.10 64.10 64.20 64.20 
N-CH3 36.84 36.84 36.84 36.85 
C16/ C26 60.43 60.43 60.44 60.44 
C17/ 18/ 19/ 20 25.75 25.75 25.77 25.77 
C17/ 18/ 19/ 20 26.01 26.01 26.02 26.02 
C15/ C25 161.38 161.38 160.74 160.74 
C14/ C24 122.76 122.76 119.54 119.54 
C13/ C23 136.65 136.66 136.91 136.90 
C12/ C22 122.19 122.19 121.29 121.29 
C11/ C21 148.88 148.88 157.02 157.02 
CH3-Py - - 24.43 24.43 
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2.11.4.7 Other characterisation 
HPLC traces were acquired using a reverse phase Phenomenex C18 150 mm × 4.6 mm 
column, 0 – 40 (%B) over 15 min with solvent A (0.06 % TFA in water) and solvent B (0.06 
% TFA in CH3CN:H2O (90:10)), at a flow rate of 1 mL/min, injection volume of 5 µL, and 
detection at 254 nm. The retention times for N4-TL-1 – 33 are reported in Table 2.9 and 
Supplementary A, Sections 3.1 – 3.4. In each instance a single peak was observed which was 
used to verify purity. Log P values were generated by Chem-draw (Professional, Version 
17.1.0.105.(19)).  
ESI-MS was used to examine hydrogenated, methylated and the benzylated polyamine 
N4-TL(s). The calculated m/z found m/z and the differences are reported in Table 2.9. The 
ESI-MS for N4-TLs-1 – 33 revealed close to calculated m/z for the [M+H]
+ compared with the 
found m/z, the difference m/z averaging to 1.07 as shown in Table 2.9. The calculated and 
found m/z were concordant with predicted ESI-MS (Supplementary A, Sections 4.1 – 4.5).  
The electronic spectra (UV-Vis) of diimine N4-TL-1a and diamine N4-TL-1 polyamine 
N4-TLs demonstrated wavelength (nm) shifts between the diimine and diamine N4-TLs (Figure 
2.15, A). N4-TL-1a contains a conjugated system between the pyridine rings and Schiff base, 
therefore a red shift towards a longer wavelength with a max at 273 nm was evident. When 
reduced to diamine N4-TL-1, the conjugation has decreased at N-CH, therefore a blue shift to 
262 nm became apparent. The max for N4-TL-13 was at the same wavelength (nm) as N4-TL-1 
at 262 nm (Figure 2.15, A). The methyl substituent on the pyridine ring does not contribute to 
any changes in the conjugation or electron delocalisation of N4-TLs. Therefore, the max for 
the hydrogenated N4-TLs-1 – 6 and the methylated analogues N4-TLs-13 – 18 exhibited max 
at the same wavelength. The chiral N4-TLs-26a and N4-TL-26 exhibited max wavelength (nm) 
trends comparable to those observed for N4-TL-1 and 1a (Figure 2.15). In agreement with 
previous observations, the methylated N4-TL-30 generated a UV peak at the same max as N4-
TL-26 at 262 nm (Figure 2.15, B). The electronic spectra of N4-TL-25 has π – π
* transition 
from the conjugated system of pyridine rings and benzyl groups. N4-TL-25 exhibited a peak 
towards a longer wavelength at 263 nm. This is because of the additional benzyl groups. The 
electronic spectra of all N4-TLs were obtained, the extinction coefficient and spectra are 
reported in Table 2.9 and in (Supplementary A, Sections 2.1 – 2.7). 
CD (circular dichroism) was used to confirm the chirality. The chiral ligands RR and 
SS-pichxn will preferentially absorb one direction of the circularly polarised light resulting in 
a spectrum that indicates a specific chirality (Supplementary A, Section 5.1). To confirm the 
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chirality of N4-TL-26 and 27 shown in Figure 2.16, it demonstrates the difference in spectral 
absorption pattern between RR- and SS- ligands.  
 
 
Figure 2.15 Electronic spectra (UV-Vis) of achiral (A) and chiral (B) N4-TLs demonstrating wavelength (nm) 
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Table 2.9 Summary of the characterisation data of achiral N4-TLs 1 – 25 and chiral N4-TLs 26 – 33. 
*Log P values were generated by Chem-draw (Professional, Version 17.1.0.105.(19)).186, 187 
 
2.10 Conclusion 
The N4-TLs were synthesised and characterised using 1 and 2D-NMR (
1H, 13C, dept, COSY, 
& HMQC), MS, UV-Vis, and were appropriate CD, were acquired to confirm successful 
synthesis, purity and to characterise the resulting structures. NMR characterisation clearly 
distinguished the typical patterns and structural features between the Schiff base, 
hydrogenated, methylated and N-methylated N4-TLs. NMR studies were used to establish 
consistency with previously published structures N4-TLs picenMe2 and picenBz2. The N4-TLs 
that were characterised can now be assessed for anticancer and antimicrobial activity. 
  
 ESI-MS (m/z)  HPLC  
Name Calc. Found Calc-Found tR (mins) *Log P 
(N4-TL No.) [M+H]+ [M+H]+    
Picen (1) 243.33 243.41 -1.08 6.68 1.13 
Picpn (2) 257.35 257.40 -1.05 6.79 1.23 
Picbn (3) 271.38 271.40 -1.02 7.09 1.69 
Picptn (4) 285.41 285.46 -1.05 7.63 2.10 
Pichex (5) 299.43 299.46 -1.03 8.35 2.52 
Pichpn (6) 313.46 313.45 -0.99 9.23 2.94 
Me2picen (7) 271.38 271.40 -1.02 8.08 2.54 
Me2picpn (8) 285.41 285.46 -1.05 8.16 2.64 
Me2picbn (9) 299.43 299.45 -1.02 8.19 3.09 
Me2picptn (10) 313.46 313.45 -0.99 8.56 3.51 
Me2pichex (11) 327.49 327.45 -0.96 9.14 3.93 
Me2pichpn (12) 341.51 341.51 -1.00 9.91 4.35 
PicenMe2 (13) 271.38 271.40 -1.02 7.22 1.88 
PicpnMe2 (14) 285.41 285.46 -1.05 7.43 1.99 
PicbnMe2 (15) 299.43 299.46 -1.03 7.71 2.44 
PicptnMe2 (16) 313.46 313.45 -0.99 8.24 2.86 
PichxnMe2 (17) 327.49 327.45 -0.96 8.94 3.28 
pichpnMe2 (18) 341.51 341.51 -1.00 9.82 3.69 
Me2picenMe2 (19) 299.43 299.46 -1.03 8.80 3.29 
Me2picpnMe2 (20) 313.46 313.45 -0.99 9.24 3.40 
Me2picbnMe2 (21) 327.59 327.45 -0.86 9.34 3.85 
Me2picptnMe2 (22) 341.51 341.51 -1.00 9.71 4.27 
Me2pichexMe2 (23) 355.54 355.51 -0.97 10.34 4.68 
Me2pichpnMe2 (24) 369.57 369.51 -0.94 11.13 5.10 
PicenBz2 (25) 423.25 423.48 -1.23 8.74 5.35 
RR-pichxn (26) 297.20 297.47 -1.27 8.59 2.24 
SS-pichxn (27) 297.20 297.47 -1.27 8.58 2.24 
RR-Me2pichxn (28) 325.23 325.52 -1.29 9.73 3.17 
SS-Me2pichxn (29) 325.23 325.52 -1.29 9.69 3.17 
RR-pichxnMe2 (30) 325.23 325.52 -1.29 9.57 2.99 
SS-pichxnMe2 (31) 325.23 325.52 -1.29 9.56 2.99 
RR-Me2pichxnMe2 (32) 355.26 353.51 -1.25 11.11 4.40 
SS-Me2pichxnMe2 (33) 355.26 353.51 -1.25 11.11 4.40 




3. CHAPTER THREE: 
Investigating the biological activity of 
synthesised N4-TL compounds against 




The biological activity of the synthesised N4-TL compounds was assessed against cancer and 
bacterial cells using MTT and MIC assays. The in vitro cytotoxicity assays revealed N4-TL-25 
was 4, 2, and 16-fold more potent than cisplatin (3.69 µM), oxaliplatin (1.68 µM), and 
carboplatin (14.43 µM), respectively, in human cancer cell. N4-TL-25 was the most active 
against ovarian cancer (GI50 = 0.06 µM) and demonstrated selectivity for MCF-7 cells at 4.3-
fold more cytotoxic (GI50 = 0.3 µM) compared with MCF10A (GI50 = 1.3 µM). The 
antimicrobial activity of N4-TLs interestingly demonstrated the activity favoured Gram-
negative over positive bacteria. The MIC for N4-TL-1 was ~8 fold more potent than 
Ampicillin (MIC = > 64 µg/mL) and streptomycin (MIC = > 64 µg/mL) for A. baumannii. 
  
104 | P a g e  
 
3.1 Introduction 
The synthetic and structural versatility of multidentate ligands, together with coordination 
complexes, they can produce have diverse applications for biological and medicinal studies. 
Multidentate ligands or chelating agents coordinate using two or more chelating atoms such 
as O, N, or S to bind to metal ions. Chelating agents (e.g. Deferoxamine and deferiprone) can 
be used to treat excessively high levels of metals in the blood such as iron, copper, or nickel, 
and heavy metal poisoning (Figure 3.1).190-192 Previous studies have assessed the biological 
activity of existing chelating agents for antimicrobial and anticancer activity because of their 
affinity for metals such as iron, copper, zinc, magnesium, and manganese that are essential for 
normal cellular functions. Bacterial and cancer cells require these essential elements for 
central metabolic processes such as cell growth and proliferation. An increase in the 
importance of these metals may be linked to the formation of superbugs or biofilms or inhibit 
the efficiency of existing drugs resulting in drug resistance. Restricting the interaction of 
metal ions by using a chelator could impair the growth and proliferation of bacterial and 
cancer cells. Current antimicrobials or anticancer drugs could be used in combination with 
chelators to improve their activity. With the threat of resistance and super strains, it is of 
increasing importance to assess the antimicrobial and anticancer activity of ligands that may 
demonstrate the potential to effectively chelate metals in vivo.  
 
Figure 3.1 Chelating agents used for chelating excess metals in the blood and heavy metal poisoning. Their 
activity has been re-assessed for bacterial and cancer studies. 
 
The biological studies of iron chelating agents such as deferoxamine and deferiprone 
were evaluated against bacterial strains Acineobacter baumannii (A.baumannii), 
P.aeruginosa, S.aureus, K.pneumoniae, and E.coli. Deferiprone exhibited a growth inhibition 
against both A.baumannii and E.coli with a MIC value of 64 µg/mL.191 Cytotoxicity effects of 
deferiprone demonstrated inhibition of prostate cancer cell (TRAMP-C2) proliferation at an 
IC50 of 50.7 ± 1.0 µM.
193 Other chelating agents such as the natural product, curcumin, have 
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been reported to exhibit potent activity against cancer cells, however, its activity is limited 
due to poor solubility and rapid metabolism.194 Therefore, to improve the properties of 
curcumin, cobalt(III) prodrugs have been developed as a bio-reductive drug chaperone 
(Figure 3.2).78, 79, 195 Tris(2-methylpyridine)amine (tpa) forms stable complexes with inert 
cobalt(III) and the resulting complex, [Co(tpa)(curcumin)]3+ has been investigated as a 
chaperone for the delivery and release of curcumin, which exhibits light initiated toxicity 
towards tumour cells. A light-selective cobalt(III) complex, [Co(tpa)(curcumin)]3+, and free 
curcumin have been reported to induce cytotoxicity, towards colon cancer (DLD-1) and breast 
cancer (MCF-7), that is dependent upon applied wavelength.78, 79 In the absence of light, this 
cobalt(III) complex was less cytotoxic (DLD-1, IC50 = 45 ± 2 μM, MCF-7, IC50 = 41 ± 4 μM) 
compared to free curcumin (DLD-1, IC50 = 19 ± 2 μM, MCF-7, IC50 = 20 ± 2 μM). However, 
after irradiation at a λ of either 470 or 520 nm for 15 mins an increase in cell death is evident 
with the cobalt(III) complex against DLD-1 with IC50 of 3 ± 1 μM and MCF-7 with IC50 of 6 
± 1 μM) compared to free curcumin against the same cells, DLD-1 with IC50 of 11 ± 2 μM 
and MCF-7 with IC50 of 13 ± 42 μM).
78, 79 
 
Figure 3.2 Cobalt(III) prodrugs developed as a bio-reductive drug chaperone for the chelating agent curcumin. 
 
The design of N4-TLs can deliver different geometric configurations that contribute to 
structural control and selectivity when coordinated. Preliminary biological studies of the N4-
TL, picenMe2 (13), have showed activity with GI50 of ~ 1.8 µM against prostate cancer (PC-3) 
cells. This provoked further investigation into the biological activity of other N4-TLs. The 
base structure selected was picen (1) and derivatives were synthesised to modulate 
hydrophobicity. Herein, this chapter reports the biological activity of the synthesised N4-TLs, 
1 – 33, against both Gram-positive and negative, and mammalian cancerous cells. The 
resulting N4-TLs were assessed using MTT and MIC assays for anticancer and antimicrobial 
activity, respectively.  
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3.2 Experimental 
3.2.1 Materials and Instrumentation 
Synthesis of N4-TLs was accomplished as described in Chapter 2. Ethanol and dimethyl 
sulfoxide were all of analytical grade or higher and were purchased from Chem-supply. 
Antibiotic references ampicillin and streptomycin were both purchased from Sigma-Aldrich. 
Deionised water used for biological experiments was obtained from a Milli-Q purification 
system (Milli-Q direct 8 system or Milli-Q synergy UV). The flask cultures, agar plates, and 
96-well plate assays for antibacterial studies containing cell cultures were incubated at 30 or 
37˚C using a Thermo scientific incubator. UV-Vis absorption spectra were recorded on a 
Biochrom Ultrospec 2100 pro at room temperature 25 ˚C with optical density at λ 600 nm 
using a 1 cm cuvette. Instrumentation and media were sterilised using a Systec DX-200 
autoclave. The stock bacterial flask cultures were analysed by titrating 100 μL of stock culture 
into 900 μL of broth to determine the optimal growth at OD600 before preparing diluted 
experimental stock cultures. Microtiter plate optical densities were obtained using a Thermo 
Scientific Multiscan Ex plate reader. A group of N4-TL samples were sent to Calvary Mater 
Newcastle Hospital, Waratah, NSW Australia for cytotoxicity studies. 
3.3 Investigating the mammalian cell toxicity 
3.3.1 In vitro growth inhibition assays (GI50) 
Cytotoxicity assay studies of N4-TLs were performed at Calvary Mater Newcastle Hospital, 
Waratah, NSW Australia. In vitro studies were performed according to described methods in 
literature and from Calvary Mater facility. N4-TLs were prepared in DMSO as stock treatment 
(30 mM) solutions and stored at -20 ˚C. All of the cell lines were cultured in a humidified 
atmosphere with 5% CO2 at 37 ˚C. The cancer cell lines were maintained in Dulbecco’s 
modified eagle’s medium (DMEM; Trace Biosciences, Australia) supplemented with 10% 
fetal bovine serum, sodium bicarbonate (10 mM), penicillin (100 IU mL-1), streptomycin (100 
μg mL-1), and L-glutamine (4 mM). The non-cancer MCF10A cell line was cultured in 
DMEM.F12 (1:1) cell culture media, 5% heat-inactivated horse serum, supplemented with 
penicillin (50 IU mL-1), streptomycin (50 μg mL-1), HEPES (20 mM), L-glutamine (2 mM), 
epidermal growth factor (20 ng mL-1), hydrocortisone (500 ng mL-1), cholera toxin (100 ng 
mL-1), and insulin (10 μg mL-1). Cytotoxicity was determined by plating cells in duplicate in 
100 mL medium at a density of 2500-4000 cells per well in 96-well plates. On day 0, (24 hr 
after plating) when cells were in logarithmic growth, medium (100 μL) or without the test 
agent was added to each well. After 72 hr ligand exposure growth inhibitory (GI) effects were 
evaluated by MTT (3-[4,5-dimethyltiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay, and 
absorbance was read at 540 nm. An eight-point dose-response curve was produced, from 
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which the GI50 value was calculated, representing the drug concentration at which cell growth 
is inhibited by 50% based on the difference between the optical density values on day 0 and 
those at the end of drug exposure. 
3.4 Methods to investigating microbial activity 
3.4.1 Microbial cultures and media 
Bacteriological agar (OxoidTM), nutrient broth (NB, DifcoTM) and tryptic soy broth (TSB, 
DifcoTM) were obtained as dehydrated powder from Labtek, and prepared according to 
supplied instructions. Cell culture 96-well microtitre plates (Greiner bio-oneTM, sterile, F-
bottom), petri dishes (Greiner bio-oneTM, sterile, 94 × 16 mm, non-vented), glass pipettes and 
sterile inoculating loops were purchased from Sigma Aldrich. Experimental instrumentation 
pipette tips (200 and 1000 μL), glass flasks, troughs, liquid media, and agar were sterilised in 
an autoclave (121 ˚C, 20 mins). Cultures were inoculated from frozen glycerol stocks and 
were maintained on nutrient broth or tryptic soy broth agar plates respectively, at 4 ˚C. Liquid 
culture bacteria were incubated in desired broth at 30 or 37 ˚C, shaken at 150 rpm and 
subcultures were carried out. The method used to quantitatively estimate the viability of 
bacterial cells in a sample requires plating a range of serial dilutions and counting the colony 
forming units (CFUs). The colony forming unit (CFU) was determined by inoculating agar 
subcultures into liquid media and growing overnight and the OD595 was obtained. A ten-fold 
dilution (104-8) of each triplicate was inoculated onto the appropriate media agar (100 μL), 
and incubated overnight at 30 or 37 ˚C. The CFU count typically ranges within 2 – 30 visible 
and independent colonies, and the CFU/mL is determined by calculating the average of 
duplicates from separate subcultures. 
3.3.2 Minimum inhibitory concentration (MIC) assay and drug treatment 
The bacterial strains tested were as follows: Gram-negative bacteria, Enterobacter aerogenes 
(UNSW 045800), Klebsiella pneumonia (ATCC BAA-1705), Acinetobacter baumannii 
(ATCC BAA-1605), Proteus vulgaris (ATCC 33420), Serratia marcescens (ATCC 27137), 
and Escherichia coli (ATCC BAA-2523) and Gram-positive Micrococcus luteus (UNSW 
011000), Bacillus cereus (UNSW 055600), and Staphylococcus saprophyticus (UNSW 
523300) were obtained from University of New South Wales (UNSW) or ATCC. The 
minimum inhibitory concentration assays of N4-TLs against Gram-negative and positive 
bacteria followed similar MIC procedures in literature.196 Bacterial cultures were prepared in 
either NB or TSB (30 mL) from agar cultures. The overnight stock cultures were diluted to 
OD595 0.1, and then plated into 96-well plates with 180 μL added to each well. The N4-TL 
samples were prepared in DMSO (6.0 – 10.5 mg/mL) with 20 μL of 10× concentration added 
to each well. Final concentration of diluted culture at OD595 0.1 was incubated with each N4-
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TL of trial concentrations of 5 and 100 μM (Figure 3.3). The N4-TLs that showed activity were 
then further studied against a range of concentrations. 
 
 
Figure 3.3 Schematic experimental design of MIC preliminary studies of N4-TLs against Gram negative and 
position bacteria. 
 
The range of concentrations used for successful N4-TLs was made to 0.5 – 64 μg/mL 
in 99.5% media, 0.5% DMSO, and control. Ampicillin and streptomycin were both used as 
references for bacterial tests. The plates were incubated at 30 or 37 ˚C, 24 h experiments were 
performed to determine the MIC. The experiments performed were done in replicates with 2 – 
5 independent trials (Figure 3.4). 
 
 
Figure 3.4 Schematic experimental design of MIC studies of N4-TLs against Gram negative bacteria. 
  
109 | P a g e  
 
3.5 Results and discussion 
The biological activity of synthesised N4-TL-1 – 33 were investigated to determine their GI50 
and MIC values. Based on previous trial studies, N4-TL-13 (picenMe2) displayed anticancer 
activity against PC-3 cells, therefore, it was of interest to further investigate the activity of N4-
TLs (1 – 33). Studies with N4-TLs showed the structure-activity relationship revealed selected 
features influenced the activity against both Gram-negative and positive bacterial strains. The 
structural features selected for the N4-TLs, polyamine chains, chiral diamino-cyclohexane 
bridge, methyl, and benzyl substituents, were used to observe if the structural relationship of 
N4-TLs influenced their biological activity.  
3.5.1 Anticancer activity of N4-TLs to determine the GI50 
The anticancer activity of N4-TLs (1 – 33) together with cisplatin, oxaliplatin, and carboplatin 
were determined at Calvary Mater Newcastle Hospital. The exposure growth inhibitory (GI) 
effects were evaluated by MTT assays. MTT assays assess the cell metabolic activity of 
viable cells by a colorimetric change of the MTT dye. The activity was investigated at 72h 
treatment exposure against 11 cell lines; colon (HT29), glioblastoma (U87), breast (MCF-7), 
ovarian (A2780), lung (H460), skin (A431), prostate (Du145), neuroblastoma (BE2-C), 
glioblastoma (SJ-G2), pancreas (MIA), and breast (normal, MCF10A). N4-TLs (1 – 33) went 
through a trial dose response at 25 µM to determine the percentage growth inhibition. Active 
N4-TLs (GI50 < 50) were further examined to determine the concentration which inhibits cell 
growth by 50%. The results have been tabulated and graphed to express the GI50 values 
calculated from dose-survival curves. 
 The anticancer activity of the N4-TLs which passed preliminary screenings are 
expressed as GI50 values for ligands, N4-TLs 7, 13, 19, 25, 26, 28, 30 – 33, are summarised in 
Table 3.1. The N4-TLs produced GI50 values against 10 cell lines which are more potent than 
carboplatin and in some cell lines they are more potent than cisplatin and oxaliplatin. The 
average GI50 of N4-TLs 7, 13, 19, 25, 26, 28, 30 – 33 for the 10 cell lines was 3.35, 2.58, 
13.04, 0.91, 2.44, 9.35, 14.00, 12.20, 1.51, and 1.80 µM, respectively. Interestingly, the 
average GI50 value of N4-TL-25 was 4, 2, and 16-fold more potent than cisplatin (3.69 µM), 
oxaliplatin (1.68 µM), and carboplatin (14.43 µM), respectively, in human cancer cell (Table 
3.2). Although the N4-TL compounds are active, the average GI50 values of N4-TLs 7, 13, 19, 
25, 26, 28, 30 – 33 are ordered most potent to least 25 > 32 > 33 > 26 > 13 > 7 > 28 > 31 > 19 
> 30.  
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N4-TL-1-6 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 
N4-TL-7 7.1 ± 1.9 >50 6.4 ± 2.8 0.3 ± 0.11 6.5 ± 2.2 >50 2.7 ± 0.2 2.3 ± 1.5 7.2 ± 4.9 21 ± 9.2 25 ± 11 
N4-TL-8-12 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 
N4-TL-13 2.7 ± 0.067 2.8 ± 0.19 2.7 ± 0.22 2.8 ± 0.15 2.7 ± 0.14 2.6 ± 0.12 1.9 ± 0.058 2.8 ± 0.15 2.3 ± 0.13 2.5 ± 0.12 2.9 ± 0.000 
N4-TL-14-18 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 
N4-TL-19 4.5 ± 0.17 27 ± 8.6 8.7 ± 2.8 0.28 ± 0.066 13 ± 1.3 20 ± 5.5 15 ± 3.5 4.9 ± 1.8 14 ± 5.1 23 ± 3.8 16 ± 3.9 
N4-TL-20-24 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 
N4-TL-25 0.20 ± 0.03 1.5 ± 0.5 0.30 ± 0.10 0.06 ± 0.03 0.83 ± 0.29 2.1 ± 0.1 1.7 ± 0.3 0.14 ± 0.03 0.22 ± 0.03 2.0 ± 0.2 1.3 ± 0.3 
N4-TL-26 2.7 ± 0.23 2.4 ± 0.17 2.1 ± 0.27 3.0 ± 0.12 2.4 ± 0.22 2.5 ± 0.23 2.1 ± 0.033 2.2 ± 0.22 2.1 ± 0.23 2.9 ± 0.13 2.2 ± 0.067 
N4-TL-27 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 
N4-TL-28 11 ± 3.0 9.0 ± 4.6 8.9 ± 3.7 12 ± 2.9 13 ± 4.6 10 ± 4.8 7.8 ± 3.2 1.8 ± 0.77 6.0 ± 2.9 14 ± 3.6 10 ± 3.8 
N4-TL-29 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 
N4-TL-30 13 ± 1 17 ± 0 15 ± 1 13 ± 0 13 ± 0 13 ± 0 13 ± 0 15 ± 1 13 ± 1 15 ± 1 14 ± 1 
N4-TL-31 13 ± 1 16 ± 0 15 ± 0 10 ± 2 13 ± 0 10 ± 2 12 ± 1 13 ± 0 10 ± 2 10 ± 1 13 ± 0 
N4-TL-32 0.20 ± 0.08 2.7 ± 0.6 0.36 ± 0.15 0.37 ± 0.22 0.64 ± 0.28 3.4 ± 0.7 2.9 ± 1.4 1.9 ± 0.5 0.11 ± 0.02 2.5 ± 1.1 0.28 ± 0.07 
N4-TL-33 0.23 ± 0.10 3.4 ± 0.8 1.3 ± 0.3 0.06 ± 0.01 0.64 ± 0.18 4.6 ± 1.1 2.9 ± 1.0 2.3 ± 0.6 0.16 ± 0.01 2.4 ± 0.6 0.28 ± 0.05 
Cisplatin 11.3 ± 1.9 3.8 ± 1.1 6.5 ± 0.8 1.0 ± 0.1 0.9 ± 0.2 2.4 ± 0.3 1.2 ± 0.1 1.9 ± 0.2 0.4 ± 0.1 7.5 ± 1.3 nd 
Oxaliplatin 0.9 ± 0.2 1.8 ± 0.2 0.5 ± 0.1 0.16 ± 0.0 1.6 ± 0.1 4.1 ± 0.5 2.9 ± 0.4 0.9 ± 0.2 3.0 ± 1.2 0.9 ± 0.2 nd 
Carboplatin >50 >50 >50 9.2 ± 2.9 14 ± 1.0 24.3 ± 2.2 14.7 ± 1.2 18.7 ± 1.2 5.7 ± 0.2 >50 nd 
*Primary cell line (Breast Normal MCF10A). 
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Table 3.2 Average of GI50 values (Concentration µM) and fold potency against cisplatin, oxaliplatin, and 
carboplatin. 
Complex *Log P Average* GI50 
values (µM) 
cisplatin oxaliplatin carboplatin 
N4-TL-7 2.49 3.35 1 - 4 
N4-TL-13 1.87 2.58 1 1 6 
N4-TL-19 3.32 13.04 - - 1 
N4-TL-25 5.35 0.91 4 2 16 
N4-TL-26 2.32 2.44 2 1 6 
N4-TL-28 3.68 9.35 - - 2 
N4-TL-30 3.06 14.00 - - 1 
N4-TL-31 3.06 12.20 - - 1 
N4-TL-32 4.41 1.51 2 1 10 
N4-TL-33 4.41 1.80 2 1 8 
Cisplatin  3.69    
Oxaliplatin  1.68    
Carboplatin  14.43    
*Average of HT29, U87, MCF-7, A270, H460, A431, Du145, BE2-C, SJ-G2, MIA cell lines 
*Log P values were generated by Chem-draw (Professional, Version 17.1.0.105.(19)).186, 187 
 
The distinguishing structural feature of these N4-TLs include N-substitution (methyl or 
benzyl), pyridine methyl substitution, achiral and chiral polyamine bridge. Each of these 
demonstrated distinct cytotoxicity effects. The methyl N-substitution for N4-TL-19 showed a 
slight improvement in activity compared to N4-TL-7. This is also evident with N4-TL-28 
compared with N4-TL-32 and 33. However, a similar ligand without the pyridine methyl 
substituent, N4-TL-13, was significantly more potent than N4-TL-7 and 19. The activity of N4-
TL-13 was fairly similar to N4-TL-26, which suggests replacing an achiral for a chiral 
polyamine bridge does not influence the activity significantly. The coordination sphere is 
identical for both N4-TL-13 and 26 making them more susceptible in coordinating with 
biological metals, therefore, possibly contributing to their activity. The introduction of benzyl 
N-substitution, N4-TL-25, resulted in an improvement in activity compared to N4-TL-13. The 
chirality of N4-TL-30 – 33 RR- and SS- dach, produced no major difference in activity. N4-TL-
26 was cytotoxic as a result of its N-methylated N4-TLs, 30 and 31. Interestingly, N4-TL-28 
was less cytotoxic than its N-methylated N4-TLs, 32 and 33. The methyl pyridine substitution 
influenced the activity when comparing N4-TLs 30 and 31 to N4-TLs, 32 and 33. These 
differences suggest that the cytotoxicity of N4-TLs could be improved by modifying the N-
substitution.  
The N4-TLs 13, 25, 26, 32, and 33 were the most potent, when their cytotoxicity was 
compared against various cell lines as demonstrated in Figure 3.5. The activity of N4-TLs 25, 
32, and 33 proved to be overall more potent than N4-TLs 13 and 26 against colon (HT29), 
glioblastoma (SJ-G2), ovarian (A2780), lung (H430), neuroblastoma (BE2-C, 25), breast 
(MCF-7, 25 and 32), and breast normal (MCF10A, 32 and 33) (Figure 3.5). It is evident that 
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N-substitution and methyl pyridine substitution, e.g. N4-TLs 25, 32, and 33, has an impact on 
the cytotoxicity. The cytotoxicity of N4-TLs 13 and 26 were almost equally active across all 
cell lines with an average GI50 of 2.58 and 2.44 µM, respectively. The chirality of the 
polyamine bridge had no influence on their activity. The N4-TLs 25, 32, and 33 were the most 
potent against colon (HT29) (GI50 = 0.20, 0.20, and 0.23 µM), glioblastoma (GI50 = 0.22, 
0.11, and 0.16 µM), and ovarian (GI50 = 0.06, 0.37, and 0.06 µM, respectively). The 
cytotoxicity of N4-TLs 13, 25, 26, 32, and 33 were evaluated against cancerous breast (MCF-
7) and non-tumour human breast (MCF10A) cells (Figure 3.5). N4-TLs 25 was the most 
selective for MCF-7 cells with a 4.3-fold increase in cytotoxicity (GI50 = 0.3 µM) compared 
with MCF10A (GI50 = 1.3 µM). N4-TLs 33, however, was 4.3-fold more cytotoxic in 
MCF10A (GI50 = 0.3 µM) than MCF-7 (GI50 = 1.3 µM). The remaining N4-TLs 13, 26, and 32 
exhibited relatively equal activity against both MCF-7 (GI50 = 2.7, 2.1, and 0.4 µM) and 
MCF10A (GI50 = 2.9, 2.2, and 0.3 µM), respectively. These results show that N4-TLs 25 has 
some selectivity for breast cancer cells. 
 
Figure 3.5 GI50 values of  N4-TL-13,  N4-TL-25,  N4-TL-26,  N4-TL-32 and  N4-TL-33 in multiple cell 
lines: colon (HT29), glioblastoma (U87 and SJ-G2), ovarian (A2780), lung (H460), skin (A431), prostate 
(Du145), neuroblastoma (BE2-C), pancreas (MIA), breast (MCF-7), and breast normal (MCF10A). 
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Overall, the GI50 studies of N4-TLs 7, 13, 19, 25, 26, 28, 30 – 33, demonstrated 
comparable results to cisplatin, oxaliplatin, and carboplatin. N-substitution improved the 
activity of N4-TLs 13, 19, and 25, whereas, no difference in activity was observed between N-
substituted chiral RR- and SS-N4-TLs 30 – 33. Methyl pyridine substitution, however, 
improved activity as shown with N4-TLs 32 and 33. The remaining N4-TLs (1 – 6, 8 – 12, 14 – 
18, 20 – 24, 27 and 29) which did not pass preliminary screenings, incorporated extended 
polyamine bridges, both hydrogenated or methylated. This structural feature did not increase 
anticancer activity but may be used for other synthetic purposes. The most cytotoxic ligand, 
N4-TL 25, which demonstrated activity against colon (HT29), glioblastoma (SJ-G2), ovarian 
(A2780), and neuroblastoma (BE2-C) in sub-micromolar concentrations and selectivity 
towards breast cancerous (MCF-7) over breast normal (MCF10A) cells.  
3.5.2 Antimicrobial activity of N4-TLs in standard growth conditions to determine MIC 
The antimicrobial activity of N4-TLs was investigated at Western Sydney University, where 
the MIC (µg/mL) was evaluated by MIC assays. MIC assays assess the lowest concentration 
of the treatment (drug) which inhibits visible growth of bacterium. The in vitro antimicrobial 
activity was tested against a selection of 6 bacteria, they include gram-positive bacteria 
M.luteus, B.cereus, S.saprophyticus and S.epidermidis and gram-negative bacteria 
E.aerogenes, K.pneuminiae, A.baumannii, P.vulgaris, S.marcescens and E.coli. The N4-TL (1 
– 33) underwent a preliminary screen using concentrations of 5 and 100 µM which were 
incubated with selected Gram-positive and negative bacteria for 24 hrs. Active N4-TLs were 
further examined to determine the lowest concentration which inhibits bacterial growth. 
Interestingly, the N4-TLs with bacterial activity during the trial favoured Gram-negative over 
Gram-positive bacteria. Therefore, only the assays against Gram-negative bacteria were 
conducted. Methods have been standardised for clinical application by various organisations 
which include the European Committee of Antimicrobial Susceptibility Testing (EUCAST) 
and the Clinical and Laboratory Standards Institute (CLSI).196 Utilising clinical standardised 
protocols for drug development can ensure accurate comparison to existing agents and high 
throughput evaluation. The MIC (µg/mL) values for active N4-TLs 1, 13, 25, 26, and 27 are 
summarised in Table 3.3 and Figure 3.6.  
N4-TLs 1, 13, 25, 26, and 27 were less effective as antimicrobial agents compared to 
streptomycin across most bacteria. The average MIC (µg/mL) for the N4-TLs 1, 13, 25, 26, 
and 27 was 8 and 16 µg/mL, respectively. Notably, the MIC for N4-TLs 1 was ~8 fold more 
potent than Ampicillin (MIC = > 64 µg/mL) and streptomycin (MIC = > 64 µg/mL) for A. 
baumannii. While, N4-TLs 13, 25, 26, and 27 were 1 or 2-fold more active than ampicillin, 
respectively, across most bacteria except E.coli and E.aerogenes. Although, the N4-TLs show 
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some antimicrobial activity their mechanism of action is unknown. The structure and nature 
of these ligands may suggest they chelate with biological available metals. The biological 
metals such as iron, zinc, magnesium, and copper are essential for cellular and subcellular 
functions, both bacterial and cancer cells may utilise these metals for their functions in order 
to survive and replicate. Chelating with biological metals may disrupt these functions, 
therefore, inhibiting the growth of bacterial and cancer cells. 
 
Table 3.3 MIC (µg/mL) values of N4-TLs and references Ampicillin and Streptomycin against Gram negative 
bacteria. 
 
A clear structure-activity relationship was observed for the N4-TLs 1, 13, 25, 26, and 
27 which was dependent on the N-substituted groups, together with achiral and chiral 
polyamine bridges. N4-TL 1 and its N-substituted derivatives (N4-TLs 13 and 25), showed that 
benzyl substitution (N4-TLs 25) was least active across all bacteria compared to the methyl 
(N4-TLs 13) and non-N-substituted ligand (N4-TLs 1). Interestingly, the log P values 
determined using Chem-draw demonstrated that the least lipophilic ligand (N4-TL 1, log P = 
1.13) was most active. This was followed closely by N4-TLs 13 (log P = 1.87). The most 
lipophilic ligand was the least active ligand (N4-TL 25, log P = 5.35). As the N4-TLs become 
increasingly non-polar with N-substitution (H < CH3 < Bz) it was observed that the activity 
decreased. In Gram-negative bacteria, N4-TLs 1 and 13 demonstrated the highest activity thus 
it can be inferred that they have a log P value optimal for absorption through both the lipid 
bilayer and peptidoglycan layer. In contrast it is hypothesised that N4-TL 25 having a higher 
log P value may demonstrate that diffusion occurs through the lipid bilayer, but its increased 
hydrophobicity hinders its ability to diffuse through the peptidoglycan layer resulting poorer 
activity. This also confirms the lack of activity against Gram-positive bacteria suggesting the 
N4-TLs are not hydrophilic enough to diffuse through the thick peptidoglycan layer. Overall, 
the order of activity increases for these ligands, N4-TLs-1 > 13 > 26 = 27 > 25 as they become 
more polar and therefore have lower log P values. 
MIC Results 
 E. coli A. baumannii K. pneumonia P. vulgaris S. marcescens E. aerogenes 
N4-TL-1 16 8 16 8 8 16 
N4-TL-13 8 64 16 8 64 32 
N4-TL-25 64 >64 >64 64 64 >64 
N4-TL-26 16 64 16 8 64 64 
N4-TL-27 16 64 16 8 64 64 
Ampicillin 2 >64 16 16 16 2 
Streptomycin 2 >64 2 2 2 2 
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Figure 3.6 Percentage growth (%) values of  N4-TL-1,  N4-TL-13,  N4-TL-25,  N4-TL-26, and  N4-TL-27 
in Gram-negative bacteria: E.coli, A.baumanni, K.pneumonia, P.vulgaris, S.marcescens, and E.aerogenes. 
 
3.6 Conclusion 
The biological activity of the synthesised N4-TLs, 1 – 33, were successfully assessed using 
MTT and MIC assays for anticancer and antimicrobial activity. The hydrophobicity was 
modulated by N-substitution and pyridine ring substitution which influenced the activity of 
N4-TLs. Preliminary in vitro cytotoxicity screening against 10 cancerous cell lines and 1 non-
cancerous cell line produced results for N4-TLs 7, 13, 19, 25, 26, 28, and 30 – 33. N4-TL, 25, 
was the most active and more potent than cisplatin, oxaliplatin, and carboplatin, on average 
but also in specific cancer cell lines. Results demonstrated that N4-TL-25 was cytotoxic 
against ovarian (A2780) cancer cell lines with a GI50 of 0.06 µM, and selectivity was 
observed between cancerous breast (MCF-7) compared with normal breast (MCF10A) cells. 
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The order of activity of the top five N4-TLs, 25 > 32 = 33 > 26 > 13 increases for these ligands 
as they become more lipophilic and therefore have a higher log P value. 
Interestingly, the MIC results of N4-TLs also correlated with their log P value. N4-TLs, 
1, 13, 25, 26, and 27 were more active against Gram negative compared to Gram positive 
bacteria. The N-substitution (N4-TLs 1, 13, and 25) and chiral bridge (N4-TLs 26 and 27) 
demonstrated that the more non-polar ligands (Bz > RR = SS >CH3 > H) had the least activity. 
N4-TL, 25, with a log P value of 5.35 is the least active across all bacteria. The most active 
N4-TL, 1, with a log P value of 1.13 is more potent that ampicillin and streptomycin against 
A.baummanii. The order of activity increases for these ligands 1 > 13 > 26 = 27 > 25 as they 
become more polar and therefore have a lower log P value. 
The biological activity of N4-TLs against mammalian cancerous and bacterial cells was 
successfully investigated. The mechanism of action is unknown, but it may be suggested the 
N4-TLs could chelate biologically important metals. Depleting the biological metals such as 
iron, copper, magnesium or zinc that both cancer and bacterial cells utilise, disrupting the 
cellular and subcellular functions for growth and proliferation and therefore, inhibiting the 
growth. Further investigation will be required to determine the mode of action. These N4-TLs 
are synthetically versatile and structurally flexible, making them ideal scaffolds for 
coordination of metals for applications in biological and medicinal studies. Ruthenium(II/III) 
complexes have demonstrated potential as anticancer agents with several exhibiting ideal 
anticancer and antimetastatic properties. In the following chapter, N4-TLs-13 and 25, were 
chosen to coordinate with ruthenium(II) as they demonstrated different activity against cancer 
and bacterial cells. Coordinating these ligands to ruthenium(II) produces different stereo-
chemistries based on reports in the literature. Determining the differences in activity of the 
N4-TLs coordinated to ruthenium(II) is of interest in this work.  
 
  




4. CHAPTER FOUR: 
The synthesis and characterisation of 







A series of complexes of the type rac-[Ru(N4-TL)(PL)]
2+ (where N4-TL = 1,6-di(2'-pyridyl)-
2,5-dimethyl-2,5-diazahexane (picenMe2, N4-TL-13) and 1,6-di(2'-pyridyl)-2,5-dibenzyl-2,5-
diazahexane (picenBz2, N4-TL-25) and PL= 1,10-phenanthroline (phen), dipyrido[3,2-d:2',3'-
f]quinoxaline (dpq), 7,8-dimethyl-dipyrido[3,2-a:2',3'-c] phenazine (dppzMe2), 2-phenyl-1H-
imidazo[4,5-f][1,10]phenanthroline (phenpyrBz), 2-(p-tolyl)-1H-imidazo[4,5-f][1,10]phen 
anthroline (phenpyrBzMe), 2-(4-nitrophenyl)-1H-imidazo[4,5-f][1,10]phenanthroline 
(phenpyrBzNO2), were synthesised forming ruthenium(II)-1 – 14. All structures were 
confirmed using NMR, ESI-MS, HPLC, UV, and for four complexes X-ray crystallography. 
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4.1 Introduction 
Platinum(II)-based complexes are well known for their anticancer properties, stimulating the 
further development of cytotoxic metal complexes with anticancer properties.19 Since 1971, 
when cisplatin entered clinical trials, there has been a continuing interest in alternatives to 
platinum-based drugs for anticancer therapy.84 Other metal-based drugs other than 
platinum(II),68-70, 72, 73 such as copper(II),74, 75 cobalt(I)/(II),78-80 iron(II),76, 77 and those which 
incorporate ruthenium(II)/(III)81-83 have been of interest. Ruthenium is a group 8 metal, 
appearing in the second transition series of the periodic table, the 4d subshell is partly filled 
where it has demonstrated to  exhibits similar properties to the group 10 metal, such as 
platinum from the third transition series with the 5d subshell partly filled. Metals with 4d and 
5d orbitals, readily form octahedral complexes. The range of oxidation states ruthenium offers 
is accessible chemically and electrochemically and the kinetic stability of the various 
oxidation states affords a wide range of mixed ligand complexes. The synthetic versatility and 
kinetic properties of ruthenium(II/III) complexes makes them excellent scaffolds for potential 
application as anticancer agents.137-139  
Ruthenium complexes have been synthesised to ameliorate cisplatin cytotoxicity and 
resistance. Several ruthenium(II/III) complexes have been developed which have shown ideal 
anticancer and antimetastatic properties. Ruthenium complexes, such as NAMI-A, KP1019, 
and ruthenium(II) arene complexes are structurally versatile and have expressed effective 
anticancer activity (Figure 4.1).23, 24, 26-28 The activity of ruthenium(II) complexes  not only 
show activity against cancer but their antimicrobial activity is also promising. 
 
Figure 4.1 These are ruthenium(III) complexes that show some anticancer or antimetastatic activity NAMI-A, 
KP1019 and generic arene complex. 
 
There is an urgency to develop new classes of antimicrobial agents due to the misuse 
and overuse of current antibacterial agents which has in turn facilitated emergence of drug 
resistant microorganisms. Ruthenium(II/III) complexes, in particular display ideal chemical 
properties due to their ligand exchange kinetics, ability to bind with nucleic acid and proteins 
through physical interactions via groove binding or intercalation, and to mimic iron when 
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bound to biological molecules. The antibacterial activities of RuII-polypyridal complexes were 
extensively reported by Dwyer and co-workers in the 1950s.140-142 Examples of these 
complexes include, mononuclear ([Ru(Me4phen)3]
2+, [Ru(2,9-Me2phen)2(dppz)]
2+) and 
dinuclear ruthenium complexes ([{Ru(bpy)2}2(µ-bbn)]
4+ ,where n = 2, 5, 7, 10, 12, or 16) 
(Figure 4.2).140, 142, 171, 197, 198  
 
Figure 4.2 RuII-polypyridal complexes which have shown the ability to bind with nucleic acid and proteins 
through physical interactions via groove binding or intercalation, and to mimic iron when bound to biological 
molecules. 
 
This chapter details the two-step synthetic strategy used to coordinate ruthenium(II) 
with N4-TL 13 and 33, (1,6-di(2'-pyridyl)-2,5-dimethyl-2,5-diazahexane (picenMe2, N4-TL-13) 
and 1,6-di(2'-pyridyl)-2,5-dibenzyl-2,5-diazahexane (picenBz2, N4-TL-33), from Chapter 2, 
and a selection of examples of bidentate ligands. A comprehensive characterisation of the 
resulting complexes was also undertaken. The N4-TLs 13 and 25 that were produced in ample 
yields (96% and 56%, respectively), show biological activity (See Chapter 3) and can adopt 
different isomeric forms upon coordination to ruthenium. Of the resulting octahedral 
ruthenium(II) complexes, the N4-TLs occupy four coordination sites with the remaining two 
sites available for coordination by a bidentate ligand. The selected bidentate ligands include 
1,10-phenanthroline (phen), dipyrido[3,2-d:2',3'-f]quinoxaline (dpq), 7,8-dimethyl-
dipyrido[3,2-a:2',3'-c] phenazine (dppzMe2), phenpyrBz, phenpyrBzMe, and phenpyrBzNO2. 
Characterisation techniques were used to verify the formulations and confirm purity.  
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4.2 Experimental 
4.2.1 Materials and Instrumentation 
Deuterated solvents DMSO-D6 and CDCl3 (~ 10 mg of sample in 500 µL of deuterated 
solvent) were purchased from Cambridge Isotope Laboratories. Solvents DMSO, ethanol, and 
acetone used were of analytical grade or higher and were obtained from chem-supply. 
Deionised water used for reactions was obtained from Milli-Q purification system (Millipore 
direct 8 system). Reagents ethylene glycol, potassium hexafluorophosphate, and 1,10-
phenanthroline (phen) were purchased from Sigma-Aldrich. Ruthenium(III) chloride (n) 
hydrate was purchased from Precious Metals Online. The synthesised N4-TLs: 1,6-di(2'-
pyridyl)-2,5-dimethyl-2,5-diazahexane (picenMe2, N4-TL-13) and 1,6-di(2'-pyridyl)-2,5-
dibenzyl-2,5-diazahexane (picenBz2, N4-TL-33) were synthesised in Chapter 2. Bidentate 
ligands dpq, dppzMe2, phenpyrBz, phenpyrBzMe, and phenpyrBzNO2 were made available 
from the laboratory of J. Aldrich-Wright at Western Sydney University. Instrumentation used 
for characterisation included; 400 MHz Bruker Avance NMR, Cary 1E spectrophotometer 
UV-Vis, Agilent technologies 1260 infinity HPLC, and Waters Xeno TQ MS. The set-up and 
parameters used for characterisation are described in Chapter 2, Section 2.2.2. 
 4.3 Synthesis of ruthenium(II) complexes 
4.3.1 Synthesis of dichlorotetrakis(dimethylsulfoxide)ruthenium(II) [Ru(DMSO)4Cl2] 
A solution of DMSO (24 mL) was added to RuCl3.nH2O (1.0 g, 4.82 mmol), the sealed 
reaction mixture was flushed with nitrogen for 10 mins. The nitrogen gas was removed, then 
refluxed at ~189 °C for 5 mins or until the solution turned orange/red. The stoppers were 
removed, and the mixture continued to be heated while nitrogen was bubbled though the 
reaction vessel until the solution reduced in volume by half (12 mL), and a yellow precipitate 
started to form. The reaction mixture was removed from heat, acetone (40 mL) was added and 
the mixture cooled slowly, whereupon a yellow precipitate formed. The precipitate was 
collected by vacuum filtration, washed with acetone (2 × 50 mL) and diethyl-ether (2 × 5 
mL). Yield: 1.40 g (60%). 1H-NMR (400 MHz, CDCl3) δ: 3.53, 3.51, 3.44, and 3.34 (Me of 
DMSO, S-Ru linked), 2.74 (Me of DMSO, O-Ru linked), 2.65 (Me of free DMSO); ratio S-
Ru: O-Ru 4:1. 13C-NMR (400 MHz, CDCl3) δ: 47.7, 46.7, 44.5, 44.3 (Me of DMSO, S-Ru 
linked), 38.8 (Me of DMSO, O-Ru linked). UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, H2O): 230 
(10.1 ± 0.1 × 103), 346 (565). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 0-40 % B 
over 15 min, tR 6.46 min at 254 nm. 
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Scheme 4.1 Synthesis of ruthenium(II) precursor cis-[Ru(DMSO)4Cl2]. 
 
4.3.2 Synthesis of cis-α-[Ru(picenMe2)(DMSO)Cl](PF6) (Ru-1) 
A solution of [Ru(DMSO)4Cl2] (0.34 g, 0.7 mmol), dissolved in water (1.25 mL) and ethanol 
(7.5 mL), was added dropwise to a warm stirred solution of picenMe2 (0.108 g, 0.4 mmol) in 
ethanol (12.5 mL). The yellow mixture was refluxed at 95 ˚C for 2 h resulting in an 
orange/red solution. The reaction solution was reduced in volume to ~5 mL by evaporating 
most of the ethanol, and then a saturated solution of potassium hexafluorophosphate (KFP6, 1 
mL) was added to precipitate the product. The product was left to precipitate 24 – 72 h, before 
collection by filtration, washed with water (2 × 3 mL), then diethyl ether (2 × 3 mL) and air 
dried. Yield: 65.8 mg (26%). (Ru-1) 1H-NMR (400 MHz, DMSO-d6) δ: 9.14 (d, 1H, J1 = 5.65 
Hz, H21), 9.10 (d, 1H, J1 = 5.23 Hz, H11), 8.06 (t, 1H, J1 = 7.72 Hz, H13), 7.96 (t, 1H, J1 = 
7.68 Hz, H23), 7.74 (d, 1H, J1 = 7.68 Hz, H14), 7.70 (d, 1H, J1 = 7.72 Hz, H24), 7.59 (m, 1H, 
H12), 7.59 (m, 1H, H22), 4.96 (d, 1H, J1 = 14.88 Hz, H16a), 4.35 (d, 1H, J1 = 8.44 Hz, 
H26a/b), 4.28 (d, 1H, J1 = 15.08 Hz, H16b), 3.21 (s, 3H, S-CH3), 2.63 (m, 1H, H2a/b), 2.55 
(s, 3H, N-CH3), 2.47 (s, 3H, N-CH3), 2.40 (m, 1H, H1a/b), 2.27 (s, 3H, S-CH3).
 13C-NMR 
(400 MHz, DMSO-d6) δ: 162.13 (C15), 161.70 (C25), 155.83 (C11), 153.37 (C12), 138.24 
(C13), 137.49 (C23), 125.19 (C12), 125.05 (C22), 123.78 (C14), 123.55 (C24), 70.02 (C26), 
67.62 (C16), 59.61 (C1), 57.45 (C2), 46.99 (N-CH3), 45.56 (N-CH3), 45.45 (S-CH3), 43.53 
(S-CH3). ESI-MS (MeOH:H2O, 0.1% Formic acid, [M]
+ m/z): Calculated (m/z): 485.08, found 
(m/z): 485.04. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, DMSO): 247 (10.1 ± 0.09 × 103), 346 (8.0 
± 0.1 × 103). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 10-100 % B over 15 min, tR 
4.44 min at 254 nm. 
4.3.3 Synthesis of cis-β-[Ru(picenBz2)(DMSO)Cl](PF6) (Ru-2) 
The method used to synthesise cis-α,β-[Ru(N4-TL)(DMSO)Cl](PF6) followed the procedure 
detailed in Section 4.3.2, where N4-TLs picenBz2 (170.0 mg, 0.4 mmol), an orange precipitate 
was obtained. Yield: 189.0 mg (60%). (Ru-2) 1H-NMR (400 MHz, DMSO-d6) δ: 8.59 (d, 1H, 
J1 = 5.00 Hz, H11), 8.07 (t, 1H, J1 = 7.70 Hz, H13), 7.87 (t, 1H, J1 = 7.76 Hz, H23), 7.82 (d, 
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1H, J1 = 7.60 Hz, H14), 7.76 (d, 1H, J1 = 5.40 Hz, H24), 7.67 (m, 1H, H12), 7.65 (m, 1H, 
H22), 7.43 – 7.56 (m, 8H, ArH), 7.29 (m, 2H, H114/224), 7.27 (m, 1H, H21), 5.01(d, 1H, J1 = 
16.84 Hz, H16a), 4.94 (d, 1H, J1 = 13.52 Hz, H220a), 4.86 (d, 1H, J1 = 14.96 Hz, H26a), 4.52 
(d, 1H, J1 = 13.52 Hz, H220b), 4.34 (m, 1H, H1a), 4.27 (d, 1H, J1 = 16.16 Hz, H110a), 3.79 
(d, 1H, J1 = 16.92 Hz, H16b), 3.59 (m, 1H, H110b), 3.55 (s, 3H, S-CH3), 3.43 (d, 1H, J1 = 
15.04 Hz, H26b), 3.02 (d, 1H, J1 = 12.36 Hz, H2a), 2.93 (m, 1H, H1b), 2.92 (s, 3H, S-CH3), 
2.26 (m, 1H, H2b). 13C-NMR (400 MHz, DMSO-d6) δ: 166.92 (C15), 163.17 (C25), 157.79 
(C11), 152.41 (C24), 138.04 (C13), 137.72 (C23), 133.22 (C21), 132.94 (22), 132.43 (C-Ar), 
131.72 (C-Ar), 129.11 (C12), 128.95 (C-Ar), 125.71 (C-Ar), 125.45 (C114/224), 125.16 
(C14), 121.42 (C-Ar), 67.67 (C220), 67.07 (C16), 64.72 (C1), 59.90 (C110), 57.44 (C26), 
51.86 (C2), 46.14 (S-CH3), 44.36 (S-CH3). ESI-MS (MeOH:H2O, 0.1% Formic acid, [M]
+ 
m/z): Calculated (m/z): 637.14, found (m/z): 637.11. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, 
DMSO): 250 (13.9 ± 0.2 × 103), 360 (7.5 ± 0.09 × 103). RP-HPLC Phenomenex C18 5 μm 






Scheme 4.2 Coordination of ruthenium(II) precursor cis-[Ru(DMSO)4Cl2] with a N4-TL, forming either cis-α or 
cis-β-[Ru(N4-TL)(DMSO)Cl]PF6. 
 
4.4 Synthesis of [Ru(N4-TLs)(N2-bidentate)](PF6)2 
4.4.1 Synthesis of rac-α-[Ru(picenMe2)(N2-bidentate)](PF6)2 
The method used to synthesise rac-α-[Ru(picenMe2)(bidentate)](PF6) followed the procedure 
detailed in literature with some changes.83 A sample of cis-α-[Ru(picenMe2)(DMSO)Cl](PF6) 
(24.8 mg, 0.038 mmol) was refluxed at 120 °C for 6 hours in 1:1:1 water, ethanol, and 
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ethylene glycol (30 mL) containing a selected bidentate ligand; phen (13.5 mg, 0.08 mmol), 
dpq (17.4 mg, 0.08 mmol), dppzMe2 (23.3 mg, 0.08 mmol), phenpyrBz (22.2 mg, 0.08 
mmol), phenpyrBzMe (23.3 mg, 0.08 mmol), and phenpyrBzNO2 (25.6 mg, 0.08 mmol). 
Then a saturated solution of KPF6 (2 mL) was added to precipitate orange/red complex after 
24 – 72 hr. The resulting ruthenium(II) complex was filtered and washed with water (2 × 5 
mL) and diethyl ether (2 × 5 mL), then air-dried. 
 
Scheme 4.3 Coordination of cis-α-[Ru(picenMe2)(DMSO)Cl]PF6 or cis-β-[Ru(picenBz2)(DMSO)Cl]PF6 with 
bidentate ligands phen, dpq, dppzMe2, phenpyrBz, phenpyrBzMe, and phenpyrBzNO2, forming racemic cis-α or 
cis-β-[Ru(picenMe2 or picenBz2)(bidentate)](PF6)2. 
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4.4.2 Synthesis of rac-β-[Ru(picenBz2)(N2-bidentate)](PF6)2 
The method used to synthesise rac-β-[Ru(picenBz2)(bidentate)](PF6) followed the procedure 
detailed in Section 4.4.1, where, rac-β-[Ru(picenBz2)(bidentate)](PF6) (24.8 mg, 0.03 mmol), 
and bidentate ligands phen (10.9 mg, 0.06 mmol), dpq (13.9 mg, 0.06 mmol), dppzMe2 (18.6 
mg, 0.06 mmol), phenpyrBz (17.8 mg, 0.06 mmol), phenpyrBzMe (18.6 mg, 0.06 mmol), and 
phenpyrBzNO2 (20.5 mg, 0.06 mmol). 
4.4.3 Synthesis of rac-α-[Ru(picenMe2)(phen)](PF6)2 (Ru-3) 
Yield: 22.2 mg (67%). (Ru-3) 1H-NMR (400 MHz, DMSO-d6) 
δ: 9.77 (d, 2H, J1 = 4.96 Hz, H7/7ʹ), 8.72 (d, 2H, J1 = 7.80 Hz, 
H9/9ʹ), 8.25 (s, 2H, H19/19ʹ), 8.07 (m, 2H, H11/21), 7.73 (t, 
2H, J1 = 7.70 Hz, H13/23), 7.63 (d, 2H, J1 = 7.68 Hz, H14/24), 
7.58 (d, 2H, J1 = 5.40 Hz, H8/8ʹ), 7.06 (t, 2H, J1 = 6.58 Hz, 
H12/22), 5.14 (d, 2H, J1 = 16.84 Hz, H16/26b), 4.54 (d, 2H, J1 
= 16.96 Hz, H16/26a), 2.88 (s, 6H, N-CH3), 2.74 (m, 4H, H1/2ab). 
13C-NMR (400 MHz, 
DMSO-d6) δ: 161.47 (C15/25), 156.87 (C7/7ʹ), 152.27 (C8/8ʹ), 148.97 (C17/17ʹ), 137.22 
(C9/9ʹ), 136.91 (C13/23), 130.49 (C18/18ʹ), 128.37 (C19/19ʹ), 126.74 (C11/21), 125.27 
(C12/22), 123.33 (C14/24), 68.49 (C16/26), 60.79 (C1/2), 47.67 (N-CH3). ESI-MS 
(MeOH:H2O, 0.1% Formic acid, [M]
+ m/z): Calculated (m/z): 697.12, found (m/z): 697.12. 
UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, DMSO): 271 (52.1 ± 3.0 × 103), 369 (15.8 ± 0.6 × 103), 
442 (8.2 ± 0.3× 103), 476 (7.3 ± 0.3× 103). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 
10-100 % B over 15 min, tR 8.84 min at 254 nm. 
4.4.4 Synthesis of rac-α-[Ru(picenMe2)(dpq)](PF6)2 (Ru-4) 
Yield: 17.0 mg (48%). (Ru-4) 1H-NMR (400 MHz, DMSO-d6) δ: 
9.87 (d, 2H, J1 = 4.96 Hz, H7/7ʹ), 9.53 (d, 2H, J1 = 8.24 Hz, H9/9ʹ), 
9.30 (s, 2H, H10/10ʹ), 8.23 (m, 2H, H11/21), 7.75 (t, 2H, J1 = 7.76 
Hz, H13/23), 7.67 (t, 4H, J1 = 6.83 Hz, H8/8ʹ/14/24), 7.09 (t, 2H, J1 
= 6.64 Hz, H12/22), 5.18 (d, 2H, J1 = 16.88 Hz, H16/26b), 4.56 (d, 
2H, J1 = 17.04 Hz, H16/26a), 3.40 (m, 2H, H1/2b), 2.89 (s, 6H, N-
CH3), 2.76 (m, 2H, H1/2a). 
13C-NMR (400 MHz, DMSO-d6) δ: 
161.38 (C15/25), 157.89 (C7/7ʹ), 152.61 (C8/8ʹ), 150.89 (C17/17ʹ), 147.19 (C10/10ʹ), 139.44 
(C19/19ʹ), 137.35 (C13/23), 133.02 (C9/9ʹ), 129.31 (C18/18ʹ), 127.78 (C11/21), 125.32 
(C12/22), 123.37 (C14/24), 68.48 (C16/26), 63.25 (C1/2b), 60.84 (C1/2a), 47.65 (N-CH3). 
ESI-MS (MeOH:H2O, 0.1% Formic acid, [M]
+ m/z): Calculated (m/z): 603.16, found (m/z): 
603.16. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, DMSO): 297 (25.2 ± 1.2 × 103), 363 (16.2 ± 0.7 
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× 103), 449 (8.1± 0.4 × 103), 476 (7.6 ± 0.4 × 103). RP-HPLC Phenomenex C18 5 μm 150 × 
4.6 mm, 10-100 % B over 15 min, tR 5.97 min at 254 nm. 
4.4.5 Synthesis of rac-α-[Ru(picenMe2)(dppzMe2)](PF6)2 (Ru-5) 
Yield: 32.3 mg (84%). (Ru-5) 1H-NMR (400 MHz, DMSO-d6) δ: 
9.83 (d, 2H, J1 = 5.36 Hz, H7/7ʹ), 9.38 (d, 2H, J1 = 8.08 Hz, H9/9ʹ), 
8.17 (m, 2H, H11/21), 7.97 (s, 2H, H20/20ʹ), 7.78 (m, 4H, 
H8/8ʹ/13/23), 7.69 (d, 2H, J1 = 7.64 Hz, H14/24), 7.14 (t, 2H, J1 = 
6.52 Hz, H12/22), 5.19 (d, 2H, J1 = 16.84 Hz, H16/26b), 4.58 (d, 2H, 
J1 = 17.04 Hz, H16/26a), 2.91 (s, 6H, N-CH3), 2.77 (m, 4H, H1/2ab), 
2.57 (s, 6H, Bz-CH3). 
13C-NMR (400 MHz, DMSO-d6) δ: 161.43 
(C15/25), 157.53 (C7/7ʹ), 152.76 (C8/8ʹ), 151.74 (C17/17ʹ), 144.19 
(C10/10ʹ), 141.59 (C19/19ʹ), 138.91 (C27/27ʹ), 137.39 (C13/23), 132.98 (C9/9ʹ), 129.79 
(C18/18ʹ), 128.02 (C11/21), 127.81 (C20/20ʹ), 125.39 (C12/22), 123.42 (C14/24), 68.48 
(C16/26), 60.85 (C1/2), 47.64 (N-CH3), 20.65 (Bz-CH3). ESI-MS (MeOH:H2O, 0.1% Formic 
acid, [M]+ m/z): Calculated (m/z): 681.21, found (m/z): 681.20. UV-Vis λmax nm (ε mol
-1 dm-3 
cm-1, DMSO): 276 (99.6 ± 2.4 × 103), 369 (34.9 ± 1.54 × 103), 388 (36.0 ± 2.0 × 103). RP-
HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 10-100 % B over 15 min, tR 15.86 min at 254 
nm. 
4.4.6 Synthesis of rac-α-[Ru(picenMe2)(phenpyrBz)](PF6)2 (Ru-6) 
Yield: 24.0 mg (64%). (Ru-6) 1H-NMR (400 MHz, DMSO-d6) δ: 
14.21 (s, 1H, -NH), 9.70 (d, 2H, J1 = 5.00 Hz, H7/7ʹ), 9.06 (d, 2H, J1 
= 8.12 Hz, H11/21), 8.28 (d, 2H, J1 = 7.88 Hz, H9/9ʹ), 8.14 (m, 2H, 
H30/30ʹ), 7.74 (t, 2H, J1 = 7.60 Hz, H13/23), 7.67–7.56 (m, 7H, 
H8/8ʹ/14/24/31/31ʹ), 7.09 (t, 2H, J1 = 6.20 Hz, H12/22), 5.18 (d, 2H, 
J1 = 16.84 Hz, H16/26b), 4.55 (d, 2H, J1 = 17.00 Hz, H16/26a), 2.89 
(s, 6H, N-CH3), 2.76 (m, 4H, H1/2ab). 
13C-NMR (400 MHz, DMSO-
d6) δ: 161.51 (C15/25), 154.52 (C7/7ʹ), 153.06 (C17/17ʹ), 152.31 
(C8/8ʹ/14/24/31/31ʹ/32), 147.29/147.01 (C19/19ʹ), 137.22 (C13/23), 136.94 (C34), 130.84 
(C11/21), 129.84 (C18/18ʹ), 129.68 (C8/8ʹ/14/24/31/31ʹ/32), 127.01 (C9/9ʹ/30/30ʹ), 125.31 
(C12/22), 123.36 (C8/8ʹ/14/24/31/31ʹ/32), 121.09 (C33), 68.43 (C16/26), 60.85 (C1/2), 47.57 
(N-CH3). ESI-MS (MeOH:H2O, 0.1% Formic acid, [M]
+ m/z): Calculated (m/z): 667.19, 
found (m/z): 667.19. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, DMSO): 286 (58.6 ± 0.7 × 103), 301 
(57.5 ± 0.8 × 103), 368 (19.2 ± 0.2 × 103), 489 (8.9 ± 0.1 ×103). RP-HPLC Phenomenex C18 5 
μm 150 × 4.6 mm, 10-100 % B over 15 min, tR 6.62 min at 254 nm. 
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4.4.7 Synthesis of rac-α-[Ru(picenMe2)(phenpyrBzMe)](PF6)2 (Ru-7) 
Yield: 26.1 mg (68%). (Ru-7) 1H-NMR (400 MHz, DMSO-d6) δ: 14.11 
(s, 1H, -NH), 9.69 (d, 2H, J1 = 5.04 Hz, H7/7ʹ), 9.03 (m, 4H, 
H11/21/30/30ʹ), 8.15 (m, 2H, H9/9ʹ), 7.74 (t, 2H, J1 = 7.52 Hz, 
H13/23), 7.65 (d, 2H, J1 = 7.68 Hz, H8/8ʹ), 7.44 (m, 4H, 
H14/24/31/31ʹ), 7.08 (t, 2H, J1 = 6.44 Hz, H12/22), 5.17 (d, 2H, J1 = 
16.84 Hz, H16/26b), 4.54 (d, 2H, J1 = 17.04 Hz, H16/26a), 2.89 (s, 6H, 
N-CH3), 2.76 (m, 4H, H1/2ab), 2.42 (s, 3H, Bz-CH3). 
13C-NMR (400 
MHz, DMSO-d6) δ: 161.51 (C15/25), 154.51 (C7/7ʹ), 153.21 (C17/17ʹ), 
152.30 (C14/24/31/31ʹ), 151.52 (C34), 140.70 (C19/19ʹ), 139.99 (C33), 137.21 (C13/23), 
130.21 (C8/8ʹ), 130.09 (C11/21/30/30ʹ), 127.11 (C18/18ʹ), 126.93 (C9/9ʹ), 125.30 (C12/22), 
124.26 (C32), 123.36 (C14/24/31/31ʹ), 68.43 (C16/26), 60.85 (C1/2), 47.56 (N-CH3), 21.49 
(Bz-CH3). ESI-MS (MeOH:H2O, 0.1% Formic acid, [M]
+ m/z): Calculated (m/z): 681.21, 
found (m/z): 681.19. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, DMSO): 287 (63.7 ± 1.6 × 103), 301 
(60.8 ± 1.5 × 103), 371 (16.9 ± 0.4 × 103), 488 (7.5 ± 0.2 × 103). RP-HPLC Phenomenex C18 
5 μm 150 × 4.6 mm, 10-100 % B over 15 min, tR 7.21 min at 254 nm. 
4.4.8 Synthesis of rac-α-[Ru(picenMe2)(phenpyrBzNO2)](PF6)2 (Ru-8) 
Yield: 21.6 mg (55%). (Ru-8) 1H-NMR (400 MHz, DMSO-d6) δ: 
14.54 (s, 1H, -NH), 9.72 (d, 2H, J1 = 5.24 Hz, H7/7ʹ), 9.03 (d, 2H, J1 = 
8.12 Hz, H11/21), 8.49 (s, 4H, H9/9ʹ/31/31ʹ), 8.15 (m, 2H, H30/30ʹ), 
7.74 (t, 2H, J1 = 4.00 Hz, H13/23), 7.66 (d, 4H, J1 = 7.68 Hz, 
H8/8ʹ/14/24), 7.09 (t, 2H, J1 = 6.24 Hz, H12/22), 5.18 (d, 2H J1 = 
16.88 Hz, H16/26b), 4.55 (d, 2H, J1 = 17.00 Hz, H16/26a), 2.90 (s, 
6H, N-CH3), 2.77 (m, 4H, H1/2ab). 
13C-NMR (400 MHz, DMSO-d6) 
δ: 161.51 (C15/25), 154.90 (C7/7ʹ), 152.34 (C8/8ʹ/14/24), 150.66 
(C17/17ʹ), 148.48 (C18/18ʹ), 147.56 (C19/19ʹ), 137.27 (C13/23), 
135.55 (C32/33/34), 130.52 (C11/21), 127.88 (C9/9ʹ31/31ʹ), 126.92 (C30/30ʹ), 125.32 
(C12/22), 125.06 (C9/9ʹ/31/31ʹ), 123.38 (C18/18ʹ/14/24), 68.43 (C16/26), 60.85 (C1/2), 47.57 
(N-CH3). ESI-MS (MeOH:H2O, 0.1% Formic acid, [M]
+ m/z): Calculated (m/z): 712.18, 
found (m/z): 712.16. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, DMSO): 293 (45.8 ± 1.3×103), 366 
(48.1 ± 1.4 × 103), 488 (11.23 ± 0.4 × 103). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 
10-100 % B over 15 min, tR 7.23 min at 254 nm. 
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4.4.9 Synthesis of rac-β-[Ru(picenBz2)(phen)](PF6)2 (Ru-9) 
Yield: 26.6 mg (86%). (Ru-9) 1H-NMR (400 MHz, DMSO-d6) δ: 
9.87 (d, 1H, J1 = 5.44 Hz, H7), 8.88 (d, 1H, J1 = 7.96 Hz, H9), 8.76 
(d, 1H, J1 = 4.07 Hz, H9ʹ), 8.43 (d, 2H, J1 = 2.24 Hz, H19/19ʹ), 
8.10 (t, 2H, J1 = 6.88 Hz, H13/23), 7.92 – 7.79 (m, 5H, 
H22/8/8ʹ/7ʹ/21), 7.58 (m, 2H, H14/24), 7.39 – 7.28 (m, 10H, Ar-
H), 7.05 (m, 1H, H12), 6.75 (d, 1H, J1 = 5.52 Hz, H11), 5.44 (d, 1H, J1 = 12.40 Hz, H110a), 
4.59 (d, 1H, J1 = 16.56 Hz, H26a), 4.43 (d, 1H, J1 = 16.48 Hz, H1a), 4.22 (d, 1H, J1 = 12.44 
Hz, H16a), 4.06 (d, 1H, J1 = 17.08 Hz, H110b), 3.85 (d, 1H, J1 = 16.56 Hz, H16b), 3.49 (d, 
1H, J1 = 12.96 Hz, H26b), 3.39 (s, 1H, H220a), 3.28 (d, 1H, J1 = 13.16 Hz, H1b), 3.05 (d, 1H, 
J1 = 11.88 Hz, H2a), 2.66 (d, 1H, J1 = 12.92 Hz, H220b), 2.41 (t, 1H, J1 = 13.32 Hz, H2b). 
13C-NMR (400 MHz, DMSO-d6) δ: 164.72 (C15), 163.90 (C25), 156.89 (C7), 152.79 (C11), 
152.24 (Ar-C), 151.35 (C8/8ʹ), 148.99 (C17/17ʹ), 148.17 (C18/18ʹ), 138.45 (C13/23), 137.72 
(C22), 137.53 (C9), 135.55 (C9ʹ), 133.84 – 129.55 (Ar-C), 129.30 (C14/24), 129.17 (Ar-C), 
128.72 (Ar-C), 128.59 (C19/19ʹ), 128.33 (Ar-C), 126.74 (Ar-C), 125.95 (C12), 125.86 
(C13/23), 125.38 (C22), 123.01 (C7ʹ/21), 66.33 (C26/220b), 66.08 (C110b/1a), 64.32 
(C26/2a), 63.28 (C220a), 60.30 (C110/26/16a/16b), 53.80 (C1/2b). ESI-MS (MeOH:H2O, 
0.1% Formic acid, [M]+ m/z): Calculated (m/z): 703.22, found (m/z): 703.19. UV-Vis λmax nm 
(ε mol-1 dm-3 cm-1, DMSO): 270 (45.5 ± 0.8 × 103), 376 (10.2 ± 0.2 × 103), 464 (8.2 ± 0.1 × 
103). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 10-100 % B over 15 min, tR 8.44 min 
at 254 nm. 
4.4.10 Synthesis of rac-β-[Ru(picenBz2)(dpq)](PF6)2 (Ru-10) 
Yield: 25.1 mg (77%). (Ru-10) 1H-NMR (400 MHz, DMSO-d6) δ: 
9.98 (d, 1H, J1 = 5.48 Hz, H7), 9.71 (d, 1H, J1 = 8.00 Hz, H7ʹ), 9.55 
(d, 1H, J1 = 8.00 Hz, H9), 9.39 (m, 2H, H10/10ʹ), 8.25 (q, 1H, 
H11), 8.12 (t, 1H, J1 = 7.72 Hz, H13), 8.01 (q, 1H, H21), 7.94 (d, 
2H, J1 = 3.88 Hz, H14/24), 7.89 (d, 1H, J1 = 5.52 Hz, H9ʹ), 7.82 (d, 
1H, J1 = 7.84 Hz, H23), 7.62 – 7.54 (m, 5H, Ar-H), 7.51 (d, 2H, J1 
= 6.64 Hz, H8/8ʹ), 7.40 – 7.28 (m, 5H, Ar-H), 7.08 (d, 1H, J1 = 5.48 Hz, H12), 7.03 (m, 1H, 
H22), 5.47 (d, 1H, J1 = 12.44 Hz, H110a), 4.61 (d, 1H, J1 = 16.52 Hz, H26a), 4.44 (d, 1H, J1 
= 16.36 Hz, H1a), 4.25 (d, 1H, J1 = 12.36 Hz, H16a), 4.08 (d, 1H, J1 = 17.12 Hz, H110b), 
3.88 (d, 1H, J1 = 16.64 Hz, H16b), 3.58 (d, 1H, J1 = 13.16 Hz, H26b), 3.39 (d, 1H, J1 = 4.96 
Hz, H220a), 3.29 (d, 1H, J1 = 6.71 Hz, H1b), 3.08 (d, 1H, J1 = 12.24 Hz, H2a), 2.88 (d, 1H, J1 
= 12.76 Hz, H220b), 2.41 (t, 1H, J1 = 13.48 Hz, H2b). 
13C-NMR (400 MHz, DMSO-d6) δ: 
164.68 (C15), 163.81 (C25), 157.78 (C7), 153.35 (C12), 153.16 (Ar-C), 151.38 (C9ʹ), 151.14 
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(C17), 150.22 (C17ʹ), 147.01 (C10/10ʹ), 140.03 (C18/18ʹ), 139.94 (C19/19ʹ), 138.60 (C13), 
137.85 (C14/24), 133.86 (Ar-C), 133.66 (C8/8ʹ), 133.44 (C7ʹ), 132.26 (Ar-C), 131.51 (C9), 
131.34 – 128.49 (Ar-C), 126.80 (C11/21), 125.86 (C22), 125.39 (C14/24), 123.16 (C23), 
66.73 (C26/220b), 66.09 (C1a/110b), 64.37 (C26/2a), 63.26 (C220a), 60.27 
(C110/26/16a/16b), 53.79 (C1/2b). ESI-MS (MeOH:H2O, 0.1% Formic acid, [M]
+ m/z): 
Calculated (m/z): 755.23, found (m/z): 755.20. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, DMSO): 
258 (57.3 ± 3.7 × 103), 300 (26.5 ± 1.9 × 103), 373 (10.6 ± 1.1 × 103), 474 (8.2 ± 0.9 × 103). 
RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 10-100 % B over 15 min, tR 8.75 min at 254 
nm. 
4.4.11 Synthesis of rac-β-[Ru(picenBz2)(dppzMe2)](PF6)2 (Ru-11) 
Yield: 29.9 mg (85%). (Ru-11) 1H-NMR (400 MHz, DMSO-d6) δ: 
9.93 (d, 1H, J1 = 5.52 Hz, H7), 9.76 (d, 1H, J1 = 8.00 Hz, H9), 
9.59 (d, 1H, J1 = 8.00 Hz, H9ʹ), 8.30 (d, 2H, J1 = 2.80 Hz, 
H11/21), 8.23 (t, 1H, J1 = 6.78 Hz, H13), 8.13 (t, 1H, J1 = 7.76 Hz, 
H23), 7.99 – 7.94 (m, 3H, H7ʹ/20/20ʹ), 7.89 (d, 1H, J1 = 5.48 Hz, 
H14), 7.82 (d, 1H, J1 = 7.76 Hz, H24), 7.62 – 7.51 (m, 7H, Ar-H), 
7.40 (d, 2H, J1 = 7.44 Hz, H8/8ʹ), 7.30 (m, 3H, Ar-H), 7.21 (d, 1H, 
J1 = 5.48 Hz, H12), 7.05 (m, 1H, H22), 5.46 (d, 1H, J1 = 12.28 Hz, 
H110a), 4.61 (d, 1H, J1 = 16.56 Hz, H26a), 4.44 (d, 1H, J1 = 16.72 Hz, H1a), 4.25 (d, 1H, J1 = 
3.10 Hz, H16a), 4.09 (d, 1H, J1 = 17.16 Hz, H110b), 3.88 (d, 1H, J1 = 16.64 Hz, H16b), 3.64 
(d, 1H, J1 = 13.32 Hz, H26b), 3.48 (s, 1H, H220a), 3.27 (s, 1H, H1b), 3.09 (d, 1H, J1 = 12.44 
Hz, H2a), 2.97 (d, 1H, J1 = 13.02 Hz, H220b), 2.66 (s, 6H, Bz-CH3), 2.41 (t, 1H, J1 = 13.24 
Hz, H2b). 13C-NMR (400 MHz, DMSO-d6) δ: 164.66 (C15), 163.83 (C25), 157.47 (C7), 
153.44 (C12), 152.83 (Ar-C), 152.20 (C17), 151.38 (C14), 151.24 (C17ʹ), 144.17 (C19/19ʹ), 
141.78 (C10/10ʹ), 139.95 (C18/18ʹ), 139.85 (C27/27ʹ), 138.59 (C23), 137.86 (C20/20ʹ), 
133.86 (Ar-C), 133.48 (C9), 132.27 (C8/8ʹ), 131.55 (C9ʹ), 131.38 – 128.50 (Ar-C), 128.27 
(C11/21), 126.85 (C7ʹ/13/Ar-C), 125.86 (C22), 125.41 (C20/20ʹ), 123.19 (C24), 66.84 
(C26/220b), 66.12 (C1a/110b), 64.39 (C2a), 63.26 (C220a), 60.31 (C110/26/16a/16b), 53.81 
(C1/2b), 20.69 (Bz-CH3). ESI-MS (MeOH:H2O, 0.1% Formic acid, [M]
+ m/z): Calculated 
(m/z): 833.27, found (m/z): 833.26. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, DMSO): 277 (10.7 ± 
3.9 ×103), 370 (40.2 ± 1.8 × 103), 381 (40.1 ± 1.8 × 103), 388 (42.1 ± 2.0 × 103). RP-HPLC 
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4.4.12 Synthesis of rac-β-[Ru(picenBz2)(phenpyrBz)](PF6)2 (Ru-12) 
Yield: 29.7 mg (86%). (Ru-12) 1H-NMR (400 MHz, DMSO-d6) δ: 
14.30 (d, 1H, J1 = 10.52 Hz, -NH), 9.84 (t, 1H, J1 = 4.64 Hz, H7), 
9.24 (m, 1H, H11), 9.08 (t, 1H, J1 = 7.08 Hz, H9), 8.36 (d, 2H, J1 = 
7.76 Hz, H7ʹ/21), 8.19 (m, 1H, H9ʹ), 8.11 (t, 1H, J1 = 7.76 Hz, 
H13), 7.92 (d, 2H, J1 = 4.88 Hz, H30/30ʹ), 7.89 (d, 2H, J1 = 5.64 
Hz, H14/24), 7.81 (d, 1H, J1 = 7.84 Hz, H23), 7.69 (t, 2H, J1 = 7.32 
Hz, H8/8ʹ), 7.63 – 7.54 (m, 4H, Ar-H), 7.51 (m, 3H, H31/31ʹ/32), 
7.41 – 7.28 (m, 6H, Ar-H), 7.04 (m, 1H, H22), 6.88 (t, 1H, J1 = 
6.76 Hz, H12), 5.45 (d, 1H, J1 = 12.28 Hz, H110a), 4.60 (d, 1H, J1 = 16.48 Hz, H26a), 4.43 
(d, 1H, J1 = 13.88 Hz, H1a), 4.23 (d, 1H, J1 = 12.28 Hz, H16a), 4.08 (d, 1H, J1 = 17.08 Hz, 
H110b), 3.88 (d, 1H, J1 = 16.64 Hz, H16b), 3.57 (d, 1H, J1 = 13.04 Hz, H26b), 3.40 (s, 1H, 
H220a), 3.29 (d, 1H, J1 = 14.84 Hz, H1b), 3.08 (d, 1H, J1 = 12.08 Hz, H2a), 2.78 (m, 1H, 
H220b), 2.42 (t, 1H, J1 = 13.00 Hz, H2b). 
13C-NMR (400 MHz, DMSO-d6) δ: 164.65 (C15), 
163.91 (C25), 154.67 (C7), 152.96 (C12), 151.34 (C14/24), 150.03 (Ar-C), 149.82 (Ar-C), 
147.44/147.21 (C17/17ʹ), 146.45/146.16 (C19/19ʹ), 138.49 (C13), 137.69 (C30/30ʹ), 
137.45/137.18 (C18/18ʹ), 133.85 (C31/31ʹ/32/Ar-C), 132.19 (C31/31ʹ/32/Ar-C), 131.25 
(C34), 131.09 (C33), 130.85 (C11), 130.02 (C31/31ʹ/32/Ar-C), 129.76 (C8/8ʹ), 129.56 
(C31/31ʹ/32/Ar-C), 129.29 (C9), 129.14 – 127.87 (C31/31ʹ/32/Ar-C), 127.06 (C7ʹ/21), 126.77 
(C22), 125.96 (C9ʹ), 125.37 (C30/30ʹ), 123.07 (C23), 66.44 (C26/220b), 66.11 (C26/1a/110b), 
64.39 (C2a), 63.26 (C220a), 60.23 (C110/26a/16ab), 53.80 (C1/2b). ESI-MS (MeOH:H2O, 
0.1% Formic acid, [M]+ m/z): Calculated (m/z): 819.26, found (m/z): 819.22. UV-Vis λmax nm 
(ε mol-1 dm-3 cm-1, DMSO): 288 (63.1 ± 1.7 × 103), 298 (62.9 ± 2.0 × 103), 376 (14.8 ± 0.5 × 
103), 479 (11.0 ± 0.5 × 103). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 10-100 % B 
over 15 min, tR 8.90 min at 254 nm. 
4.4.13 Synthesis of rac-β-[Ru(picenBz2)(phenpyrBzMe)](PF6)2 
(Ru-13) 
Yield: 22.2 mg (63%). (Ru-13) 1H-NMR (400 MHz, DMSO-d6) δ: 
14.20 (d, 1H, J1 = 9.32 Hz, -NH), 9.83 (m, 1H, H7), 9.22 (d, 1H, 
J1 = 3.46 Hz, H11), 9.06 (t, 1H, J1 = 7.48 Hz, H9), 8.25 (d, 2H, J1 
= 8.00 Hz, H7ʹ/21), 8.19 (d, 1H, J1 = 5.20 Hz, H9ʹ), 8.11 (t, 1H, 
7.68 Hz, H13), 7.92 (d, 2H, J1 = 4.20 Hz, H30/30ʹ), 7.89 (d, 2H, J1 
= 5.20, H14/24), 7.81 (d, 1H, J1 = 7.88 Hz, H23), 7.58 (m, 2H, 
H8/8ʹ), 7.51 – 7.30 (m, 12H, H31/31ʹ/Ar-H), 7.03 (m, 1H, H22), 
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6.87 (t, 1H, J1 = 6.76Hz, H12), 5.45 (d, 1H, J1 = 12.32 Hz, H110a), 4.50 (d, 1H, J1 = 16.52 
Hz, H26a), 4.44 (d, 1H, J1 = 13.92 Hz, H1a), 4.22 (d, 1H, J1 = 12.28 Hz, H16a), 4.08 (d, 1H, 
J1 = 17.00 Hz, H110b), 3.87 (d, 1H, J1 = 16.48 Hz, H16b), 3.57 (d, 1H, J1 = 13.08 Hz, H26b), 
3.40 (s, 1H, H220a), 3.28 (m, 1H, H1b), 3.08 (d, 1H, J1 = 12.72 Hz, H2a), 2.78 (m, 1H, 
H220b), 2.45 (s, 3H, Bz-CH3), 2.43 (m, 1H, H2b). 
13C-NMR (400 MHz, DMSO-d6) δ: 164.65 
(C15), 163.91 (C25), 153.12 (C7), 152.86 (C34), 151.34 (C12), 149.95 (C14/24), 149.78 
(C31/31ʹ/Ar-C), 147.36/147.08 (C17/17ʹ), 146.38/146.04 (C19/19ʹ), 140.70 (C33), 138.48 
(C13), 137.67 (C30/30ʹ), 137.15 (C18/18ʹ), 133.85 – 131.00 (C31/31ʹ/Ar-C), 130.29 (C11), 
129.56/129.29 (C31/31ʹ/Ar-C), 129.13 (C9), 128.53/127.30 (C31/31ʹ.Ar-C), 126.99 (C21/7ʹ), 
126.77 (C8/8ʹ), 126.07 (C22), 125.96 (C9ʹ), 125.36 (C30/30ʹ), 123.06 (C23), 122.11 (C32), 
64.46 (C26/220b), 66.12 (C1a/110b), 64.39 (C220a), 60.23 (C110/26/16a/16b), 53.82 
(C1/2b), 21.52 (C2b/Bz-CH3). ESI-MS (MeOH:H2O, 0.1% Formic acid, [M]
+ m/z): 
Calculated (m/z): 833.27, found (m/z): 833.24. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, DMSO): 
290 (68.8 ± 2.4 × 103), 299 (67.0 ± 2.2 × 103), 375 (16.0 ± 0.5 × 103), 479 (11.5 ± 0.4 × 103). 
RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 10-100 % B over 15 min, tR 18.29 min at 
254 nm. 
4.4.14 Synthesis of rac-β-[Ru(picenBz2)(phenpyrBzNO2)](PF6)2 (Ru-14) 
Yield: 28.5 mg (79%). (Ru-14) 1H-NMR (400 MHz, DMSO-d6) 
δ: 14.66 (s, 1H, -NH), 9.85 (d, 1H, J1 = 5.52 Hz, H7), 9.23 (d, 
1H, J1 = 8.08 Hz, H11), 9.07 (d, 1H, J1 = 8.08 Hz, H9), 8.57 (m, 
2H, H7ʹ/21), 8.18 (t, 1H, J1 = 5.92 Hz, H9ʹ), 8.11 (t, 1H, J1 = 
7.68 Hz, H13), 7.93 (d, 2H, J1 = 4.12 Hz, H30/30ʹ), 7.89 (d, 2H, 
J1 = 5.76 Hz, H14/24), 7.82 (d, 1H, J1 = 7.84 Hz, H23), 7.59 
(m, 4H, H31/31ʹ/Ar-H), 7.51 (d, 2H, J1 = 6.72 Hz, H8/8ʹ), 7.42 
– 7.28 (m, 8H, H31/31ʹ/Ar-H), 7.05 (m, 1H, H22), 6.91 (d, 1H, 
J1 = 5.52 Hz, H12), 5.46 (d, 1H, J1 = 12.36 Hz, H110a), 4.60 (d, 
1H, J1 = 16.48 Hz, H26a), 4.45 (m, 1H, H1a), 4.24 (d, 1H, J1 = 
12.36 Hz, H16a), 4.08 (d, 1H, J1 = 17.08 Hz, H110b), 3.88 (d, 1H, J1 = 16.52 Hz, H16b), 3.57 
(d, 1H, J1 = 13.00 Hz, H26b), 3.40 (s, 1H, H220a), 3.28 (s, 1H, H1b), 3.08 (d, 1H, J1 = 12.64 
Hz, H2a), 2.80 (d, 1H, J1 = 13.08 Hz, H220b), 2.42 (t, 1H, J1 = 13.32 Hz, H2b). 
13C-NMR 
(400 MHz, DMSO-d6) δ: 164.65 (C15), 163.89 (C25), 154.89 (C7), 152.92 (C12), 151.34 
(C34), 150.80 (C14/24), 150.23 (C31/31ʹ/Ar-C), 148.45 (C17/17ʹ), 147.73 (C19/19ʹ), 146.71 
(C33), 138.52 (C13), 137.73 (C30/30ʹ), 135.95 (C32), 133.86 (C8/8ʹ), 132.19 (C31/31ʹ/Ar-C), 
131.26 (C18/18ʹ), 131.08 (C11), 129.57 (C9), 129.29/129.14 (C31/31ʹ/Ar-C), 128.53 (C7ʹ/21), 
127.89 (C31/31ʹ/Ar-C), 126.79 (C22), 125.95 (C9ʹ), 125.39 (C30/30ʹ), 125.15 (C7ʹ/21), 
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123.09 (C23), 66.46 (C26/220b), 66.11 (C1a/110b), 63.26 (C220/2a), 60.25 
(C110/26/16a/16b), 53.81 (C1/2b). ESI-MS (MeOH:H2O, 0.1% Formic acid, [M]
+ m/z): 
Calculated (m/z): 864.24, found (m/z): 864.21. UV-Vis λmax nm (ε mol
-1 dm-3 cm-1, DMSO): 
258 (61.2 ± 1.9 × 103), 290 (49.8 ± 1.3 × 103), 374 (44.6 ± 0.8 × 103), 479 (13777 ± 259 × 
103). RP-HPLC Phenomenex C18 5 μm 150 × 4.6 mm, 10-100 % B over 15 min, tR 18.22 min 
at 254 nm. 
4.5 Results and Discussion 
4.5.1 Synthesis of [Ru(DMSO)4Cl2] 
The synthesis of ruthenium(II) precursor dichlorotetrakis(dimethylsulfoxide)ruthenium(II) 
[Ru(DMSO)4Cl2] was prepared following the method from literature.
199 The reaction involves 
ligand substitution and addition, where a chlorine ligand from RuCl3.xH2O is replaced with 
DMSO and an additional three DMSO ligands are added forming an octahedral ruthenium(II) 
complex [Ru(DMSO)4Cl2]. The reaction was refluxed under inert atmosphere until the colour 
of the solution changed from an intense purple to a deep orange/red, yielding yellow 
crystalline powder. The product was recrystallised producing yields of 85% and characterised 
using NMR, HPLC, and UV-Vis. 
4.5.1.1 Characterisation of synthesised dichloro(dimethylsulfoxide)ruthenium(II) 
[Ru(DMSO)4Cl2] 
The synthesised ruthenium(II) precursor, cis-[Ru(DMSO)4Cl2], was isolated as a bright 
yellow crystalline product, which was characterised using 1H and 13C NMR, UV-Vis, and 
HPLC. NMR spectra were obtained on the 400 MHz Bruker Avance NMR using deuterated 
solvent CDCl3, with temperatures maintained at 25 ℃. The 
1H and 13C-NMR were obtained 
directly from recrystallised product. The 1H-NMR displayed 6 singlets with chemically 
distinct proton peaks in the aliphatic region at δ 3.54, 3.51, 3.45, 3.34, 2.74, and 2.65 (Figure 
4.3). The proton peaks arise from the monodentate DMSO ligand which are identified as 
being S- or O-bonded, methyl groups. The 13C spectra demonstrated the carbon peaks 
correlating the methyl groups on the DMSO, the peaks were found in the aliphatic region at δ 
47.70, 46.74, 44.51, 44.32, 40.93, and 38.83 (Figure 4.3). The retention time obtained for cis-
[Ru(DMSO)4Cl2] using HPLC displayed a single peak at tR 6.46 min at 254 nm. The 
electronic spectra of the π – π* transition was observed with the sulphur-oxygen bond of 
DMSO (S=O) at 230 nm, and the metal to ligand charge transfer between ruthenium and 
DMSO at 346 nm. 
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Figure 4.3 1H and 13C-NMR of cis-[Ru(DMSO)4Cl2] was obtained on the 400 MHz Bruker Avance NMR using 
deuterated solvent CDCl3 with temperature maintained at 25 ℃. 
 
4.5.2 Synthesis of [Ru(N4-TL)(DMSO)Cl] where N4-TLs are picenMe2 and picenBz2 
The ruthenium(II) precursor, cis-[Ru(DMSO)4Cl2], was used to coordinate of N4-TLs, 
picenMe2 (N4-TL-13) and picenBz2 (N4-TL-25). N4-TLs 13 and 25, were selected as they 
demonstrated promising anticancer and antibacterial activity (Chapter 3). Secondary nitrogen 
substituents, of methyl or benzyl on N4-TL-13 and N4-TL-25 provided some control over the 
structural isomers that were produced upon coordination. The electron pairs from the nitrogen 
atoms on N4-TLs form bonds with the central metal ruthenium(II) occupying four coordination 
sites while the remaining two are DMSO and Cl. Ruthenium(II) N4-TL complexes, cis--
[Ru(picenMe2)(DMSO)Cl](PF6) (Ru-1) and cis--[Ru(picenBz2)(DMSO)Cl](PF6) (Ru-2) 
(Figure 4.4), were synthesised following a published method.83 
 
Figure 4.4 The ruthenium(II) precursor, cis-[Ru(DMSO)4Cl2] coordinated to N4-TLs, picenMe2 (N4-TL-13) and 
picenBz2 (N4-TL-25), forming cis-α-[Ru(picenMe2)(DMSO)Cl](PF6) (Ru-1) and cis-β-
[Ru(picenBz2)(DMSO)Cl](PF6) (Ru-2). 
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Synthesis involved refluxing the N4-TL with [Ru(DMSO)4Cl2] in a solvent mixture of 
H2O/EtOH (1:5). The khaki reaction solution, gradually turned deep orange as coordination of 
the bidentate ligand took place, indicating that the reaction was completed. A solvent ratio of 
H2O/EtOH (1:5) assisted in solubilising the starting reactants and initiated product 
precipitation through slow evaporation of EtOH. A counter ion, potassium 
hexafluorophosphate (PF6
-), was also added to facilitate precipitation.  
Although, it is possible for three steric isomers (cis-α or cis-β or trans) to form during 
the coordination of ruthenium(II) to a N4-TL, precipitation afforded cis--
[Ru(picenMe2)(DMSO)Cl](PF6) (Ru-1) and cis--[Ru(picenBz2)(DMSO)Cl](PF6) (Ru-2) 
which were isolated as spherical dark green and needle-like orange crystals, respectively. 
They were clearly distinguished by NMR analysis and were consistent with reported 
structures in the literature.83 Each produced non-symmetrical 1H and 13C-NMR spectra, where 
the aromatic peaks were comparable to the component N4-TL, whereas, the remaining 
aliphatic peaks required further NMR experiments with dept, COSY, and HMQC. HPLC of 
cis--Ru-1 and cis--Ru-2 demonstrated only very minor impurities identified as starting 
materials. Further purification of the complexes was not required. Although other isomeric 
forms of the precursors are likely, for this synthesis only the cis--Ru-1 and cis--Ru-2 were 
isolated. Other isomers would be present; however, they did not precipitate out of solution. 
Further isolation to obtain other isomers was not pursued. The intermediate ruthenium(II) 
complexes cis--Ru-1 and cis--Ru-2 were successfully synthesised and characterised to 
enable coordination to the bidentate ligands. 
4.5.2.1 Characterisation of cis-α-[Ru(picenMe2)(DMSO)Cl]PF6 
The N4-TL-13, picenMe2, readily coordinates to cis-[Ru(DMSO)4Cl2] to produce dark yellow-
green crystals of cis-α-[Ru(picenMe2)(DMSO)Cl]PF6 (Ru-1) in moderate yields (Table 4.1 
and Figure 4.5). It was expected the structural isomers would form due to torsional strains, 
steric constraints, and kinetic effects and would be either dissymmetric cis-α or asymmetric 
cis-β form. As the geometrical cis arrangement around an octahedral can be defined as the 
metal-N4-TL fragment taking four coordination positions with two remaining positions that 
can accommodate either two monodentate or one bidentate ligand. NMR-spectra of Ru-1 
confirmed that cis-α isomer was favoured as described in the literature.82, 83 Various 
techniques such as 1D and 2D-NMR (1H, 13C, dept, HMQC, and COSY), UV-Vis, HPLC, and 
MS were used in combination to characterise Ru-1 (Table 4.2).  
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Table 4.1 Summary of the characterisation data of racemic cis-α or cis-β-[Ru(N4-TL)(DMSO)Cl] and the complexes that result from coordination of the selected bidentates, phen, dpq, 
dppzMe2, phenpyrBz, phenpyrBzMe, and phenpyrBzNO2, to form [Ru(N4-TL)(bidentate)](PF6)2. 
 
    ESI-MS (m/z) UV/ λmax (nm) HPLC 






λmax (nm) (ε/mol-1.dm3cm-1× 103) tR (mins) @ 254 
Ru-1 cis--[Ru(picenMe2)(DMSO)Cl](PF6)  C18H28ClF6N4OPRuS 26 485.08 485.04 247 (10.1 ± 0.1), 346 (8.0 ± 0.1). 4.44 
Ru-2 cis--[Ru(picenBz2)(DMSO)Cl](PF6) C30H36ClF6N4OPRuS 60 637.13 637.11 250 (13.9 ± 0.2), 360 (7.5 ± 0.1). 8.63 
Ru-3 cis--[Ru(picenMe2)(phen)](PF6)2 C28H30F12N6P2Ru 67 697.12 697.12 271(51.2 ± 3.0), 369(15.8 ± 0.6), 442(8.2 ± 0.3), 
476(7.3 ± 0.3) 
8.84 
Ru-4 cis--[Ru(picenMe2)(DPQ)](PF6)2 C30H30F12N8P2Ru 48 603.16 603.16 297(25.2 ± 1.2), 363(16.2 ± 0.7), 449(8.1 ± 0.4), 
476(7.6 ± 0.4) 
5.97 
Ru-5 cis--[Ru(picenMe2)(dppzMe2)](PF6)2 C36H36F12N8P2Ru 84 681.21 681.20 276(99.6 ± 2.4), 369(34.9 ± 1.5), 388(36.0 ± 2.0) 15.86 
Ru-6 cis--[Ru(picenMe2)(phenpyrBz)](PF6)2 C35H34F12N8P2Ru 64 667.19 667.19 286(58.6 ± 0.7), 301(57.5 ± 0.8), 368(19.2 ± 0.2), 
489(8.9 ± 0.1) 
6.62 
Ru-7 cis--[Ru(picenMe2)(phenpyrBzMe)](PF6)2 C36H36F12N8P2Ru 68 681.21 681.19 287(63.7 ± 1.6), 301(60.8 ± 1.5), 371(16.9 ± 0.4), 
488(7.5 ± 0.2) 
7.21 
Ru-8 cis--[Ru(picenMe2)(phenpyrBzNO2)](PF6)2 C35H33F12N9O2P2Ru 55 712.18 712.16 293(45.8 ± 1.3), 366(48.1 ± 1.4), 488(11.2 ± 0.4) 7.23 
Ru-9 cis--[Ru(picenBz2)(phen)](PF6)2 C40H38F12N6P2Ru 86 703.22 703.19 270(45.5 ± 0.8), 376(10.2 ± 0.2), 464(8.2 ± 0.1) 8.44 
Ru-10 cis--[Ru(picenBz2)(DPQ)](PF6)2 C42H38F12N8P2Ru 77 755.23 755.20 258(57.3 ± 3.7), 300(26.5 ± 1.9), 373(10.6 ± 1.1), 
474(8.2 ± 0.9) 
8.75 
Ru-11 cis--[Ru(picenBz2)(dppzMe2)](PF6)2 C48H44F12N8P2Ru 85 833.27 833.26 277(10.6 ± 3.9), 370(40.2 ± 1.8), 381(40.1 ± 1.8), 
388(42.1 ± 2.0) 
11.16 
Ru-12 cis--[Ru(picenBz2)(phenpyrBz)](PF6)2 C47H42F12N8P2Ru 86 819.26 819.22 288(63.1 ± 1.7), 298(62.9 ± 2.0), 376(14.8 ± 0.5), 
479(11.0 ± 0.5) 
8.90 
Ru-13 cis--[Ru(picenBz2)(phenpyrBzMe)](PF6)2 C48H44F12N8P2Ru 63 833.27 833.24 290(68.8 ± 2.4), 299(67.0 ± 2.2), 375(16.0 ± 0.5), 
479(11.5 ± 0.4) 
18.29 
Ru-14 cis--[Ru(picenBz2)(phenpyrBzNO2)](PF6)2 C47H41F12N9O2P2Ru 79 864.24 864.21 258(61.2 ± 1.9), 290(49.8 ± 1.3), 374(44.6 ± 0.8), 
479(13.8 ± 0.3) 
18.22 
135 | P a g e  
 
Upon coordination, the previously symmetrical N4-TL becomes non-symmetrical 
because of the position of the N4-TL with respect to monodentate ligands DMSO and Cl, of 
the cis-isomers. Ru-1, is a cis-α isomer and has a pseudo C2 symmetry, and this is reflected in 
the NMR spectra. This is more complicated due to the disposition of the DMSO and Cl 
ligands, when compared to a symmetrical analogue, cis-α-[Co(picenBz2)Cl2]
+.82, 83 The 1H-
NMR chemical shifts depict the characteristic structural configuration for cis-α Ru-1 where 
the aromatic protons H11 and H21 each resonate at a unique chemical shift, only a few 
fractions of a ppm apart, 9.14 and 9.10 ppm, respectively. This pattern is repeated with the 
remaining aromatic protons showing peaks for H13/23, H14/24, and H12/22. For the almost 
equivalent protons, the slightly downfield proton is closest to the electronegative monodentate 
DMSO (Figure 4.5). 
 
Figure 4.5 1H-NMR of cis-α-[Ru(picenMe2)(DMSO)Cl]PF6 was obtained on the 400 MHz Bruker Avance NMR 
using deuterated solvent DMSO-d6 with temperature maintained at 35 ℃. Cis-α complex presenting a pseudo 
dissymmetric C2 symmetry. 
 
In the proton spectrum of Ru-1, the pyridine aromatic protons (H11 – 14, 21 – 24) 
resonate downfield at ~7 – 10 ppm. Proton peaks H11/21 are furthest downfield at ~9.14 and 
9.10 ppm as a consequence of the proximity to the electronegative pyridine nitrogen. H13/23 
occur at ~8.06 and 7.96 ppm as they are para to the electronegative nitrogen, H14/24 at ~7.74 
and 7.70 ppm are closest to the diamine and are slightly upfield. H12/22 resonate at ~7.61 and 
7.58 ppm, respectively as they are the furthest from the diamine and pyridine nitrogens 
(Figure 4.5 and Supplementary C, Section 1.1). In the aliphatic region the peak H16a is 
slightly downfield at ~ 5 ppm as it is neighbouring the amine and close to the electronegative 
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monodentate. H16b/26ab occurs at ~ 4.3 ppm due to the effect of the neighbouring diamines 
(Figure 4.5). The most upfield peaks are due to the S-CH3 from the DMSO ligand and 
resonate at 3.2 and 2.3 ppm, respectively. The protons of the ethylene diamine bridge, H1ab 
and H2ab are further downfield at 2.6 and 2.4 ppm as they are shielded, H1ab is more 
downfield than H2ab due to the proximity to the electronegative monodentate. The protons of 
the methyl substituents on the secondary amines experience a lower magnetic field as the 
protons are shielded, therefore the chemical shift is upfield at 2.5 and 2.4 ppm, respectively, 
and integrated for 3 protons. The observed NMR spectra were consistent with similar 
ruthenium(II) complexes reported in literature.83 Further 2D-NMR experiments were used to 
confirm the proton assignments and to view correlations.  
COSY and HMQC-NMR were used to identify 1H – 1H and 1H – 13C correlations 
which are shown in Supplementary C, Sections 1.13 and 1.17. In the complex Ru-1, the 
pyridine aromatic protons H11 – 14, 21 – 24 show proton correlations between each other. 
Both H14/24 – 12/22 are similar protons due to the symmetry of the aromatic ring and 
therefore display long range 4J-coupling with diamine protons H16/26. In the aliphatic region, 
the diamine protons H16/26, H1/2 and S-CH3 correlate with each other, whereas no 
correlation is evident with the methyl groups. Carbon and proton correlations for complex Ru-
1 were confirmed using HMQC. The aromatic protons H11 – 14, 21 – 24 correlate with C11 – 
14, 21 – 24 at ~ 120 – 160 ppm. The aliphatic diamine peaks H16/26 correlate with C16/26 at 
~ 65 – 70 ppm. H1/2 correlates with C1/2 at ~55 – 60 ppm, and S-CH3/N-CH3 correlates with 
S-CH3/N-CH3 at ~ 40 – 50 ppm. 
13C and dept spectra corroborate the assignments with 
additional singlet peaks C15/25 visible in the 13C NMR spectrum but absent in the dept-NMR 
spectrum (Supplementary C, Sections 1.5 and 1.9). The positive dept CH/CH3 peaks confirm 
presence of the aromatic peaks C11 – 14, 21 – 24, the S-CH3 from the DMSO and methyl 
groups, N-CH3. Whereas, the negative dept CH2 confirm diamine peaks C16/26 and 
polyamine peaks C1/2.  
4.5.2.2 Characterisation of cis--[Ru(picenBz2)(DMSO)Cl]PF6 
Ru-2, cis-β-[Ru(picenBz2)(DMSO)Cl]PF6, was successfully synthesised producing orange 
needle-like crystals. Various characterisation techniques such as 1D and 2D-NMR (1H, 13C, 
dept, HMQC, and COSY), UV-Vis, HPLC, and MS was employed to confirm the isomeric 
structure. NMR experiments confirmed that the cis-β-isomer was favoured (Figure 4.6 and 
Supplementary C, Section 1.2). The cis-β complex, Ru-2, is asymmetric which produces a 
unique NMR spectrum for each proton. This is exemplified by its complex spectra of Ru-2 in 
comparison with that of cis-α complex Ru-1. 1H-NMR chemical shifts depict the 
characteristic structural configuration for cis-β Ru-2 which is evident with the aromatic 
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protons. The aromatic proton peaks resonate at larger chemical shift to their corresponding 
protons due to the shielding and de-shielding effect and proximity to the electronegative 
monodentate ligand. Aromatic proton H21 resonates at a higher field than its corresponding 
peak H11 due to shielding effects from the adjacent pyridyl ring. Whereas, proton H11 
resonates at a lower field than its corresponding peak H21 from the de-shielding effect as H11 
is cis to the monodentate ligands DMSO and Cl (Figure 4.6 and Table 4.2). This is clearly 
observed with the remaining aromatic protons peaks H13/23, H14/24, and H12/22.  
1H-NMR studies of Ru-2 (Figure 4.6) display pyridine peaks H11 – 14, 21 – 24 and 
benzyl rings (Ar-H) resonating in the downfield aromatic region at ~7.0 – 9.0 ppm. As 
mentioned, the shielding and de-shielding effects from the cis-β structure influences the 
high/low field chemical shifts for the pyridine protons. Proton H11 is furthest downfield at 
~8.6 ppm by the close proximity to the electronegative pyridine nitrogen, followed by H13 at 
~8.2 ppm is para to the electronegative nitrogen, H14 at ~7.8 ppm is closest to the pyridine 
nitrogen and diamine, and H12 at ~7.7 ppm is furthest from the diamine and pyridine 
nitrogen. The corresponding peaks H21 – 24 are slightly upfield seeing a lower field than H11 
– 14 from the shielding effects. The benzyl aromatic protons are seen at ~7.5 ppm as a 
multiplet peak. In the aliphatic region the most downfield peaks H16a/220a/26a at ~5.0 ppm 
are neighbouring the diamines and the corresponding protons H220b/16b/26b at ~4.5, 3.9, and 
3.1 ppm, respectively, are upfield from the shielding effects. The remaining aliphatic peaks 
H1a/2a/110a are slightly downfield than their corresponding protons H1b/2b/110b from the 
de-shielding effect. NMR spectra were consistent with similar ruthenium(II) complexes 
reported in literature  
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Figure 4.6 1H-NMR of cis-β-[Ru(picenBz2)(DMSO)Cl]PF6 was obtained on the 400 MHz Bruker Avance NMR 
using deuterated solvent DMSO-d6 with temperature maintained at 35 ℃. 
 
COSY and HMQC were used to confirm the assigned protons (Supplementary C, 
Sections 1.14 and 1.18). COSY studies indicate clear correlations between neighbouring 
protons 1H – 1H as shown in Supplementary C, Section 1.18. There is clear evidence of 
proton correlations in the aromatic region between the pyridine and benzyl rings in the COSY. 
In the aliphatic region, the diamine protons H16a/26a correlate to their corresponding protons 
H16b/26b, and the remaining aliphatic protons H220a/b, H110a/b, S-CH3, H1a/b, and H2a/b 
show correlation to their corresponding protons. Carbon and proton correlations were 
analysed using HMQC for complex Ru-2. The aromatic pyridine and benzyl protons correlate 
with their carbons at ~ 110 – 150 ppm. The aliphatic peaks H16/26/110/220/1/2/S-CH3 
correlate with their corresponding carbons at ~ 40 – 70 ppm. 13C and dept spectra allow the 
assignment of the singlets, C15/25 and Ar-C which are visible in 13C and absent in dept-NMR 
(Supplementary C, Sections 1.6 and 1.10). The positive dept CH/CH3 peaks validate the 
pyridine and benzyl aromatic peaks and S-CH3 from the DMSO ligand. Whereas, the negative 
dept CH2 confirm diamine peaks C16/26, diamine bridge C1/2 and benzyl alkane carbons 
C110/220. The NMR experiments confirmed the synthesis and structure of cis-β-
[Ru(picenBz2)(DMSO)Cl]PF6, (Ru-2) which is consistent with published structures.
82 
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Table 4.2 Summary of 1H and 13C NMR data of cis-α-[Ru(picenMe2)(DMSO)Cl]PF6, cis-β-[Ru(picenBz2)(DMSO)Cl]PF6. 
 Ru-1 Ru-2  Ru-1 Ru-2 
Label cis-α-[Ru(picenMe2)(DMSO)(Cl)]PF6 cis-β-[Ru(picenBz2)(DMSO)(Cl)]PF6 Label cis-α-[Ru(picenMe2)(DMSO)(Cl)]PF6 cis-β-[Ru(picenBz2)(DMSO)(Cl)]PF6 
1H-NMR   13C-NMR   
S-CH3 3.21(3H, s) 3.55(3H, s) S-CH3 45.44 46.14 
S-CH3 2.27(3H, s) 2.92(3H, s) S-CH3 43.53 44.36 
N-CH3 2.55(3H, s) - N-CH3 46.99 - 
N-CH3 2.47(3H, s) - N-CH3 45.56 - 
H1a 2.40(1H, m) 4.34(1H, m) C1 59.61 64.72 
H1b 2.40(1H, m) 2.93(1H, m) C2 57.45 51.86 
H2a 2.63(1H, m) 3.02(1H, d) J1 = 12.36 Hz C110 - 59.90 
H2b 2.63(1H, m) 2.26(1H, m) C220 - 67.67 
H110a - 4.27(1H, d) J1 = 16.16 Hz C16 67.62 67.07 
H110b - 3.59(1H, m) C26 70.02 57.44 
H220a - 4.94(2H, d) J1 = 13.52 Hz C-Ar - 132.43 
H220b - 4.52(1H, d) J1 = 13.52 Hz C-Ar - 131.72 
H16a 4.96(1H, d) J1 = 14.88 Hz 5.01(1H, d) J1 = 16.84 Hz C-Ar - 128.95 
H16b 4.28(1H, d) J1 = 15.08 Hz 3.79(1H, d) J1 = 16.92 Hz C-Ar - 125.71 
H26a 4.35(1H, d) J1 = 8.44 Hz 4.86(1H, d) J1 = 14.96 Hz C-Ar - 121.42 
H26b 4.35(1H, d) J1 = 8.44 Hz 3.43(1H, d) J1 = 15.04 Hz C15 162.13 166.92 
ArH - 7.43 – 7.56 (8H, m) C25 161.70 163.17 
H12 7.59(1H, m) 7.67(1H, m) C12 125.19 129.11 
H22 7.59(1H, m) 7.65(1H, m) C22 125.05 132.94 
H13 8.06(1H, t) J1 = 7.72 Hz 8.07(1H, t) J1 = 7.70 Hz C13 138.24 138.04 
H23 7.96(1H, t) J1 = 7.68 Hz 7.87(1H, t) J1 = 7.76 Hz C23 137.49 137.72 
H14 7.74(1H, d) J1 = 7.68 Hz 7.82(1H, d) J1 = 7.60 Hz C14 123.78 125.16 
H24 7.70(1H, d) J1 = 7.72 Hz 7.76(1H, d) J1 = 5.40 Hz C24 123.55 152.41 
H11 9.10(1H, d) J1 = 5.23 Hz 8.59(1H, d) J1 = 5.00 Hz C11 155.83 157.79 
H21 9.14(1H, d) J1 = 5.65 Hz 7.27(1H, m) C21 153.37 133.22 
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4.5.3 Coordination of [Ru(picenMe2 and picenBz2)(DMSO)Cl]PF6 with bidentate ligands 
Coordination of the precursor ruthenium(II) complexes, Ru-1 and Ru-2, with selected 
bidentate ligands, phen, dpq, dppzMe2, phenpyrBz, phenpyrBzMe, and phenpyrBzNO2, to 
form [Ru(N4-TL)(bidentate)](PF6)2 followed methods reported in the literature.
82, 83 1,10-
Phenanthroline based bidentate ligands are reported to intercalate between adjacent bases of 
DNA stabilising it through π – π stacking facilitated by an electron deficient planar aromatic 
ring. This structural feature is reported to influence biological activity once coordinated to 
metals like platinum(II) and ruthenium(II).111, 200 Octahedral complexes, Ru-1 and Ru-2, 
consist of a stable N4-TL occupying four coordination sites, where the remaining two 
coordination sites are bound by as DMSO and Cl ion. The coordination reaction involves the 
reflux of Ru-1 and Ru-2 with each bidentate ligand in a solvent of H2O/EtOH/ethylene glycol. 
This method produced 12 Ru(II) complexes (rac--[Ru(picenMe2)(bidentate)](PF6)2, Ru-3 – 
8) and (rac-β-[Ru(picenMe2)(bidentate)](PF6)2, Ru-9 – 14) (Table 4.1). The solvent mixture 
used for the reaction assisted in solubilising the starting reactants together it allowed the 
reflux temperature to be greater than 100 oC as well as facilitating precipitate formation. The 
addition of ethylene glycol solubilises and lowers the specific heat capacity allowing for high 
reflux temperatures without damaging the product. The initial yellow reaction mixture 
transitioned to a clear orange/red colour at completion (Figure 4.7). The addition of PF6
- 
gradually precipitated the ruthenium(II) complexes to yield an orange/red solids. 
Ruthenium(II) complexes were successfully synthesised producing yields of 48 – 86% (Table 
4.1).  
 
Figure 4.7 The reaction of racemic cis-α-[Ru(picenMe2)(DMSO)Cl]PF6 with 1,10-phenanthroline (Ru-2) 
showing the (A) initial preparation, (B) refluxing where the reactants have dissolved and turned yellow, and the 
(C) final product orange precipitate/solution. 
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The ruthenium(II) complexes comprising of N4-TL-13, picenMe2, favoured the 
formation of the pseudo C2 symmetry rac-α-[Ru(picenMe2)(bidentate)](PF6)2. Whereas, using 
N4-TL-33, picenBz2, favoured the formation of rac-β-[Ru(picenMe2)(bidentate)](PF6)2. 1D-
NMR studies can clearly distinguish the isomers formed. Additional 2D-NMR was used to 
determine the 1H and 13C correlations and assisted with distinguishing overlapping peaks of 
the rac-β-ruthenium(II) complexes. The results were consistent with similar structures found 
in literature.82, 83 
4.5.4 NMR characterisation of [Ru(picenMe2 or picenBz2)(DMSO)Cl]PF6 with bidentate 
The complexes that result when rac-α-[Ru(picenMe2)(bidentate)](PF6)2 or rac-β-
[Ru(picenMe2)(bidentate)](PF6)2 are coordinated to phen, dpq, dppzMe2, phenpyrBz, 
phenpyrBzMe, and phenpyrBzNO2, exhibit distinct NMR characteristics due to the isomeric 
structures they form upon coordination. These features are influenced the by the steric 
hindrance of substituents on the secondary nitrogens of N4-TLs. In the case of picenMe2, the 
methyl groups are less bulky and exert limited steric effect, which favours the cis-α-isomer. 
Whereas, for picenBz2, the bulky benzyl groups impose greater steric effect favouring the cis-
β-isomer. The isomeric configuration is retained upon the coordination of bidentate ligands, 
due to the kinetic inertness of ruthenium(II). NMR spectroscopy was used successfully to 
confirm identify and purity.  
4.5.4.1 NMR characterisation of rac-α-[Ru(picenMe2)(Bidentate)](PF6)2, where bidentate 
is phen (Ru-3), dpq(Ru-4), and dppzMe2 (Ru-5) 
Coordination of selected bidentate ligands phen (Ru-3), dpq (Ru-4), or dppzMe2 (Ru-5) to 
Ru-1 was successfully achieved, with the products recovered as orange/red precipitates, in 
yields of 67 – 84%, respectively. The C2-symmetry of the precursor, rac-α-
[Ru(picenMe2)(DMSO)Cl]PF6, is retained upon the coordination of bidentate ligands. This is 
evident in the NMR spectra, seen as two-fold symmetry, where the symmetrical proton and 
carbon peaks resonate at the same chemical shift. The chemical shifts in the NMR spectra are 
consistent with similar structures reported in literature.83 
NMR elucidation of Ru-3 is provided to explain the proton assign for the complexes, 
Ru-4 and Ru-5. The proton NMR of Ru-3 clearly shows the aromatic peaks of the pyridine of 
picenMe2, H11 – 14 at ~7.0 – 8.2 ppm, and the remaining chemical shifts are concordant with 
those assigned in Section 4.5.2.1. The phen aromatic peaks H7 – 9, 19 resonate at ~7.5 – 10.0 
ppm. The doublets for H7 is observed at ~9.8 ppm, is furthest downfield as it neighbours the 
electronegative nitrogen coordinated directly to ruthenium while the H9 that resonates at ~8.7 
ppm is para to the electronegative nitrogen. H19 at ~8.2 ppm a singlet with no neighbouring 
protons but has a conjugated system, while the doublet of doublets of H8 experiences a higher 
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field and is observed at ~7.6 ppm due to shielding (Figure 4.8, Table 4.3, Supplementary C, 
Section 1.3).  
 
Figure 4.8 1H-NMR spectra of Ru-3 – 5 was obtained on the 400 MHz Bruker Avance NMR using deuterated 
solvent DMSO-d6, with temperatures maintained at 35 ℃. 
 
The complex Ru-4, the dpq ligand has an addition ring, therefore, there is no H19 peak 
however, a singlet proton peak for H10 is present at ~9.3 ppm as it neighbours an 
electronegative nitrogen and conjugated system (Figure 4.8, Table 4.3). The same chemical 
shift patterns are also evident for Ru-5, where the C19 and C10 of the dppzMe2 have no 
protons, but the additional aromatic proton H20 is present at ~8.0 ppm. The CH3 groups of the 
dppzMe2 are furthest upfield at ~2.6 ppm integrating to 6H (Figure 4.8, Table 4.3). In the 
aliphatic region, complexes Ru-3-5, have similar proton chemical shifts where the diamine 
peaks H16ab is slightly downfield, followed by the dimethyl substituents on the N4-TL, and 
diamine bridge protons H1ab (Supplementary C, Section 1.3). Further NMR experiments 
using 2D-NMR were used to corroborate the assignments.  
The proton correlations that were evident in the COSY of Ru-3 are illustrated in 
Supplementary C, Section 1.9. The phen protons H7 - 9 correlate with each other and close-
range neighbouring with H11 is also seen, whereas, H19, a singlet proton has no neighbouring 
protons to correlate with. The amine protons H16ab correlate with the remaining protons N-
CH3 and H1ab are singlet protons with no proton correlations. These correlations are also 
reflected in Ru-4 and Ru-5. Minor difference occurs as to the bidentate ligands become longer 
as shown in Supplementary C, Section 1.19. Carbon and proton correlations were obtained 
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using HMQC, for Ru-3 (Figure 4.9, Table 4.3), the H7 – 9, H19 of the phen and H11 – 14 
aromatic protons of the picenMe2 correlates with their corresponding carbons at ~ 120 – 150 
ppm. The aliphatic protons H16, H1, and N-CH3 correlate with C16, C1, and N-CH3 at ~ 50 – 
70 ppm, respectively. The carbon assignments evident in the HMQC of Ru-3 are also evident 
for Ru-4 and Ru-5 (Figure 4.9, Table 4.3 and 4.4, Supplementary C, Section 1.5). Carbon and 
dept spectra of Ru-3 ratify the assignment of carbons C15, 17, and 18, visible in the 13C-NMR 
but absent on the dept-NMR. The positive-dept for CH/CH3 peaks correctly confirm the phen, 
pyridine aromatic carbons and methyl substituent. Whereas, negative-dept CH2 peaks endorse 
the aliphatic carbons C16 (diamine) and C1 (polyamine) assignments. The carbon and dept 
spectra for Ru-4 and Ru-5 were successfully assigned aided by the spectra of Ru-3, as 
demonstrated in (Figure 4.9, Table 4.3 and 4.4, Supplementary C, Sections 1.7 and 1.11). 
 
Figure 4.9 13C and HMQC-NMR of Ru-3 – 5 was obtained on the 400 MHz Bruker Avance NMR using 
deuterated solvent DMSO-d6, with temperatures maintained at 35 ℃. 
 
4.5.4.2 NMR characterisation of rac-α-[Ru(picenMe2)(Bidentate)](PF6)2, where bidentate 
is phenpyrBz (Ru-6), phenpyrBzMe (Ru-7), and phenpyrBzNO2 (Ru-8) 
Ru-1 was successfully coordinated to the bidentate ligands phenpyrBz (Ru-6), phenpyrBzMe 
(Ru-7), and phenpyrBzNO2 (Ru-8) with the orange/red precipitate recovered in reasonable 
yields of 55 – 68%. The 1H spectrum of Ru-6 is explained as an exemplar for the remaining 
complexes, Ru-7 and Ru-8.  
The 1H NMR of Ru-6 has all the structural elements that have been previously 
identified for Ru-1 – 5 aromatic peaks from the picenMe2 N4-TL H11 – 14 (Figure 4.10, Table 
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4.5, Supplementary C, Section 1.3). The bidentate ligand, while phen-based has both 
similarities and difference. For phenpyrBz, H7 – 9, H30 – 32, are found in the aromatic 
region. Furthest downfield is the -NH from the imidazole at ~14.0 ppm as the proton is 
directly bound to the electronegative nitrogen. The H7 – 9 protons of phenpyrBz resonate in 
the aromatic region of the spectrum and demonstrate identical coupling to that of phen. The 
additional aromatic peaks H30 – 32 are due to the benzyl of the phenpyrBz and are slightly 
downfield from H12 at ~7.5 and 8.2 ppm. In complex Ru-7, the phenpyrBzMe has a methyl 
group substituent on position C32, therefore, no proton peak is observed for H32, but a 
methyl peak is visible at ~2.4 ppm, integrating to 3H (Figure 4.10, Table 4.5). The chemical 
shift pattern is evident with complex, Ru-8, the phenpyrBzNO2 has a NO2 substituent on 
position C32 so no peak is seen for H32 (Figure 4.10, Table 4.5). The aromatic chemical 
shifts for Ru-7 and Ru-8, peaks H30 and H31 are shifted to a lower field by the addition of -
CH3 and -NO2, respectively. In the aliphatic region, complexes Ru-6 and Ru-8, the proton 
peaks resonate at the same chemical shift where the diamine peaks H16ab is slightly 
downfield, followed by the dimethyl substituents on the N4-TL, and diamine bridge protons 
H1ab. Ru-7 has identical aliphatic chemical shifts as Ru-6 and Ru-8 but with an additional -
CH3 on phenpyrBzMe at position C32 resonating at ~2.4 ppm (Supplementary C, Section 
1.3). The proton NMR of Ru-6 – 8 was successfully assigned with the aid of additional 2D-
NMR experiments.  
 
Figure 4.10 1H-NMR spectra of Ru-6 – 8 was obtained on the 400 MHz Bruker Avance NMR using deuterated 
solvent DMSO-d6, with temperatures maintained at 35 ℃. 
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The COSY spectra of Ru-6 provides evidence of proton correlations (Supplementary 
C, Section 1.9) where H7 – 9, H30 – 32 of phenpyrBz and H11 – 14 the aromatic protons of 
picenMe2 exhibit proton correlations. The -NH (imidazole) proton has no neighbouring 
protons, therefore, no correlations are evident on the COSY spectrum. Protons in the aliphatic 
region H16/26ab correlate with each other and the remaining protons H1/2 and N-CH3 are 
singlets without any neighbouring protons. COSY correlations of Ru-7 and Ru-8 show 
similarities to Ru-6 with minor difference where Ru-7 has additional protons for Bz-CH3 in 
the aliphatic region. HMQC experiments for Ru-6 (Figure 4.11, Supplementary C, Section 
1.15), indicated correlations for phenpyrBz H7 – 9, 30 – 32 and the aromatic protons of 
picenMe2 H11 – 14 with their corresponding carbons between ~120 – 150 ppm, while the 
aliphatic protons H16, H1, and N-CH3 correlate with C16, C1, and N-CH3 at ~ 50 – 70 ppm, 
respectively. Carbon (Figure 4.11, Table 4.6) and Dept spectra of Ru-6 supports the carbon 
assignments (Supplementary C, Sections 1.7 and 1.11). 
 
Figure 4.11 13C and HMQC-NMR of Ru-6 – 8 was obtained on the 400 MHz Bruker Avance NMR using 
deuterated solvent DMSO-d6, with temperatures maintained at 35 ℃. 
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Table 4.3 Summary of 1H-NMR data of rac-α-[Ru(picenMe2)(PL)](PF6)2, where PL is a bidentate such as phen 
(Ru-3), dpq (Ru-4) or dppzMe2 (Ru-5). 
 
 









   
N-CH3 2.88(6H, s) 2.89(6H, s) 2.91(6H, s) 
Bz-CH3 - - 2.57(6H, s) 
H1a 2.74(4H, m) 2.76(2H, m) 2.77(4H, m) 
H1b 2.74(4H, m) 3.40(2H, m) 2.77(4H, m) 
H2a 2.74(4H, m) 2.76(2H, m) 2.77(4H, m) 
H2b 2.74(4H, m) 3.40(2H, m) 2.77(4H, m) 
H16a 4.54(2H, d) J1 = 16.96 Hz 4.56(2H, d) J1 = 17.04 Hz 4.58(2H, d) J1 = 17.04 Hz 
H16b 5.14(2H, d) J1 = 16.84 Hz 5.18(2H, d) J1 = 16.88 Hz 5.19(2H, d) J1 = 16.84 Hz 
H26a 4.54(2H, d) J1 = 16.96 Hz 4.56(2H, d) J1 = 17.04 Hz 4.58(2H, d) J1 = 17.04 Hz 
H26b 5.14(2H, d) J1 = 16.84 Hz 5.18(2H, d) J1 = 16.88 Hz 5.19(2H, d) J1 = 16.84 Hz 
H7 9.77 (2H, d) J1 = 4.96 Hz 9.87(2H, d) J1 = 4.96 Hz 9.83(2H, d) J1 = 5.36 Hz 
H7ʹ 9.77 (2H, d) J1 = 4.96 Hz 9.87(2H, d) J1 = 4.96 Hz 9.83(2H, d) J1 = 5.36 Hz 
H8 7.58(2H, d) J1 = 5.40 Hz 7.67(4H, t) J1 = 6.83 Hz 7.78(4H, m) 
H8ʹ 7.58(2H, d) J1 = 5.40 Hz 7.67(4H, t) J1 = 6.83 Hz 7.78(4H, m) 
H9 8.72(2H, d) J1 = 7.80 Hz 9.53(2H, d) J1 = 8.24 Hz 9.38(2H, d) J1 = 8.08 Hz 
H9ʹ 8.72(2H, d) J1 = 7.80 Hz 9.53(2H, d) J1 = 8.24 Hz 9.38(2H, d) J1 = 8.08 Hz 
H10 - 9.30(2H, s) - 
H10ʹ - 9.30(2H, s) - 
H19 8.25(2H, s) - - 
H19ʹ 8.25(2H, s) - - 
H20 - - 7.97(2H, s) 
H20ʹ - - 7.97(2H, s) 
H12 7.06(2H, t) J1 = 6.58 Hz 7.09(2H, t) J1 = 6.64 Hz 7.14(2H, t) J1 = 6.52 Hz 
H22 7.06(2H, t) J1 = 6.58 Hz 7.09(2H, t) J1 = 6.64 Hz 7.14(2H, t) J1 = 6.52 Hz 
H13 7.73(2H, t) J1 = 7.70 Hz 7.75(2H, t) J1 = 7.76 Hz 7.78(4H, m) 
H23 7.73(2H, t) J1 = 7.70 Hz 7.75(2H, t) J1 = 7.76 Hz 7.78(4H, m) 
H14 7.63(2H, d) J1 = 7.68 Hz 7.67(4H, t) J1 = 6.83 Hz 7.69(2H, d) J1 = 7.64 Hz 
H24 7.63(2H, d) J1 = 7.68 Hz 7.67(4H, t) J1 = 6.83 Hz 7.69(2H, d) J1 = 7.64 Hz 
H11 8.07(2H, m) 8.23(2H, m) 8.17(2H, m) 
H21 8.07(2H, m) 8.23(2H, m) 8.17(2H, m) 
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Table 4.4 Summary of 13C-NMR data of rac-α-[Ru(picenMe2)(PL)](PF6)2, where PL is a bidentate such as phen 











13C-NMR    
N-CH3 47.67 47.65 47.64 
Bz-CH3 - - 20.65 
C1a 60.79 60.84 60.85 
C1b 60.79 63.25 60.85 
C2a 60.79 60.84 60.85 
C2b 60.79 63.25 60.85 
C16a 68.49 68.48 68.48 
C16b 68.49 68.48 68.48 
C26a 68.49 68.48 68.48 
C26b 68.49 68.48 68.48 
C7 156.87 157.89 157.53 
C7ʹ 156.87 157.89 157.53 
C8 152.27 152.61 152.76 
C8ʹ 152.27 152.61 152.76 
C9 137.22 133.02 132.98 
C9ʹ 137.22 133.02 132.98 
C10 - 147.19 144.19 
C10ʹ - 147.19 144.19 
C17 148.97 150.89 151.74 
C17ʹ 148.97 150.89 151.74 
C18 130.49 129.31 129.79 
C18ʹ 130.49 129.31 129.79 
C19 128.37 139.44 141.59 
C19ʹ 128.37 139.44 141.59 
C20 - - 127.81 
C20ʹ - - 127.81 
C12 125.27 125.32 125.39 
C22 125.27 125.32 125.39 
C13 136.91 137.35 137.39 
C23 136.91 137.35 137.39 
C14 123.33 123.37 123.42 
C24 123.33 123.37 123.42 
C11 126.74 127.78 128.02 
C21 126.74 127.78 128.02 
C15 161.47 161.38 161.43 
C25 161.47 161.38 161.43 
C27 - - 138.91 
C27ʹ - - 138.91 
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Table 4.5 Summary of 1H-NMR data of rac-α-[Ru(picenMe2)(PL)](PF6)2, where PL is a bidentate such as 














1H-NMR    
N-CH3 2.89(6H, s) 2.89(6H, s) 2.90(6H, s) 
Bz-CH3 - 2.42(3H, s) - 
-NH 14.21(1H, s) 14.11(1H, s) 14.54(1H, s) 
H1a 2.76(4H, m) 2.76(4H, m) 2.77(4H, m) 
H1b 2.76(4H, m) 2.76(4H, m) 2.77(4H, m) 
H2a 2.76(4H, m) 2.76(4H, m) 2.77(4H, m) 
H2b 2.76(4H, m) 2.76(4H, m) 2.77(4H, m) 
H16a 4.55(2H, d) J1 = 17.00 Hz 4.54(2H, d) J1 = 17.04 Hz 4.55(2H, d) J1 = 17.00 Hz 
H16b 5.18(2H, d) J1 = 16.84 Hz 5.17(2H, d) J1 = 16.84 Hz 5.18(2H, d) J1 = 16.88 Hz 
H26a 4.55(2H, d) J1 = 17.00 Hz 4.54(2H, d) J1 = 17.04 Hz 4.55(2H, d) J1 = 17.00 Hz 
H26b 5.18(2H, d) J1 = 16.84 Hz 5.17(2H, d) J1 = 16.84 Hz 5.18(2H, d) J1 = 16.88 Hz 
H7 9.70(2H, d) J1 = 5.00 Hz 9.69(2H, d) J1 = 5.04 Hz 9.72(2H, d) J1 = 5.24 Hz 
H7ʹ 9.70(2H, d) J1 = 5.00 Hz 9.69(2H, d) J1 = 5.04 Hz 9.72(2H, d) J1 = 5.24 Hz 
H8 7.67 – 7.56(7H, m) 7.65(2H, d) J1 = 7.68 Hz 7.66(4H, d) J1 = 7.68 Hz 
H8ʹ 7.67 – 7.56(7H, m) 7.65(2H, d) J1 = 7.68 Hz 7.66(4H, d) J1 = 7.68 Hz 
H9 8.28(2H, d) J1 = 7.88 Hz 8.15(2H, m) 8.49(4H, s) 
H9ʹ 8.28(2H, d) J1 = 7.88 Hz 8.15(2H, m) 8.49(4H, s) 
H30 8.14(2H, m) 9.03(4H, m) 8.15(2H, m) 
H30ʹ 8.14(2H, m) 9.03(4H, m) 8.15(2H, m) 
H31 7.67 – 7.56(7H, m) 7.44(4H, m) 8.49(4H, s) 
H31ʹ 7.67 – 7.56(7H, m) 7.44(4H, m) 8.49(4H, s) 
H12 7.09(2H, t) J1 = 6.20 Hz 7.08(2H, t) J1 = 6.44 Hz 7.09(2H, t) J1 = 6.24 Hz 
H22 7.09(2H, t) J1 = 6.20 Hz 7.08(2H, t) J1 = 6.44 Hz 7.09(2H, t) J1 = 6.24 Hz 
H13 7.74(2H, t) J1 = 7.60 Hz 7.74(2H, t) J1 = 7.52 Hz 7.74(2H, t) J1 = 4.00 Hz 
H23 7.74(2H, t) J1 = 7.60 Hz 7.74(2H, t) J1 = 7.52 Hz 7.74(2H, t) J1 = 4.00 Hz 
H14 7.67 – 7.56(7H, m) 7.44(4H, m) 7.66(4H, d) J1 = 7.68 Hz 
H24 7.67 – 7.56(7H, m) 7.44(4H, m) 7.66(4H, d) J1 = 7.68 Hz 
H11 9.06(2H, d) J1 = 8.12 Hz 9.03(4H, m) 9.03(2H, d) J1 = 8.12 Hz 
H21 9.06(2H, d) J1 = 8.12 Hz 9.03(4H, m) 9.03(2H, d) J1 = 8.12 Hz 
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Table 4.6 Summary of 13C-NMR data of rac-α-[Ru(picenMe2)(PL)](PF6)2, where PL is a bidentate such as 











13C-NMR    
N-CH3 47.58 47.56 47.57 
Bz-CH3 - 21.49 - 
C1a 60.85 60.85 60.85 
C1b 60.85 60.85 60.85 
C2a 60.85 60.85 60.85 
C2b 60.85 60.85 60.85 
C16a 68.43 68.43 68.43 
C16b 68.43 68.43 68.43 
C26a 68.43 68.43 68.43 
C26b 68.43 68.43 68.43 
C7 154.52 154.51 154.90 
C7ʹ 154.52 154.51 154.90 
C8 152.31/129.68/123.36 130.21 152.34 
C8ʹ 152.31/129.68/123.36 130.21 152.34 
C9 127.01 126.93 127.88/125.06 
C9ʹ 127.01 126.93 127.88/125.06 
C17 153.06 153.21 150.66 
C17ʹ 153.06 153.21 150.66 
C18 129.84 127.11 148.48/123.38 
C18ʹ 129.84 127.11 148.48/123.38 
C19 147.29 140.70 147.56 
C19ʹ 147.01 140.70 147.56 
C12 125.31 125.30 125.32 
C22 125.31 125.30 125.32 
C13 137.22 137.21 137.27 
C23 137.22 137.21 137.27 
C14 152.31/129.68/123.36 152.30/123.36 152.34/123.38 
C24 152.31/129.68/123.36 152.30/123.36 152.34/123.38 
C11 130.84 130.09 130.52 
C21 130.84 130.09 130.52 
C15 161.51 161.51 161.51 
C25 161.51 161.51 161.51 
C30 127.01 130.09 126.92 
C30ʹ 127.01 130.09 126.92 
C31 152.31/129.68/123.36 152.30/123.36 127.88/125.06 
C31ʹ 152.31/129.68/123.36 152.30/123.36 127.88/125.06 
C32 152.31/129.68/123.36 124.26 135.55 
C33 121.09 133.99 135.55 
C34 136.94 151.52 135.55 
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4.5.4.3 NMR characterisation of rac--[Ru(picenBz2)(Bidentate)](PF6)2, where bidentate 
is phen (Ru-9), dpq (Ru-10), and dppzMe2 (Ru-11) 
Coordination of rac--[Ru(picenBz2)(Bidentate)](PF6)2 (Ru-2) to the bidentate ligands: phen, 
dpq, and dppzMe2 successfully produced (Ru-9 – 11) as an orange/red precipitate in moderate 
yields 77 – 86%). 1H NMR spectra of the rac--complexes (Ru-9 – 11) produce more 
complicated spectra than the cis- analogues (Ru-3 – 5). The NMR elucidation of Ru-9 is 
provided as an example for characterising the remaining complexes, Ru-10 and Ru-11. 
In complex Ru-9, the aromatic peaks of phen H7/7ʹ – 9/9ʹ, 19/19ʹ and picenBz2 H11 – 
14, 21 – 24 resonate between ~6.5 – 10.0 ppm (Figure 4.12, Table 4.7 and 4.8). The most 
downfield peak H7 resonates as a double at ~9.8 ppm, whereas, H7ʹ is upfield at ~7.8 ppm 
due to the shielding effect from the pyridine ring of the cis-β configuration of picenBz2. The 
remaining aromatic protons follow a similar trend as described above due to cis-β C1-
symmetry. The aliphatic protons of picenBz2 resonate at ~2.0 – 5.5 ppm and exhibit a similar 
tendency as described above (Supplementary C, Section 1.4). 2D-NMR studies were required 
to assigning the remaining protons (Figure 4.13 and Supplementary C, Sections 1.8, 1.12, 
1.16, and 1.20). The assigned proton spectra were concordant to similar structures described 
in the literature.82, 83 
 
Figure 4.12 1H-NMR spectra of Ru-9 – 11 was obtained on the 400 MHz Bruker Avance NMR using deuterated 
solvent DMSO-d6, with temperatures maintained at 35 ℃. 
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Figure 4.13 13C and HMQC-NMR of Ru-9 – 11 was obtained on the 400 MHz Bruker Avance NMR using 
deuterated solvent DMSO-d6, with temperatures maintained at 35 ℃. 
 
4.5.4.4 Characterisation of rac--[Ru(picenBz2)(Bidentate)](PF6)2, where bidentate is 
phenpyrBz (Ru-12), phenpyrBzMe(Ru-13) and phenpyrBzNO2(Ru-14) 
The bidentate ligands phenpyrBz (Ru-12), phenpyrBzMe (Ru-13), and phenpyrBzNO2 (Ru-
14) also formed reasonable yields (63 – 86%) of orange/red products when coordinated to cis-
-[Ru(picenBz2)(DMSO)Cl](PF6)2. Complex Ru-12 was used as an example for the NMR 
spectral analysis. The proton spectrum of Ru-12 (Figure 4.14, Table 4.9) display the familiar 
array of aromatic peaks for picenBz2 H11 – 14, 21 – 24, benzyl substituent on the secondary 
nitrogen, and phenpyrBz H7/7ʹ – 9/9ʹ, 30/30ʹ, 31/31ʹ, and 32 with the expected coupling. 
Furthest downfield is the -NH from the imidazole at ~14.0 ppm as the proton is directly bound 
to the electronegative nitrogen. The phenpyrBz aromatic peak H7 resonates at ~9.8 ppm 
whereas, the corresponding proton H7ʹ is upfield at ~8.4 ppm due to shielding by the pyridine 
ring of the cis-β configuration of picenBz2. Therefore, the electron density is higher, and the 
magnetic field sees a lower frequency for H7ʹ. The remaining aromatic protons follow a 
similar trend as described above due to cis-β C1-symmetry and proton position, resulting in 
shielding and de-shielding effect depending upon position. The aromatic proton peaks 
between ~7.0 – 8.5 ppm are not well defined due to the increased aromatic rings in the 
structure which causes an overlap of the peaks (Supplementary C, Section 1.4).  
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Figure 4.14 1H-NMR spectra of Ru-12 – 14 was obtained on the 400 MHz Bruker Avance NMR using 
deuterated solvent DMSO-d6, with temperatures maintained at 35 ℃. 
 
For complex Ru-13, the phenpyrBzMe has a methyl group substituent in position C32, 
therefore, no proton peak is present for H32 and a methyl peak is visible at ~2.4 ppm 
integrating to 3H (Figure 4.14, Table 4.9). The same trend is displayed with complex, Ru-14, 
where phenpyrBzNO2 has a NO2 substituent in position C32, therefore, no peak is seen for 
H32 (Figure 4.14, Table 4.9). In the aliphatic region, for complexes Ru-12 and Ru-14, the 
proton peaks resonate at the same chemical shift, Whereas, Ru-13 has identical aliphatic 
peaks as Ru-12 and Ru-14 except the additional -CH3 in position C32 resonating at ~2.4 ppm 
(Supplementary C, Section 1.4). The proton NMR spectrum of Ru-12 - 14 was successfully 
assigned using additional 2D-NMR. COSY studies presented clear correlations between 
neighbouring protons 1H – 1H as shown in Supplementary C, Section 1.20, for Ru-12 – 14. 
For complex, Ru-12, the -NH imidazole proton has no evident proton correlations 
demonstrated on the COSY spectra. The aromatic peaks for phenpyrBz, benzyl substituent 
(Ar-H), and picenBz2 display correlations with neighbouring and close-range protons. Protons 
in the aliphatic region H1/2, H16/26, and H110/220 correlate with their corresponding and 
neighbouring protons. COSY correlations of Ru-13 and Ru-14 demonstrated similarities to 
Ru-12 with minor difference where Ru-13 has additional protons for Bz-CH3 in the aliphatic 
region as shown in Supplementary C, Section 1.20.  
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Carbon and proton correlations were confirmed using HMQC for Ru-12 (Figure 4.15, 
Table 4.10), the aromatic protons for picenBz2 H11 – 14, 21 – 24, Ar-H, and phenpyrBz H7/7' 
– 9/9ʹ, 30/30ʹ, 31/31ʹ, and 32 correlate with their corresponding carbon at ~120 – 150 ppm, as 
have been previously shown (Supplementary C, Section 1.16). Aliphatic protons H1/2, 
H16/26, and H110/220 correlate with C1/2, C16/26, and C110/220 at ~40 – 70 ppm. Carbon 
and dept spectra of Ru-12 correlate the assignments with singlet carbons C15, 17, 18, 19, 33, 
and 34 visible on the 13C-NMR and absent on the dept-NMR. The positive-dept CH/CH3 
peaks correctly confirm phenpyrBz, picenBz2, and Ar-C. Whereas, negative-dept CH2 peaks 
confirm the aliphatic carbons C1/2, C16/26, and H110/220. The carbon and dept spectra for 
Ru-13 and Ru-14 were successfully assigned using the spectra of Ru-12 as guidance, as 
demonstrated in Supplementary C, Sections 1.8 and 1.12. 
 
Figure 4.15 13C and HMQC-NMR of Ru-12 – 14 was obtained on the 400 MHz Bruker Avance NMR using 
deuterated solvent DMSO-d6, with temperatures maintained at 35 ℃. 
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Table 4.7 Summary of 1H-NMR data of rac-β-[Ru(picenBz2)(PL)](PF6)2, where PL is a bidentate such as 
phen(Ru-9), DPQ (Ru-10), or dppzMe2 (Ru-11). 
 
 







1H-NMR    
Bz-CH3 -  2.66(6H, s) 
H1a 4.43(1H, d) J1 = 16.48 Hz 4.44(1H, d) J1 = 16.36 Hz 4.44(1H, d) J1 = 16.72 Hz 
H1b 3.28(1H, d) J1 = 13.16 Hz 3.29(1H, d) J1 = 6.71 Hz 3.27(1H, s) 
H2a 3.05(1H, d) J1 = 11.88 Hz 3.08(1H, d) J1 = 12.24 Hz 3.09(1H, d) J1 = 12.44 Hz 
H2b 2.41(1H, t) J1 = 13.32 Hz 2.41(1H, t) J1 = 13.48 Hz 2.41(1H, t) J1 = 13.24 Hz 
H16a 4.22(1H, d) J1 = 12.44 Hz 4.25(1H, d) J1 = 12.36 Hz 4.25(1H, d) J1 = 3.10 Hz 
H16b 3.85(1H, d) J1 = 16.56 Hz 3.88(1H, d) J1 = 16.64 Hz 3.88(1H, d) J1 = 16.64 Hz 
H26a 4.59(1H, d) J1 = 16.56 Hz 4.61(1H, d) J1 = 16.52 Hz 4.61(1H, d) J1 = 16.56 Hz 
H26b 3.49(1H, d) J1 = 12.96 Hz 3.58(1H, d) J1 = 13.16 Hz 3.64(1H, d) J1 = 13.32 Hz 
H110a 5.44(1H, d) J1 = 12.40 Hz 5.47(1H, d) J1 = 12.44 Hz 5.46(1H, d) J1 = 12.28 Hz 
H110b 4.06(1H, d) J1 = 17.08 Hz 4.08(1H, d) J1 = 17.12 Hz 4.09(1H, d) J1 = 17.16 Hz 
H220a 3.39(1H, s) 3.39(1H, d) J1 = 4.96 Hz 3.48(1H, s) 
H220b 2.66(1H, d) J1 = 12.92 Hz 2.88(1H, d) J1 = 12.76 Hz 2.97(1H, d) J1 = 13.02 Hz 
Ar-H 7.39 – 7.28(10H, m) 7.62 – 7.54(5H, m) 7.62 – 7.51(7H, m) 
Ar-H - 7.40 – 7.28(5H, m) 7.30(3H, m) 
H7 9.87(1H, d) J1 = 5.44 Hz 9.98(1H, d) J1 = 5.48 Hz 9.93(1H, d) J1 = 5.52 Hz 
H7ʹ 7.92 – 7.79(5H, m) 9.71(1H, d) J1 = 8.00 Hz 7.99 – 7.94(3H, m) 
H8 7.92 – 7.79(5H, m) 7.51(2H, d) J1 = 6.64 Hz 7.40(2H, d) J1 = 7.44 Hz 
H8ʹ 7.92 – 7.79(5H, m) 7.51(2H, d) J1 = 6.64 Hz 7.40(2H, d) J1 = 7.44 Hz 
H9 8.88(1H, d) J1 = 7.96 Hz 9.55(1H, d) J1 = 8.00 Hz 9.76(1H, d) J1 = 8.00 Hz 
H9ʹ 8.76(1H, d) J1 = 4.07 Hz 7.89(1H, d) J1 = 5.52 Hz 9.59(1H, d) J1 = 8.00 Hz 
H10 - 9.39(1H, m) - 
H10ʹ - 9.39(1H, m) - 
H19 8.43(2H, d) J1 = 2.24 Hz - - 
H19ʹ 8.43(2H, d) J1 = 2.24 Hz - - 
H20 - - 7.99 – 7.94(3H, m) 
H20ʹ - - 7.99 – 7.94(3H, m) 
H12 7.05(1H, m) 7.08(1H, d) J1 = 5.48 Hz 7.21(1H, d) J1 = 5.48 Hz 
H22 7.92 – 7.79(5H, m) 7.03(1H, m) 7.05(1H, m) 
H13 8.10(2H, t) J1 = 6.88 Hz 8.12(1H, t) J1 = 7.72 Hz 8.23(1H, t) J1 = 6.78 Hz 
H23 8.10(2H, t) J1 = 6.88 Hz 7.82(1H, d) J1 = 7.84 Hz 8.13(1H, t) J1 = 7.76 Hz 
H14 7.58(2H, m) 7.94(2H, d) J1 = 3.88 Hz 7.89(1H, d) J1 = 5.48 Hz 
H24 7.58(2H, m) 7.94(2H, d) J1 = 3.88 Hz 7.82(1H, d) J1 = 7.76 Hz 
H11 6.75(1H, d) J1 = 5.52 Hz 8.25(1H, m) 8.30(2H, d) J1 = 2.80 Hz 
H21 7.92 – 7.79(5H, m) 8.01(1H, m) 8.30(2H, d) J1 = 2.80 Hz 
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Table 4.8 Summary of 13C-NMR data of rac-β-[Ru(picenBz2)(PL)](PF6)2, where PL is a bidentate such as 
phen(Ru-9), DPQ (Ru-10), or dppzMe2 (Ru-11). 
 







13C-NMR    
Bz-CH3 - - 20.69 
C1a 66.08 66.09 66.12 
C1b 53.80 53.79 53.81 
C2a 64.32 64.37 64.39 
C2b 53.80 53.79 53.81 
C16a 60.30 60.27 60.31 
C16b 60.30 60.27 60.31 
C26a 64.32/60.30 64.37/60.27 60.31 
C26b 66.33 66.73 66.84 
C110a 60.30 60.27 60.31 
C110b 66.08 66.09 66.12 
C220a 63.28 63.26 63.26 
C220b 66.33 66.73 66.84 
Ar-C 152.24/129.17/128.72/128.33 153.16/133.96/132.26 152.83/133.86/126.85 
Ar-C 133.84 – 129.55/126.74 131.34 – 128.49 131.38 – 128.50 
C7 156.89 157.78 157.47 
C7ʹ 123.01 133.44 126.85 
C8 151.35 133.66 132.27 
C8ʹ 151.35 133.66 132.27 
C9 137.53 131.51 133.48 
C9ʹ 135.55 151.38 131.55 
C10 - 147.01 141.78 
C10ʹ - 147.01 141.78 
C17 148.99 151.14 152.20 
C17ʹ 148.99 150.22 151.24 
C18 148.18 140.03 139.95 
C18ʹ 148.18 140.03 - 
C19 128.59 139.94 144.14 
C19ʹ 128.59 139.94 - 
C20 - - 137.86/125.41 
C20ʹ - - 137.86 
C12 125.95 153.35 153.44 
C22 137.72/125.38 125.86 125.86 
C13 138.45/125.86 138.60 126.85 
C23 138.45/125.86 123.16 138.59 
C14 129.30 137.85/125.38 151.38 
C24 129.30 137.85/125.39 123.19 
C11 152.79 126.80 128.27 
C21 123.01 126.80 128.27 
C15 164.72 164.68 164.66 
C25 163.90 163.81 163.83 
C27 - - 139.85 
C27ʹ - - 139.85 
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Table 4.9 Summary of 1H-NMR data of rac-β-[Ru(picenBz2)(PL)](PF6)2, where PL is a bidentate such as 












1H-NMR    
Bz-CH3 - 2.45(3H, s) - 
-NH 14.30(1H, d) J1 = 10.52 Hz 14.20(1H, d) J1 = 9.32 Hz 14.66(1H, s) 
H1a 4.43(1H, d) J1 = 13.88 Hz 4.44(1H, d) J1 = 13.92 Hz 4.45(1H, m) 
H1b 3.29(1H, d) J1 = 14.84 Hz 3.28(1H, m) 3.28(1H, s) 
H2a 3.08(1H, d) J1 = 12.08 Hz 3.08(1H, d) J1 = 12.72 Hz 3.08(1H, d) J1 = 12.64 Hz 
H2b 2.42(1H, t) J1 = 13.00 Hz 2.43(1H, m) 2.42(1H, t) J1 = 13.32 Hz 
H16a 4.23(1H, d) J1 = 12.28 Hz 4.22(1H, d) J1 = 12.28 Hz 4.24(1H, d) J1 = 12.36 Hz 
H16b 3.88(1H, d) J1 = 16.64 Hz 3.87(1H, d) J1 = 16.48 Hz 3.88(1H, d) J1 = 16.52 Hz 
H26a 4.60(1H, d) J1 = 16.48 Hz 4.50(1H, d) J1 = 16.52 Hz 4.60(1H, d) J1 = 16.48 Hz 
H26b 3.57(1H, d) J1 = 13.04 Hz 3.57(1H, d) J1 = 13.08 Hz 3.57(1H, d) J1 = 13.00 Hz 
H110a 5.45(1H, d) J1 = 12.28 Hz 5.45(1H, d) J1 = 13.32 Hz 5.46(1H, d) J1 = 12.36 Hz 
H110b 4.08(1H, d) J1 = 17.08 Hz 4.08(1H, d) J1 = 17.00 Hz 4.08(1H, d) J1 = 16.48 Hz 
H220a 3.40(1H, s) 3.40(1H, s) 3.40(1H, s) 
H220b 2.78(1H, m) 2.78(1H, m) 2.80(1H, d) J1 = 13.08 Hz 
Ar-H 7.63 – 7.54(4H, m) 7.51 – 7.30(12H, m) 7.59(4H, m) 
Ar-H 7.41 – 7.28(6H, m) - 7.41 – 7.28(8H, m) 
H7 9.84(1H, t) J1 = 4.64 Hz 9.83(1H, m) 9.85(1H, d) J1 = 5.52 Hz 
H7ʹ 8.36(2H, d) J1 = 7.76 Hz 8.25(2H, d) J1 = 8.00 Hz 8.57(2H, m) 
H8 7.69(2H, t) J1 = 7.32 Hz 7.58(2H, m) 7.51(2H, d) J1 = 6.72 Hz 
H8ʹ 7.69(2H, t) J1 = 7.32 Hz 7.58(2H, m) 7.51(2H, d) J1 = 6.72 Hz 
H9 9.08(1H, t) J1 = 7.08 Hz 9.06(1H, t) J1 = 7.48 Hz 9.07(1H, d) J1 = 8.08 Hz 
H9ʹ 8.19(1H, m) 8.19(1H, d) J1 = 5.20 Hz 8.18(1H, t) J1 = 5.92 Hz 
H30 7.92(2H, d) J1 = 4.88 Hz 7.92(2H, d) J1 = 4.20 Hz 7.93(2H, d) J1 = 4.12 Hz 
H30ʹ 7.92(2H, d) J1 = 4.88 Hz 7.92(2H, d) J1 = 4.20 Hz 7.93(2H, d) J1 = 4.12 Hz 
H31 7.51(3H, m) 7.51 – 7.30(12H, m) 7.59(4H, m) 
H31ʹ 7.51(3H, m) 7.51 – 7.30(12H, m) 7.59(4H, m) 
H32 7.51(3H, m) - - 
H12 6.88(1H, t) 6.87(1H, t) J1 = 6.76 Hz 6.91(1H, d) J1 = 5.52 Hz 
H22 7.04(1H, m) 7.03(1H, m) 7.05(1H, m) 
H13 8.11(1H, t) J1 = 7.76 Hz 8.11(1H, t) J1 = 7.68 Hz 8.11(1H, t) J1 = 7.68 Hz 
H23 7.81(1H, d) J1 = 7.84 Hz 7.81(1H, d) J1 = 7.88 Hz 7.82(1H, d) J1 = 7.84 Hz 
H14 7.89(2H, d) J1 = 5.64 Hz 7.89(2H, d) J1 = 5.20 Hz 7.89(2H, d) J1 = 5.76 Hz 
H24 7.89(2H, d) J1 = 5.64 Hz 7.89(2H, d) J1 = 5.20 Hz 7.89(2H, d) J1 = 5.76 Hz 
H11 9.24(1H, m) 9.22(1H, d) J1 = 3.46 Hz 9.23(1H, d) J1 = 8.08 Hz 
H21 8.36(2H, d) J1 = 7.76 Hz 8.25(2H, d) J1 = 8.00 Hz 8.57(2H, m) 
157 | P a g e  
 
Table 4.10 Summary of 13C-NMR data of rac-β-[Ru(picenBz2)(PL)](PF6)2, where PL is a bidentate such as 
phenpyrBz (Ru-12), phenpyrBzMe (Ru-13), or phenpyrBzNO2 (Ru-14). 







13C-NMR    
Bz-CH3 - 21.52 - 
C1a 66.11 66.12 66.11 
C1b 53.80 53.82 53.81 
C2a 64.39 21.52 63.26 
C2b 53.80 53.82 53.81 
C16a 60.23 60.23 60.25 
C16b 60.23 60.23 60.25 
C26a 66.11 60.23 60.25 
C26b 66.44 64.46 66.46 
C110a 60.23 60.23 60.25 
C110b 66.11 66.12 66.11 
C220a 63.26 64.39 63.26 
C220b 66.44 64.46 66.46 
Ar-C 150.03/149.82/133.85/132.19 149.78 150.23/132.19/129.14 
Ar-C 127.87 133.85 – 131.00 127.89 
C7 154.67 153.12 154.89 
C7ʹ 127.06 126.99 128.53/125.15 
C8 129.76 126.77 133.86 
C8ʹ 129.76 126.77 133.86 
C9 129.29 129.13 129.57 
C9ʹ 125.96 125.96 125.95 
C17 147.44 147.36 148.45 
C17ʹ 147.21 147.08 148.45 
C18 137.45 137.15 131.26 
C18ʹ 137.18 137.15 131.26 
C19 146.45 146.38 147.73 
C19ʹ 146.16 146.04 147.73 
C12 152.96 151.34 152.92 
C22 126.77 126.07 126.79 
C13 138.49 138.48 138.52 
C23 123.07 123.06 123.09 
C14 151.34 149.95 150.80 
C24 151.34 149.95 150.80 
C11 130.85 130.29 131.08 
C21 127.06 126.99 128.53/125.15 
C15 164.65 164.65 164.65 
C25 163.91 163.91 163.89 
C30 137.69/125.37 137.67/125.36 137.73/125.39 
C30ʹ 137.69/125.37 137.67/125.36 137.73/125.39 
C31 133.85/132.19/127.87 149.78 150.23/132.19/129.29/127.89 
C31ʹ 133.85/132.19/127.87 149.78 150.23/132.19/129.29/127.89 
C32 132.19/127.87 122.11 135.95 
C33 131.09 140.70 146.71 
C34 131.25 152.86 151.34 
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4.6 Single crystal X-ray diffraction of Ruthenium(II) complexes 
Single crystals of complexes, Ru-3 – 6 and Ru–12, were successful obtained via slow 
evaporation from acetone/water mixture or by diffusion of diethyl ether into complexes 
dissolved in either methanol or ethanol (Table 4.11). The single crystal X-ray diffraction 
measurements for Ru-3 – 6 and Ru–12 were carried out on the MX1 beamline at the 
Australian Synchrotron, as part of Australian Nuclear Science and Technology Organization 
(ANSTO). Diffraction data were collected using a monochromated synchrotron X-ray 
radiation (λ = 0.71080) at 100(2) K and were corrected for Lorentz and polarization effects 
using the XDS software. Absorption corrections were applied to the data using SADABS. The 
structures were solved by using SHELXT and the full-matrix least-squares refinements were 
carried out using SHELXL-2014 via Olex2 interface. All non-hydrogen atoms with full 
occupancy were located from the electron density maps and refined anisotropically. Hydrogen 
atoms bound to carbon and nitrogen atoms were added in the ideal positions and refined using 
a riding model. All tables are illustrated in supplementary data C, Sections 5.1 – 5.5. 
4.6.2 Results and Discussion 
4.6.2.1 X-ray crystal structure of Ru-3 – 6 and Ru-12 
The molecular structures of rac-α-[Ru(picenMe2)(PL)](PF6)2, (PL = phen (Ru-3), dpq (Ru-4), 
dppzMe2 (Ru-5), and phenpyrBz (Ru-6)) and rac-β-[Ru(picenBz2)(phenpyrBz)](PF6)2 (Ru-
12) are shown in Figure 4.16. The ruthenium(II) complexes Ru-3 – 6, display the expected 
octahedral coordination with N4-TLs, picenMe2 and picenBz2, and polyaromatic ligands phen, 
dpq, dppzMe2, and phenpyrBz. The bond lengths and any angular distortions of Ru-3 – 6 and 
12 are consistent with multidentate behaviour of the ligands. The bonding parameters of the 
complexes are presented in Table 4.12 and Supplementary data C, Sections 5.1 – 5.5. For 
example, the bond lengths for Ru-3 are Ru-Npyridine 2.073(3), 2.067(3), Ru-Nen 2.153(3), 
2.158(3), and Ru-Nphen 2.092(3) and 2.095(3) Å, respectively, are expectedly similar 
indicating the cis-α isomeric form and very minor distortions, to which this is comparable 
with published structures. The cis-α C2-symmetry is obvious for Ru-3 with the bond angle 
from the pyridine nitrogens in the axial and equatorial positions to ruthenium is relatively 
close to linear with N1-Ru-N4 at 174.28˚, N3-Ru-N5, and N2-Ru-N6 at 172.00˚ and 172.75˚, 
respectively, the bond angles between ethylenediamine nitrogen and phen is relatively close to 
linear. The remaining complexes, Ru-3 – 6, also demonstrated cis-α C2-symmetry and 
complexes, Ru-12 demonstrated cis-β which was evident from the bond length/angles as 
shown in Supplementary data C, Sections 5.1 – 5.5. This trend is also observed with Co(III) 
and Ru(II) complexes. The crystal packing of Ru-3 – 5 is demonstrated in Figure 7, stacking 
pattern is observed and no apparent H-bonding noted. 
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Table 4.11 Crystal data and structure refinement for Ru-3 – 6 and 12. 
 
 Ru-3 Ru-4 Ru-5 Ru-6 Ru-12 
Chemical formula C28H30N6Ru·2(F6P) C30H30N8Ru·2(F6P)  C36H36N8Ru·2(F6P) C35H34N8Ru·2(F6P) C47H42N8Ru·2(F6P)· 
Molecular Weight 842.59 893.62 971.74 957.71 1109.91 
Crystal system, space group Monoclinic, P21/n Tetragonal, P41 Orthorhombic, Fdd2 Monoclinic, Cc Monoclinic, P2/n 
Temperature (K) 100(2) 100(2) 100(2) 100(2) 100(2) 
a/Å 18.585(4) 17.450(3) 23.752(5) 19.664(4) 20.561(4) 
b/Å 17.674(4) 17.450(3) 15.729(3) 15.844(3) 10.009(2) 
c/Å 20.028(4) 12.557(3) 19.930(4) 14.416(3) 25.865(5) 
α/º 90 90 90 90 90 
β/º 104.50(3) 90 90 127.11(3) 106.49(3) 
γ/º 90 90 90 90 90 
Volume/Å3 6369(2) 3823.4(13) 7446(3) 3581.7(17) 5104.0(19) 
Z 8 4 8 4 4 
ρcalcg/cm3 1.755 1.577 1.734 1.778 1.521 
Radiation type Silicon double crystal 
monochromated 
synchrotron, λ = 0.7108 Å 
Silicon double crystal 
monochromated 
synchrotron, λ = 0.7108 Å 
Silicon double crystal 
monochromated 
synchrotron, λ = 0.7108 Å 
Silicon double crystal 
monochromated 
synchrotron, λ = 0.7108 Å 
Silicon double crystal 
monochromated 
synchrotron, λ = 0.7108 Å 
µ (mm-1) 0.695 0.588 0.609 0.632 0.460 
Crystal size (mm) 0.080 × 0.060 × 0.010 0.120 × 0.010 × 0.010 0.110 × 0.080 × 0.010 0.10 × 0.10 ×0.01 0.150 × 0.040 × 0.030 
F(000) 3376 1824 3920 1932 2380 
2Θ range for data 
collection/° 
2.674 to 50 2.334 to 49.998 3.718 to 49.998 3.654 to 49.998 2.244 to 50 
Index ranges -22 ≤ h ≤ 22, -21 ≤ k ≤ 21, 
-23 ≤ l ≤ 23  
-20 ≤ h ≤ 20, -20 ≤ k ≤ 20, 
-14 ≤ l ≤ 14 
-28 ≤ h ≤ 28, -18 ≤ k ≤ 18, 
-23 ≤ l ≤ 23 
-21 ≤ h ≤ 21, -18 ≤ k ≤ 18, 
-17 ≤ l ≤ 17  
-24 ≤ h ≤ 24, -11 ≤ k ≤ 11, 
-30 ≤ l ≤ 30  
Reflections collected 77932 47021  22426 21068 61002 
Independent reflections 10661 [Rint = 0.0430, Rsigma 
= 0.0212] 
6725 [Rint = 0.1000, Rsigma 
= 0.0409] 
3279 [Rint = 0.0321, Rsigma 
= 0.0173] 
5916 [Rint = 0.0395, Rsigma 
= 0.0298] 
8960 [Rint = 0.0455, Rsigma 
= 0.0227] 
Data/restraints/parameters 10661/0/887 6725/22/500 3279/1/270 5916/2/525 8960/0/672 
Goodness of fit  1.056 1.064 1.071 1.053 1.030 
Final R indexes [I>=2σ (I)] R1 = 0.0349, wR2 = 0.0904 R1 = 0.0516, wR2 = 0.1321 R1 = 0.0275, wR2 = 0.0693  R1 = 0.0270, wR2 = 0.0712 R1 = 0.0456, wR2 = 0.1167 
Final R indexes [all data] R1 = 0.0436, wR2 = 0.0960  R1 = 0.0539, wR2 = 0.1341 R1 = 0.0289, wR2 = 0.0702  R1 = 0.0271, wR2 = 0.0714 R1 = 0.0526, wR2 = 0.1220 
Largest diff. peak/hole / e Å3 1.87/-1.25 1.43/-0.83 0.73/-0.78  0.54/-0.76 1.77/-0.79 
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Figure 4.16 The crystal structures of Ru-3 – 6 and 12 with atomic labelling (a – e), and molecular stacking in the 
crystals (f – j). 
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Bond Dimensions at Ru-3 
Bond Lengths (Å)  
N1 N2 N3 N4 N5 N6 
2.073(3) 2.153(3) 2.158(3) 2.067(3) 2.092(3) 2.095(3) 
Bond Angles (˚) 
 N2 N3 N4 N5 N6 
N1 78.53(10) 98.45(10) 174.28(10) 89.42(10) 94.24(10) 
N2  82.38(10) 96.33(10) 100.72(10) 172.75(10) 
N3   78.23(10) 172.00(10) 99.40(10) 
N4    94.05(10) 90.91(10) 
N5     78.45(10) 
Bond Dimensions at Ru-4 
Bond Lengths (Å)  
N1 N2 N3 N4 N5 N6 
2.064(7) 2.161(7) 2.158(7) 2.075(8) 2.082(8) 2.099(7) 
Bond Angles (˚) 
 N2 N3 N4 N5 N6 
N1 78.6(3) 98.6(3) 175.9(3) 88.2(3) 95.4(3) 
N2  81.8(3) 98.1(3) 99.8(3) 173.9(3) 
N3   78.5(3) 173.2(3) 100.4(3) 
N4    94.7(3) 87.9(3) 
N5     78.8(3) 
Bond Dimensions at Ru-5 
Bond Lengths (Å)  
N1' N1 N2' N2 N3' N3 
2.070(4) 2.070(4) 2.166(5) 2.166(5) 2.089(5) 2.089(5) 
Bond Angles (˚) 
 N1 N2' N2 N3' N3 
N1' 176.10(2) 78.70(15) 98.31(16) 94.59(17) 88.43(17) 
N1  98.31(16) 78.70(15) 88.43(17) 94.59(17) 
N2'   82.10(3) 173.24(18) 99.94(14) 
N2    99.94(14) 173.24(18) 
N3'     78.3(3) 
Bond Dimensions at Ru-6 
Bond Lengths (Å)  
N1 N2 N3 N4 N5 N6 
2.073(4) 2.173(4) 2.177(5) 2.070(4) 2.073(5) 2.095(4) 
Bond Angles (˚) 
 N2 N3 N4 N5 N6 
N1 78.49(15) 99.00(13) 176.40(16) 89.52(15) 95.91(15) 
N2  81.50(18) 98.41(15) 100.84(17) 174.39(18) 
N3   78.63(14) 171.47(15) 99.37(17) 
N4    92.89(16) 87.19(15) 
N5     79.11(17) 
Bond Dimensions at Ru-12 
Bond Lengths (Å)  
N1 N2 N3 N4 N5 N6 
2.070(3) 2.156(3) 2.173(3) 2.061(3) 2.068(3) 2.114(3) 
Bond Angles (˚) 
 N2 N3 N4 N5 N6 
N1 80.29(11) 88.10(10) 96.84(11) 87.75(11) 166.44(10) 
N2  84.26(10) 163.46(11) 93.96(10) 99.77(10) 
N3   79.36(11) 175.71(10) 105.42(10) 
N4    102.23(11) 86.83(11) 
N5     78.71(10) 
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4.7 Other characterisation 
Other characterisation techniques were used to provide structural information and confirm 
purity of the isolated product Ru-1 – 14. HPLC traces were acquired using an Onyx-
monolithic C18 100 × 4.6 mm column, 10 – 100 (%B) over 15 min with solvent A: 0.06 % 
TFA in water and solvent B: 0.06 % TFA in CH3CN:H2O (90:10), at a flow rate of 1 mL/min, 
injection volume of 5 – 20 µL, and detection at 254 nm. The retention times for Ru-1 – 14 are 
reported in Table 4.13. In each instance a single peak was observed which was used to verify 
purity as shown in Supplementary C, Sections 3.1 – 3.4. ESI-MS was used to examine Ru-1 – 
14, the calculated m/z found m/z and the differences are reported in Table 4.13 with the m/z 
ranging between 480 – 840. The ESI-MS for Ru-1 – 14 revealed close to calculated m/z for 
the [M]+ compared with the found m/z, the difference m/z averaging to 0.02 as shown in Table 
4.13. The calculated and found m/z were concordant with predicted ESI-MS (Supplementary 
C, Sections 4.1 – 4.4). 
In the electronic spectra of N4-TL-13 and 25, peaks at 262 and 263 nm, respectively, 
are due to a π–π* transition. Upon coordination to cis-[Ru(DMSO)4Cl2] however, a red shift is 
observed together Ru-1 and 2 with broads peaks at 346 and 360 nm, respectively, for the 
metal to ligand charge transfer band. The π–π* transition for (S=O) from the DMSO ligand is 
observed as bands at 247 and 250 nm for Ru-1 and 2, respectively. The π–π* and MLCT 
transitions for the Ru-complexes, Ru-3 – 14, are observed as broad bands and vary as a 
consequence of increased conjugation in the bidentate ligands and shift towards longer 
wavelength (Figure 4.17, A and B). The electronic spectra of Ru-1 – 14 were obtained 
together with the extinction coefficient and spectra are reported in (Supplementary C, 
Sections 2.1 – 2.4). Overall, the characterisation studies of complexes Ru-1 – 14 were 
successful, producing structural information and confirming similarities with other published 
structures.  
 
Figure 4.17 Electronic spectra (UV-Vis) of rac-α-[Ru(picenMe2)(bidentate)](PF6)2,Ru-3 – 8, (A) and rac-β-
[Ru(picenBz2)(bidentate)](PF6)2 Ru-9 – 14 (B) demonstrating π–π* and MLCT transitions and spectra shifting 
towards a longer wavelength (nm) after coordination.  
A B 
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Table 4.13 Summary of the characterisation data of Ruthenium(II) complexes Ru-1 – 14. 
 
4.8 Conclusion 
Twelve racemic cis-α-[Ru(picenMe2)(bidentate)](PF6)2 and cis-β-[Ru(picenBz2)(bidentate)] 
(PF6)2 complexes (where bidentate is phen, dpq, dppzMe2, phenpyrBz, phenpyrBzMe, and 
phenpyrBzNO2, where 8 are novel, were synthesised in reasonable yields and characterised 
using NMR, HPLC, ESI-MS, and UV-Vis. Complexes, Ru-3 – 6 and 12, produced crystals 
that were suitable for x-ray analysis. X-ray crystallography studies illustrated complexes Ru-3 
– 6 formed racemic cis-α, and cis-β for Ru-12. NMR characterisation clearly distinguished the 
stereochemistry produced for racemic cis-α and cis-β complexes with symmetrical and 
asymmetrical spectra, respectively. The characterisation of ruthenium(II) complexes can now 
be assessed for anticancer and antimicrobial activity. 
  








tR (mins) at 
254 
λmax (nm) (ε/mol-1.dm3cm-1× 103) 
Ru-1 485.08 485.04 -0.04 4.44 247(10.1 ± 0.1), 346(8.0 ± 0.1). 
Ru-2 637.13 637.11 -0.02 8.63 250(13.9 ± 0.2), 360(7.5 ± 0.1). 
Ru-3 697.12 697.12 0 8.84 
271(51.2 ± 3.0), 369(15.8 ± 0.6), 
442(8.2 ± 0.3), 476(7.3 ± 0.3) 
Ru-4 603.16 603.16 0 5.97 
297(25.2 ± 1.2), 363(16.2 ± 0.7), 
449(8.1 ± 0.4), 476(7.6 ± 0.4) 
Ru-5 681.21 681.20 -0.01 15.86 
276(99.6 ± 2.4), 369(34.9 ± 1.5), 
388(36.0 ± 2.0) 
Ru-6 667.19 667.19 0 6.62 
286(58.6 ± 0.7), 301(57.5 ± 0.8), 
368(19.2 ± 0.2), 489(8.9 ± 0.1) 
Ru-7 681.21 681.19 -0.02 7.21 
287(63.7 ± 1.6), 301(60.8 ± 1.5), 
371(16.9 ± 0.4), 488(7.5 ± 0.2) 
Ru-8 712.18 712.16 -0.02 7.23 
293(45.8 ± 1.3), 366(48.1 ± 1.4), 
488(11.2 ± 0.4) 
Ru-9 703.22 703.19 -0.03 8.44 
270(45.5 ± 0.8), 376(10.2 ± 0.2), 
464(8.2 ± 0.1) 
Ru-10 755.23 755.20 -0.03 8.75 
258(57.3 ± 3.7), 300(26.5 ± 1.9), 
373(10.6 ± 1.1), 474(8.2 ± 0.9) 
Ru-11 833.27 833.26 -0.01 11.16 
277(10.6 ± 3.9), 370(40.2 ± 1.8), 
381(40.1 ± 1.8), 388(42.1 ± 2.0) 
Ru-12 819.26 819.22 -0.04 8.90 
288(63.1 ± 1.7), 298(62.9 ± 2.0), 
376(14.8 ± 0.5), 479(11.0 ± 0.5) 
Ru-13 833.27 833.24 -0.03 18.29 
290(68.8 ± 2.4), 299(67.0 ± 2.2), 
375(16.0 ± 0.5), 479(11.5 ± 0.4) 
Ru-14 864.24 864.21 -0.03 18.22 
258(61.2 ± 1.9), 290(49.8 ± 1.3), 
374(44.6 ± 0.8), 479(13.8 ± 0.3) 




5. CHAPTER FIVE: Bacterial and 







The biological activity of the synthesised ruthenium(II) complexes, Ru-1 – 14 was assessed 
against cancer and bacterial cells using MTT and MIC assays. The in vitro cytotoxicity assays 
revealed Ru-7 was 10-, 5-, and 40-fold and Ru-13 was 5-, 2-, and 19-fold more potent than 
cisplatin (3.69 µM), oxaliplatin (1.68 µM), and carboplatin (14.43 µM) respectively, in 
human cancer cell lines. Ru-7 was the most cytotoxic complex overall, particularly against 
ovarian (A2780) cells with a GI50 of 0.064 µM. The antimicrobial activity of Ru-5 and Ru-11 
demonstrated comparable results with the references rac-[Ru(2,9-Me2phen)(dppz)]Cl2, 
ampicillin, and streptomycin with an MIC of 5 µM against E.aerogenes, S.aureus, and 
M.luteus, respectively.  
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5.1 Introduction 
Advances in medicinal chemistry have led to the development of organo-metallic agents with 
promising anticancer and antimicrobial properties. Ruthenium(II/III) complexes are of interest 
as they are structurally versatile providing a greater number of accessible coordination 
geometries. A wide range of ruthenium-based agents have been synthesised to ameliorate 
cisplatin activity, such as resistant tumours and reduce host toxicity at active doses. Several 
ruthenium(II/III) complexes have been developed which have shown unique anticancer and 
antimetastatic activity. Ruthenium complexes, such as NAMI-A, KP1019, and ruthenium(II) 
arene complexes are structurally versatile and have been reported to express anticancer 
activity.23, 24, 26-28 Ruthenium(II) complexes are not only active in cancer studies but 
demonstrate promising antimicrobial activity. There is a necessity to develop new 
antimicrobial agents as drug resistant microorganisms have emerged as a consequence of the 
misuse and overuse of existing agents. The antimicrobial activities of RuII-polypyridyl 
complexes that were extensively reported by Dwyer and co-workers in the 1950s showed 
promising antibacterial and cytotoxic activity.140, 142, 143 Ruthenium(II/III) complexes, exhibit 
ideal chemical properties which are advantageous for biological activity. 
 Recent advances have shown the development of new ruthenium(II/II) complexes 
such as ruthenium(II) arene agents. Ruthenium(II) complexes of N, O- and N, N- pyrazolone-
based hydrazone ligands have gained prominence due to a wide range of reported biological 
activity.201, 202 The cytotoxicity of complexes, [Ru(p-cymene)(L1 – L3)Cl]
+ where (1) L1 = 2-
((5-hydroxo-3-methyl-1-phenyl-1H-pyrazol-4-yl)(phenyl)methylene)-1-(2,4-nitrophenyl)-
hydrazine), (2) L2 = 2-((5-hydroxo-3-methyl-1-phenyl-1H-pyrazol-4-yl)(phenyl)methylene)-
1-(4-nitrophenyl)-hydrazine), (3) L3 = 2-((5-hydroxo-3-methyl-1-phenyl-1H-pyrazol-4-
yl)(phenyl)methylene)-1-(pyridine-2-yl)-hydrazine) have been evaluated against human breast 
adenocarcinoma (MCF-7), cisplatin resistant breast (MCF-7CR), and non-tumorigenic breast 
cells (MCF-10A) (Figure 5.1). Complexes 1 – 3 have demonstrated activity against MCF-7 
with IC50 values of 130 ± 28, 65 ± 25, and 42 ± 13 µM, respectively, which are comparable to 
cisplatin (IC50 = 36.2 ± 3.4 µM). Interestingly, complex 3 (IC50 = 60 ± 31 µM) showed better 
results than cisplatin (IC50 > 200 µM) against MCF-7CR while showing selectivity for cancer 
cells as it is not active in normal MCF-10A (IC50 = 125 ± 21 µM). Other ruthenium(II) arene 
complexes have been reported with promising antiproliferation against human and cisplatin 
resistant cell lines. Whilst the activity of ruthenium(II) complexes have also focused towards 
antimicrobial activity. 
Despite the development of a wide variety of ruthenium complexes as anticancer and 
anti-metastatic agents, the limited anticancer activity of ruthenium(II) complexes does not 
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impair their potential antimicrobial activity. Ruthenium(II) polypyridyl complexes such as 
mono-nuclear rac-[Ru(2,9-Me2phen)(dppz)]Cl2 (4) demonstrated activity against S.aureus 
(MSSA160) and it resistant strains MRSA41 and MRSA252 with MIC of 8, 4, and 2 µg/mL, 
respectively (Figure 5.1). Dinuclear complexes such as ΔΔ/ΛΛ-[{Ru(phen)2}2{µ-bbn}]
4+ 
(Rubbn) (where phen = 1,10-phenanthroline; bbn = bis[4(4'-methyl-2,2'-bipyridyl)]-1,n-alkane 
(n = 10, 12, 14 or 16)) demonstrated activity against S.aureus and E.coli with an average MIC 
of 2.4 and 3.3 µg/mL, respectively (Figure 5.1).171 Linear and non-linear ruthenium(II) Rubbn 
complexes with the ligand bis[4(4'-methyl-2,2'-bipyridyl)]-1,7-heptane (linear = Rubb7-TL 
and non-linear = Rubb7-TNL) have shown to be active against S.aureus (MIC = 8 and 4 
µg/mL) and E.coli (MIC = 16 and 8 µg/mL). The results demonstrated that both Rubb7-TL 
and Rubb7-TNL had significant antimicrobial activity, with Rubb7-TNL being slightly more 
active than the corresponding analogue Rubb7-TL.
198 Ruthenium complexes of this type have 
the potential to be used as broad-spectrum antibiotics that may work effectively against drug 
resistant strains. Overall, ruthenium(II/III) complexes have shown to be promising as 
anticancer and antimicrobial agents. 
 
Figure 5.1 The structures of N, O and N, N-pyrazolone based hydrazone [1 – 3], mono-nuclear rac-[Ru(2,9-
Me2phen)(dppz)]Cl2 [4], di-nuclear [Rubbn], tetranuclear linear [Rubb7-TL] and non-linear [Rubb7-TNL] 
ruthenium(II) complexes. 
 
This chapter reports on the evaluation of the biological activity of synthesised 
ruthenium(II) complexes, Ru-1 – 14, these compounds were assessed against mammalian 
cancer cells using MTT assay to determine the GI50 values. The antimicrobial activity was 
evaluated against Gram-positive and negative bacteria using MIC assays. 
167 | P a g e  
 
5.2 Experimental 
5.2.1 Materials and Instrumentation 
Synthesis of ruthenium(II) complexes were accomplished as described in Chapter 4, Section 
4.4. The treatment samples were prepared in DMSO purchased from Chem-supply for 
biological activity. The same materials and instrumentation that were used to determine the 
biological activity of ruthenium(II) complexes as reported in Chapter 3, Sections 3.3 and 3.4, 
have been applied here. 
5.3 Results and Discussion 
The anticancer activities were explored for ruthenium(II) complexes, Ru-1 – 14, together with 
picenMe2, picenBz2 and control compounds cisplatin, oxaliplatin, and carboplatin. The 
exposure growth inhibitory (GI) effects were evaluated by MTT assays of 72 h treatment 
exposure against 10 human cell lines; colon (HT29), glioblastoma (U87), breast (MCF-7), 
ovarian (A2780), lung (H460), skin (A431), prostate (Du145), neuroblastoma (BE2-C), 
glioblastoma (SJ-G2), pancreas (MIA), along with normal breast (MCF10A). The results have 
been tabulated and graphed to express the GI50 values calculated from dose-survival curves. 
5.3.1 Anticancer activity of ruthenium(II) picenMe2 complexes and determining the GI50 
The anticancer activities of N4-TL and ruthenium(II) complexes that passed preliminary 
screening (Ru-5 – 8, Figure 5.2) are expressed as GI50 values are summarised in Table 5.1. 
Complexes, Ru-1, 3 and 4, failed the preliminary screening with greater than 50 µM IG50 
values. Ruthenium complexes, Ru-5 – 8 and N4-TL-13, have GI50 values that are more potent 
than carboplatin against 10 cell lines and, in some cell lines, they are more potent than 
cisplatin and oxaliplatin. The average GI50 values of Ru-5 – 8 and N4-TL-13 for the 10 cell 
lines was 2.01, 17.47, 0.36, 2.91, and 2.58 µM, respectively. Interestingly, the average GI50 
values for Ru-7 was 10-, 5-, and 40-fold more potent than cisplatin (3.69 µM), oxaliplatin 
(1.68 µM), and carboplatin (14.43 µM) respectively, in human cancer cell lines as shown in 
Table 5.2. Additionally, N4-TL-13 was found to be active against the 10 cell lines and was 
equivalent to cisplatin and oxaliplatin, and 6-fold more active than carboplatin as reported in 
Table 10. While all the ruthenium complexes (Ru-5 – 8) showed some activity against cancer 
cell lines, their average GI50 values rank them Ru-7 > 5 > 8 > 6 from most to least active, 
where the N4-TL and polyaromatic ligands effected the cytotoxicity of these complexes. 
 
168 | P a g e  
 



























N4-TL-13 2.7 ± 0.067 2.8 ± 0.19 2.7 ± 0.22 2.8 ± 0.15 2.7 ± 0.14 2.6 ± 0.12 1.9 ± 0.058 2.8 ± 0.15 2.3 ± 0.13 2.5 ± 0.12 2.9 ± 0.000 
N4-TL-25 0.20 ± 0.03 1.5 ± 0.5 0.30 ± 0.10 0.06 ± 0.03 0.83 ± 0.29 2.1 ± 0.1 1.7 ± 0.3 0.14 ± 0.03 0.22 ± 0.03 2.0 ± 0.2 1.3 ± 0.3 
Ru-1 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 
Ru-2 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 
Ru-3 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 
Ru-4 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 
Ru-5 3.0±0.24 3.5 ± 0.27 0.16 ± 0.011 0.14 ± 0.13 3.2 ± 0.15 1.7 ± 0.12 3.5 ± 0.27 0.54 ± 0.21 1.8 ± 0.31 2.6 ± 0.13 3.8 ± 0.54 
Ru-6 18 ± 1.0 25 ± 3.8 22 ± 2.4 0.67 ± 0.37 17 ± 2.4 21 ± 2.0 17 ± 0.58 12 ± 1.3 18 ± 3.6 24 ± 5.6 18 ± 1.7 
Ru-7 0.32 ± 0.050 0.35 ± 0.052 0.42 ± 0.092 0.064 ± 0.037 0.27 ± 0.015 0.40 ± 0.047 0.85 ± 0.18 0.26 ± 0.039 0.36 ± 0.070 0.32 ± 0.033 0.42 ± 0.023 
Ru-8 2.7 ± 0.23 3.4 ± 0.50 3.2 ± 0.67 0.11 ± 0.066 5.3 ± 0.99 3.4 ± 0.29 3.0 ± 0.20 2.3 ± 0.78 2.8 ± 0.12 2.9 ± 0.27 2.8 ± 0.54 
Ru-9 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 
Ru-10 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 
Ru-11 2.2 ± 0.088 2.9 ± 0.033 0.13 ± 0.019 0.075 ± 0.058 2.1 ± 0.067 1.4 ± 0.24 3.4 ± 0.088 0.44 ± 0.00000 1.5 ± 0.32 2.2 ± 0.088 3.3 ± 0.27 
Ru-12 6.3 ± 1.2 8.8 ± 2.2 5.0 ± 0.44 0.46 ± 0.19 6.4 ± 1.0 6.3 ± 0.33 4.1 ± 0.94 1.8 ± 1.6 8.2 ± 1.3 12 ± 1.4 6.9 ± 2.6 
Ru-13 0.39 ± 0.046 0.67 ± 0.27 0.76 ± 0.18 0.79 ± 0.71 0.34 ± 0.0088 0.57 ± 0.11 0.80 ± 0.087 1.5 ± 1.3 0.47 ± 0.12 1.3 ± 0.99 0.42 ± 0.052 
Ru-14 3.0 ± 0.058 3.8 ± 0.21 2.4 ± 0.23 0.96 ± 0.47 6.1 ± 0.52 3.1 ± 0.088 3.0 ± 0.29 3.0 ± 0.46 3.5 ± 0.33 3.2 ± 0.34 2.8 ± 0.30 
Cisplatin 11.3 ± 1.9 3.8 ± 1.1 6.5 ± 0.8 1.0 ± 0.1 0.9 ± 0.2 2.4 ± 0.3 1.2 ± 0.1 1.9 ± 0.2 0.4 ± 0.1 7.5 ± 1.3 nd 
Oxaliplatin 0.9 ± 0.2 1.8 ± 0.2 0.5 ± 0.1 0.16 ± 0.0 1.6 ± 0.1 4.1 ± 0.5 2.9 ± 0.4 0.9 ± 0.2 3.0 ± 1.2 0.9 ± 0.2 nd 
Carboplatin >50 >50 >50 9.2 ± 2.9 14 ± 1.0 24.3 ± 2.2 14.7 ± 1.2 18.7 ± 1.2 5.7 ± 0.2 >50 nd 
*Primary cell line (Breast Normal MCF10A). 
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Table 5.2 Average of GI50 values (Concentration µM) and fold more potent against cisplatin, oxaliplatin, and 
carboplatin. 
Complex Average* GI50 
values (µM) 
cisplatin oxaliplatin carboplatin 
N4-TL-13 2.58 ≡ ≡ 6 
N4-TL-25 0.91 4 2 16 
Ru-5 2.01 2 1 7 
Ru-6 17.47 - - 1 
Ru-7 0.36 10 5 40 
Ru-8 2.91 ≡ ≡ 5 
Ru-11 1.63 2 ≡ 9 
Ru-12 5.94 - - 2 
Ru-13 0.76 5 2 19 
Ru-14 3.21 ≡ - 4 
Cisplatin 3.69    
Oxaliplatin 1.68    
Carboplatin 14.43    
*Average of HT29, U87, MCF-7, A270, H460, A431, Du145, BE2-C, SJ-G2, MIA cell lines 
 
Figure 5.2 Racemic cis-α-[Ru(picenMe2)(bidentate)](PF6)2 coordinated to N2-bidentate ligands phen, dpq, 
dppzMe2, phenpyrBz, phenpyrBzMe, and phenpyrBzNO2. 
 
The anticancer activity of the basic unmodified structure/scaffold, picenMe2 (N4-TL-
13) may arise from is potential to coordinate metal complexes in vitro. N4-TL-13 was active 
against all cell lines with an overall average GI50 of 2.58 µM. The addition of polyaromatic 
ligands altered this baseline cytotoxicity; in the case of Ru-5 and Ru-7, the addition of the 
polyaromatic ligands, dppzMe2 and phenpyrBzMe, enhanced the cytotoxicity and decreased 
the GI50 values of these ligands. Ru-7 was the most potent with sub-micromolar GI50 
concentrations against the 10 cell lines. This was followed by Ru-5 (dppzMe2) which was 
particularly potent against ovarian (A2780), neuroblastoma (BE2-C), and breast (MCF-7) 
with GI50 values of 0.14, 0.54, and 0.16 µM, respectively. However, when phenpyrBzNO2 
and phenpyrBz were added to form Ru-8 and Ru-6, the average GI50 against 10 cell lines 
increased. Despite the poor performance on average, Ru-8 and Ru-6 are cytotoxic and 
therefore anticancer activity seems to be improved when methyl substituents are present on 
the N4-TL and the polyaromatic ligands. 
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Complexes Ru-5 – 8, and N4-TL-13 are cytotoxic against certain cell lines as 
illustrated in Figure 5.3. Cytotoxicity was more evident in the methyl substituted 
polyaromatic ligands Ru-5 (dppzMe2) and Ru-7 (phenpyrBzMe). Ru-7 was the most cytotoxic 
complex, particularly against ovarian (A2780) cells with a GI50 of 0.064 µM. Complexes Ru-
5 was ~ 24-fold cytotoxic in MCF-7 (GI50 = 0.16 ± 0.011 µM) compared to MCF10A (GI50 = 
3.8 ± 0.54 µM). This suggests some capacity for cancer-specific activity over normal cells. In 
contrast, N4-TL-13 and Ru-6 – 8 demonstrate almost equivalently activity against both MCF-7 
and MCF10A. Overall, the GI50 values of the ruthenium(II) complexes, Ru-5 – 8, and N4-TL-
12, showed comparable activity to cisplatin, oxaliplatin, and carboplatin. The cytotoxicity of 
ruthenium(II) complexes, Ru-5 – 8, showed to be more potent in sub-micromolar 
concentrations compared to recently published ruthenium structures. Based on cytotoxicity 
assessments, Ru-7 was demonstrated to be the most cytotoxic compound and it outperforms 
traditional anticancer agents.198, 201, 202 
 
Figure 5.3 GI50 values of  N4-TL-13,  Ru-5,  Ru-6,  Ru-7, and  Ru-8 in multiple cell lines: colon 
(HT29), glioblastoma (U87 and SJ-G2), ovarian (A2780), lung (H460), skin (A431), prostate (Du145), 
neuroblastoma (BE2-C), pancreas (MIA), breast (MCF-7), and breast normal (MCF10A).  
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5.3.2 Anticancer activity of ruthenium(II) picenBz2 complexes and determining the GI50 
Cytotoxicity studies of ruthenium(II) complexes, Ru-11 – 14, and N4-TL-25 are expressed as 
GI50 values which are summarised in Table 5.1 and Figure 5.4. Complexes Ru-2, 9, and 10, 
failed preliminary screenings with greater than 50 µM GI50 values. Ruthenium(II) complexes, 
Ru-11 – 14, and N4-TL-25 have GI50 values more potent than carboplatin against 10 cell lines 
and, in some cell lines, they are more potent than cisplatin and oxaliplatin. The average GI50 
values for Ru-11 – 14 and N4-TL-25 for 10 cell lines was 1.63, 5.94, 0.76, 3.21, and 0.91 µM, 
respectively. Interestingly, the average GI50 values for Ru-13 was 5-, 2-, and 19-fold more 
potent than cisplatin (3.68 µM), oxaliplatin (1.68 µM), and carboplatin (14.43 µM), 
respectively, in human cancer cell lines as shown in Table 5.2. Additionally, N4-TL-25 was 
found to be potent against the 10 cell lines and was 4-, 2-, and 16-fold more active than 
cisplatin, oxaliplatin, and carboplatin, respectively, as reported in Table 5.2. While all of the 
ruthenium(II) complexes Ru-11 – 14 show some activity against cell lines, their average GI50 
values rank them Ru-13 > 11 > 14 > 12, from most to least active, where the N4-TL and 
polyaromatic ligands affected the cytotoxicity of these complexes. 
 
Figure 5.4 Racemic cis-β-[Ru(picenMe2)(bidentate)](PF6)2 coordinated to N2-bidentate ligands phen, dpq, 
dppzMe2, phenpyrBz, phenpyrBzMe, and phenpyrBzNO2. 
 
As mentioned in Section 5.3.1, the activity of picenBz2 (25), like picenMe2 (13), may 
arise with in vitro metal coordination. N4-TL-25 having an average GI50 of 0.91 µM and was 
2.84-fold more potent than N4-TL-13 against all cell lines. The addition of polyaromatic 
ligands altered this by enhancing the cytotoxicity, like Ru-5 (dppzMe2) and Ru-7 
(phenpyrBzMe), the same trend was observed with Ru-11 and Ru-13. Complex, Ru-13, was 
the most potent with an average GI50 value of 0.76 µM against all 10 cell lines. This was 
followed by Ru-11 which was active, much like Ru-5, against ovarian (A2780), 
neuroblastoma (BE2-C), and breast (MCF-7) with GI50 values of 0.075, 0.44, and 0.13 µM, 
respectively (Figure 5.5). Interestingly, the activity of Ru-11 was 1.23-fold more active than 
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Ru-5, while Ru-13 was 2.11-fold less active than Ru-7 indicating that other structural features 
may play a role modulating the activity of these complexes. However, for the remaining 
coordinated polyaromatic ligands, phenpyrBz and phenpyrBzMe, forming Ru-12 and Ru-14, 
the average GI50 against 10 cell lines was greater than cisplatin, oxaliplatin, and carboplatin. 
Although the average GI50 values were poor, Ru-12 and Ru-14 also demonstrated an increase 
in cytotoxicity with methyl substituents on the polyaromatic bidentate ligands. 
 
Figure 5.5 GI50 values of  N4-TL-25,  Ru-11,  Ru-12,  Ru-13, and  Ru-14 in multiple cell lines: colon 
(HT29), glioblastoma (U87 and SJ-G2), ovarian (A2780), lung (H460), skin (A431), prostate (Du145), 
neuroblastoma (BE2-C), pancreas (MIA), breast (MCF-7), and breast normal (MCF10A). 
 
Complexes Ru-11 – 14, together with N4-TL-25, demonstrated cytotoxicity against 
various cell lines as illustrated in Figure 5.5. The cytotoxicity was more evident in the methyl 
substituted polyaromatic bidentate ligands for complexes Ru-11 (dppzMe2) and Ru-13 
(phenpyrBzMe). Ru-13 was the most active, particularly against colon (HT29), lung (H460), 
and glioblastoma (SJ-G2) with GI50 values of 0.39, 0.34, and 0.47 µM, respectively. Complex 
Ru-11 demonstrated cancer-specific activity over normal cells, approximately 25-fold 
cytotoxic in MCF-7 (GI50 = 0.13 ± 0.019 µM) compared with MCF10A (GI50 = 3.3 ± 0.27 
µM). This trend is also observed with N4-TL-25, whereas, Ru-12 – 14 demonstrated almost 
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equivalent activity against both MCF-7 and MCF10A. Overall, the GI50 values of the 
ruthenium(II) complexes, Ru-11 – 14 together with N4-TL-25 showed comparable results with 
cisplatin, oxaliplatin, and carboplatin. The cytotoxicity of ruthenium(II) complexes, Ru-11 – 
14, proved to be more potent in sub-micromolar concentrations compared to recently 
published ruthenium structures.198, 201, 202 Based on cytotoxicity assessments, Ru-13 is by far 
the most cytotoxic compound as it outperforms platinum anticancer agents in vitro.  
5.3.3 Antimicrobial activity of ruthenium(II) complexes in standard growth conditions 
to determine MIC 
The in vitro antimicrobial activity was evaluated for ruthenium(II) complexes, (Ru-1 – 14), to 
determine the MIC using methods which have been standardised for clinical application by 
various organisations such as, EUCAST and CLSI.196 The ruthenium(II) complexes were 
tested against a selection of 6 bacterial strains, they included gram-positive bacteria B.cereus, 
S.aureus, and M.luteus, and gram-negative bacteria E.coli, K.pneumoniae, and E.aerogenes. 
Complexes, Ru-1 – 14, together with references rac-[Ru(2,9-Me2phen)(dppz)]Cl2, Ampicillin 
and Streptomycin underwent MIC screening using concentrations 0.5 – 64 µg/mL which were 
incubated with selected Gram-positive and negative bacteria for 24 hrs. There were solubility 
issues during the incubation process causing some of the complexes to precipitate out of 
solution, resulting in inconsistent OD600 values. Therefore, the assays were modified by using 
concentrations of 5, 25, 50, and 100 µM for clear and concise results. The MIC values were 
recorded in micro-molar concentrations (µM), the results are summarised for Ru-1 – 14 in 
Table 5.3 and Figure 5.6. 
 
Table 5.3 MIC (µg/mL) values of ruthenium(II) complexes and references Ampicillin and Streptomycin against 



















 E. coli K. pneumonia E.aerogenes B.cereus S.aureus M.luteus 
Ru-1 >100 >100 >100 >100 >100 >100 
Ru-2 >100 >100 >100 >100 >100 >100 
Ru-3 >100 >100 100 >100 >100 100 
Ru-4 >100 >100 50 >100 >100 50 
Ru-5 50 100 5 25 5 5 
Ru-6 100 >100 5 100 25 5 
Ru-7 100 >100 5 100 25 5 
Ru-8 100 >100 5 50 25 5 
Ru-9 >100 >100 >100 >100 >100 100 
Ru-10 >100 >100 >100 >100 >100 100 
Ru-11 >100 >100 5 >100 25 5 
Ru-12 >100 >100 25 >100 100 50 
Ru-13 >100 >100 5 50 50 25 
Ru-14 >100 >100 5 >100 100 25 
rac-[Ru(2,9-
Me2phen)(dppz)]Cl2 
25 >100 5 5 5 5 
Ampicillin 5 5 5 25 25 5 
Streptomycin 5 50 5 100 5 5 
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Ruthenium complexes, Ru-5 and Ru-11, were active against both Gram-positive and 
negative bacteria. The MIC (µM) values for Ru-5 and Ru-11 were comparable with the 
references rac-[Ru(2,9-Me2phen)(dppz)]Cl2, ampicillin, and streptomycin with a MIC of 5 
µM against E.aerogenes, S.aureus, and M.luteus, respectively (Figure 5.6). The complex, rac-
[Ru(2,9-Me2phen)(dppz)]Cl2, was used as a reference as it is an octahedral complex with tris 
phen bidentate coordinated and has been reported to demonstrated antimicrobial activity.197 
Complex Ru-5 was more active than rac-[Ru(2,9-Me2phen)(dppz)]Cl2 against B.cereus (MIC 
= 50 µM), M.luteus (MIC = 5 – 100 µM), K.pneumonia (MIC = 5 – 100 µM), and 
E.aerogenes (MIC = 5 – 50µM) as illustrated in Figure 5.6. Although, the ruthenium 
complexes show some antimicrobial activity, their mechanism of action is unknown. The 
polyaromatic ligands such as dppz or dppzMe2 suggest their intercalating characteristics 
towards DNA-binding contribute to the biological activity. The N4-TL may also influence the 
activity if it disassociates from the complex. Overall, complex Ru-5 proved to be the most 
potent and was comparable with the references. 
 
Figure 5.6 Percentage growth (%) values of  Ru-5,  Ru-11, and  rac-[Ru(2,9-Me2phen)2(dppz)]Cl2, in 
Gram-positive bacteria: B.cereus, S.aureus, and M.luteus, and Gram-negative bacteria: E.coli, K.pneumonia, and 
E.aerogenes.  
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5.4 Conclusion 
The biological activity of the synthesised Ru-1 – 14, were successfully assessed using MTT 
and MIC assays for anticancer and antimicrobial activity, respectively. The in vitro 
cytotoxicity of rac-α-[Ru(picenMe2)(Bidentate)](PF6)2 revealed Ru-5 – 8 to be overall more 
potent than cisplatin, oxaliplatin, and carboplatin, on average but also in specific cancer cell 
lines. The polyaromatic ligands altered the cytotoxicity; in the case of complexes Ru-5 and 7 
the ligands dppzMe2 and phenpyrBzMe, enhanced the cytotoxicity and decreased the GI50 
value. Complex Ru-7 was the most potent, particularly against ovarian (A2780) cells with a 
GI50 of 0.064 µM. Cancer specific activity over normal cells was demonstrated with Ru-5 
against MCF-7 and MCF10A. The overall ranking by average GI50 values was Ru-7 > 5 > 8 > 
6, from most to least active. Similarly, the activity of rac-β-[Ru(picenBz2)(Bidentate)](PF6)2 
(Ru-11 – 14) showed similar cytotoxicity trends as Ru-5 – 8. Notably, the methyl substituted 
polyaromatic ligands, demonstrated enhanced activity with Ru-11 (dppzMe2) and 13 
(phenpyrBzMe), this was also observed with complexes Ru-5 and 7. However, the difference 
in activity between Ru-11/13 and Ru-5/7 indicate the type of N4-TL used may have 
contributed to the overall modulation of the activity of these complexes. Complex Ru-13 was 
the most potent, particularly against Lung (H460) cells, followed by Ru-11 demonstrating 
cancer-specific activity over normal cells much like Ru-5. The overall ranking by average 
GI50 values was Ru-13 > 11 > 14 > 12, from most to least active. 
The in vitro antimicrobial activity of Ru-1 – 14 was successfully evaluated to 
determine the MIC values against gram-positive and negative bacteria. The activity of the 
ruthenium complexes slightly favoured Gram-positive over negative bacteria. Complexes Ru-
5 and 11 have structural similarities with the reference compound, rac-[Ru(2,9-
Me2phen)(dppz)]Cl2, show comparable activity. Complexes Ru-5 and 11, were as active as 
ampicillin and streptomycin with a MIC of 5 µM against E.aerogenes, S.aureus, and 
M.luteus. Further investigation and experimental modification will be required to observe a 
greater range of concentrations and overcome solubility issues in future studies. The 
mechanism of action is unknown, the choice of large planar polyaromatic bidentate ligands 
could facilitate DNA-binding for intercalation, but DNA-binding affinity is yet to be 
determined. The individual structural components allow synthetic versatility, making them 
ideal coordination scaffolds for applications in biological and medicinal studies. 
  














6. Conclusion and Future Work 
  
177 | P a g e  
 
6.1 Conclusion to the overall outcome of this research 
The research has focused on the synthetic techniques to expand the utility of N4-TLs; it 
includes the synthesis of N4-TLs, the coordination of N4-TLs and bidentate ligands to 
ruthenium(II), and the assessment of their cytotoxicity and antimicrobial activities against a 
panel of cancer cells and bacterial strains. In Chapter 2, the N4-tetradentate ligands, N4-TLs-1 
– 33, with varying length of diamine chain and functionalised groups, were synthesised in 
yields of 56 – 96% and characterised using NMR, HPLC, ESI-MS, UV-Vis, and where 
appropriate CD. The synthesis required different reaction types which included, Schiff-base 
(condensation reaction), hydrogenation (reductive amination), methylation 
(substitution/reductive amination), and benzylation synthesis (nucleophilic Sn2 reaction). 
NMR characterisation demonstrated symmetrical spectra and clearly distinguished the typical 
patterns and structural features between Schiff-base, hydrogenated, N-methylated, and N-
benzylated N4-TLs. The proton spectra illustrated the chemical shift of the imine peak at ~8.15 
– 8.45 ppm and after hydrogenation the amine peak at ~3.5 – 4 ppm. The functional groups on 
the secondary amine methyl and benzyl, and chiral diamine bridge chemical shifts were 
observed at ~2.0 – 2.5, 7.0 – 7.4, and 1.0 – 2.2 ppm, respectively.  
In Chapter 3, the biological activity of the N4-TLs-1 – 33 was assessed using MTT and 
MIC assays for anticancer and antibacterial activity, respectively. The hydrophobicity was 
modulated by N-substitution and by methyl pyridine substitution which influenced the activity 
of N4-TLs. The order of activity increased for ligands as they became more lipophilic 
expressed as higher log P value. In vitro cytotoxicity revealed N4-TL-25 was overall the most 
active at 4, 2, and 16-fold more potent than cisplatin (3.69 µM), oxaliplatin (1.68 µM), and 
carboplatin (14.43 µM), respectively, in human cancer cells. Cell specific activity was 
observed with N4-TL 25 against ovarian (A2780) cancer cells with a GI50 of 0.06 µM. 
Selectivity was demonstrated with N4-TL 25 for MCF-7 cells at 4.3-fold more cytotoxic (GI50 
= 0.3 µM) compared with MCF10A (GI50 = 1.3 µM).  
The antimicrobial MIC assays of N4-TLs demonstrated correlations with their log P 
values. The order of activity increased as they become more polar and therefore have lower 
log P values. Interestingly the activity of the N4-TLs favoured Gram-negative over Gram-
positive bacteria. The average MIC values for these ligands was 8 and 16 µg/mL. Overall, N4-
TLs-1 was the most active demonstrating an ~8-fold increase in potency compared to 
Ampicillin (MIC = > 64 µg/mL) and streptomycin (MIC = > 64 µg/mL) for A. baumannii.  
In Chapter 4, twelve racemic cis-α-[Ru(picenMe2)(bidentate)](PF6)2 and cis-β-
[Ru(picenBz2)(bidentate)](PF6)2 complexes Ru-3 – 14 (where bidentate ligands are phen, dpq, 
dppzMe2, phenpyrBz, phenpyrBzMe, and phenpyrBzNO2), of which 8 are novel, were 
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synthesised in yields of 55 – 86% and were characterised in detail. The synthesis involved 
preparing the ruthenium(II) precursor [Ru(DMSO)4Cl2] which was used to coordinate to N4-
TLs, picenMe2 (N4-TL-13) and picenBz2 (N4-TL-25) as they both demonstrated biological 
activity and provided an element of control over the structural isomers produced upon 
coordination. They were successfully coordinated to selected bidentate ligands to produce 
racemic cis-α and cis-β products. The isomeric structures formed upon coordination 
demonstrated distinct NMR spectra. These features are influenced by the steric hindrance of 
substituents on the secondary nitrogens of N4-TLs. In the case of picenMe2, the methyl groups 
are less bulky and exert a limited steric effect, which favours the cis-α-isomer. Whereas, for 
picenBz2, the bulky benzyl groups impose greater steric effect favouring the cis-β-isomer. The 
isomeric configurations were retained upon the coordination of bidentate ligands, due to the 
kinetic inertness of ruthenium(II). NMR spectra for cis-α complexes demonstrated a two-fold 
C2-symmetry, where the symmetrical proton and carbon peaks resonate at the same chemical 
shift. The cis-β complexes however, produced asymmetric spectra. X-ray crystallography 
studies illustrate that complexes Ru-3 – 6 form racemic cis-α, and for Ru-12 cis-β. 
In Chapter 5, the biological activity of the N4-TLs-1 – 14 was assessed using MTT and 
MIC assays for anticancer and antibacterial activity, respectively. The In vitro cytotoxicity 
studies were successfully evaluated via MTT assays. Complexes, Ru-5 – 8, racemic cis-α-
[Ru(picenMe2)(bidentate)](PF6)2 produced GI50 values which are more potent than cisplatin, 
oxaliplatin, and carboplatin. The polyaromatic ligands altered the cytotoxicity; in the case of 
complexes Ru-5 and 7 the ligands dppzMe2 and phenpyrBzMe, enhanced the cytotoxicity and 
decreased the GI50 value. Ru-7 was 10-, 5-, and 40-fold more potent than cisplatin (3.69 µM), 
oxaliplatin (1.68 µM), and carboplatin (14.43 µM) respectively, in human cancer cell lines. 
Cell specific activity was observed with Ru-7 particularly against ovarian (A2780) cancer 
cells with a GI50 of 0.064 µM. Similar, the activity of rac-β-[Ru(picenBz2)(bidentate)](PF6)2 
(Ru-11 – 14) showed cytotoxicity trends similar to Ru-5 – 8. The methyl substituted 
polyaromatic ligands dppzMe2 and phenpyrBzMe, for complexes Ru-11 and 13 enhanced the 
activity and decreased the GI50 similarly to Ru-5 and 7. Complex, Ru-13 the most active was 
5-, 2-, and 19-fold more potent than cisplatin (3.68 µM), oxaliplatin (1.68 µM), and 
carboplatin (14.43 µM), respectively, in human cancer cell lines. However, the difference in 
activity between Ru-11/13 and Ru-5/7 indicate the N4-TL used may have contributed to the 
overall modulation of the activity of these complexes.  
The antimicrobial activity of Ru-1 – 14 was more evident for Gram-positive than 
Gram-negative bacteria. Interestingly, the change in polarity after the N4-TL was coordination 
influenced its activity towards the bacterial cells. Complexes Ru-5 and 11, much like the 
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reference compound rac-[Ru(2,9-Me2phen)(dppz)]Cl2, have structural similarities which 
show comparable activity to ampicillin and streptomycin with a MIC of 5 µM against 
E.aerogenes, S.aureus, and M.luteus.  
This work provides comprehensive synthetic details for the production of N4-TLs and 
their respective ruthenium(II) complexes. The N4-TLs and respective ruthenium(II) complexes 
have been synthesised in respectable yields and in high purity as confirmed by several 
different characterisation techniques. The biological activity of the synthesised compounds 
have shown promising results for both anticancer and antimicrobial applications and with 
future research will be of substantial benefit to the field. 
6.2 Future development opportunities  
Strategies for the future development of N4-TLs should focus on expanding the library of N4-
TLs by adding other secondary N-substituents or substituents on the pyridine. By evaluating 
the biological activity of the resulting N4-TLs and comparing them with the N4-TLs reported 
here to determine if other substituents influence activity. Understanding the mechanism of 
action of these N4-TLs will require further investigation. It is hypothesised that these N4-TLs 
may act as chelators which has an affinity for biological metals like iron, copper, zinc, and/or 
others. Using UV titration techniques to assess binding constants will help determine the 
affinity of N4-TLs to biologically relevant metals such as iron, copper, or zinc. Whereas, 
coordinating N4-TLs to metals like platinum, iron, or copper and investigating the biological 
activity will allow a comparison to be made with ruthenium(II). The stereo-chemistries 
formed upon coordination of N4-TLs with ruthenium(II) can be assessed to determine if the 
ligand substituents influence the stereo-chemistry.  
Future work on racemic cis-α/β-[Ru(N4-TL)(bidentate)](PF6)2 complexes may focus on 
resolving the active racemic α and β complexes. Platinum(II) complexes, such as 56MESS 
and 56MERR have shown the resolved chirality of these complexes affect the biological 
activity. Further investigation into the biological activity of ruthenium(II) complexes would 
be of interest. Techniques such as DNA binding studies, ICP-MS, and flow-cytometry may 
assist in the understanding of the mechanism of action such as the affinity for DNA, quantify 
the presences of the complex within a cell, and determine the type of cell death. Other 
strategies could focus on incorporating ruthenium and platinum as a multinuclear complex to 
assess the impact on biological activity. 
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6.3 Preliminary studies 
Preliminary studies have involved the synthesis of Schiff-base and hydrogenated achiral and 
chiral N4-TLs using different pyridine substituents such as 3-methyl, 4-methyl, 4-ethyl, 5-
chloro, and 6-bromo. Both the Schiff-base, and hydrogenated N4-TLs were coordinated to 
copper(II) forming a range of geometries. This has been confirmed with X-ray 
crystallography studies. Preliminary biological studies have been completed via MTT and 
MIC assays to determine the anticancer and antibacterial activity, respectively. Initial trials 
revealed promising anticancer activity with GI50 of < 10 µM against 11 human cell lines. 
There were no apparent effects of the copper(II) complexes against Gram-positive or negative 
bacteria. Additional studies will be required to further investigate their anticancer activity by 
assessing the activity with resistant cells and exploring their binding affinity with DNA. 
 
 




Scheme 6.2 Coordination of Schiff-base and hydrogenated N4-TLs with copper(II) perchlorate hexahydrate. 
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Supplementary A: Instrumental analysis data of N4-TLs-1-33 
1 Nuclear Magnetic Resonance Spectroscopy (NMR) 
1.1 1H-NMR (Schiff Base-achiral N4-TLs-1a-12a)  
400 MHz Bruker Avance NMR using deuterated solvent CDCl3, with temperatures maintained at 25 ℃, 256 
accumulations. 
 
A.1 1H-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1,2-diaminoethane (picen, 1a). 
 
A.2 1H-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1,3-diaminopropane (picpn, 2a). 
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A.4 1H-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1,5-diaminopentane (picptn, 4a). 
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A.6 1H-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1,7-diaminoheptane (pichpn, 6a). 
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A.8 1H-NMR spectra of diimine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,3-diaminopropane (Me2picpn, 8a). 
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A.10 1H-NMR spectra of diimine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,5-diaminopentane (Me2picptn, 10a). 
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A.12 1H-NMR spectra of diimine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,7-diaminoheptane (Me2pichpn, 12a). 
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1.2  1H-NMR (Hydrogenated-achiral N4-TLs-1-12) 
400 MHz Bruker Avance NMR using deuterated solvent D2O, with temperatures maintained at 25 ℃, 256 
accumulations. 
 
A.13 1H-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,2-diaminoethane (picen, 1). 
 
A.14 1H-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,3-diaminopropane (picpn, 2). 
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A.16 1H-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,5-diaminopentane (picptn, 4). 
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A.18 1H-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,7-diaminoheptane (pichpn, 6). 
 
203 | P a g e  
 
 




A.20 1H-NMR spectra of diamine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,3-diaminopropane (Me2picpn, 8). 
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A.22 1H-NMR spectra of diamine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,5-diaminopentane (Me2picptn, 10). 
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A.24 1H-NMR spectra of diamine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,7-diaminoheptane (Me2pichpn, 12). 
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1.3 1H-NMR (Methylated-achiral N4-TLs-13-24) 
400 MHz Bruker Avance NMR using deuterated solvent CDCl3, with temperatures maintained at 25 ℃, 256 
accumulations. 
 
A.25 1H-NMR spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,2-diaminoethane (picenMe2, 13). 
 
 
A.26 1H-NMR spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,3-diaminopropane (picpnMe2 14). 
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A.28 1H-NMR spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,5-diaminopentane (picptnMe2, 16). 
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A.30 1H-NMR spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,7-diaminoheptane (pichpnMe2, 18). 
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A.32 1H-NMR spectra of N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,3-diaminopropane 
(Me2picpnMe2, 20). 
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A.34 1H-NMR spectra of N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,5-diaminopentane 
(Me2picptnMe2, 22). 
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A.36 1H-NMR spectra of N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,7-diaminoheptane 
(Me2pichpnMe2, 24). 
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1.4 1H-NMR (Benzylated N4-TL-25) 
400 MHz Bruker Avance NMR using deuterated solvent DMSO, with temperatures maintained at 35 ℃, 256 
accumulations. 
 
A.37 1H-NMR spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dibenzyl-1,2-diaminohexane (picenBz2, 25). 
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1.5 1H-NMR (Imine-chiral N4-TLs-26a-29a) 
400 MHz Bruker Avance NMR using deuterated solvent DMSO, with temperatures maintained at 35 ℃, 256 
accumulations. 
 
A.38 1H-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1R,2R-1,2-diaminocyclohexane (RRpichxn, 26a). 
 
A.39 1H-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1S,2S-1,2-diaminocyclohexane (SSpichxn, 27a). 
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A.41 1H-NMR spectra of diimine N,Nʹ-bis(6-methyl-pyridylmethyl)-1S,2S-1,2-diaminocyclohexane 
(SSMe2pichxn, 29a). 
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1.6 1H-NMR (Hydrogenated-chiral N4-TL-26-29) 
400 MHz Bruker Avance NMR using deuterated solvent DMSO, with temperatures maintained at 35 ℃, 256 
accumulations. 
 
A.42 1H-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1R,2R-1,2-diaminocyclohexane (RRpichxn, 26). 
 
 
A.43 1H-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1S,2S-1,2-diaminocyclohexane (SSpichxn, 27). 
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A.45 1H-NMR spectra of diamine N,Nʹ-bis(6-methyl-pyridylmethyl)-1S,2S-1,2-diaminocyclohexane 
(SSMe2pichxn, 29). 
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1.7 1H-NMR (Methylated-chiral N4-TLs-30-33) 
400 MHz Bruker Avance NMR using deuterated solvent DMSO, with temperatures maintained at 35 ℃, 256 
accumulations. 
 
A.46 1H-NMR spectra of N,Nʹ-bis(pyridylmethyl)- N,N'-dimethyl-1R,2R-1,2-diaminocyclohexane 
(RRpichxnMe2, 30). 
 
A.47 1H-NMR spectra of N,Nʹ-bis(pyridylmethyl)- N,N'-dimethyl-1S,2S-1,2-diaminocyclohexane (SSpichxnMe2, 
31). 
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A.48 1H-NMR spectra of N,Nʹ-bis(6-methyl-pyridylmethyl)- N,N'-dimethyl-1R,2R-1,2-diaminocyclohexane 
(RRMe2pichxnMe2, 32). 
 
A.49 1H-NMR spectra of N,Nʹ-bis(6-methyl-pyridylmethyl)- N,N'-dimethyl-1S,2S-1,2-diaminocyclohexane 
(SSMe2pichxnMe2, 33). 
 
219 | P a g e  
 
1.8 13C-NMR (Schiff Base-achiral N4-TLs-1a-12a) 
400 MHz Bruker Avance NMR using deuterated solvent CDCl3, with temperatures maintained at 25 ℃, 1024 
accumulations. 
 
A.50 13C-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1,2-diaminoethane (picen, 1a). 
 
A.5113C-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1,3-diaminopropane (picpn, 2a). 
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A.53 13C-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1,5-diaminopentane (picptn, 4a). 
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A.55 13C-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1,7-diaminoheptane (pichpn, 6a). 
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A.57 13C-NMR spectra of diimine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,3-diaminopropane (Me2picpn, 8a). 
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A.59 13C-NMR spectra of diimine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,5-diaminopentane (Me2picptn, 10a). 
224 | P a g e  
 
 




A.61 13C-NMR spectra of diimine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,7-diaminoheptane (Me2pichpn, 12a). 
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1.9 13C-NMR (Hydrogenated-achiral N4-TLs-1-12) 
400 MHz Bruker Avance NMR using deuterated solvent D2O, with temperatures maintained at 25 ℃, 1024 
accumulations. 
 
A.62 13C-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,2-diaminoethane (picen, 1). 
 
A.63 13C-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,3-diaminopropane (picpn, 2). 
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A.65 13C-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,5-diaminopentane (picptn, 4). 
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A.67 13C-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,7-diaminoheptane (pichpn, 6). 
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A.69 13C-NMR spectra of diamine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,3-diaminopropane (Me2picpn, 8). 
229 | P a g e  
 
 





A.71 13C-NMR spectra of diamine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,5-diaminopentane (Me2picptn, 10). 
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A.73 13C-NMR spectra of diamine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,7-diaminoheptane (Me2pichpn, 12). 
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1.10 13C-NMR (Methylated-achiral N4-TLs-13-24) 
400 MHz Bruker Avance NMR using deuterated solvent CDCl3, with temperatures maintained at 25 ℃, 1024 
accumulations. 
 
A.74 13C-NMR spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,2-diaminoethane (picenMe2, 13). 
 
A.75 13C-NMR spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,3-diaminopropane (picpnMe2 14). 
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A.77 13C-NMR spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,5-diaminopentane (picptnMe2, 16). 
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A.79 13C-NMR spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,7-diaminoheptane (pichpnMe2, 18). 
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A.81 13C-NMR spectra of N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,3-diaminopropane 
(Me2picpnMe2, 20). 
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A.83 13C-NMR spectra of N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,5-diaminopentane 
(Me2picptnMe2, 22). 
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A.85 13C-NMR spectra of N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,7-diaminoheptane 
(Me2pichpnMe2, 24). 
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1.11 13C-NMR (Benzylated N4-TL-25) 
400 MHz Bruker Avance NMR using deuterated solvent DMSO, with temperatures maintained at 35 ℃, 1024 
accumulations. 
 
A.86 13C-NMR spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dibenzyl-1,2-diaminohexane (picenBz2, 25). 
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1.12 13C-NMR (Imine-chiral N4-TLs-26a-29a) 
400 MHz Bruker Avance NMR using deuterated solvent DMSO, with temperatures maintained at 35 ℃, 1024 
accumulations. 
 
A.87 13C-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1R,2R-1,2-diaminocyclohexane (RRpichxn, 26a). 
 
 
A.88 13C-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1S,2S-1,2-diaminocyclohexane (SSpichxn, 27a). 
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A.90 13C-NMR spectra of diimine N,Nʹ-bis(6-methyl-pyridylmethyl)-1S,2S-1,2-diaminocyclohexane 
(SSMe2pichxn, 29a). 
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1.13 13C-NMR (Hydrogenated-chiral N4-TLs-26-29) 
400 MHz Bruker Avance NMR using deuterated solvent DMSO, with temperatures maintained at 35 ℃, 256 
accumulations. 
 
A.91 13C-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1R,2R-1,2-diaminocyclohexane (RRpichxn, 26). 
 
 
A.92 13C-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1S,2S-1,2-diaminocyclohexane (SSpichxn, 27). 
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A.94 13C-NMR spectra of diamine N,Nʹ-bis(6-methyl-pyridylmethyl)-1S,2S-1,2-diaminocyclohexane 
(SSMe2pichxn, 29). 
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1.14 13C-NMR (Methylated-chiral N4-TLs-30-33) 
400 MHz Bruker Avance NMR using deuterated solvent DMSO, with temperatures maintained at 35 ℃, 1024 
accumulations. 
 
A.95 13C-NMR spectra of N,Nʹ-bis(pyridylmethyl)- N,N'-dimethyl-1R,2R-1,2-diaminocyclohexane 
(RRpichxnMe2, 30). 
 
A.96 13C-NMR spectra of N,Nʹ-bis(pyridylmethyl)- N,N'-dimethyl-1S,2S-1,2-diaminocyclohexane 
(SSpichxnMe2, 31). 
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A.98 13C-NMR spectra of N,Nʹ-bis(6-methyl-pyridylmethyl)- N,N'-dimethyl-1S,2S-1,2-diaminocyclohexane 
(SSMe2pichxnMe2, 33). 
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1.15 Dept-NMR (Imine-achiral N4-TLs-1a-12a) 
400 MHz Bruker Avance NMR using deuterated solvent CDCl3, with temperatures maintained at 25 ℃, 256 
accumulations. 
 
A.99 Dept-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1,2-diaminoethane (picen, 1a). 
 
 
A.100 Dept-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1,3-diaminopropane (picpn, 2a). 
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A.102 Dept-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1,5-diaminopentane (picptn, 4a). 
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A.104 Dept-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1,7-diaminoheptane (pichpn, 6a). 
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A.106 Dept-NMR spectra of diimine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,3-diaminopropane (Me2picpn, 8a). 
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A.108 Dept-NMR spectra of diimine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,5-diaminopentane (Me2picptn, 10a). 
249 | P a g e  
 
 
A.109 Dept-NMR spectra of diimine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,6-diaminohexane (Me2pichex, 11a). 
 
 
A.110 Dept-NMR spectra of diimine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,7-diaminoheptane (Me2pichpn, 12a). 
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1.16 Dept-NMR (Hydrogenated-achiral N4-TLs-1-12) 
400 MHz Bruker Avance NMR using deuterated solvent D2O, with temperatures maintained at 25 ℃, 256 
accumulations. 
 




A.112 Dept-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,3-diaminopropane (picpn, 2). 
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A.114 Dept-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,5-diaminopentane (picptn, 4). 
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A.116 Dept-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,7-diaminoheptane (pichpn, 6). 
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A.118 Dept-NMR spectra of diamine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,3-diaminopropane (Me2picpn, 8). 
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A.120 Dept-NMR spectra of diamine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,5-diaminopentane (Me2picptn, 10). 
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A.122 Dept-NMR spectra of diamine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,7-diaminoheptane (Me2pichpn, 12). 
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1.17 Dept-NMR (Methylated-achiral N4-TLs-13-24) 
400 MHz Bruker Avance NMR using deuterated solvent CDCl3, with temperatures maintained at 25 ℃, 256 
accumulations. 
 
A.123 Dept-NMR spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,2-diaminoethane (picenMe2, 13). 
 
A.124 Dept-NMR spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,3-diaminopropane (picpnMe2 14). 
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A.126 Dept-NMR spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,5-diaminopentane (picptnMe2, 16). 
258 | P a g e  
 
 




A.128 Dept-NMR spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,7-diaminoheptane (pichpnMe2, 18). 
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A.130 Dept-NMR spectra of N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,3-diaminopropane 
(Me2picpnMe2, 20). 
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A.132 Dept-NMR spectra of N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,5-diaminopentane 
(Me2picptnMe2, 22). 
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A.134 Dept-NMR spectra of N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,7-diaminoheptane 
(Me2pichpnMe2, 24). 
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1.18 Dept-NMR (Benzylated N4-TL-25) 
400 MHz Bruker Avance NMR using deuterated solvent DMSO, with temperatures maintained at 35 ℃, 256 
accumulations. 
 
A.135 Dept-NMR spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dibenzyl-1,2-diaminohexane (picenBz2, 25). 
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1.19 Dept-NMR (Imine-chiral N4-TLs-26a-29a) 
400 MHz Bruker Avance NMR using deuterated solvent DMSO, with temperatures maintained at 35 ℃, 256 
accumulations. 
 
A.136 Dept-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1R,2R-1,2-diaminocyclohexane (RRpichxn, 26a). 
 
A.137 Dept-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1S,2S-1,2-diaminocyclohexane (SSpichxn, 27a). 
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A.139 Dept-NMR spectra of diimine N,Nʹ-bis(6-methyl-pyridylmethyl)-1S,2S-1,2-diaminocyclohexane 
(SSMe2pichxn, 29a). 
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1.20 Dept-NMR (Hydrogenated-chiral N4-TLs-26-29) 
400 MHz Bruker Avance NMR using deuterated solvent DMSO, with temperatures maintained at 35 ℃, 256 
accumulations. 
 
A.140 Dept-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1R,2R-1,2-diaminocyclohexane (RRpichxn, 26). 
 
 
A.141 Dept-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1S,2S-1,2-diaminocyclohexane (SSpichxn, 27). 
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A.143 Dept-NMR spectra of diamine N,Nʹ-bis(6-methyl-pyridylmethyl)-1S,2S-1,2-diaminocyclohexane 
(SSMe2pichxn, 29). 
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1.21 Dept-NMR (Methylated-chiral N4-TLs-30-33) 
400 MHz Bruker Avance NMR using deuterated solvent DMSO, with temperatures maintained at 35 ℃, 256 
accumulations. 
 
A.144 Dept-NMR spectra of N,Nʹ-bis(pyridylmethyl)- N,N'-dimethyl-1R,2R-1,2-diaminocyclohexane 
(RRpichxnMe2, 30). 
 
A.145 Dept-NMR spectra of N,Nʹ-bis(pyridylmethyl)- N,N'-dimethyl-1S,2S-1,2-diaminocyclohexane 
(SSpichxnMe2, 31). 
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A.147 Dept-NMR spectra of N,Nʹ-bis(6-methyl-pyridylmethyl)- N,N'-dimethyl-1S,2S-1,2-diaminocyclohexane 
(SSMe2pichxnMe2, 33). 
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1.22 HMQC-NMR (Imine-achiral N4-TLs-1a-12a) 
400 MHz Bruker Avance NMR using deuterated solvent CDCl3, with temperatures maintained at 25 ℃, 4 
accumulations. 
 
A.148 HMQC-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1,2-diaminoethane (picen, 1a). 
 
 
A.149 HMQC-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1,3-diaminopropane (picpn, 2a). 
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A.151 HMQC-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1,5-diaminopentane (picptn, 4a). 
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A.153 HMQC-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1,7-diaminoheptane (pichpn, 6a). 
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A.154 HMQC-NMR spectra of diimine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,2-diaminoethane (Me2picen, 7a). 
 
 
A.155 HMQC-NMR spectra of diimine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,3-diaminopropane (Me2picpn, 
8a). 
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A.156 HMQC-NMR spectra of diimine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,4-diaminobutane (Me2picbn, 9a). 
 
 
A.157 HMQC-NMR spectra of diimine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,5-diaminopentane (Me2picptn, 
10a). 
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A.159 HMQC-NMR spectra of diimine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,7-diaminoheptane (Me2pichpn, 
12a). 
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1.23 HMQC-NMR (Hydrogenated-achiral N4-TLs-1-12) 
400 MHz Bruker Avance NMR using deuterated solvent D2O, with temperatures maintained at 25 ℃, 4 
accumulations. 
 
A.160 HMQC-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,2-diaminoethane (picen, 1). 
 
 
A.161 HMQC-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,3-diaminopropane (picpn, 2). 
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A.162 HMQC-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,4-diaminobutane (picbn, 3). 
 
 
A.163 HMQC-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,5-diaminopentane (picptn, 4). 
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A.165 HMQC-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,7-diaminoheptane (pichpn, 6). 
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A.167 HMQC-NMR spectra of diamine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,3-diaminopropane (Me2picpn, 8). 
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A.169 HMQC-NMR spectra of diamine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,5-diaminopentane (Me2picptn, 
10). 
280 | P a g e  
 
 





A.171 HMQC-NMR spectra of diamine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,7-diaminoheptane (Me2pichpn, 
12). 
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1.24 HMQC-NMR (Methylated-achiral N4-TLs-13-24) 
400 MHz Bruker Avance NMR using deuterated solvent CDCl3, with temperatures maintained at 25 ℃, 4 
accumulations. 
 
A.172 HMQC-NMR spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,2-diaminoethane (picenMe2, 13). 
 
A.173 HMQC-NMR spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,3-diaminopropane (picpnMe2 14). 
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A.175 HMQC-NMR spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,5-diaminopentane (picptnMe2, 16). 
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A.177 HMQC-NMR spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,7-diaminoheptane (pichpnMe2, 18). 
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A.179 HMQC-NMR spectra of N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,3-diaminopropane 
(Me2picpnMe2, 20). 
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A.181 HMQC-NMR spectra of N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,5-diaminopentane 
(Me2picptnMe2, 22). 
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A.183 HMQC-NMR spectra of N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,7-diaminoheptane 
(Me2pichpnMe2, 24). 
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1.25 HMQC-NMR (Benzylated N4-TL-25) 
400 MHz Bruker Avance NMR using deuterated solvent DMSO, with temperatures maintained at 35 ℃, 8 
accumulations. 
 
A.184 HMQC-NMR spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dibenzyl-1,2-diaminohexane (picenBz2, 25). 
 
  
288 | P a g e  
 
1.26 HMQC-NMR (Imine-chiral N4-TLs-26a-29a) 
400 MHz Bruker Avance NMR using deuterated solvent DMSO, with temperatures maintained at 35 ℃, 4 
accumulations. 
 
A.185 HMQC-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1R,2R-1,2-diaminocyclohexane (RRpichxn, 
26a). 
 
A.186 HMQC-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1S,2S-1,2-diaminocyclohexane (SSpichxn, 27a). 
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A.188 HMQC-NMR spectra of diimine N,Nʹ-bis(6-methyl-pyridylmethyl)-1S,2S-1,2-diaminocyclohexane 
(SSMe2pichxn, 29a). 
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1.27 HMQC-NMR (Hydrogenated-chiral N4-TLs-26-29) 
400 MHz Bruker Avance NMR using deuterated solvent DMSO, with temperatures maintained at 35 ℃, 4 
accumulations. 
 
A.189 HMQC-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1R,2R-1,2-diaminocyclohexane (RRpichxn, 
26). 
 
A.190 HMQC-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1S,2S-1,2-diaminocyclohexane (SSpichxn, 27). 
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A.192 HMQC-NMR spectra of diamine N,Nʹ-bis(6-methyl-pyridylmethyl)-1S,2S-1,2-diaminocyclohexane 
(SSMe2pichxn, 29). 
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1.28 HMQC-NMR (Methylated-chiral N4-TLs-30-33) 
400 MHz Bruker Avance NMR using deuterated solvent DMSO, with temperatures maintained at 35 ℃, 4 
accumulations. 
 
A.193 HMQC-NMR spectra of N,Nʹ-bis(pyridylmethyl)- N,N'-dimethyl-1R,2R-1,2-diaminocyclohexane 
(RRpichxnMe2, 30). 
 
A.194 HMQC-NMR spectra of N,Nʹ-bis(pyridylmethyl)- N,N'-dimethyl-1S,2S-1,2-diaminocyclohexane 
(SSpichxnMe2, 31). 
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A.195 HMQC-NMR spectra of N,Nʹ-bis(6-methyl-pyridylmethyl)- N,N'-dimethyl-1R,2R-1,2-
diaminocyclohexane (RRMe2pichxnMe2, 32). 
 
 
A.196 HMQC-NMR spectra of N,Nʹ-bis(6-methyl-pyridylmethyl)- N,N'-dimethyl-1S,2S-1,2-
diaminocyclohexane (SSMe2pichxnMe2, 33). 
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1.29 COSY-NMR (Imine-achiral N4-TLs-1a-12a) 
400 MHz Bruker Avance NMR using deuterated solvent CDCl3, with temperatures maintained at 25 ℃, 2 
accumulations. 
 
A.197 COSY-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1,2-diaminoethane (picen, 1a). 
 
 
A.198 COSY-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1,3-diaminopropane (picpn, 2a). 
295 | P a g e  
 
 








A.200 COSY-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1,5-diaminopentane (picptn, 4a). 
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A.202 COSY-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1,7-diaminoheptane (pichpn, 6a). 
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A.204 COSY-NMR spectra of diimine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,3-diaminopropane (Me2picpn, 8a). 
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A.205 COSY-NMR spectra of diimine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,4-diaminobutane (Me2picbn, 9a). 
 
 
A.206 COSY-NMR spectra of diimine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,5-diaminopentane (Me2picptn, 
10a). 
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A.208 COSY-NMR spectra of diimine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,7-diaminoheptane (Me2pichpn, 
12a). 
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1.30 COSY-NMR (Hydrogenated-achiral N4-TLs-1-12) 
400 MHz Bruker Avance NMR using deuterated solvent D2O, with temperatures maintained at 25 ℃, 2 
accumulations. 
 
A.209 COSY-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,2-diaminoethane (picen, 1). 
 
A.210 COSY-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,3-diaminopropane (picpn, 2). 
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A.212 COSY-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,5-diaminopentane (picptn, 4). 
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A.214 COSY-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,7-diaminoheptane (pichpn, 6). 
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A.216 COSY-NMR spectra of diamine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,3-diaminopropane (Me2picpn, 8). 
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A.217 COSY-NMR spectra of diamine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,4-diaminobutane (Me2picbn, 9). 
 
 
A.218 COSY-NMR spectra of diamine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,5-diaminopentane (Me2picptn, 
10). 
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A.219 COSY-NMR spectra of diamine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,6-diaminohexane (Me2pichex, 11). 
 
 
A.220 COSY-NMR spectra of diamine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,7-diaminoheptane (Me2pichpn, 
12). 
306 | P a g e  
 
1.31 COSY-NMR (Methylated-achiral N4-TLs-13-24) 
400 MHz Bruker Avance NMR using deuterated solvent CDCl3, with temperatures maintained at 25 ℃, 256 
accumulations. 
 
A.221 COSY-NMR spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,2-diaminoethane (picenMe2, 13). 
 
A.222 COSY-NMR spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,3-diaminopropane (picpnMe2 14). 
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A.224 COSY-NMR spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,5-diaminopentane (picptnMe2, 16). 
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A.226 COSY-NMR spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,7-diaminoheptane (pichpnMe2, 18). 
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A.228 COSY-NMR spectra of N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,3-diaminopropane 
(Me2picpnMe2, 20). 
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A.230 COSY-NMR spectra of N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,5-diaminopentane 
(Me2picptnMe2, 22). 
311 | P a g e  
 
 




A.232 COSY-NMR spectra of N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,7-diaminoheptane 
(Me2pichpnMe2, 24). 
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1.32 COSY-NMR (Benzylated N4-TL-25) 
400 MHz Bruker Avance NMR using deuterated solvent DMSO, with temperatures maintained at 35 ℃, 2 
accumulations. 
 
A.233 COSY-NMR spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dibenzyl-1,2-diaminohexane (picenBz2, 25). 
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1.33 COSY-NMR (Imine-chiral N4-TLs-26a-29a) 
400 MHz Bruker Avance NMR using deuterated solvent DMSO, with temperatures maintained at 35 ℃, 2 
accumulations. 
 
A.234 COSY-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1R,2R-1,2-diaminocyclohexane (RRpichxn, 
26a). 
 
A.235 COSY-NMR spectra of diimine N,Nʹ-bis(pyridylmethyl)-1S,2S-1,2-diaminocyclohexane (SSpichxn, 27a). 
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A.237 COSY-NMR spectra of diimine N,Nʹ-bis(6-methyl-pyridylmethyl)-1S,2S-1,2-diaminocyclohexane 
(SSMe2pichxn, 29a). 
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1.34 COSY-NMR (Hydrogenated-chiral N4-TLs-26-29) 
400 MHz Bruker Avance NMR using deuterated solvent DMSO, with temperatures maintained at 35 ℃, 256 
accumulations. 
 
A.238 COSY-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1R,2R-1,2-diaminocyclohexane (RRpichxn, 26). 
 
 
A.239 COSY-NMR spectra of diamine N,Nʹ-bis(pyridylmethyl)-1S,2S-1,2-diaminocyclohexane (SSpichxn, 27). 
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A.241 COSY-NMR spectra of diamine N,Nʹ-bis(6-methyl-pyridylmethyl)-1S,2S-1,2-diaminocyclohexane 
(SSMe2pichxn, 29). 
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1.35 COSY-NMR (Methylated-chiral N4-TLs-30-33) 
400 MHz Bruker Avance NMR using deuterated solvent DMSO, with temperatures maintained at 35 ℃, 1024 
accumulations. 
 
A.242 COSY-NMR spectra of N,Nʹ-bis(pyridylmethyl)- N,N'-dimethyl-1R,2R-1,2-diaminocyclohexane 
(RRpichxnMe2, 30). 
 
A.243 COSY-NMR spectra of N,Nʹ-bis(pyridylmethyl)- N,N'-dimethyl-1S,2S-1,2-diaminocyclohexane 
(SSpichxnMe2, 31). 
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A.244 COSY-NMR spectra of N,Nʹ-bis(6-methyl-pyridylmethyl)- N,N'-dimethyl-1R,2R-1,2-diaminocyclohexane 
(RRMe2pichxnMe2, 32). 
 
A.245 COSY-NMR spectra of N,Nʹ-bis(6-methyl-pyridylmethyl)- N,N'-dimethyl-1S,2S-1,2-diaminocyclohexane 
(SSMe2pichxnMe2, 33). 
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2. Ultra-Violet Visible Spectroscopy (UV-Vis) 
2.1 UV-Vis (Schiff Base-achiral N4-TLs-1a-12a) 
1 cm quartz cell, corrected for solvent baseline with either chloroform, acetonitrile or DMSO 
 







A.247 UV-Vis spectra of diimine N,Nʹ-bis(pyridylmethyl)-1,3-diaminopropane (picpn, 2a). 
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A.249 UV-Vis spectra of diimine N,Nʹ-bis(pyridylmethyl)-1,5-diaminopentane (picptn, 4a). 
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A.251 UV-Vis spectra of diimine N,Nʹ-bis(pyridylmethyl)-1,7-diaminoheptane (pichpn, 6a). 
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A.253 UV-Vis spectra of diimine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,3-diaminopropane (Me2picpn, 8a). 
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A.255 UV-Vis spectra of diimine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,5-diaminopentane (Me2picptn, 10a). 
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A.257 UV-Vis spectra of diimine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,7-diaminoheptane (Me2pichpn, 12a). 
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2.2 UV-Vis (Hydrogenated-achiral N4-TLs-1-12) 
1 cm quartz cell, corrected for solvent baseline with either chloroform, acetonitrile or DMSO 
 









A.259 UV-Vis spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,3-diaminopropane (picpn, 2). 
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A.261 UV-Vis spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,5-diaminopentane (picptn, 4). 
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A.263 UV-Vis spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,7-diaminoheptane (pichpn, 6). 
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A.265 UV-Vis spectra of diamine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,3-diaminopropane (Me2picpn, 8). 
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A.267 UV-Vis spectra of diamine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,5-diaminopentane (Me2picptn, 10). 
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A.269 UV-Vis spectra of diamine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,7-diaminoheptane (Me2pichpn, 12). 
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2.3 UV-Vis (Methylated-achiral N4-TLs-13-24) 
1 cm quartz cell, corrected for solvent baseline with either chloroform, acetonitrile or DMSO 
 








A.271 UV-Vis spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,3-diaminopropane (picpnMe2 14). 
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A.273 UV-Vis spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,5-diaminopentane (picptnMe2, 16). 
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A.275 UV-Vis spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,7-diaminoheptane (pichpnMe2, 18). 
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A.277 UV-Vis spectra of N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,3-diaminopropane 
(Me2picpnMe2, 20). 
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A.279 UV-Vis spectra of N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,5-diaminopentane 
(Me2picptnMe2, 22). 
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A.281 UV-Vis spectra of N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,7-diaminoheptane 
(Me2pichpnMe2, 24). 
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2.4 UV-Vis (Benzylated N4-TL-25) 
1 cm quartz cell, corrected for solvent baseline with either chloroform, acetonitrile or DMSO 
 
 
A.282 UV-Vis spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dibenzyl-1,2-diaminohexane (picenBz2, 25). 
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2.5 UV-Vis (Schiff-base chiral N4-TLs-26a-29a) 
1 cm quartz cell, corrected for solvent baseline with either chloroform, acetonitrile or DMSO 
 









A.284 UV-Vis spectra of diimine N,Nʹ-bis(pyridylmethyl)-1S,2S-1,2-diaminocyclohexane (SSpichxn, 27a). 
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A.286 UV-Vis spectra of diimine N,Nʹ-bis(6-methyl-pyridylmethyl)-1S,2S-1,2-diaminocyclohexane 
(SSMe2pichxn, 29a). 
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2.6 UV-Vis (Hydrogenated chiral N4-TLs-26-29) 
1 cm quartz cell, corrected for solvent baseline with either chloroform, acetonitrile or DMSO 
 









A.288 UV-Vis spectra of diamine N,Nʹ-bis(pyridylmethyl)-1S,2S-1,2-diaminocyclohexane (SSpichxn, 27). 
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A.290 UV-Vis spectra of diamine N,Nʹ-bis(6-methyl-pyridylmethyl)-1S,2S-1,2-diaminocyclohexane 
(SSMe2pichxn, 29). 
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2.7 UV-Vis (Methylated chiral N4-TLs-30-33) 
1 cm quartz cell, corrected for solvent baseline with either chloroform, acetonitrile or DMSO 
 








A.292 UV-Vis spectra of N,Nʹ-bis(pyridylmethyl)- N,N'-dimethyl-1S,2S-1,2-diaminocyclohexane (SSpichxnMe2, 
31). 
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A.294 UV-Vis spectra of N,Nʹ-bis(6-methyl-pyridylmethyl)- N,N'-dimethyl-1S,2S-1,2-diaminocyclohexane 
(SSMe2pichxnMe2, 33). 
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3. High performance liquid chromatography (HPLC) 
3.1 HPLC (Hydrogenated-achiral N4-TLs-1-12) 
 
 






A.296 HPLC spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,3-diaminopropane (picpn, 2). 
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A.298 HPLC spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,5-diaminopentane (picptn, 4). 
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A.300 HPLC spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,7-diaminoheptane (pichpn, 6). 
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A.302 HPLC spectra of diamine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,3-diaminopropane (Me2picpn, 8). 
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A.304 HPLC spectra of diamine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,5-diaminopentane (Me2picptn, 10). 
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A.306 HPLC spectra of diamine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,7-diaminoheptane (Me2pichpn, 12). 
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HPLC (Methylated-achiral N4-TLs-13-24) 
 
 







A.308 HPLC spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,3-diaminopropane (picpnMe2 14). 
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A.310 HPLC spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,5-diaminopentane (picptnMe2, 16). 
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A.312 HPLC spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,7-diaminoheptane (pichpnMe2, 18). 
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A.314 HPLC spectra of N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,3-diaminopropane (Me2picpnMe2, 
20). 
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A.316 HPLC spectra of N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,5-diaminopentane (Me2picptnMe2, 
22). 
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A.318 HPLC spectra of N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,7-diaminoheptane (Me2pichpnMe2, 
24). 
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3.2 HPLC (Benzylated N4-TL-25) 
 
 
A.319 HPLC spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dibenzyl-1,2-diaminohexane (picenBz2, 25). 
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3.3 HPLC (Hydrogenated-chiral N4-TLs-26-29) 
 
 






A.321 HPLC spectra of diamine N,Nʹ-bis(pyridylmethyl)-1S,2S-1,2-diaminocyclohexane (SSpichxn, 27). 
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A.323 HPLC spectra of diamine N,Nʹ-bis(6-methyl-pyridylmethyl)-1S,2S-1,2-diaminocyclohexane 
(SSMe2pichxn, 29). 
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3.4 HPLC (Methylated-chiral N4-TLs-30-33) 
 
 





A.325 HPLC spectra of N,Nʹ-bis(pyridylmethyl)-N,N'-dimethyl-1S,2S-1,2-diaminocyclohexane (SSpichxnMe2, 
31). 
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A.327 HPLC spectra of N,Nʹ-bis(6-methyl-pyridylmethyl)-N,N'-dimethyl-1S,2S-1,2-diaminocyclohexane 
(SSMe2pichxnMe2, 33). 
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4. Electrospray Ionisation Mass Spectroscopy (ESI-MS) 
4.1 ESI-MS (Hydrogenated-achiral N4-TLs-1-12) 
 








A.330 ESI-MS spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,4-diaminobutane (picbn, 3). 
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A.333 ESI-MS spectra of diamine N,Nʹ-bis(pyridylmethyl)-1,7-diaminoheptane (pichpn, 6). 
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A.336 ESI-MS spectra of diamine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,4-diaminobutane (Me2picbn, 9). 
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A.339 ESI-MS spectra of diamine N,Nʹ-bis(6-methyl-2-pyridylmethyl)-1,7-diaminoheptane (Me2pichpn, 12). 
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4.2 ESI-MS (Methylated-achiral N4-TLs-13-24) 
 
 
A.340 ESI-MS spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,2-diaminoethane (picenMe2, 13). 
 
 
A.341 ESI-MS spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,3-diaminopropane (picpnMe2 14). 
 
 
A.342 ESI-MS spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,4-diaminobutane (picbnMe2, 15). 
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A.345 ESI-MS spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dimethyl-1,7-diaminoheptane (pichpnMe2, 18). 
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A.348 ESI-MS spectra of N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,4-diaminobutane (Me2picbnMe2, 
21). 
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A.351 ESI-MS spectra of N,N'-bis(6-methyl-2-pyridylmethyl)-N,N'-dimethyl-1,7-diaminoheptane 
(Me2pichpnMe2, 24). 
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4.3 ESI-MS (Benzylated N4-TL-25) 
 
 
A.352 ESI-MS spectra of N,N'-bis(2-pyridylmethyl)-N,N'-dibenzyl-1,2-diaminohexane (picenBz2, 25). 
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4.4 ESI-MS (Hydrogenated-chiral N4-TLs-26-29)  
 
A.353 ESI-MS spectra of diamine N,Nʹ-bis(pyridylmethyl)-1R,2R-1,2-diaminocyclohexane (RRpichxn, 26). 
 
 
A.354 ESI-MS spectra of diamine N,Nʹ-bis(pyridylmethyl)-1S,2S-1,2-diaminocyclohexane (SSpichxn, 27). 
 
 
A.355 ESI-MS spectra of diamine N,Nʹ-bis(6-methyl-pyridylmethyl)-1R,2R-1,2-diaminocyclohexane 
(RRMe2pichxn, 28). 
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4.5 ESI-MS (Methylated-chiral N4-TLs-30-33)  
 
 
A.357 ESI-MS spectra of N,Nʹ-bis(pyridylmethyl)-N,N'-dimethyl-1R,2R-1,2-diaminocyclohexane 
(RRpichxnMe2, 30). 
 
A.358 ESI-MS spectra of N,Nʹ-bis(pyridylmethyl)-N,N'-dimethyl-1S,2S-1,2-diaminocyclohexane (SSpichxnMe2, 
31). 
 
A.359 ESI-MS spectra of N,Nʹ-bis(6-methyl-pyridylmethyl)-N,N'-dimethyl-1R,2R-1,2-diaminocyclohexane 
(RRMe2pichxnMe2, 32). 
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5. Circular Dichroism (CD) 
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Supplementary B: Biological Activity of N4-TLs-1-33 




Figure B1 GI50 values of  N4-TL-7,  N4-TL-19,  N4-TL-28,  N4-TL-30 and  N4-TL-31 in 
multiple cell lines: colon (HT29), glioblastoma (U87 and SJ-G2), ovarian (A2780), lung 
(H460), skin (A431), prostate (Du145), neuroblastoma (BE2-C), pancreas (MIA), breast 
(MCF-7), and breast normal (MCF10A). 
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Supplementary C: Instrumental analysis data of Ru-1-14 
1 Nuclear Magnetic Resonance Spectroscopy (NMR) 
1.1 1H-NMR Ru-1 
400 MHz Bruker Avance NMR using deuterated solvent DMSO, with temperatures maintained at 35 ℃, 256 
accumulations. Structures drawn 2D for better clarity of the complexes. 
 
C.1 1H-NMR spectra of Cis-α-[Ru(picenMe2)(DMSO)Cl]PF6 (Ru-1). 
1.2 1H-NMR Ru-2 
 
C.2 1H-NMR spectra of Cis-β-[Ru(picenBz2)(DMSO)Cl]PF6 (Ru-2). 
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1.3 1H-NMR Ru-3 – 8 
 




C.4 1H-NMR spectra of racemic Cis-α-[Ru(picenMe2)(DPQ)](PF6)2 (Ru-4). 
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C.6 1H-NMR spectra of racemic Cis-α-[Ru(picenMe2)(phenpyrBz)](PF6)2 (Ru-6). 
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C.8 1H-NMR spectra of racemic Cis-α-[Ru(picenMe2)(phenpyrBzNO2)](PF6)2 (Ru-8). 
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1.4 1H-NMR Ru-9 – 14 
 





C.10 1H-NMR spectra of racemic Cis-β-[Ru(picenBz2)(DPQ)](PF6)2 (Ru-10). 
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C.12 1H-NMR spectra of racemic Cis-β-[Ru(picenBz2)(phenpyrBz)](PF6)2 (Ru-12). 
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C.14 1H-NMR spectra of racemic Cis-β-[Ru(picenBz2)(phenpyrBzNO2)](PF6)2 (Ru-14). 
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1.5 13C-NMR Ru-1 
400 MHz Bruker Avance NMR using deuterated solvent DMSO, with temperatures maintained at 35 ℃, 1024 
accumulations. 
 
C.15 13C-NMR spectra of Cis-α-[Ru(picenMe2)(DMSO)Cl]PF6 (Ru-1). 
1.6 13C-NMR Ru-2 
 
C.16 13C-NMR spectra of Cis-β-[Ru(picenBz2)(DMSO)Cl]PF6 (Ru-2). 
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1.7 13C-NMR Ru-3 – 8  
 
C.17 13C-NMR spectra of racemic Cis-α-[Ru(picenMe2)(phen)](PF6)2 (Ru-3). 
 
 
C.18 13C-NMR spectra of racemic Cis-α-[Ru(picenMe2)(DPQ)](PF6)2 (Ru-4). 
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C.20 13C-NMR spectra of racemic Cis-α-[Ru(picenMe2)(phenpyrBz)](PF6)2 (Ru-6). 
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C.22 13C-NMR spectra of racemic Cis-α-[Ru(picenMe2)(phenpyrBzNO2)](PF6)2 (Ru-8). 
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1.8 13C-NMR Ru-9 – 14  
 




C.24 13C-NMR spectra of racemic Cis-β-[Ru(picenBz2)(DPQ)](PF6)2 (Ru-10). 
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C.26 13C-NMR spectra of racemic Cis-β-[Ru(picenBz2)(phenpyrBz)](PF6)2 (Ru-12). 
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C.28 13C-NMR spectra of racemic Cis-β-[Ru(picenBz2)(phenpyrBzNO2)](PF6)2 (Ru-14). 
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1.9 Dept-NMR Ru-1 
400 MHz Bruker Avance NMR using deuterated solvent DMSO, with temperatures maintained at 35 ℃, 256 
accumulations. 
 
C.29 Dept-NMR spectra of Cis-α-[Ru(picenMe2)(DMSO)Cl]PF6 (Ru-1). 
1.10 Dept-NMR Ru-2 
 
C.30 Dept-NMR spectra of Cis-β-[Ru(picenBz2)(DMSO)Cl]PF6 (Ru-2). 
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1.11 Dept-NMR Ru-3 – 8  
 




C.32 Dept-NMR spectra of racemic Cis-α-[Ru(picenMe2)(DPQ)](PF6)2 (Ru-4). 
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C.34 Dept-NMR spectra of racemic Cis-α-[Ru(picenMe2)(phenpyrBz)](PF6)2 (Ru-6). 
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C.36 Dept-NMR spectra of racemic Cis-α-[Ru(picenMe2)(phenpyrBzNO2)](PF6)2 (Ru-8). 
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1.12 Dept-NMR Ru-9 – 14 
 
C.37 Dept-NMR spectra of racemic Cis-β-[Ru(picenBz2)(phen)](PF6)2 (Ru-9). 
 
 
C.38 Dept-NMR spectra of racemic Cis-β-[Ru(picenBz2)(DPQ)](PF6)2 (Ru-10). 
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C.40 Dept-NMR spectra of racemic Cis-β-[Ru(picenBz2)(phenpyrBz)](PF6)2 (Ru-12). 
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C.42 Dept-NMR spectra of racemic Cis-β-[Ru(picenBz2)(phenpyrBzNO2)](PF6)2 (Ru-14). 
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1.13 HMQC-NMR Ru-1 
 
C.43 HMQC-NMR spectra of Cis-α-[Ru(picenMe2)(DMSO)Cl]PF6 (Ru-1). 
1.14 HMQC-NMR Ru-2 
 
C.44 HMQC-NMR spectra of Cis-β-[Ru(picenBz2)(DMSO)Cl]PF6 (Ru-2). 
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1.15 HMQC-NMR Ru-3 – 8  
 
C.45 HMQC-NMR spectra of racemic Cis-α-[Ru(picenMe2)(phen)](PF6)2 (Ru-3). 
 
 
C.46 HMQC-NMR spectra of racemic Cis-α-[Ru(picenMe2)(DPQ)](PF6)2 (Ru-4). 
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C.48 HMQC-NMR spectra of racemic Cis-α-[Ru(picenMe2)(phenpyrBz)](PF6)2 (Ru-6). 
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C.50 HMQC-NMR spectra of racemic Cis-α-[Ru(picenMe2)(phenpyrBzNO2)](PF6)2 (Ru-8). 
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1.16 HMQC-NMR Ru-9 – 14  
 




C.52 HMQC-NMR spectra of racemic Cis-β-[Ru(picenBz2)(DPQ)](PF6)2 (Ru-10). 
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C.54 HMQC-NMR spectra of racemic Cis-β-[Ru(picenBz2)(phenpyrBz)](PF6)2 (Ru-12). 
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C.56 HMQC-NMR spectra of racemic Cis-β-[Ru(picenBz2)(phenpyrBzNO2)](PF6)2 (Ru-14). 
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1.17 COSY-NMR Ru-1 
 
C.57 COSY-NMR spectra of Cis-α-[Ru(picenMe2)(DMSO)Cl]PF6 (Ru-1). 
1.18 COSY-NMR Ru-2 
 
C.58 COSY-NMR spectra of Cis-β-[Ru(picenBz2)(DMSO)Cl]PF6 (Ru-2). 
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1.19 COSY-NMR Ru-3 – 8  
 
C.59 COSY-NMR spectra of racemic Cis-α-[Ru(picenMe2)(phen)](PF6)2 (Ru-3). 
 
 
C.60 COSY-NMR spectra of racemic Cis-α-[Ru(picenMe2)(DPQ)](PF6)2 (Ru-4). 
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C.62 COSY-NMR spectra of racemic Cis-α-[Ru(picenMe2)(phenpyrBz)](PF6)2 (Ru-6). 
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C.64 COSY-NMR spectra of racemic Cis-α-[Ru(picenMe2)(phenpyrBzNO2)](PF6)2 (Ru-8). 
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1.20 COSY-NMR Ru-9 – 14  
 
C.65 COSY-NMR spectra of racemic Cis-β-[Ru(picenBz2)(phen)](PF6)2 (Ru-9). 
 
 
C.66 COSY-NMR spectra of racemic Cis-β-[Ru(picenBz2)(DPQ)](PF6)2 (Ru-10). 
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C.68 COSY-NMR spectra of racemic Cis-β-[Ru(picenBz2)(phenpyrBz)](PF6)2 (Ru-12). 
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C.70 COSY-NMR spectra of racemic Cis-β-[Ru(picenBz2)(phenpyrBzNO2)](PF6)2 (Ru-14). 
411 | P a g e  
 
2 Ultra-Violet Visible Spectroscopy (UV-Vis) 
2.1 UV-Vis Ru-1 
1 cm quartz cell, corrected for solvent baseline with either chloroform, acetonitrile or DMSO 
 








C.72 UV-Vis spectra of Cis-β-[Ru(picenBz2)(DMSO)Cl]PF6 (Ru-2). 
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2.3 UV-Vis Ru-3 – 8  
 











C.74 UV-Vis spectra of racemic Cis-α-[Ru(picenMe2)(DPQ)](PF6)2 (Ru-4). 
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C.76 UV-Vis spectra of racemic Cis-α-[Ru(picenMe2)(phenpyrBz)](PF6)2 (Ru-6). 
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C.78 UV-Vis spectra of racemic Cis-α-[Ru(picenMe2)(phenpyrBzNO2)](PF6)2 (Ru-8). 
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2.4 UV-Vis Ru-9 – 14  
 











C.80 UV-Vis spectra of racemic Cis-β-[Ru(picenBz2)(DPQ)](PF6)2 (Ru-10). 
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C.82 UV-Vis spectra of racemic Cis-β-[Ru(picenBz2)(phenpyrBz)](PF6)2 (Ru-12). 
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C.84 UV-Vis spectra of racemic Cis-β-[Ru(picenBz2)(phenpyrBzNO2)](PF6)2 (Ru-14). 
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3. High performance liquid chromatography (HPLC) 
3.1 HPLC Ru-1 
 
 




3.2 HPLC Ru-2 
 
C.86 HPLC spectra of Cis-β-[Ru(picenBz2)(DMSO)Cl]PF6 (Ru-2). 
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3.3 HPLC Ru-3 – 8  
 







C.88 HPLC spectra of racemic Cis-α-[Ru(picenMe2)(DPQ)](PF6)2 (Ru-4). 
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C.90 HPLC spectra of racemic Cis-α-[Ru(picenMe2)(phenpyrBz)](PF6)2 (Ru-6). 
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C.92 HPLC spectra of racemic Cis-α-[Ru(picenMe2)(phenpyrBzNO2)](PF6)2 (Ru-8). 
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3.4 HPLC Ru-9 – 14  
 







C.94 HPLC spectra of racemic Cis-β-[Ru(picenBz2)(DPQ)](PF6)2 (Ru-10). 
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C.96 HPLC spectra of racemic Cis-β-[Ru(picenBz2)(phenpyrBz)](PF6)2 (Ru-12). 
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C.98 HPLC spectra of racemic Cis-β-[Ru(picenBz2)(phenpyrBzNO2)](PF6)2 (Ru-14). 
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4. Electrospray Ionisation Mass Spectroscopy (ESI-MS) 
4.1 ESI-MS Ru-1 
 
C.99 ESI-MS spectra of Cis-α-[Ru(picenMe2)(DMSO)Cl]PF6 (Ru-1). 
4.2 ESI-MS Ru-2 
 
C.100 ESI-MS spectra of Cis-β-[Ru(picenBz2)(DMSO)Cl]PF6 (Ru-2). 
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4.3 ESI-MS Ru-3 – 8  
 
C.101 ESI-MS spectra of racemic Cis-α-[Ru(picenMe2)(phen)](PF6)2 (Ru-3). 
 
 
C.102 ESI-MS spectra of racemic Cis-α-[Ru(picenMe2)(DPQ)](PF6)2 (Ru-4). 
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C.104 ESI-MS spectra of racemic Cis-α-[Ru(picenMe2)(phenpyrBz)](PF6)2 (Ru-6). 
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C.106 ESI-MS spectra of racemic Cis-α-[Ru(picenMe2)(phenpyrBzNO2)](PF6)2 (Ru-8). 
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4.4 ESI-MS Ru-9 – 14  
 
C.107 ESI-MS spectra of racemic Cis-β-[Ru(picenBz2)(phen)](PF6)2 (Ru-9). 
 
 
C.108 ESI-MS spectra of racemic Cis-β-[Ru(picenBz2)(DPQ)](PF6)2 (Ru-10). 
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C.110 ESI-MS spectra of racemic Cis-β-[Ru(picenBz2)(phenpyrBz)](PF6)2 (Ru-12). 
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C.112 ESI-MS spectra of racemic Cis-β-[Ru(picenBz2)(phenpyrBzNO2)](PF6)2 (Ru-14). 
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5. Crystallography 
Crystals obtained via slow evaporation from either acetone/water mixture or diffusion of diethyl ether. The 
single crystal X-ray diffraction measurements for Ru-X-X were carried out on the MX1 beamline at the 
Australian Synchrotron at 100 ℃, a part of Australian Nuclear Science and Technology Organisation (ANSTO). 
Diffraction data were collected using a Si<111> monochromated synchrotron X-ray radiation (λ = 0.71080) at 
100(2) K and were corrected for Lorentz and polarization effects using the XDS software. 
 
5.1 [Ru(picenMe2)(phen)](PF6)2 (Ru-3) 
Deposition Number: 1959523 
Data Block Name: data_p21byn-_a 
Unit Cell Parameters: a 18.585(4), b 17.674(4), c 20.028(4) 
Space Group: P21/n 
 
Table 1. Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement Parameters (Å2×103) for 
Ru-3. Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
 
Atom x y z U(eq) 
Ru1 947.1(2) 7298.6(2) 6452.7(2) 10.86(7) 
N1 1527.1(14) 6641.3(15) 7268.1(13) 14.8(5) 
N2 1920.4(15) 7981.0(14) 6847.7(13) 15.4(5) 
N3 1547.2(14) 6983.3(15) 5701.8(13) 15.8(6) 
N4 469.9(14) 7998.3(15) 5634.5(13) 15.0(5) 
N5 259.3(15) 7676.5(14) 7066.3(13) 15.0(5) 
N6 53.3(14) 6543.1(14) 6174.0(13) 13.6(5) 
C1 1409.8(18) 5899.0(18) 7366.9(17) 18.3(7) 
C2 1820(2) 5503(2) 7928.6(18) 23.6(8) 
C3 2379(2) 5871(2) 8402.7(18) 28.3(8) 
C4 2509(2) 6627(2) 8303.3(17) 26.8(8) 
C5 2069.7(18) 6999.6(19) 7735.9(16) 18.4(7) 
C6 2172.9(19) 7824.4(19) 7602.4(16) 20.5(7) 
C7 1850.9(19) 8813.3(17) 6733.7(17) 19.5(7) 
C8 2511.8(18) 7685.4(19) 6526.6(17) 19.4(7) 
C9 2171.2(18) 7543.9(19) 5774.2(17) 18.7(7) 
C10 1870.5(19) 6205.6(18) 5751.3(17) 20.1(7) 
C11 1036.7(18) 7100.9(19) 5007.6(16) 19.3(7) 
C12 575.3(18) 7799.9(18) 5011.9(16) 18.0(7) 
C13 266(2) 8217(2) 4421.0(17) 24.8(8) 
C14 -154(2) 8847(2) 4468.9(19) 29.1(8) 
C15 -253(2) 9056.5(19) 5102.2(19) 24.9(8) 
C16 67.9(18) 8627.4(18) 5671.9(17) 19.3(7) 
C17 -49.2(19) 5967.9(18) 5728.5(17) 20.2(7) 
C18 -663.0(19) 5483.8(18) 5612.6(18) 21.7(7) 
C19 -1205.8(19) 5591.9(18) 5954.0(18) 22.2(7) 
C20 -1125.3(18) 6197.4(18) 6420.7(16) 17.2(7) 
C21 -487.7(17) 6654.0(17) 6518.8(15) 13.7(6) 
C22 -383.8(18) 7269.1(17) 6985.7(15) 13.8(6) 
C23 -1674.3(19) 6378(2) 6785.6(18) 24.3(8) 
C24 -1586.1(19) 6981(2) 7211.3(18) 24.5(8) 
C25 -936.0(19) 7450.0(19) 7325.6(16) 18.4(7) 
C26 -826(2) 8080(2) 7762.6(17) 24.5(8) 
C27 -187(2) 8492.3(19) 7837.5(17) 24.6(8) 
C28 341(2) 8272.8(18) 7489.5(17) 20.2(7) 
Ru2 5893.0(2) 7643.9(2) 5763.3(2) 13.88(8) 
N7 5438.4(15) 8212.3(15) 4847.3(14) 17.8(6) 
N8 4726.8(15) 7649.6(15) 5737.5(14) 17.6(6) 
N9 5906.4(16) 8561.6(16) 6475.0(14) 21.2(6) 
N10 6261.4(15) 7098.5(16) 6702.5(14) 18.9(6) 
N11 6976.3(15) 7717.1(15) 5639.2(14) 19.4(6) 
N12 5934.2(15) 6686.7(15) 5165.6(13) 16.7(6) 
C29 5819(2) 8637.0(19) 4488.6(17) 21.2(7) 
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C30 5478(2) 8963(2) 3862.7(18) 26.8(8) 
C31 4725(2) 8854.4(19) 3589.9(17) 24.5(8) 
C32 4326(2) 8436.1(19) 3960.4(17) 20.9(7) 
C33 4697.9(18) 8120.1(18) 4581.2(16) 17.0(7) 
C34 4310.1(19) 7636.3(19) 4998.7(17) 19.5(7) 
C35 4445.4(19) 7036(2) 6113.3(18) 23.1(7) 
C36 4575.7(19) 8396.3(19) 6029.4(17) 22.1(7) 
C37 5175(2) 8558(2) 6660.2(18) 24.6(8) 
C38 6046(2) 9333.3(19) 6235(2) 29.9(8) 
C39 6482(2) 8377(2) 7118.3(17) 25.1(8) 
C40 6464.5(19) 7550(2) 7264.1(18) 21.7(7) 
C41 6651(2) 7259(2) 7929.7(19) 29.5(8) 
C42 6659(2) 6483(2) 8019.7(19) 34.9(9) 
C43 6479(2) 6017(2) 7449.1(19) 31.3(9) 
C44 6274.1(19) 6340(2) 6798.2(18) 24.5(8) 
C45 7506.0(19) 8231(2) 5880.4(18) 25.4(8) 
C46 8187(2) 8245(2) 5696.8(19) 29.4(8) 
C47 8334(2) 7720(2) 5254(2) 30.7(9) 
C48 7802.9(19) 7159(2) 4993.3(17) 24.4(8) 
C49 7130.2(18) 7179.2(19) 5199.9(16) 18.6(7) 
C50 6578.2(18) 6623.4(19) 4952.3(16) 18.1(7) 
C51 7912(2) 6574(2) 4538.7(18) 30.8(9) 
C52 7399(2) 6032(2) 4321.5(18) 31.6(9) 
C53 6714.8(19) 6031(2) 4532.5(16) 22.1(7) 
C54 6176(2) 5465(2) 4340.1(17) 26.4(8) 
C55 5534(2) 5529.5(19) 4547.5(17) 25.0(8) 
C56 5430.0(19) 6139.7(19) 4954.5(17) 21.6(7) 
P1 4377.4(5) 8751.0(5) 8310.8(4) 16.92(18) 
F1 4705.6(11) 9502.3(11) 8051.6(10) 26.6(4) 
F2 5132.6(11) 8316.1(11) 8325.0(11) 28.5(5) 
F3 4039.8(12) 8503.3(13) 7526.2(10) 32.5(5) 
F4 4044.3(12) 8002.6(11) 8569.9(11) 31.5(5) 
F5 3618.2(12) 9191.9(12) 8300.8(11) 30.6(5) 
F6 4702.5(13) 9006.5(13) 9096.4(10) 34.4(5) 
P2 4234.7(5) 5533.2(5) 7457.7(4) 21.5(2) 
F7 4698.1(13) 6265.7(12) 7761.4(11) 33.7(5) 
F8 4809.7(14) 5009.4(13) 7999.2(11) 38.9(6) 
F9 4736.4(12) 5432.4(12) 6917.4(10) 30.1(5) 
F10 3772.9(12) 4783.4(11) 7145.4(10) 30.4(5) 
F11 3660.8(12) 6032.6(12) 6906.2(12) 35.6(5) 
F12 3746.5(14) 5609.2(14) 8000.7(12) 40.8(6) 
P3 2998.8(5) 5879.7(5) 3976.0(4) 20.37(19) 
F13 3248.6(15) 6037.7(14) 4787.5(11) 43.2(6) 
F14 3074.4(12) 6766.4(12) 3832.1(12) 33.2(5) 
F15 3849.3(12) 5763.6(14) 3971.8(13) 40.5(6) 
F16 2755.7(15) 5734.4(14) 3167.5(11) 44.9(6) 
F17 2928.2(12) 4994.4(12) 4116.5(11) 30.5(5) 
F18 2150.7(12) 6009.5(13) 3986.7(14) 41.7(6) 
P4 2320.6(5) 4520.4(5) 10100.0(4) 21.03(19) 
F19 2554.4(15) 4792.0(13) 10886.4(11) 44.9(6) 
F20 3163.2(13) 4447.7(15) 10089.4(14) 50.5(7) 
F21 2305.6(14) 5380.8(12) 9868.7(11) 36.7(5) 
F22 2079.8(12) 4255.1(12) 9313(1) 30.1(5) 
F23 1456.2(13) 4592.5(14) 10101.3(12) 41.4(6) 
F24 2309.3(17) 3656.9(13) 10334.8(13) 51.0(7) 
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Table 2. Anisotropic Displacement Parameters (Å2×103) for Ru-3. The Anisotropic displacement factor 
exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
 
Atom U11 U22 U33 U23 U13 U12 
Ru1 10.49(14) 12.74(13) 10.85(13) -2.77(9) 5.49(10) -3.05(9) 
N1 13.8(14) 19.8(14) 13.1(13) -3.2(10) 7.8(11) -0.5(10) 
N2 16.3(15) 16.4(13) 14.5(13) -3(1) 5.8(11) -1.8(10) 
N3 12.9(14) 18.7(14) 17.6(13) -2.9(11) 7.0(11) -2.2(11) 
N4 11.7(14) 18.0(13) 16.3(13) -2.7(11) 5.4(11) -5.7(10) 
N5 16.5(15) 15.2(13) 14.8(13) -0.4(10) 6.9(11) -1.5(10) 
N6 10.1(14) 17.0(13) 14.3(12) -1.5(10) 4.1(10) -0.4(10) 
C1 17.7(18) 18.6(16) 22.2(16) 0.1(13) 11.7(14) 1.8(13) 
C2 24(2) 23.7(18) 27.6(18) 6.6(14) 15.4(16) 6.6(14) 
C3 28(2) 38(2) 20.2(17) 9.4(15) 8.2(15) 10.3(16) 
C4 25(2) 39(2) 15.7(16) 0.0(15) 4.1(14) 1.9(16) 
C5 18.0(18) 23.9(17) 15.3(15) -2.7(13) 7.7(13) -0.7(13) 
C6 19.4(19) 24.5(17) 15.5(16) -4.2(13) 0.3(14) -6.6(13) 
C7 19.7(19) 15.8(16) 24.2(17) -3.4(13) 7.7(14) -8.0(13) 
C8 11.0(18) 24.5(17) 24.0(17) -4.9(13) 6.9(14) -5.4(13) 
C9 13.8(18) 24.7(17) 20.0(17) -1.6(13) 8.8(14) -4.6(13) 
C10 19.4(18) 20.9(17) 21.8(17) -5.7(13) 8.7(14) 0.3(13) 
C11 19.4(19) 26.5(17) 12.8(15) -5.2(13) 5.2(13) -1.1(14) 
C12 17.0(18) 22.6(17) 15.9(16) -2.5(13) 6.6(13) -6.5(13) 
C13 27(2) 30.2(19) 17.1(16) 2.7(14) 6.2(14) -6.0(15) 
C14 29(2) 34(2) 22.2(18) 10.5(15) 2.2(15) -1.6(16) 
C15 24(2) 19.2(17) 31.6(19) 5.9(14) 7.0(16) -1.1(14) 
C16 14.5(18) 21.4(17) 22.4(17) 1.4(13) 5.0(14) -4.3(13) 
C17 18.0(18) 22.0(17) 21.9(17) -9.5(13) 7.5(14) -2.4(13) 
C18 17.4(19) 18.8(16) 26.8(18) -7.0(14) 1.7(15) -5.0(13) 
C19 17.5(19) 19.4(17) 27.0(18) 2.6(14) 0.7(15) -7.4(13) 
C20 14.0(18) 20.5(16) 17.4(16) 6.7(12) 4.8(13) -1.1(13) 
C21 13.3(17) 16.1(15) 11.7(14) 3.5(12) 2.9(12) 0.4(12) 
C22 14.3(17) 15.6(15) 12.0(14) 4.5(12) 4.1(13) 2.8(12) 
C23 10.4(18) 37(2) 26.0(18) 4.0(15) 5.3(14) -6.2(14) 
C24 15.2(19) 38(2) 24.7(18) 3.1(15) 13.1(15) 1.3(14) 
C25 16.5(18) 24.7(17) 15.9(16) 4.1(13) 7.3(14) 3.4(13) 
C26 25(2) 34(2) 18.5(17) -0.1(14) 13.7(15) 7.5(15) 
C27 34(2) 22.8(17) 20.3(17) -6.4(14) 12.3(15) 1.7(15) 
C28 26(2) 17.3(16) 20.0(16) -6.1(13) 10.0(14) -3.8(13) 
Ru2 11.21(15) 17.61(14) 14.41(13) 1.9(1) 6.18(10) -2.36(9) 
N7 20.7(16) 17.3(13) 19.1(14) 0.4(11) 11.8(12) -0.7(11) 
N8 12.8(15) 23.6(14) 17.9(14) 4.8(11) 6.5(11) -1.2(11) 
N9 23.4(17) 22.4(15) 19.1(14) 0.0(11) 7.8(12) -2.1(11) 
N10 12.3(15) 26.5(15) 18.4(14) 3.1(11) 4.8(11) -1.9(11) 
N11 15.8(16) 24.4(15) 18.5(14) 6.9(11) 5.2(12) -0.1(11) 
N12 14.9(15) 20.0(14) 15.0(13) 4.7(11) 3.2(11) 0.5(11) 
C29 20.6(19) 23.8(17) 22.4(17) 3.4(14) 11.4(14) -3.6(14) 
C30 35(2) 25.0(18) 25.1(18) 6.0(14) 15.2(17) -3.0(15) 
C31 34(2) 25.6(18) 13.7(16) 4.6(13) 6.6(15) 4.6(15) 
C32 20.3(19) 23.3(17) 18.1(16) -0.5(13) 2.8(14) 0.9(13) 
C33 16.3(18) 19.0(16) 17.1(15) -2.4(13) 6.9(13) -0.2(12) 
C34 12.8(18) 26.3(18) 19.5(16) 4.4(13) 4.3(14) -1.8(13) 
C35 16.1(19) 31.2(19) 24.8(18) 11.0(15) 10.2(15) -1.7(14) 
C36 20.3(19) 26.6(18) 22.4(17) 6.2(14) 11.2(14) 5.0(14) 
C37 26(2) 28.4(19) 23.3(18) -0.1(14) 13.5(15) 1.9(15) 
C38 41(2) 19.0(17) 31(2) -1.5(15) 12.4(18) -7.4(16) 
C39 22(2) 31.2(19) 20.1(17) -4.2(14) 2.4(14) -6.5(15) 
C40 10.6(18) 32.6(19) 23.2(17) 0.9(14) 6.4(14) -0.8(13) 
C41 18(2) 51(2) 18.7(18) 4.3(16) 2.5(15) 1.2(16) 
C42 27(2) 52(3) 21.8(19) 15.9(18) -0.6(16) 6.1(18) 
C43 23(2) 38(2) 32(2) 17.9(17) 4.4(16) 4.1(16) 
C44 19(2) 29.9(19) 25.4(18) 5.4(15) 6.9(15) 2.1(14) 
C45 17.6(19) 33(2) 24.8(18) 5.6(15) 4.2(15) -7.7(14) 
C46 15(2) 41(2) 32(2) 10.7(17) 3.1(15) -8.0(15) 
C47 10.6(19) 50(2) 32(2) 19.3(18) 5.4(16) 1.5(16) 
C48 13.3(19) 42(2) 18.4(17) 15.7(15) 4.4(14) 7.4(15) 
C49 14.0(18) 26.4(17) 15.1(16) 9.5(13) 3.4(13) 3.8(13) 
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C50 15.0(18) 27.3(17) 12.1(15) 9.1(13) 3.5(13) 5.5(13) 
C51 24(2) 50(2) 22.4(18) 11.6(17) 13.8(16) 14.3(18) 
C52 34(2) 46(2) 17.6(17) 3.7(16) 10.8(16) 18.3(18) 
C53 20(2) 33.3(19) 11.4(15) 3.6(14) 1.1(13) 7.7(14) 
C54 36(2) 28.9(19) 12.8(16) 0.6(14) 2.3(15) 10.1(16) 
C55 31(2) 22.7(18) 18.1(17) -0.1(14) 0.2(15) 0.4(15) 
C56 20.4(19) 24.0(17) 19.8(17) 2.0(13) 4.2(14) -0.4(14) 
P1 17.3(5) 20.6(4) 14.0(4) 0.8(3) 6.0(3) 0.8(3) 
F1 27.5(12) 23(1) 31.0(11) 6.6(8) 10.4(9) -1.3(8) 
F2 21.5(11) 30.2(11) 36.5(12) 5.7(9) 12.2(9) 6.9(8) 
F3 26.3(12) 51.4(14) 19.5(10) -9.9(9) 5.3(9) -11.9(10) 
F4 33.5(13) 22.9(11) 44.8(13) 7.2(9) 22.2(11) -1.1(9) 
F5 25.3(12) 36.1(12) 36.0(12) 12.5(9) 18(1) 13.2(9) 
F6 43.1(14) 42.3(13) 15(1) -3.0(9) 2.1(9) -0.5(10) 
P2 29.4(5) 19.1(4) 17.6(4) -0.9(3) 8.8(4) -5.3(4) 
F7 40.2(14) 28.4(11) 33.1(12) -9.7(9) 10.3(10) -12.4(10) 
F8 49.2(15) 36.4(13) 25.3(11) 6.5(9) -1.1(10) 2.4(11) 
F9 34.7(13) 33.0(12) 25.9(11) -4.9(9) 13.6(9) -6.2(9) 
F10 44.1(14) 23.8(11) 23.7(10) 1.0(8) 9.3(9) -13.4(9) 
F11 30.7(13) 28.8(11) 44.2(13) 11.7(10) 3.5(10) 1.0(9) 
F12 46.7(15) 48.7(14) 35.9(13) -11.9(11) 27.1(11) -13.4(11) 
P3 14.0(5) 28.5(5) 18.8(4) 5.8(3) 4.3(3) -3.9(3) 
F13 62.7(18) 42.6(14) 21.4(11) 0.3(10) 5.1(11) -14.8(12) 
F14 29.1(13) 29.7(12) 43.1(13) 13.4(10) 13.3(10) -2.7(9) 
F15 18.7(12) 48.2(14) 58.4(15) 22.0(12) 16.9(11) 4.4(10) 
F16 56.0(17) 53.1(15) 18.3(11) 1.8(10) -4.5(10) 9.7(12) 
F17 25.6(12) 27.9(11) 34.5(12) 5.7(9) 1.1(9) -7.8(9) 
F18 20.1(13) 40.6(13) 70.8(17) 7.1(12) 23.3(12) -2.6(10) 
P4 28.6(5) 18.0(4) 16.1(4) -1.2(3) 4.8(4) 5.4(3) 
F19 68.0(18) 39.7(13) 19.4(11) -6.6(10) -3.4(11) 22.2(12) 
F20 22.0(14) 58.8(17) 66.8(17) -25.4(14) 3.7(12) 8.9(11) 
F21 54.3(16) 20.2(11) 36.1(12) 4.1(9) 12.5(11) 7(1) 
F22 29.4(12) 41.7(12) 20.1(10) -11.7(9) 8.0(9) 0.2(9) 
F23 35.4(14) 51.9(15) 43.5(14) -16.0(11) 22.1(11) -2.6(11) 
F24 94(2) 21.5(12) 42.3(14) 4.3(10) 25.5(14) 9.1(12) 
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Table 3. Bond Lengths for Ru-3. 
 
Atom Atom Length/Å   Atom Atom Length/Å 
Ru1 N1 2.073(3)   N9 C38 1.490(4) 
Ru1 N2 2.153(3)   N9 C39 1.490(4) 
Ru1 N3 2.158(3)   N10 C40 1.354(5) 
Ru1 N4 2.067(3)   N10 C44 1.353(4) 
Ru1 N5 2.092(3)   N11 C45 1.337(4) 
Ru1 N6 2.095(3)   N11 C49 1.373(4) 
N1 C1 1.353(4)   N12 C50 1.372(4) 
N1 C5 1.350(4)   N12 C56 1.339(4) 
N2 C6 1.492(4)   C29 C30 1.382(5) 
N2 C7 1.489(4)   C30 C31 1.381(5) 
N2 C8 1.499(4)   C31 C32 1.387(5) 
N3 C9 1.504(4)   C32 C33 1.380(5) 
N3 C10 1.493(4)   C33 C34 1.501(4) 
N3 C11 1.489(4)   C36 C37 1.488(5) 
N4 C12 1.356(4)   C39 C40 1.493(5) 
N4 C16 1.352(4)   C40 C41 1.389(5) 
N5 C22 1.370(4)   C41 C42 1.382(6) 
N5 C28 1.337(4)   C42 C43 1.380(6) 
N6 C17 1.334(4)   C43 C44 1.386(5) 
N6 C21 1.369(4)   C45 C46 1.403(5) 
C1 C2 1.381(5)   C46 C47 1.358(6) 
C2 C3 1.382(5)   C47 C48 1.403(5) 
C3 C4 1.381(5)   C48 C49 1.412(5) 
C4 C5 1.388(5)   C48 C51 1.426(5) 
C5 C6 1.503(5)   C49 C50 1.417(5) 
C8 C9 1.502(5)   C50 C53 1.405(5) 
C11 C12 1.505(5)   C51 C52 1.343(6) 
C12 C13 1.390(5)   C52 C53 1.437(5) 
C13 C14 1.377(5)   C53 C54 1.399(5) 
C14 C15 1.377(5)   C54 C55 1.363(5) 
C15 C16 1.375(5)   C55 C56 1.394(5) 
C17 C18 1.398(5)   P1 F1 1.601(2) 
C18 C19 1.366(5)   P1 F2 1.594(2) 
C19 C20 1.404(5)   P1 F3 1.600(2) 
C20 C21 1.406(4)   P1 F4 1.601(2) 
C20 C23 1.432(5)   P1 F5 1.607(2) 
C21 C22 1.415(4)   P1 F6 1.603(2) 
C22 C25 1.403(4)   P2 F7 1.589(2) 
C23 C24 1.349(5)   P2 F8 1.611(2) 
C24 C25 1.436(5)   P2 F9 1.606(2) 
C25 C26 1.400(5)   P2 F10 1.617(2) 
C26 C27 1.368(5)   P2 F11 1.596(2) 
C27 C28 1.394(5)   P2 F12 1.587(2) 
Ru2 N7 2.077(3)   P3 F13 1.599(2) 
Ru2 N8 2.155(3)   P3 F14 1.606(2) 
Ru2 N9 2.155(3)   P3 F15 1.596(2) 
Ru2 N10 2.071(3)   P3 F16 1.589(2) 
Ru2 N11 2.093(3)   P3 F17 1.601(2) 
Ru2 N12 2.085(3)   P3 F18 1.598(2) 
N7 C29 1.355(4)   P4 F19 1.599(2) 
N7 C33 1.355(4)   P4 F20 1.577(3) 
N8 C34 1.489(4)   P4 F21 1.588(2) 
N8 C35 1.487(4)   P4 F22 1.597(2) 
N8 C36 1.498(4)   P4 F23 1.612(2) 
N9 C37 1.496(4)   P4 F24 1.599(2) 
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Table 4. Bond Angles for Ru-3. 
 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
N1 Ru1 N2 78.53(10)   C40 N10 Ru2 116.1(2) 
N1 Ru1 N3 98.45(10)   C44 N10 Ru2 125.4(2) 
N1 Ru1 N5 89.42(10)   C44 N10 C40 118.4(3) 
N1 Ru1 N6 94.24(10)   C45 N11 Ru2 129.9(2) 
N2 Ru1 N3 82.38(10)   C45 N11 C49 116.7(3) 
N4 Ru1 N1 174.28(10)   C49 N11 Ru2 113.2(2) 
N4 Ru1 N2 96.33(10)   C50 N12 Ru2 113.9(2) 
N4 Ru1 N3 78.23(10)   C56 N12 Ru2 130.1(2) 
N4 Ru1 N5 94.05(10)   C56 N12 C50 116.0(3) 
N4 Ru1 N6 90.91(10)   N7 C29 C30 122.0(3) 
N5 Ru1 N2 100.72(10)   C31 C30 C29 119.4(3) 
N5 Ru1 N3 172.00(10)   C30 C31 C32 119.1(3) 
N5 Ru1 N6 78.45(10)   C33 C32 C31 118.9(3) 
N6 Ru1 N2 172.75(10)   N7 C33 C32 122.4(3) 
N6 Ru1 N3 99.40(10)   N7 C33 C34 115.6(3) 
C1 N1 Ru1 126.0(2)   C32 C33 C34 122.0(3) 
C5 N1 Ru1 115.8(2)   N8 C34 C33 110.0(3) 
C5 N1 C1 118.2(3)   C37 C36 N8 109.1(3) 
C6 N2 Ru1 106.89(19)   C36 C37 N9 108.9(3) 
C6 N2 C8 107.0(3)   N9 C39 C40 109.7(3) 
C7 N2 Ru1 117.7(2)   N10 C40 C39 115.5(3) 
C7 N2 C6 109.4(2)   N10 C40 C41 122.0(3) 
C7 N2 C8 108.9(2)   C41 C40 C39 122.6(3) 
C8 N2 Ru1 106.61(18)   C42 C41 C40 119.0(4) 
C9 N3 Ru1 106.45(18)   C43 C42 C41 119.4(3) 
C10 N3 Ru1 117.45(19)   C42 C43 C44 119.1(4) 
C10 N3 C9 108.2(2)   N10 C44 C43 122.1(4) 
C11 N3 Ru1 107.17(18)   N11 C45 C46 123.2(4) 
C11 N3 C9 107.1(2)   C47 C46 C45 120.1(3) 
C11 N3 C10 110.0(2)   C46 C47 C48 119.1(3) 
C12 N4 Ru1 116.2(2)   C47 C48 C49 117.7(3) 
C16 N4 Ru1 125.5(2)   C47 C48 C51 123.4(3) 
C16 N4 C12 118.2(3)   C49 C48 C51 118.8(3) 
C22 N5 Ru1 114.0(2)   N11 C49 C48 123.1(3) 
C28 N5 Ru1 129.4(2)   N11 C49 C50 117.1(3) 
C28 N5 C22 116.5(3)   C48 C49 C50 119.8(3) 
C17 N6 Ru1 129.4(2)   N12 C50 C49 116.5(3) 
C17 N6 C21 116.5(3)   N12 C50 C53 123.3(3) 
C21 N6 Ru1 114.1(2)   C53 C50 C49 120.2(3) 
N1 C1 C2 122.3(3)   C52 C51 C48 121.4(3) 
C1 C2 C3 119.2(3)   C51 C52 C53 120.9(3) 
C4 C3 C2 119.0(3)   C50 C53 C52 118.7(3) 
C3 C4 C5 119.2(3)   C54 C53 C50 118.2(3) 
N1 C5 C4 122.0(3)   C54 C53 C52 123.0(3) 
N1 C5 C6 116.0(3)   C55 C54 C53 118.5(3) 
C4 C5 C6 122.0(3)   C54 C55 C56 120.2(3) 
N2 C6 C5 109.8(3)   N12 C56 C55 123.7(3) 
N2 C8 C9 108.6(3)   F1 P1 F4 179.64(12) 
C8 C9 N3 109.1(3)   F1 P1 F5 89.91(11) 
N3 C11 C12 109.9(3)   F1 P1 F6 90.24(12) 
N4 C12 C11 115.5(3)   F2 P1 F1 90.02(11) 
N4 C12 C13 121.5(3)   F2 P1 F3 90.72(12) 
C13 C12 C11 123.0(3)   F2 P1 F4 90.34(11) 
C14 C13 C12 119.3(3)   F2 P1 F5 179.65(14) 
C13 C14 C15 119.4(3)   F2 P1 F6 90.26(12) 
C16 C15 C14 119.1(3)   F3 P1 F1 89.77(12) 
N4 C16 C15 122.6(3)   F3 P1 F4 90.22(12) 
N6 C17 C18 123.5(3)   F3 P1 F5 89.63(12) 
C19 C18 C17 120.3(3)   F3 P1 F6 179.03(14) 
C18 C19 C20 118.1(3)   F4 P1 F5 89.72(11) 
C19 C20 C21 118.4(3)   F4 P1 F6 89.76(12) 
C19 C20 C23 122.6(3)   F6 P1 F5 89.40(12) 
C21 C20 C23 119.0(3)   F7 P2 F8 90.34(13) 
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N6 C21 C20 123.2(3)   F7 P2 F9 89.87(12) 
N6 C21 C22 116.6(3)   F7 P2 F10 179.20(14) 
C20 C21 C22 120.3(3)   F7 P2 F11 91.07(13) 
N5 C22 C21 116.9(3)   F8 P2 F10 89.30(12) 
N5 C22 C25 123.1(3)   F9 P2 F8 89.46(13) 
C25 C22 C21 120.0(3)   F9 P2 F10 89.42(11) 
C24 C23 C20 120.6(3)   F11 P2 F8 178.38(13) 
C23 C24 C25 121.4(3)   F11 P2 F9 89.72(13) 
C22 C25 C24 118.7(3)   F11 P2 F10 89.29(12) 
C26 C25 C22 118.3(3)   F12 P2 F7 90.97(12) 
C26 C25 C24 123.0(3)   F12 P2 F8 89.08(14) 
C27 C26 C25 118.6(3)   F12 P2 F9 178.33(14) 
C26 C27 C28 119.8(3)   F12 P2 F10 89.73(12) 
N5 C28 C27 123.7(3)   F12 P2 F11 91.71(14) 
N7 Ru2 N8 78.01(10)   F13 P3 F14 89.76(13) 
N7 Ru2 N9 98.91(10)   F13 P3 F17 90.44(12) 
N7 Ru2 N11 93.20(11)   F15 P3 F13 89.54(15) 
N7 Ru2 N12 87.17(10)   F15 P3 F14 89.61(12) 
N8 Ru2 N9 81.80(11)   F15 P3 F17 90.01(12) 
N10 Ru2 N7 174.97(10)   F15 P3 F18 179.02(15) 
N10 Ru2 N8 97.22(10)   F16 P3 F13 179.15(15) 
N10 Ru2 N9 78.65(11)   F16 P3 F14 89.43(13) 
N10 Ru2 N11 91.58(11)   F16 P3 F15 90.18(15) 
N10 Ru2 N12 95.31(11)   F16 P3 F17 90.36(13) 
N11 Ru2 N8 171.19(10)   F16 P3 F18 90.40(15) 
N11 Ru2 N9 100.36(11)   F17 P3 F14 179.57(13) 
N12 Ru2 N8 99.86(11)   F18 P3 F13 89.87(15) 
N12 Ru2 N9 173.91(10)   F18 P3 F14 89.61(12) 
N12 Ru2 N11 78.89(11)   F18 P3 F17 90.77(12) 
C29 N7 Ru2 125.8(2)   F19 P4 F23 89.99(14) 
C29 N7 C33 118.2(3)   F20 P4 F19 90.68(15) 
C33 N7 Ru2 116.0(2)   F20 P4 F21 91.10(15) 
C34 N8 Ru2 107.07(19)   F20 P4 F22 89.80(13) 
C34 N8 C36 107.5(2)   F20 P4 F23 179.33(14) 
C35 N8 Ru2 117.6(2)   F20 P4 F24 90.71(16) 
C35 N8 C34 109.3(3)   F21 P4 F19 88.88(13) 
C35 N8 C36 108.7(3)   F21 P4 F22 90.76(12) 
C36 N8 Ru2 106.28(19)   F21 P4 F23 88.86(13) 
C37 N9 Ru2 107.5(2)   F21 P4 F24 178.20(15) 
C38 N9 Ru2 116.7(2)   F22 P4 F19 179.40(14) 
C38 N9 C37 109.0(3)   F22 P4 F23 89.53(12) 
C39 N9 Ru2 107.1(2)   F22 P4 F24 89.37(13) 
C39 N9 C37 106.5(3)   F24 P4 F19 90.98(13) 
C39 N9 C38 109.5(3)   F24 P4 F23 89.34(15) 
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Table 5 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters (Å2×103) for Ru-3. 
 
Atom x y z U(eq) 
H1 1040 5646 7045 22 
H2 1721 4995 7987 28 
H3 2663 5614 8783 34 
H4 2887 6884 8613 32 
H6A 1888 8129 7848 25 
H6B 2693 7959 7769 25 
H7A 1767 8919 6250 29 
H7B 2300 9057 6981 29 
H7C 1440 9000 6896 29 
H8A 2717 7219 6751 23 
H8B 2911 8052 6581 23 
H9A 2544 7346 5558 22 
H9B 1983 8014 5547 22 
H10A 2269 6167 6161 30 
H10B 2057 6108 5354 30 
H10C 1493 5842 5771 30 
H11A 714 6665 4884 23 
H11B 1323 7155 4667 23 
H13 343 8071 3998 30 
H14 -368 9128 4077 35 
H15 -533 9482 5144 30 
H16 6 8776 6099 23 
H17 306 5885 5482 24 
H18 -702 5086 5301 26 
H19 -1617 5274 5879 27 
H23 -2095 6076 6729 29 
H24 -1954 7095 7435 29 
H26 -1179 8216 7997 29 
H27 -106 8918 8120 30 
H28 774 8557 7555 24 
H29 6326 8711 4669 25 
H30 5751 9254 3627 32 
H31 4490 9059 3163 29 
H32 3816 8370 3793 25 
H34A 3809 7823 4953 23 
H34B 4277 7121 4828 23 
H35A 4572 6554 5954 35 
H35B 3915 7077 6030 35 
H35C 4668 7083 6599 35 
H36A 4560 8793 5691 26 
H36B 4098 8382 6143 26 
H37A 5177 8174 7007 30 
H37B 5090 9046 6849 30 
H38A 6492 9328 6075 45 
H38B 6102 9685 6610 45 
H38C 5634 9484 5865 45 
H39A 6388 8663 7501 30 
H39B 6969 8517 7065 30 
H41 6769 7581 8309 35 
H42 6784 6277 8461 42 
H43 6496 5494 7501 38 
H44 6141 6025 6415 29 
H45 7419 8596 6185 30 
H46 8537 8614 5879 35 
H47 8781 7731 5125 37 
H51 8347 6567 4389 37 
H52 7489 5653 4031 38 
H54 6255 5055 4077 32 
H55 5164 5165 4417 30 
H56 4986 6168 5087 26 
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5.2 [Ru(picenMe2)(dpq)](PF6)2 (Ru-4) 
Deposition Number: 1959524 
Data Block Name: data_p4_a_sq 
Unit Cell Parameters: a 17.450(3), b 17.450(3), c 12.557(3) 
Space Group: P41 
 
Table 1. Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement Parameters (Å2×103) for 
Ru-4. Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
Ru1 8142.8(4) 3454.2(4) 8012.6(5) 31.5(2) 
N1 8298(4) 3651(4) 9619(6) 30.7(15) 
N2 9356(4) 3701(4) 8077(6) 32.7(15) 
N3 8562(4) 2291(4) 7948(7) 37.6(16) 
N4 8063(5) 3219(5) 6397(6) 39.8(19) 
N5 7715(4) 4564(4) 7881(6) 34.8(16) 
N6 6959(4) 3255(4) 8119(6) 34.7(16) 
C1 7814(6) 3476(5) 10408(8) 35.7(18) 
C2 7941(6) 3676(6) 11455(8) 44(2) 
C3 8621(5) 4056(5) 11728(7) 38(2) 
C4 9137(5) 4235(5) 10926(7) 36(2) 
C5 8958(5) 4032(5) 9879(7) 33.7(19) 
C6 9480(5) 4243(5) 8977(7) 34.4(19) 
C7 9726(5) 4019(5) 7107(7) 37(2) 
C8 9754(6) 2966(6) 8350(7) 38(2) 
C9 9399(6) 2336(5) 7707(7) 40(2) 
C10 8434(6) 1810(6) 8935(8) 44(2) 
C11 8179(6) 1908(6) 7019(7) 42(2) 
C12 8119(5) 2468(6) 6102(7) 39(2) 
C13 8061(6) 2231(6) 5076(8) 46(2) 
C14 7961(6) 2799(6) 4287(7) 43(2) 
C15 7922(6) 3545(6) 4546(8) 41(2) 
C16 7977(5) 3748(6) 5625(8) 41(2) 
C17 8094(6) 5229(5) 7726(7) 39(2) 
C18 7738(5) 5935(5) 7684(7) 37(2) 
C19 6973(6) 5987(5) 7809(6) 36(2) 
C20 6552(5) 5320(5) 7950(7) 33.5(17) 
C21 6940(5) 4626(5) 7984(7) 32.9(17) 
C22 5704(5) 5329(4) 8040(7) 36.3(18) 
C23 5339(4) 6005(4) 7993(6) 28.1(16) 
C24 4579(5) 5984(6) 8014(8) 49(2) 
C25 4182(5) 5301(5) 8072(7) 45(2) 
C26 4542(4) 4621(5) 8105(6) 30.9(17) 
C27 5316(4) 4637(5) 8098(7) 36.2(19) 
C28 5727(5) 3915(6) 8122(7) 40(2) 
C29 6522(5) 3915(5) 8091(7) 32.7(17) 
C30 5361(5) 3190(5) 8223(6) 37(2) 
C31 5772(6) 2557(6) 8282(7) 44(2) 
C32 6580(6) 2605(6) 8228(7) 42(2) 
P1 9773.0(14) 6582.1(14) 8923.4(18) 36.2(5) 
F1 10476(3) 6997(3) 8343(5) 47.8(14) 
F2 9688(3) 6016(3) 7920(5) 43.5(12) 
F3 10337(3) 5989(3) 9477(5) 50.4(14) 
F4 9053(3) 6172(4) 9491(4) 52.2(15) 
F5 9854(4) 7150(4) 9922(4) 54.9(16) 
F6 9200(3) 7175(4) 8362(5) 50.4(14) 
P2 6126.2(17) 2007.4(15) 11587(2) 48.0(6) 
F7 6848(5) 1815(5) 10873(8) 100(3) 
F8 5624(6) 1507(5) 10792(7) 92(3) 
F9 6276(6) 1263(4) 12289(7) 85(2) 
F10 5408(4) 2213(5) 12275(7) 80(2) 
F11 6634(4) 2498(4) 12376(7) 73(2) 
F12 6012(5) 2757(4) 10889(6) 77(2) 
O1 9639(8) 2319(7) 11139(9) 38(3) 
O2 11054(9) 2067(9) 10313(13) 61(4) 
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Table 2. Anisotropic Displacement Parameters (Å2×103) for Ru-4. The Anisotropic displacement factor 
exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
 
Atom U11 U22 U33 U23 U13 U12 
Ru1 39.4(4) 35.3(4) 19.7(3) 1.5(3) -3.9(3) -5.9(3) 
N1 36(4) 33(4) 22(4) 2(3) -1(3) 7(3) 
N2 38(4) 38(4) 22(3) -1(3) -1(3) -5(3) 
N3 48(4) 35(4) 29(4) -5(4) -2(4) -1(3) 
N4 47(5) 43(4) 30(4) 2(4) -8(3) -17(4) 
N5 47(4) 40(4) 17(3) 1(3) -5(3) -9(3) 
N6 37(4) 45(4) 22(4) 1(3) -2(3) -10(3) 
C1 47(5) 36(5) 24(4) 4(4) -4(4) -7(4) 
C2 53(6) 46(5) 34(6) 2(4) -3(4) 12(5) 
C3 47(5) 44(5) 22(4) -4(4) -5(4) -7(4) 
C4 41(5) 43(5) 24(4) 1(4) -8(4) -1(4) 
C5 43(5) 35(5) 24(4) -3(3) -1(4) -8(4) 
C6 38(5) 40(5) 26(4) 0(4) -8(4) -4(4) 
C7 41(5) 37(5) 33(5) 8(4) 4(4) -6(4) 
C8 43(5) 48(5) 22(4) -3(4) -2(3) 3(4) 
C9 56(6) 33(5) 31(5) -3(4) -3(4) 4(4) 
C10 56(6) 48(6) 30(5) 3(4) -1(4) -4(5) 
C11 59(6) 43(5) 25(4) -7(4) 1(4) -11(4) 
C12 37(5) 48(5) 31(5) 0(4) -3(4) -8(4) 
C13 53(6) 51(6) 33(5) -2(4) 4(4) -14(5) 
C14 43(5) 64(7) 22(4) 11(4) 3(4) -6(5) 
C15 42(5) 59(6) 22(5) 1(4) 1(4) -17(5) 
C16 43(5) 50(5) 31(5) 8(5) 2(4) -8(4) 
C17 45(5) 45(5) 26(5) 6(4) -6(3) -13(4) 
C18 39(5) 38(5) 33(5) 0(4) -5(4) -4(4) 
C19 51(5) 39(5) 19(4) 3(3) -3(4) -2(4) 
C20 44(5) 42(4) 14(3) -2(4) -1(4) -3(4) 
C21 41(4) 43(4) 15(3) -2(4) -3(4) -2(3) 
C22 49(5) 49(5) 10(3) 1(4) 0(4) -2(4) 
C23 33(4) 37(4) 14(3) 0(3) 3(3) 5(3) 
C24 71(7) 60(6) 18(4) -3(5) 6(5) 1(5) 
C25 47(5) 70(6) 16(4) -2(5) -5(4) 5(4) 
C26 37(4) 49(5) 7(3) -4(3) -1(3) -3(4) 
C27 44(5) 54(5) 11(4) -4(4) 0(4) 1(4) 
C28 49(5) 53(5) 18(4) -7(4) 2(4) -9(4) 
C29 45(5) 38(4) 15(3) -2(3) 2(4) -5(3) 
C30 38(5) 50(5) 24(5) 1(4) -2(3) -8(4) 
C31 64(6) 46(5) 23(4) -6(4) 1(4) -23(5) 
C32 53(6) 41(5) 33(5) 2(4) 3(4) -4(4) 
P1 39.6(12) 43.2(13) 25.9(11) -4.3(9) 0.4(9) 0.2(10) 
F1 46(3) 52(3) 45(3) -2(3) 1(2) -11(3) 
F2 44(3) 52(3) 34(3) -10(3) 3(2) -9(2) 
F3 43(3) 55(3) 53(3) 3(3) -7(3) 3(3) 
F4 46(3) 80(4) 30(3) 0(3) 11(2) -10(3) 
F5 78(4) 56(4) 30(3) -15(3) 1(3) -3(3) 
F6 49(3) 60(4) 42(3) -4(3) 1(2) 16(3) 
P2 54.1(16) 40.6(14) 49.3(15) -5.0(11) 10.3(12) -0.9(11) 
F7 109(7) 63(5) 128(8) 4(5) 72(6) 12(4) 
F8 127(7) 80(5) 70(5) -22(4) -14(5) -26(5) 
F9 119(7) 54(4) 81(5) 1(4) 2(5) -1(4) 
F10 60(4) 81(5) 100(6) -29(5) 30(4) -8(4) 
F11 57(4) 61(4) 102(6) -6(4) -18(4) -12(3) 
F12 118(7) 52(4) 60(4) 8(3) 4(4) 17(4) 
O1 64(8) 30(6) 18(6) -10(5) -13(5) -2(6) 
O2 62(9) 62(9) 59(10) 22(8) -17(8) 1(7) 
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Table 3. Bond Lengths for Ru-4. 
 
Atom Atom Length/Å   Atom Atom Length/Å 
Ru1 N1 2.064(7)   C15 C16 1.405(14) 
Ru1 N2 2.161(7)   C17 C18 1.380(14) 
Ru1 N3 2.158(7)   C18 C19 1.348(13) 
Ru1 N4 2.075(8)   C19 C20 1.387(12) 
Ru1 N5 2.082(8)   C20 C21 1.389(12) 
Ru1 N6 2.099(7)   C20 C22 1.485(12) 
N1 C1 1.338(13)   C21 C29 1.447(11) 
N1 C5 1.369(12)   C22 C23 1.342(10) 
N2 C6 1.489(11)   C22 C27 1.386(10) 
N2 C7 1.486(11)   C23 C24 1.327(11) 
N2 C8 1.498(12)   C24 C25 1.381(11) 
N3 C9 1.493(13)   C25 C26 1.343(10) 
N3 C10 1.514(13)   C26 C27 1.351(10) 
N3 C11 1.502(12)   C27 C28 1.450(13) 
N4 C12 1.364(13)   C28 C29 1.387(13) 
N4 C16 1.347(13)   C28 C30 1.423(13) 
N5 C17 1.350(11)   C30 C31 1.318(15) 
N5 C21 1.361(11)   C31 C32 1.414(15) 
N6 C29 1.382(12)   P1 F1 1.600(6) 
N6 C32 1.320(12)   P1 F2 1.608(6) 
C1 C2 1.378(14)   P1 F3 1.588(6) 
C2 C3 1.402(14)   P1 F4 1.613(6) 
C3 C4 1.386(13)   P1 F5 1.605(6) 
C4 C5 1.397(12)   P1 F6 1.602(6) 
C5 C6 1.500(12)   P2 F7 1.582(8) 
C8 C9 1.498(12)   P2 F8 1.588(8) 
C11 C12 1.515(13)   P2 F9 1.591(8) 
C12 C13 1.357(13)   P2 F10 1.565(7) 
C13 C14 1.413(14)   P2 F11 1.582(8) 
C14 C15 1.343(15)   P2 F12 1.587(7) 
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Table 4. Bond Angles for Ru-4. 
 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
N1 Ru1 N2 78.6(3)   C19 C18 C17 120.0(9) 
N1 Ru1 N3 98.6(3)   C18 C19 C20 118.9(9) 
N1 Ru1 N4 175.9(3)   C19 C20 C21 118.5(8) 
N1 Ru1 N5 88.2(3)   C19 C20 C22 121.9(8) 
N1 Ru1 N6 95.4(3)   C21 C20 C22 119.6(7) 
N3 Ru1 N2 81.8(3)   N5 C21 C20 123.4(8) 
N4 Ru1 N2 98.1(3)   N5 C21 C29 116.2(8) 
N4 Ru1 N3 78.5(3)   C20 C21 C29 120.3(8) 
N4 Ru1 N5 94.7(3)   C23 C22 C20 118.6(7) 
N4 Ru1 N6 87.9(3)   C23 C22 C27 122.4(8) 
N5 Ru1 N2 99.8(3)   C27 C22 C20 118.8(7) 
N5 Ru1 N3 173.2(3)   C24 C23 C22 116.7(8) 
N5 Ru1 N6 78.8(3)   C23 C24 C25 121.8(9) 
N6 Ru1 N2 173.9(3)   C26 C25 C24 121.9(9) 
N6 Ru1 N3 100.4(3)   C25 C26 C27 116.7(8) 
C1 N1 Ru1 127.0(7)   C22 C27 C28 121.1(8) 
C1 N1 C5 117.7(8)   C26 C27 C22 120.4(8) 
C5 N1 Ru1 115.2(6)   C26 C27 C28 118.5(8) 
C6 N2 Ru1 107.3(5)   C29 C28 C27 119.6(8) 
C6 N2 C8 107.6(7)   C29 C28 C30 116.8(9) 
C7 N2 Ru1 118.0(6)   C30 C28 C27 123.5(8) 
C7 N2 C6 108.7(7)   N6 C29 C21 116.0(7) 
C7 N2 C8 107.9(7)   N6 C29 C28 123.5(8) 
C8 N2 Ru1 107.0(5)   C28 C29 C21 120.5(8) 
C9 N3 Ru1 106.9(5)   C31 C30 C28 120.4(9) 
C9 N3 C10 109.8(7)   C30 C31 C32 119.4(9) 
C9 N3 C11 107.5(7)   N6 C32 C31 123.7(10) 
C10 N3 Ru1 116.2(6)   F1 P1 F2 89.5(3) 
C11 N3 Ru1 107.3(6)   F1 P1 F4 178.8(4) 
C11 N3 C10 108.8(7)   F1 P1 F5 90.5(3) 
C12 N4 Ru1 116.7(6)   F1 P1 F6 89.2(3) 
C16 N4 Ru1 125.1(7)   F2 P1 F4 90.1(3) 
C16 N4 C12 118.1(9)   F3 P1 F1 91.1(3) 
C17 N5 Ru1 129.4(7)   F3 P1 F2 90.0(3) 
C17 N5 C21 115.6(8)   F3 P1 F4 90.0(3) 
C21 N5 Ru1 115.0(6)   F3 P1 F5 90.3(4) 
C29 N6 Ru1 113.8(5)   F3 P1 F6 179.6(4) 
C32 N6 Ru1 130.0(7)   F5 P1 F2 179.7(4) 
C32 N6 C29 116.2(8)   F5 P1 F4 89.8(3) 
N1 C1 C2 123.1(9)   F6 P1 F2 89.6(3) 
C1 C2 C3 119.3(10)   F6 P1 F4 89.7(4) 
C4 C3 C2 118.6(8)   F6 P1 F5 90.0(3) 
C3 C4 C5 118.8(8)   F7 P2 F8 88.1(6) 
N1 C5 C4 122.4(8)   F7 P2 F9 90.6(5) 
N1 C5 C6 116.7(7)   F7 P2 F12 87.8(5) 
C4 C5 C6 120.9(8)   F8 P2 F9 89.5(5) 
N2 C6 C5 109.2(7)   F10 P2 F7 178.7(6) 
C9 C8 N2 108.2(7)   F10 P2 F8 91.8(5) 
N3 C9 C8 109.5(7)   F10 P2 F9 90.7(5) 
N3 C11 C12 109.4(8)   F10 P2 F11 88.8(5) 
N4 C12 C11 114.8(8)   F10 P2 F12 90.9(5) 
C13 C12 N4 123.0(9)   F11 P2 F7 91.3(5) 
C13 C12 C11 122.0(9)   F11 P2 F8 179.3(5) 
C12 C13 C14 117.5(10)   F11 P2 F9 90.1(5) 
C15 C14 C13 121.1(9)   F11 P2 F12 88.2(4) 
C14 C15 C16 118.4(10)   F12 P2 F8 92.1(5) 
N4 C16 C15 121.9(10)   F12 P2 F9 177.7(5) 
N5 C17 C18 123.6(9)           
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Table 5 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters (Å2×103) for Ru-4. 
 
Atom x y z U(eq) 
H1 7370 3205 10242 43 
H2 7580 3560 11974 53 
H3 8723 4186 12432 45 
H4 9594 4486 11082 43 
H6A 9374 4762 8746 41 
H6B 10009 4218 9210 41 
H7A 9694 3652 6540 56 
H7B 10254 4130 7256 56 
H7C 9468 4482 6900 56 
H8A 10296 3005 8189 45 
H8B 9698 2858 9104 45 
H9A 9473 2436 6954 48 
H9B 9642 1852 7878 48 
H10A 8741 2006 9508 66 
H10B 8579 1289 8791 66 
H10C 7903 1828 9131 66 
H11A 7671 1736 7224 51 
H11B 8474 1463 6802 51 
H13 8087 1714 4899 55 
H14 7920 2654 3576 51 
H15 7861 3917 4023 49 
H16 7952 4263 5813 50 
H17 8623 5211 7642 46 
H18 8027 6375 7570 44 
H19 6731 6462 7801 43 
H23 5606 6466 7949 34 
H24 4307 6442 7988 59 
H25 3649 5312 8088 53 
H26 4272 4162 8132 37 
H30 4829 3162 8248 45 
H31 5532 2084 8359 53 
H32 6860 2153 8270 51 
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5.3 [Ru(picenMe2)(dppzMe2)](PF6)2 (Ru-5) 
Deposition Number: 1959525 
Data Block Name: data_fdd2_a 
Unit Cell Parameters: a 23.752(5), b 15.729(3), c 19.930(4) 
Space Group: Fdd2 
 
Table 1. Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement Parameters (Å2×103) for 
Ru-5. Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
 
Atom x y z U(eq) 
Ru1 2500 2500 2884.0(3) 15.08(15) 
N1 2231.1(16) 3751(2) 2849(2) 19.6(7) 
N2 1902(2) 2454(3) 2064(3) 21.2(12) 
N3 3044(2) 2691(3) 3694(2) 17.6(10) 
N4 3092.6(17) 2557(3) 6108(2) 19.5(8) 
C1 2483(2) 4418(3) 3156(3) 23(1) 
C2 2264(2) 5221(3) 3132(3) 29.2(12) 
C3 1762(2) 5370(3) 2800(3) 31.0(11) 
C4 1500(2) 4693(3) 2491(3) 29.1(11) 
C5 1743(2) 3895(3) 2520(2) 22.6(10) 
C6 1476(2) 3127(3) 2198(3) 23.4(11) 
C7 1615(2) 1638(3) 1938(2) 24.8(10) 
C8 2222(3) 2714(4) 1449(3) 26.3(13) 
C9 3594(2) 2893(3) 3693(3) 19.5(10) 
C10 3910.5(19) 3003(3) 4270(2) 20.1(9) 
C11 3666(2) 2888(3) 4889(2) 19.4(9) 
C12 3093(2) 2673(3) 4911(2) 17.0(9) 
C13 2803(2) 2591(3) 4309(3) 17.1(12) 
C14 2800.3(19) 2556(3) 5547(2) 17.7(9) 
C15 2803(2) 2510(3) 6690(2) 18.8(10) 
C16 3082(3) 2476(3) 7310(3) 21.6(16) 
C17 2805.6(17) 2477(4) 7902(5) 22.1(8) 
C18 3123(3) 2449(4) 8558(3) 24.0(16) 
P1 2643.9(6) 5197.1(9) 5180.0(7) 27.3(3) 
F1 3113.7(13) 5885(2) 5366(2) 43.1(8) 
F2 2936(2) 4533(3) 5658(3) 69.0(14) 
F3 3018.7(16) 4857(3) 4581(2) 64.1(14) 
F4 2171.0(14) 4510(2) 4999(2) 41.8(10) 
F5 2350.9(16) 5848(3) 4678(2) 59.1(11) 
F6 2250.0(18) 5539(3) 5760(2) 60.0(13) 
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Table 2. Anisotropic Displacement Parameters (Å2×103) for Ru-5. The Anisotropic displacement factor 
exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
 
Atom U11 U22 U33 U23 U13 U12 
Ru1 18.9(2) 12.0(2) 14.3(2) 0 0 -0.6(3) 
N1 22.8(18) 18.8(19) 17.1(17) 0.3(17) -0.3(17) -0.2(15) 
N2 25(3) 19(2) 21(2) -2.8(17) -1(2) -3.2(18) 
N3 23(2) 12.0(19) 18(2) 1.3(18) 2.4(19) 5.4(19) 
N4 19.3(19) 21(2) 18.1(19) 0.9(16) -0.3(16) -0.3(16) 
C1 25(2) 18(2) 26(2) -0.4(18) -6(2) -1.7(19) 
C2 36(3) 16(2) 36(3) -5(2) -3(2) 0(2) 
C3 38(3) 20(2) 35(3) 0(2) -5(3) 4.6(19) 
C4 31(3) 25(3) 32(3) 0(2) -7(2) 2(2) 
C5 25(2) 23(2) 20(2) 0.6(19) -2.5(19) -0.3(19) 
C6 27(3) 21(3) 23(3) 1(2) -6(2) -1(2) 
C7 31(3) 24(2) 20(2) -4.7(19) -2(2) -8(2) 
C8 34(3) 29(3) 16(3) 3(3) -4(2) -12(3) 
C9 21(2) 16(2) 22(2) 0.6(19) 3(2) 2.1(19) 
C10 18(2) 19(2) 23(2) -0.6(19) 3.7(19) -1.0(18) 
C11 21(2) 19(2) 18(2) -1.3(18) -4.3(18) 1.2(18) 
C12 20(2) 11(2) 21(2) -1.9(17) -1.8(19) 3.1(17) 
C13 16(3) 15(2) 20(3) 2(2) 2(2) 0.4(19) 
C14 18(2) 16(2) 19(2) 0.9(16) -2.0(19) 1.1(16) 
C15 21(2) 19(2) 17(2) -0.2(18) 1.7(18) 1.4(19) 
C16 17(3) 26(3) 21(3) -1(2) -3(2) -1.4(19) 
C17 23(2) 22(2) 22(2) -0.2(17) -2(4) -2(3) 
C18 28(4) 26(3) 18(3) -1(2) -6(2) -2(2) 
P1 23.4(7) 25.4(7) 33.2(8) -6.2(5) 1.5(6) -0.3(5) 
F1 30.3(16) 40.3(17) 59(2) -20.8(19) 7.2(17) -9.0(13) 
F2 71(3) 47(2) 89(3) 11(2) -43(3) 0(2) 
F3 30(2) 96(3) 66(3) -48(3) 3(2) -1(2) 
F4 27.0(18) 31.1(19) 67(3) -11.0(18) -5.7(18) -0.8(14) 
F5 40(2) 61(3) 77(3) 29(2) -3(2) -6.1(19) 
F6 52(3) 71(3) 57(3) -38(2) 29(2) -25(2) 
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Table 3. Bond Lengths for Ru-5. 11/2-X,1/2-Y,+Z 
Atom Atom Length/Å   Atom Atom Length/Å 
Ru1 N11 2.070(4)   C8 C81 1.483(13) 
Ru1 N1 2.070(4)   C9 C10 1.384(7) 
Ru1 N2 2.166(5)   C10 C11 1.376(7) 
Ru1 N21 2.166(5)   C11 C12 1.402(7) 
Ru1 N31 2.089(5)   C12 C13 1.388(8) 
Ru1 N3 2.089(5)   C12 C14 1.457(6) 
N1 C1 1.354(6)   C13 C131 1.466(12) 
N1 C5 1.351(6)   C14 C141 1.437(9) 
N2 C6 1.489(7)   C15 C151 1.439(10) 
N2 C7 1.475(6)   C15 C16 1.403(8) 
N2 C8 1.499(8)   C16 C17 1.350(12) 
N3 C9 1.345(7)   C17 C171 1.454(8) 
N3 C13 1.363(8)   C17 C18 1.510(11) 
N4 C14 1.317(6)   P1 F1 1.597(3) 
N4 C15 1.350(6)   P1 F2 1.575(4) 
C1 C2 1.367(7)   P1 F3 1.583(4) 
C2 C3 1.384(8)   P1 F4 1.600(4) 
C3 C4 1.378(7)   P1 F5 1.591(4) 
C4 C5 1.384(7)   P1 F6 1.582(4) 
C5 C6 1.507(7)         
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Table 4. Bond Angles for Ru-5. 11/2-X,1/2-Y,+Z 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
N11 Ru1 N1 176.1(2)   C81 C8 N2 109.1(4) 
N11 Ru1 N2 98.31(16)   N3 C9 C10 123.8(5) 
N1 Ru1 N2 78.70(15)   C11 C10 C9 119.9(4) 
N11 Ru1 N21 78.70(15)   C10 C11 C12 118.0(4) 
N1 Ru1 N21 98.31(16)   C11 C12 C14 121.3(4) 
N11 Ru1 N31 94.59(17)   C13 C12 C11 118.5(4) 
N11 Ru1 N3 88.43(17)   C13 C12 C14 120.2(4) 
N1 Ru1 N31 88.42(17)   N3 C13 C12 123.9(5) 
N1 Ru1 N3 94.59(17)   N3 C13 C131 115.8(3) 
N21 Ru1 N2 82.1(3)   C12 C13 C131 120.3(3) 
N31 Ru1 N2 99.94(14)   N4 C14 C12 119.2(4) 
N3 Ru1 N2 173.24(18)   N4 C14 C141 121.6(3) 
N31 Ru1 N21 173.24(18)   C141 C14 C12 119.2(2) 
N3 Ru1 N21 99.94(14)   N4 C15 C151 120.7(3) 
N31 Ru1 N3 78.8(3)   N4 C15 C16 121.2(5) 
C1 N1 Ru1 125.8(3)   C16 C15 C151 118.1(4) 
C5 N1 Ru1 116.1(3)   C17 C16 C15 122.7(6) 
C5 N1 C1 118.0(4)   C16 C17 C171 119.1(4) 
C6 N2 Ru1 106.6(3)   C16 C17 C18 121.0(4) 
C6 N2 C8 107.3(4)   C171 C17 C18 120.0(4) 
C7 N2 Ru1 117.5(3)   F1 P1 F4 179.6(2) 
C7 N2 C6 109.6(5)   F2 P1 F1 90.1(2) 
C7 N2 C8 109.4(4)   F2 P1 F3 89.1(3) 
C8 N2 Ru1 106.0(4)   F2 P1 F4 89.8(2) 
C9 N3 Ru1 129.4(4)   F2 P1 F5 178.2(3) 
C9 N3 C13 115.9(5)   F2 P1 F6 92.5(3) 
C13 N3 Ru1 114.8(4)   F3 P1 F1 90.6(2) 
C14 N4 C15 117.4(4)   F3 P1 F4 89.8(2) 
N1 C1 C2 122.2(5)   F3 P1 F5 89.4(3) 
C1 C2 C3 120.1(5)   F5 P1 F1 90.9(2) 
C4 C3 C2 118.2(5)   F5 P1 F4 89.2(2) 
C3 C4 C5 119.6(5)   F6 P1 F1 90.8(2) 
N1 C5 C4 122.0(4)   F6 P1 F3 177.9(3) 
N1 C5 C6 115.7(4)   F6 P1 F4 88.8(2) 
C4 C5 C6 122.3(4)   F6 P1 F5 89.0(3) 
N2 C6 C5 111.1(4)           
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Table 5. Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters (Å2×103) for Ru-5. 
Atom x y z U(eq) 
H1 2815 4326 3392 28 
H2 2452 5667 3340 35 
H3 1606 5912 2785 37 
H4 1161 4773 2264 35 
H6A 1186 2903 2492 28 
H6B 1299 3293 1780 28 
H7A 1885 1223 1793 37 
H7B 1335 1714 1595 37 
H7C 1437 1446 2343 37 
H8A 2013 2556 1051 32 
H8B 2273 3326 1446 32 
H9 3772 2962 3281 23 
H10 4288 3155 4239 24 
H11 3874 2950 5281 23 
H16 3473 2452 7313 26 
H18A 3024 2935 8824 36 
H18B 3520 2455 8471 36 
H18C 3026 1939 8796 36 
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5.4 [Ru(picenMe2)(phenpyrBz)](PF6)2 (Ru-6) 
Deposition Number: 1959526 
Data Block Name: data_cc_a 
Unit Cell Parameters: a 19.664(4), b 15.844(3), c 14.416(3) 
Space Group: cc 
 
Table 1. Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement Parameters (Å2×103) for 
Ru-6. Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
 
Atom x y z U(eq) 
Ru1 1805.5(2) 6250.6(2) 5043.6(2) 20.54(11) 
N1 1419(2) 5023(2) 4460(3) 23.3(7) 
N2 427(3) 6389(3) 3879(4) 24.0(9) 
N3 1575(3) 6284(2) 6342(4) 21.8(10) 
N4 2121(2) 7487(2) 5614(3) 24.9(7) 
N5 2097(3) 6399(3) 3890(4) 24.5(9) 
N6 3116(3) 5991(3) 6129(3) 24.0(8) 
N7 4680(3) 6360(2) 4030(4) 23.6(8) 
N8 5536(3) 6088(2) 5932(3) 26.9(8) 
C1 1920(3) 4333(3) 4926(4) 27.8(10) 
C2 1612(3) 3531(3) 4483(4) 30.6(10) 
C3 776(3) 3422(3) 3542(4) 32.6(11) 
C4 258(3) 4136(3) 3043(4) 28.7(9) 
C5 602(3) 4917(3) 3513(4) 25.4(9) 
C6 83(3) 5722(3) 2980(4) 24.3(9) 
C7 83(3) 7226(3) 3298(4) 28.5(9) 
C8 125(4) 6211(3) 4585(5) 25.2(13) 
C9 704(3) 6617(3) 5755(4) 27.1(10) 
C10 1658(3) 5478(3) 6928(4) 27.4(9) 
C11 2186(3) 6916(3) 7232(4) 27.5(10) 
C12 2280(3) 7650(3) 6657(4) 27.1(9) 
C13 2539(3) 8438(3) 7159(4) 31.2(10) 
C14 2617(3) 9094(3) 6590(4) 33.8(11) 
C15 2454(4) 8924(3) 5531(5) 34.5(10) 
C16 2204(3) 8121(3) 5067(4) 28.1(9) 
C17 1583(3) 6610(3) 2761(4) 24.7(9) 
C18 1864(3) 6759(3) 2094(4) 26.2(9) 
C19 2716(3) 6667(3) 2577(4) 24.8(9) 
C20 3277(3) 6430(3) 3749(4) 24.5(9) 
C21 2955(3) 6315(3) 4386(4) 23.6(11) 
C22 3501(4) 6097(3) 5598(4) 24.4(11) 
C23 4382(3) 6007(3) 6199(4) 23.8(9) 
C24 4890(3) 5781(3) 7385(4) 25.5(9) 
C25 4498(3) 5657(3) 7903(4) 28.7(9) 
C26 3616(3) 5759(3) 7250(4) 26.5(10) 
C27 4169(3) 6313(2) 4380(4) 24.6(10) 
C28 4711(3) 6131(3) 5561(4) 25.9(10) 
C29 5498(4) 6220(2) 4991(4) 25.4(11) 
C30 6216(3) 6206(3) 4952(5) 22.9(10) 
C31 6114(3) 6062(3) 3915(4) 28.1(10) 
C32 6792(3) 6035(4) 3877(4) 33.8(11) 
C33 7612(4) 6161(3) 4902(5) 33.7(13) 
C34 7728(4) 6310(3) 5937(5) 29.5(11) 
C35 7050(4) 6329(3) 5984(4) 26.6(10) 
P1 4049.9(9) 8901.8(8) 4558.6(11) 31.7(3) 
F1 3062(2) 8725(2) 3865(3) 55.1(10) 
F2 4013(2) 9630(2) 5294(3) 49.6(8) 
F3 3857(2) 9583.1(18) 3605(2) 39.2(7) 
F4 4268(3) 8216(2) 5526(3) 49.4(9) 
F5 4099(2) 8183(2) 3826(3) 46.4(8) 
F6 5054(2) 9079(2) 5263(3) 47.8(8) 
P2 9137.3(8) 8481.9(9) 5512.6(11) 32.4(3) 
F7 9267(2) 8130(2) 4582(3) 49.4(9) 
F8 8567(2) 9229(2) 4642(3) 46.1(8) 
451 | P a g e  
 
F9 8304(2) 7926(2) 4930(3) 49.0(8) 
F10 9954(2) 9062(3) 6087(3) 65.6(11) 
F11 9001(2) 8824(2) 6444(3) 45.3(8) 
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Table 2. Anisotropic Displacement Parameters (Å2×103) for Ru-6. The Anisotropic displacement factor 
exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
 
Atom U11 U22 U33 U23 U13 U12 
Ru1 23.68(18) 16.25(16) 22.29(16) 0.04(12) 14.19(13) 0.15(13) 
N1 26.8(19) 21.8(18) 25.5(17) 0.1(14) 18.0(15) -0.8(14) 
N2 27(2) 19.9(17) 24.8(19) 2.5(15) 15.2(16) 2.6(16) 
N3 27(2) 21(2) 23(2) 1.6(13) 18.0(19) 1.3(13) 
N4 25.1(18) 23.3(19) 25.3(17) 0.0(14) 14.7(14) 0.5(14) 
N5 27(2) 17.8(16) 25(2) 0.2(16) 14.4(19) 1.8(17) 
N6 31(2) 17.6(18) 25.8(19) -2.0(16) 18.6(17) -4.0(17) 
N7 22(2) 26.1(18) 24.6(18) 1.3(14) 14.7(16) 0.2(14) 
N8 26(2) 25.3(18) 25.4(19) 1.8(15) 13.3(17) 1.0(15) 
C1 39(3) 23(2) 27(2) 2.0(17) 22.4(19) 3.0(18) 
C2 44(3) 21(2) 35(2) 0(2) 28(2) 1(2) 
C3 49(3) 21(2) 35(2) -3.6(18) 30(2) -5(2) 
C4 33(2) 25(2) 30(2) -2.8(18) 19.9(19) -5.7(19) 
C5 28(2) 26(2) 27(2) 1.6(17) 19.4(18) 3.5(18) 
C6 26(2) 21(2) 22(2) -3.2(17) 13.1(18) -0.7(18) 
C7 31(2) 21(2) 31(2) 3.9(16) 17.3(19) 5.1(16) 
C8 27(3) 24(3) 27(3) 1.9(16) 18(2) 1.7(17) 
C9 30(2) 24(3) 29(2) -0.9(18) 18.6(19) 1.1(18) 
C10 34(2) 22(2) 31(2) 6.2(16) 22.0(19) 1.8(17) 
C11 34(3) 22(2) 30(2) -2.8(18) 21(2) -0.2(18) 
C12 27(2) 26(2) 28(2) 0.9(17) 15.8(18) 1.3(17) 
C13 34(3) 25(2) 30(2) -6.9(18) 17(2) -1.9(18) 
C14 36(3) 20(2) 42(3) -7.0(19) 22(2) -4.7(18) 
C15 36(3) 24(2) 45(3) -1(2) 25(2) -1(2) 
C16 33(2) 25(2) 25(2) -0.5(17) 17.1(18) -1.3(18) 
C17 25(2) 21(2) 26(2) -1.1(16) 14.6(18) 0.7(16) 
C18 26(2) 25(2) 24(2) 1.5(16) 13.2(17) -0.9(17) 
C19 30(2) 23(2) 26(2) -0.5(16) 19.2(19) -1.2(16) 
C20 26(2) 18.1(18) 27(2) -1.1(17) 15.2(19) -1.1(17) 
C21 30(3) 15(2) 26(2) -1.9(15) 17(2) -0.9(15) 
C22 31(3) 16.4(19) 23(2) 2.3(18) 15(2) 1.0(19) 
C23 26(2) 16.7(19) 29(2) -1.6(16) 16.6(19) -1.2(17) 
C24 24(2) 18.9(19) 29(2) -1.3(16) 13.9(18) -1.2(16) 
C25 33(2) 22(2) 28(2) -0.4(17) 16.9(19) -1.1(18) 
C26 32(3) 19(2) 25(2) 0.2(17) 16(2) 1.3(18) 
C27 29(3) 20(2) 28(2) 0.1(15) 19(2) -0.2(16) 
C28 22(2) 24(2) 29(2) -0.3(17) 15(2) 0.6(16) 
C29 31(3) 20(2) 24(2) -0.5(15) 16(2) -0.6(16) 
C30 20(3) 23(2) 29(3) 0.7(15) 17(2) -0.6(14) 
C31 31(3) 29(2) 27(2) -1.9(19) 20(2) -4(2) 
C32 35(3) 35(3) 34(3) -1(2) 22(2) -4(2) 
C33 37(3) 34(3) 38(3) 4(2) 27(3) -1(2) 
C34 29(3) 30(3) 33(3) 2.9(17) 20(2) 3.6(17) 
C35 31(3) 27(2) 25(2) 2.1(16) 18(2) 3.6(17) 
P1 34.0(7) 29.1(6) 25.7(6) -0.1(5) 14.6(6) -6.0(5) 
F1 43(2) 80(3) 38.4(19) -4.6(16) 22.6(17) -22.4(16) 
F2 65(2) 37.3(17) 35.9(15) -0.7(13) 25.3(15) 9.0(15) 
F3 44.1(17) 32.9(15) 33.3(14) 9.7(12) 19.5(13) -1.4(12) 
F4 74(3) 30.8(16) 38.0(16) 0.6(14) 31.4(18) -7.6(16) 
F5 69(2) 32.1(16) 41.9(17) -6.5(13) 35.0(17) -8.1(15) 
F6 33.7(16) 44.2(19) 46.2(18) 8.6(15) 14.0(14) -1.0(14) 
P2 32.7(7) 32.0(7) 28.5(6) 0.1(5) 16.3(5) 7.0(6) 
F7 52(2) 64(2) 35.5(17) 6.0(15) 27.8(16) 25.5(17) 
F8 51.5(19) 31.2(16) 40.0(17) 0.9(13) 19.3(15) 7.8(14) 
F9 58(2) 46.8(18) 38.4(16) -5.6(14) 27.3(15) -15.4(16) 
F10 40(2) 96(3) 44(2) -6(2) 16.1(17) -19(2) 
F11 40.3(19) 56(2) 34.6(16) -7.8(13) 20.1(15) 10.4(13) 
F12 76(3) 65(2) 38.4(16) 21.0(16) 32.4(17) 46(2) 
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Table 3. Bond Lengths for Ru-6. 
 
Atom Atom Length/Å   Atom Atom Length/Å 
Ru1 N1 2.073(4)   C14 C15 1.385(8) 
Ru1 N2 2.173(4)   C15 C16 1.383(7) 
Ru1 N3 2.177(5)   C17 C18 1.388(6) 
Ru1 N4 2.070(4)   C18 C19 1.380(7) 
Ru1 N5 2.073(5)   C19 C20 1.402(6) 
Ru1 N6 2.095(4)   C20 C21 1.408(7) 
N1 C1 1.348(6)   C20 C27 1.419(7) 
N1 C5 1.352(6)   C21 C22 1.435(7) 
N2 C6 1.482(6)   C22 C23 1.400(8) 
N2 C7 1.494(6)   C23 C24 1.410(6) 
N2 C8 1.482(7)   C23 C28 1.421(7) 
N3 C9 1.476(7)   C24 C25 1.371(7) 
N3 C10 1.485(5)   C25 C26 1.397(7) 
N3 C11 1.494(6)   C27 C28 1.388(7) 
N4 C12 1.362(6)   C29 C30 1.447(8) 
N4 C16 1.347(6)   C30 C31 1.401(7) 
N5 C17 1.341(6)   C30 C35 1.413(8) 
N5 C21 1.386(8)   C31 C32 1.368(8) 
N6 C22 1.375(7)   C32 C33 1.396(9) 
N6 C26 1.340(6)   C33 C34 1.387(8) 
N7 C27 1.372(7)   C34 C35 1.376(9) 
N7 C29 1.366(7)   P1 F1 1.584(4) 
N8 C28 1.371(7)   P1 F2 1.598(3) 
N8 C29 1.328(7)   P1 F3 1.603(3) 
C1 C2 1.387(6)   P1 F4 1.608(3) 
C2 C3 1.371(7)   P1 F5 1.596(3) 
C3 C4 1.396(7)   P1 F6 1.608(4) 
C4 C5 1.377(6)   P2 F7 1.609(3) 
C5 C6 1.520(6)   P2 F8 1.593(3) 
C8 C9 1.495(7)   P2 F9 1.583(3) 
C11 C12 1.503(6)   P2 F10 1.582(4) 
C12 C13 1.378(6)   P2 F11 1.614(3) 
C13 C14 1.387(7)   P2 F12 1.585(3) 
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Table 4. Bond Angles for Ru-6. 
 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
N1 Ru1 N2 78.49(15)   C19 C20 C21 119.0(4) 
N1 Ru1 N3 99.00(13)   C19 C20 C27 125.3(4) 
N1 Ru1 N6 95.91(15)   C21 C20 C27 115.7(4) 
N2 Ru1 N3 81.50(18)   N5 C21 C20 122.6(5) 
N4 Ru1 N1 176.40(16)   N5 C21 C22 115.8(5) 
N4 Ru1 N2 98.41(15)   C20 C21 C22 121.7(5) 
N4 Ru1 N3 78.63(14)   N6 C22 C21 116.6(5) 
N4 Ru1 N5 92.89(16)   N6 C22 C23 122.4(4) 
N4 Ru1 N6 87.19(15)   C23 C22 C21 121.0(5) 
N5 Ru1 N1 89.52(15)   C22 C23 C24 118.8(4) 
N5 Ru1 N2 100.84(17)   C22 C23 C28 117.5(4) 
N5 Ru1 N3 171.47(15)   C24 C23 C28 123.7(4) 
N5 Ru1 N6 79.11(17)   C25 C24 C23 118.5(4) 
N6 Ru1 N2 174.39(18)   C24 C25 C26 119.6(4) 
N6 Ru1 N3 99.37(17)   N6 C26 C25 123.6(4) 
C1 N1 Ru1 125.5(3)   N7 C27 C20 130.8(4) 
C1 N1 C5 117.9(4)   N7 C27 C28 105.8(4) 
C5 N1 Ru1 116.6(3)   C28 C27 C20 123.4(5) 
C6 N2 Ru1 107.6(3)   N8 C28 C23 129.4(4) 
C6 N2 C7 109.3(3)   N8 C28 C27 109.9(4) 
C6 N2 C8 107.7(4)   C27 C28 C23 120.7(4) 
C7 N2 Ru1 117.0(3)   N7 C29 C30 122.8(5) 
C8 N2 Ru1 106.2(3)   N8 C29 N7 111.7(5) 
C8 N2 C7 108.7(4)   N8 C29 C30 125.6(5) 
C9 N3 Ru1 106.7(3)   C31 C30 C29 122.0(5) 
C9 N3 C10 109.0(4)   C31 C30 C35 118.3(5) 
C9 N3 C11 107.9(3)   C35 C30 C29 119.7(5) 
C10 N3 Ru1 117.3(3)   C32 C31 C30 122.1(5) 
C10 N3 C11 109.4(4)   C31 C32 C33 119.0(5) 
C11 N3 Ru1 106.2(3)   C34 C33 C32 119.9(6) 
C12 N4 Ru1 115.6(3)   C35 C34 C33 121.5(6) 
C16 N4 Ru1 125.8(3)   C34 C35 C30 119.2(5) 
C16 N4 C12 118.5(4)   F1 P1 F2 91.0(2) 
C17 N5 Ru1 129.2(4)   F1 P1 F3 90.69(19) 
C17 N5 C21 116.1(5)   F1 P1 F4 90.7(2) 
C21 N5 Ru1 114.5(4)   F1 P1 F5 89.8(2) 
C22 N6 Ru1 113.8(3)   F1 P1 F6 179.9(2) 
C26 N6 Ru1 129.2(3)   F2 P1 F3 90.07(18) 
C26 N6 C22 117.0(4)   F2 P1 F4 90.39(18) 
C29 N7 C27 107.0(4)   F2 P1 F6 89.1(2) 
C29 N8 C28 105.6(4)   F3 P1 F4 178.5(2) 
N1 C1 C2 121.9(5)   F3 P1 F6 89.39(18) 
C3 C2 C1 120.0(5)   F5 P1 F2 179.1(2) 
C2 C3 C4 118.3(4)   F5 P1 F3 89.46(18) 
C5 C4 C3 119.1(5)   F5 P1 F4 90.06(18) 
N1 C5 C4 122.7(4)   F5 P1 F6 90.1(2) 
N1 C5 C6 115.6(4)   F6 P1 F4 89.2(2) 
C4 C5 C6 121.7(4)   F7 P2 F11 179.3(2) 
N2 C6 C5 110.1(4)   F8 P2 F7 89.51(19) 
N2 C8 C9 110.2(4)   F8 P2 F11 90.83(18) 
N3 C9 C8 108.9(4)   F9 P2 F7 89.9(2) 
N3 C11 C12 110.3(4)   F9 P2 F8 89.11(19) 
N4 C12 C11 116.1(4)   F9 P2 F11 89.4(2) 
N4 C12 C13 121.1(4)   F9 P2 F12 91.3(2) 
C13 C12 C11 122.7(4)   F10 P2 F7 91.0(2) 
C12 C13 C14 120.4(4)   F10 P2 F8 89.4(2) 
C15 C14 C13 118.2(4)   F10 P2 F9 178.3(2) 
C16 C15 C14 119.4(5)   F10 P2 F11 89.7(2) 
N4 C16 C15 122.4(4)   F10 P2 F12 90.1(2) 
N5 C17 C18 124.1(4)   F12 P2 F7 90.54(18) 
C19 C18 C17 120.1(4)   F12 P2 F8 179.6(3) 
C18 C19 C20 118.0(4)   F12 P2 F11 89.12(18) 
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Table 5. Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters (Å2×103) for Ru-6. 
 
Atom x y z U(eq) 
H7 4517 6459 3336 28 
H8 5986 5994 6628 32 
H1 2488 4397 5563 33 
H2 1972 3066 4824 37 
H3 559 2887 3244 39 
H4 -311 4084 2403 34 
H6A 104 5911 2358 29 
H6B -508 5611 2652 29 
H7A 218 7643 3869 43 
H7B -524 7189 2728 43 
H7C 335 7384 2924 43 
H8A 112 5606 4676 30 
H8B -449 6427 4189 30 
H9A 702 7224 5669 32 
H9B 507 6495 6216 32 
H10A 1213 5098 6374 41 
H10B 1612 5585 7543 41 
H10C 2203 5228 7245 41 
H11A 2737 6652 7782 33 
H11B 1979 7116 7658 33 
H13 2663 8531 7883 37 
H14 2774 9632 6912 41 
H15 2512 9347 5135 41 
H16 2090 8014 4351 34 
H17 1003 6659 2402 30 
H18 1478 6921 1320 31 
H19 2912 6760 2137 30 
H24 5477 5718 7807 31 
H25 4818 5506 8683 34 
H26 3362 5660 7614 32 
H31 5567 5983 3230 34 
H32 6708 5934 3179 41 
H33 8080 6145 4892 40 
H34 8276 6398 6614 35 
H35 7139 6422 6688 32 
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5.5 [Ru(picenBz2)(phenpyrBz)](PF6)2 (Ru-12) 
Deposition Number:  
Data Block Name: data_cc_a 
Unit Cell Parameters: a 20.561(4), b 10.009(2), c 25.865(5) 
Space Group: P2/n 
 
Table 1. Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement Parameters (Å2×103) for 
Ru-12. Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
 
Atom x y z U(eq) 
Ru1 5280.7(2) 7059.1(2) 3018.5(2) 18.48(11) 
N1 4340.2(14) 7840(3) 2618.0(11) 21.8(6) 
N2 4939.9(13) 5560(3) 2402.4(11) 20.7(6) 
N3 5684.5(13) 8034(3) 2425.2(11) 21.1(6) 
N4 5676.1(13) 8775(3) 3428.8(12) 24.0(6) 
N5 4824.5(13) 6155(3) 3544.8(11) 21.4(6) 
N6 6111.4(13) 6039(3) 3540.0(11) 20.6(6) 
N7 5340.5(14) 2708(3) 4970.1(11) 23.4(6) 
N8 6440.5(14) 2755(3) 5025.6(11) 23.6(6) 
C1 4091.0(17) 9032(3) 2721.9(14) 25.1(7) 
C2 3436.1(18) 9430(4) 2469.5(14) 28.2(8) 
C3 3019.8(17) 8596(4) 2093.5(15) 29.5(8) 
C4 3263.4(16) 7375(4) 1989.2(14) 26.0(7) 
C5 3922.3(16) 7006(3) 2262.9(13) 22.2(7) 
C6 4181.5(15) 5627(3) 2220.2(14) 22.5(7) 
C7 5159.1(16) 4148(3) 2570.0(13) 21.3(7) 
C8 4957.6(17) 3103(3) 2130.5(13) 22.1(7) 
C9 4341.6(17) 2422(3) 2030.8(14) 25.7(7) 
C10 4155.6(18) 1481(4) 1619.1(15) 29.9(8) 
C11 4583.9(19) 1194(4) 1307.7(15) 31.5(8) 
C12 5201.3(19) 1844(4) 1407.1(15) 29.8(8) 
C13 5388.6(17) 2787(3) 1818.4(14) 26.3(7) 
C14 5223.5(17) 5983(3) 1951.8(13) 23.2(7) 
C15 5246.3(16) 7498(3) 1905.5(13) 23.1(7) 
C16 6429.1(16) 7893(3) 2451.1(14) 23.3(7) 
C17 6624.4(16) 8495(4) 1980.7(14) 25.3(7) 
C18 6610.7(19) 7718(4) 1531.0(16) 32.4(8) 
C19 6752(2) 8285(4) 1085.1(17) 40.2(9) 
C20 6917(2) 9627(4) 1085.3(17) 41.2(10) 
C21 6952.4(19) 10395(4) 1535.0(16) 35.9(9) 
C22 6810.0(17) 9836(4) 1982.8(15) 28.5(8) 
C23 5551.1(17) 9478(3) 2511.8(14) 25.2(7) 
C24 5799.5(17) 9749(3) 3107.4(15) 26.4(7) 
C25 6167.2(18) 10889(4) 3321.4(17) 32.8(8) 
C26 6415.3(19) 11021(4) 3879.4(17) 36.9(9) 
C27 6291.5(19) 10021(4) 4204.4(17) 35.9(9) 
C28 5921.8(17) 8913(4) 3968.6(14) 28.4(8) 
C29 4172.4(16) 6243(4) 3546.7(13) 24.4(7) 
C30 3893.7(17) 5471(4) 3874.0(14) 26.8(7) 
C31 4283.7(17) 4587(3) 4231.6(13) 24.2(7) 
C32 4978.8(16) 4496(3) 4256.9(13) 20.7(7) 
C33 5229.2(16) 5297(3) 3908.9(13) 20.4(7) 
C34 5932.8(16) 5264(3) 3918.7(13) 19.8(6) 
C35 5453.0(17) 3652(3) 4621.7(13) 22.4(7) 
C36 6132.4(16) 3687(3) 4646.7(13) 22.0(7) 
C37 6406.1(16) 4493(3) 4301.2(13) 21.1(7) 
C38 7090.1(16) 4539(3) 4310.7(14) 24.1(7) 
C39 7266.8(17) 5350(4) 3947.3(14) 26.9(7) 
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C40 6772.7(16) 6079(3) 3571.8(13) 23.3(7) 
C41 5934.8(17) 2185(3) 5202.7(13) 23.5(7) 
C42 6051.6(18) 1049(3) 5578.5(13) 24.4(7) 
C43 5489.1(18) 397(4) 5660.9(14) 28.1(8) 
C44 5578.5(19) -719(4) 5991.8(14) 30.3(8) 
C45 6219(2) -1209(4) 6234.2(14) 30.7(8) 
C46 6780.6(19) -566(4) 6151.4(14) 29.8(8) 
C47 6698.7(18) 555(4) 5827.8(14) 29.4(8) 
P1 8450.7(6) 2187.7(13) 5467.2(5) 43.5(3) 
F1 7816.3(13) 1557(3) 5012.8(10) 50.9(6) 
F2 7898.5(14) 3082(3) 5648.2(11) 53.6(7) 
F3 8365.2(14) 1072(3) 5882.6(10) 53.8(7) 
F4 9033.1(15) 2861(4) 5931.0(13) 77.3(10) 
F5 8962.3(16) 1262(4) 5279.5(13) 80.3(11) 
F6 8515.2(14) 3323(4) 5054.6(13) 72.8(10) 
P2 7500 4001.3(14) 2500 36.3(3) 
F7 7009.6(13) 4005(3) 1895.7(11) 57.7(7) 
F8 7500 2462(4) 2500 106(2) 
F9 6853.7(14) 4050(5) 2716.5(14) 97.2(14) 
F10 7500 5582(4) 2500 119(3) 
P3 2500 3578.8(12) 2500 21.5(3) 
F11 3296.4(10) 3573(2) 2806.4(8) 31.3(5) 
F12 2615.5(15) 2436(4) 2119.0(17) 107.4(16) 
F13 2619.1(16) 4622(5) 2097.6(16) 112.6(17) 
O1 6694(2) 7103(4) 5070.4(16) 69.2(10) 
C48 7760(3) 8110(6) 5183(2) 64.3(15) 
C49 7314(3) 7142(5) 5321(2) 53.3(12) 
C50 7597(4) 6251(7) 5755(3) 96(2) 
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Table 2. Anisotropic Displacement Parameters (Å2×103) for Ru-12. The Anisotropic displacement factor 
exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
 
Atom U11 U22 U33 U23 U13 U12 
Ru1 16.32(15) 15.45(15) 24.72(16) -0.27(10) 7.52(10) 0.92(9) 
N1 22.6(14) 17.2(14) 28.0(14) 2.2(11) 11.2(12) 0.8(11) 
N2 17.0(13) 20.1(14) 26.0(14) 3.4(11) 7.5(11) 0.4(10) 
N3 18.4(13) 15.8(13) 30.1(15) 0.5(11) 8.3(11) 1.2(10) 
N4 19.0(13) 22.0(14) 31.6(15) -3.2(12) 8.0(12) 3.0(11) 
N5 19.4(13) 19.6(14) 27.2(14) -3.5(11) 10.0(11) -0.8(11) 
N6 20.4(13) 18.6(14) 24.8(14) -3.7(11) 9.6(11) -0.9(11) 
N7 25.2(14) 23.3(15) 24.2(14) -1.1(12) 11.3(12) -3.8(11) 
N8 23.5(14) 23.7(15) 24.4(14) 2.9(12) 8.4(12) 0.2(11) 
C1 24.1(16) 21.3(17) 32.8(18) 0.8(14) 12.9(14) 2.3(13) 
C2 30.0(18) 25.0(18) 35.2(19) 5.2(15) 18.3(15) 7.2(14) 
C3 20.7(16) 36(2) 33.8(19) 9.6(16) 11.7(15) 9.4(15) 
C4 17.8(15) 31.3(19) 29.8(18) 3.6(15) 8.0(14) 1.1(14) 
C5 20.2(16) 23.1(17) 26.0(16) 3.9(14) 11.2(13) 2.1(13) 
C6 16.1(15) 20.4(17) 31.2(18) -0.8(14) 6.9(13) -0.4(12) 
C7 22.0(16) 17.1(16) 25.8(16) 1.6(13) 8.4(13) 2.5(13) 
C8 22.3(16) 17.2(16) 26.1(16) 2.8(13) 5.7(13) 2.3(13) 
C9 25.9(17) 20.6(17) 33.9(19) 0.5(14) 13.7(15) 0.6(14) 
C10 25.4(17) 22.1(18) 41(2) -1.9(16) 6.9(15) -2.5(14) 
C11 36(2) 23.3(18) 32.2(19) -3.7(15) 5.1(16) 2.3(15) 
C12 32.7(19) 25.3(19) 33.8(19) -2.3(15) 13.6(16) 3.9(15) 
C13 23.6(17) 22.3(18) 33.6(19) -0.5(14) 9.2(14) 1.8(13) 
C14 22.6(16) 23.1(17) 25.9(17) 1.2(14) 9.9(13) -0.2(13) 
C15 20.6(16) 21.7(17) 27.7(17) 2.2(14) 7.9(13) 1.5(13) 
C16 17.9(16) 21.7(17) 31.1(18) 4.3(14) 8.2(13) 4.1(12) 
C17 19.0(15) 26.8(18) 31.8(18) 5.4(15) 10.0(14) 5.1(13) 
C18 34.2(19) 28(2) 41(2) 4.0(16) 20.9(17) 4.7(15) 
C19 48(2) 41(2) 39(2) 0.6(18) 25.6(19) 5.9(19) 
C20 43(2) 48(3) 41(2) 13.1(19) 26.5(19) 5.2(19) 
C21 36(2) 31(2) 48(2) 8.3(18) 22.6(18) 0.2(16) 
C22 24.7(17) 27.2(18) 37(2) 1.7(15) 14.5(15) 0.6(14) 
C23 22.6(16) 15.2(16) 39(2) 3.0(14) 11.3(14) 1.5(13) 
C24 20.8(16) 21.2(17) 38.3(19) -2.3(15) 10.1(14) 4.0(13) 
C25 30.9(19) 19.3(18) 53(2) -2.8(16) 18.7(17) 0.6(15) 
C26 33(2) 27(2) 51(2) -16.6(18) 12.6(18) -3.1(16) 
C27 29.5(19) 33(2) 44(2) -13.7(18) 9.0(17) 0.5(16) 
C28 25.7(17) 27.8(18) 31.6(19) -7.1(15) 7.7(15) 2.6(14) 
C29 18.5(15) 28.4(18) 26.1(17) -2.0(14) 6.0(13) 3.3(13) 
C30 20.4(16) 29.1(19) 32.9(18) -5.6(15) 11.0(14) -2.2(14) 
C31 25.4(17) 24.4(17) 27.2(17) -4.7(14) 14.6(14) -4.0(14) 
C32 20.1(15) 20.9(16) 23.1(16) -4.4(13) 9.3(13) -1.5(13) 
C33 19.6(15) 17.6(16) 24.4(16) -4.2(13) 6.6(13) 0.2(12) 
C34 20.6(15) 16.8(15) 23.2(16) -3.6(13) 8.2(13) -1.1(12) 
C35 25.6(16) 20.4(16) 24.2(16) -2.7(13) 11.9(13) -3.2(13) 
C36 25.0(16) 20.8(17) 20.8(16) -1.1(13) 7.5(13) -0.1(13) 
C37 22.1(16) 18.5(16) 23.5(16) -2.0(13) 7.9(13) -0.3(13) 
C38 20.2(16) 24.8(17) 27.0(17) 1.9(14) 6.1(13) 1.7(13) 
C39 19.0(16) 30.3(19) 32.6(18) 3.0(15) 9.3(14) -0.5(14) 
C40 20.9(16) 22.4(17) 27.7(17) 2.8(14) 8.7(13) -0.2(13) 
C41 29.1(17) 20.9(17) 23.0(16) -3.6(13) 11.4(14) -3.0(14) 
C42 33.3(18) 22.3(17) 19.8(16) -3.3(13) 11.0(14) -2.5(14) 
C43 30.8(18) 30.8(19) 25.2(17) -0.7(15) 12.1(14) -0.8(15) 
C44 37(2) 30.9(19) 26.1(18) 2.5(15) 13.4(15) -5.5(16) 
C45 45(2) 23.2(18) 24.5(17) 1.7(14) 10.5(16) -1.4(16) 
C46 34.2(19) 28.7(19) 26.3(18) 1.9(15) 7.9(15) 2.1(15) 
C47 29.7(18) 28.1(19) 31.4(18) 0.8(15) 10.3(15) -2.5(15) 
P1 33.9(5) 55.5(7) 39.0(6) 12.1(5) 6.7(5) 9.5(5) 
F1 48.7(15) 58.1(16) 42.3(14) -2.9(12) 6.9(11) 6.4(12) 
F2 51.7(15) 50.9(16) 53.5(15) -2.9(12) 7.6(12) 12.7(12) 
F3 56.3(16) 58.1(17) 49.9(15) 18.4(13) 20.0(13) 19.2(13) 
F4 47.4(17) 103(3) 61.8(19) 18.3(18) -16.5(14) -14.7(16) 
F5 64.2(19) 121(3) 66.1(19) 34(2) 35.7(16) 50(2) 
F6 40.4(15) 98(2) 74(2) 47.1(19) 7.0(14) 0.7(15) 
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P2 31.3(7) 22.2(7) 63(1) 0 25.7(7) 0 
F7 38.2(13) 76(2) 62.6(17) 21.5(15) 20.4(12) 1.6(13) 
F8 207(7) 17.7(19) 72(3) 0 2(4) 0 
F9 36.7(15) 184(4) 82(2) -65(3) 35.1(16) -44(2) 
F10 53(3) 25(2) 248(8) 0 -8(4) 0 
P3 20.5(6) 20.8(6) 24.9(6) 0 9.3(5) 0 
F11 22.2(10) 36.9(12) 33.5(11) 1.3(9) 6.0(9) -5.4(9) 
F12 42.9(17) 133(3) 124(3) -95(3) -13.2(18) 27.1(19) 
F13 46.5(17) 161(4) 111(3) 106(3) -8.4(18) -28(2) 
O1 70(3) 77(3) 64(2) -16(2) 23(2) -15(2) 
C48 56(3) 87(4) 56(3) 20(3) 26(3) 4(3) 
C49 60(3) 55(3) 51(3) -17(2) 24(2) -9(2) 
C50 89(5) 74(4) 118(6) 30(4) 15(4) -18(4) 
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Table 3. Bond Lengths for Ru-12. 
 
Atom Atom Length/Å   Atom Atom Length/Å 
Ru1 N1 2.070(3)   C24 C25 1.393(5) 
Ru1 N2 2.156(3)   C25 C26 1.394(6) 
Ru1 N3 2.173(3)   C26 C27 1.377(6) 
Ru1 N4 2.061(3)   C27 C28 1.384(5) 
Ru1 N5 2.068(3)   C29 C30 1.385(5) 
Ru1 N6 2.114(3)   C30 C31 1.364(5) 
N1 C1 1.355(4)   C31 C32 1.415(4) 
N1 C5 1.353(4)   C32 C33 1.407(5) 
N2 C6 1.497(4)   C32 C35 1.426(5) 
N2 C7 1.509(4)   C33 C34 1.440(4) 
N2 C14 1.505(4)   C34 C37 1.405(5) 
N3 C15 1.490(4)   C35 C36 1.380(5) 
N3 C16 1.520(4)   C36 C37 1.432(5) 
N3 C23 1.499(4)   C37 C38 1.400(4) 
N4 C24 1.351(5)   C38 C39 1.367(5) 
N4 C28 1.350(5)   C39 C40 1.396(5) 
N5 C29 1.345(4)   C41 C42 1.470(5) 
N5 C33 1.369(4)   C42 C43 1.396(5) 
N6 C34 1.379(4)   C42 C47 1.394(5) 
N6 C40 1.339(4)   C43 C44 1.387(5) 
N7 C35 1.370(4)   C44 C45 1.378(5) 
N7 C41 1.308(5)   C45 C46 1.391(5) 
N8 C36 1.370(4)   C46 C47 1.382(5) 
N8 C41 1.374(4)   P1 F1 1.616(3) 
C1 C2 1.378(5)   P1 F2 1.616(3) 
C2 C3 1.379(5)   P1 F3 1.594(3) 
C3 C4 1.376(5)   P1 F4 1.585(3) 
C4 C5 1.389(5)   P1 F5 1.578(3) 
C5 C6 1.495(4)   P1 F6 1.590(3) 
C7 C8 1.513(5)   P2 F7 1.602(3) 
C8 C9 1.396(5)   P2 F71 1.602(3) 
C8 C13 1.394(5)   P2 F8 1.541(4) 
C9 C10 1.392(5)   P2 F91 1.583(3) 
C10 C11 1.382(5)   P2 F9 1.583(3) 
C11 C12 1.384(5)   P2 F10 1.582(4) 
C12 C13 1.393(5)   P3 F112 1.604(2) 
C14 C15 1.522(5)   P3 F11 1.604(2) 
C16 C17 1.511(5)   P3 F12 1.571(3) 
C17 C18 1.393(5)   P3 F122 1.571(3) 
C17 C22 1.395(5)   P3 F13 1.542(3) 
C18 C19 1.388(5)   P3 F132 1.542(3) 
C19 C20 1.386(6)   O1 C49 1.256(6) 
C20 C21 1.378(6)   C48 C49 1.446(7) 
C21 C22 1.390(5)   C49 C50 1.422(8) 
C23 C24 1.504(5)         
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Table 4. Bond Angles for Ru-12. 
 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
N1 Ru1 N2 80.29(11)   C31 C32 C35 124.1(3) 
N1 Ru1 N3 88.10(10)   C33 C32 C31 118.8(3) 
N1 Ru1 N6 166.44(10)   C33 C32 C35 117.1(3) 
N2 Ru1 N3 84.26(10)   N5 C33 C32 122.4(3) 
N4 Ru1 N1 96.84(11)   N5 C33 C34 116.0(3) 
N4 Ru1 N2 163.46(11)   C32 C33 C34 121.6(3) 
N4 Ru1 N3 79.36(11)   N6 C34 C33 116.3(3) 
N4 Ru1 N5 102.23(11)   N6 C34 C37 122.6(3) 
N4 Ru1 N6 86.83(11)   C37 C34 C33 121.1(3) 
N5 Ru1 N1 87.75(11)   N7 C35 C32 129.2(3) 
N5 Ru1 N2 93.96(10)   N7 C35 C36 110.1(3) 
N5 Ru1 N3 175.71(10)   C36 C35 C32 120.6(3) 
N5 Ru1 N6 78.71(10)   N8 C36 C35 105.8(3) 
N6 Ru1 N2 99.77(10)   N8 C36 C37 130.2(3) 
N6 Ru1 N3 105.42(10)   C35 C36 C37 123.8(3) 
C1 N1 Ru1 125.8(2)   C34 C37 C36 115.6(3) 
C5 N1 Ru1 115.5(2)   C38 C37 C34 119.0(3) 
C5 N1 C1 118.3(3)   C38 C37 C36 125.3(3) 
C6 N2 Ru1 107.01(19)   C39 C38 C37 118.0(3) 
C6 N2 C7 109.4(2)   C38 C39 C40 120.4(3) 
C6 N2 C14 110.0(2)   N6 C40 C39 123.6(3) 
C7 N2 Ru1 115.57(19)   N7 C41 N8 112.1(3) 
C14 N2 Ru1 105.08(19)   N7 C41 C42 124.7(3) 
C14 N2 C7 109.7(2)   N8 C41 C42 123.0(3) 
C15 N3 Ru1 102.77(18)   C43 C42 C41 118.4(3) 
C15 N3 C16 110.5(2)   C47 C42 C41 122.4(3) 
C15 N3 C23 113.1(3)   C47 C42 C43 119.1(3) 
C16 N3 Ru1 120.6(2)   C44 C43 C42 120.0(3) 
C23 N3 Ru1 101.80(19)   C45 C44 C43 120.6(3) 
C23 N3 C16 107.9(2)   C44 C45 C46 119.6(3) 
C24 N4 Ru1 113.6(2)   C47 C46 C45 120.4(3) 
C28 N4 Ru1 126.5(2)   C46 C47 C42 120.3(3) 
C28 N4 C24 118.8(3)   F1 P1 F2 86.48(14) 
C29 N5 Ru1 127.8(2)   F3 P1 F1 89.77(16) 
C29 N5 C33 116.8(3)   F3 P1 F2 88.38(15) 
C33 N5 Ru1 115.3(2)   F4 P1 F1 175.71(19) 
C34 N6 Ru1 113.3(2)   F4 P1 F2 89.27(18) 
C40 N6 Ru1 130.3(2)   F4 P1 F3 89.53(17) 
C40 N6 C34 116.3(3)   F4 P1 F6 90.86(18) 
C41 N7 C35 105.6(3)   F5 P1 F1 91.04(18) 
C36 N8 C41 106.3(3)   F5 P1 F2 177.2(2) 
N1 C1 C2 122.3(3)   F5 P1 F3 90.39(16) 
C1 C2 C3 119.1(3)   F5 P1 F4 93.2(2) 
C4 C3 C2 119.2(3)   F5 P1 F6 91.33(19) 
C3 C4 C5 119.5(3)   F6 P1 F1 89.71(16) 
N1 C5 C4 121.4(3)   F6 P1 F2 89.88(17) 
N1 C5 C6 116.7(3)   F6 P1 F3 178.22(17) 
C4 C5 C6 121.6(3)   F7 P2 F71 179.8(2) 
C5 C6 N2 112.3(3)   F8 P2 F7 90.12(12) 
N2 C7 C8 115.8(3)   F8 P2 F71 90.12(12) 
C9 C8 C7 121.1(3)   F8 P2 F9 91.78(18) 
C13 C8 C7 120.5(3)   F8 P2 F91 91.78(18) 
C13 C8 C9 118.4(3)   F8 P2 F10 180.0 
C10 C9 C8 120.6(3)   F91 P2 F7 90.79(15) 
C11 C10 C9 120.3(3)   F9 P2 F71 90.79(15) 
C10 C11 C12 119.8(3)   F91 P2 F71 89.20(15) 
C11 C12 C13 120.0(3)   F9 P2 F7 89.20(15) 
C12 C13 C8 120.8(3)   F91 P2 F9 176.4(4) 
N2 C14 C15 111.6(3)   F10 P2 F71 89.88(12) 
N3 C15 C14 108.2(3)   F10 P2 F7 89.88(12) 
C17 C16 N3 115.0(3)   F10 P2 F9 88.22(18) 
C18 C17 C16 120.2(3)   F10 P2 F91 88.22(18) 
C18 C17 C22 118.8(3)   F11 P3 F112 179.58(18) 
C22 C17 C16 121.0(3)   F12 P3 F112 90.13(13) 
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C19 C18 C17 120.4(4)   F122 P3 F112 89.56(14) 
C20 C19 C18 120.3(4)   F122 P3 F11 90.13(13) 
C21 C20 C19 119.7(4)   F12 P3 F11 89.56(14) 
C20 C21 C22 120.4(4)   F12 P3 F122 86.6(4) 
C21 C22 C17 120.4(4)   F13 P3 F112 90.25(14) 
N3 C23 C24 107.7(3)   F13 P3 F11 90.03(14) 
N4 C24 C23 115.5(3)   F132 P3 F11 90.25(14) 
N4 C24 C25 121.5(3)   F132 P3 F112 90.03(14) 
C25 C24 C23 122.9(3)   F13 P3 F122 175.9(3) 
C24 C25 C26 119.1(4)   F132 P3 F122 89.3(3) 
C27 C26 C25 119.1(4)   F132 P3 F12 175.9(3) 
C26 C27 C28 119.2(4)   F13 P3 F12 89.3(3) 
N4 C28 C27 122.3(4)   F132 P3 F13 94.8(4) 
N5 C29 C30 123.5(3)   O1 C49 C48 121.0(5) 
C31 C30 C29 120.7(3)   O1 C49 C50 121.1(5) 
C30 C31 C32 117.7(3)   C50 C49 C48 117.9(5) 
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Table 5. Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters (Å2×103) for Ru-12. 
 
Atom x y z U(eq) 
H7 4959 2502 5025 28 
H8 6866 2566 5131 28 
H1 4372 9601 2972 30 
H2 3277 10250 2552 34 
H3 2580 8856 1913 35 
H4 2989 6801 1737 31 
H6A 4022 5330 1848 27 
H6B 4000 5023 2438 27 
H7A 4970 3894 2859 26 
H7B 5649 4137 2715 26 
H9 4053 2600 2242 31 
H10 3741 1043 1553 36 
H11 4458 566 1032 38 
H12 5491 1650 1199 36 
H13 5807 3212 1886 32 
H14A 4945 5616 1614 28 
H14B 5678 5626 2016 28 
H15A 5430 7745 1612 28 
H15B 4792 7865 1832 28 
H16A 6700 8311 2780 28 
H16B 6543 6950 2472 28 
H18 6506 6813 1530 39 
H19 6736 7761 785 48 
H20 7002 10009 783 49 
H21 7072 11291 1539 43 
H22 6839 10359 2286 34 
H23A 5069 9665 2379 30 
H23B 5788 10042 2320 30 
H25 6246 11553 3095 39 
H26 6661 11775 4030 44 
H27 6454 10089 4578 43 
H28 5840 8239 4190 34 
H29 3894 6855 3316 29 
H30 3436 5555 3850 32 
H31 4099 4062 4451 29 
H38 7414 4034 4557 29 
H39 7719 5415 3950 32 
H40 6910 6623 3331 28 
H43 5054 711 5494 34 
H44 5203 -1140 6051 36 
H45 6275 -1965 6452 37 
H46 7214 -893 6315 36 
H47 7077 982 5776 35 
H48A 7550 8457 4829 96 
H48B 8181 7687 5189 96 
H48C 7845 8827 5440 96 
H50A 7610 6679 6090 145 
H50B 8049 6014 5755 145 
H50C 7323 5460 5714 145 
 
 
